Sample records for advance cancer research

  1. Prostate Cancer Stem Cells: Research Advances

    Dagmara Jaworska


    Full Text Available Cancer stem cells have been defined as cells within a tumor that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. Experimental evidence showed that these highly tumorigenic cells might be responsible for initiation and progression of cancer into invasive and metastatic disease. Eradicating prostate cancer stem cells, the root of the problem, has been considered as a promising target in prostate cancer treatment to improve the prognosis for patients with advanced stages of the disease.

  2. Major clinical research advances in gynecologic cancer in 2015


    In 2015, fourteen topics were selected as major research advances in gynecologic oncology. For ovarian cancer, high-level evidence for annual screening with multimodal strategy which could reduce ovarian cancer deaths was reported. The best preventive strategies with current status of evidence level were also summarized. Final report of chemotherapy or upfront surgery (CHORUS) trial of neoadjuvant chemotherapy in advanced stage ovarian cancer and individualized therapy based on gene characteristics followed. There was no sign of abating in great interest in immunotherapy as well as targeted therapies in various gynecologic cancers. The fifth Ovarian Cancer Consensus Conference which was held in November 7–9 in Tokyo was briefly introduced. For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was reviewed. For corpus cancer, the safety concern of power morcellation in presumed fibroids was explored again with regard to age and prevalence of corpus malignancy. Hormone therapy and endometrial cancer risk, trabectedin as an option for leiomyosarcoma, endometrial cancer and Lynch syndrome, and the radiation therapy guidelines were also discussed. In addition, adjuvant therapy in vulvar cancer and the updated of targeted therapy in gynecologic cancer were addressed. For breast cancer, palbociclib in hormone-receptor-positive advanced disease, oncotype DX Recurrence Score in low-risk patients, regional nodal irradiation to internal mammary, supraclavicular, and axillary lymph nodes, and cavity shave margins were summarized as the last topics covered in this review. PMID:27775259

  3. Advances in Research on Circulating Tumor Cells in Lung Cancer

    Yingjian SONG


    Full Text Available Metastatic and recurrent tumors have been identified as the leading attribute to the lung cancer deaths. Cancer research has demonstrated the critical role circulating tumor cells (CTCs play in the metastatic spread of carcinomas and the recurrence of lung cancer. The rapid advancement of technology in targeted therapy resolves the embarrassing situation for those late-stage patients whose tumor tissues cannot be obtained. CTCs, as a substitute for the tumor tissues, represent a decisive tool to the cancer treatment strategy. Thus, CTCs exert a fundamental role in the early detection of micro-metastasis, assisting in diagnosis, prognosis and monitoring of the recurrent tumors, and subsequently choosing an individualized approach for the therapeutic treatment. This article will review the advances, which have been made in the research area of CTCs with the aid of its applications in cancer therapy.

  4. Advances in cancer research. Volume 41

    Klein, G.; Weinhouse, S.


    This book contains seven chapters. They are: The Epidemiology of Diet and Cancer; Molecular Aspects of Immunoglobin Expression by Human B Cell Leukemias and Lymphomas; Mouse Mammary Tumor Virus: Transcriptional Control and Involvement in Tumorigenesis; Dominant Susceptibility to Cancer in Man; Multiple Myeloma; Waldenstreom's Macroglobulinemia, and Benign Monoclonal Gammopathy: Characteristics of the B Cell Clone, Immunoregulatory Cell Populations and Clinical Implications; Idiotype Network Interactions in Tumor Immunity; and Chromosomal Location of Immunoglobulin Genes: Partial Mapping of these Genes in the Rabbit and Comparison with Ig Genes Carrying Chromosomes of Man and Mouse.

  5. Advancing Global Cancer Research @ AACR 2015

    Research Priorities for NCI’s Center for Global Health' and included presentations on our mission, objectives, currently funded programs, and future programs given by Dr. Lisa Stevens and Paul Pearlman, as well as three special presentations by NCI grantees.

  6. Research advances in relationship between diabetes and pancreatic cancer

    HE Xiangyi


    Full Text Available Pancreatic cancer (PC is one of common malignant digestive diseases. It is mostly diagnosed at advanced stage, with an extremely poor progression. The relationship between diabetes and PC was shown by numerous epidemiological studies for decades. Retrospective clinical studies and research on molecular mechanisms in recent years have led to a new understanding of the relationship between diabetes, especially new-onset diabetes, and PC, the effect of antidiabetic medication on PC, and the molecular mechanisms underlying the connection between diabetes and PC. It is suggested by recent data that long-standing diabetes is one of the risk factors for PC development, new-onset diabetes may facilitate early diagnosis of PC, diabetes may have an impact on the prognosis of PC, the option of antidiabetic medication may influence the incidence of PC, and exploring the molecular mechanisms underlying the association between diabetes and PC may help to identify the new therapeutic target for PC.

  7. Research advances in molecular targeted therapy for pancreatic cancer

    XU Ying


    Full Text Available Pancreatic cancer remains one of the malignant tumors with the worst prognosis, and its incidence is associated with Western diet, smoking, drinking, obesity, chronic pancreatitis, and a family history of pancreatic cancer. Currently, the treatment of pancreatic cancer focuses on surgery and chemotherapy, but no ideal therapeutic effect has been achieved. An understanding of the specific molecular mechanism of the development of pancreatic cancer helps to better prevent and treat pancreatic cancer. This article introduces the latest advances in the specific molecular mechanism of the development of pancreatic cancer and its targeted therapy and points out that molecular-targeted therapy in addition to traditional treatment helps to improve the prognosis of patients with pancreatic cancer.

  8. Advancing Transdisciplinary Research: The Transdisciplinary Research on Energetics and Cancer Initiative.

    Gehlert, Sarah; Hall, Kara; Vogel, Amanda; Hohl, Sarah; Hartman, Sheri; Nebeling, Linda; Redline, Susan; Schmitz, Kathryn; Thornquist, Mark; Patterson, Ruth; Thompson, Beti


    Strategies for constructing and maintaining cross-disciplinary teams are in their infancy. We outline strategies to support one form, transdisciplinary research, in a major initiative of the National Cancer Institute, the Transdisciplinary Research in Energetics and Cancer 2 (TREC2) initiative. Discussion of the TREC2 sites' experiences with transdisciplinarity is structured around a conceptual model that identifies four iterative phases of transdisciplinary research. An active coordination center, regular face-to-face meetings, and input from external advisors were instrumental in moving TREC2 to the translation phase. The possibilities for advancements in the science of energetics and cancer increased as investigator ties became denser. TREC2 can be seen as a flagship effort in transdisciplinary science that provides lessons on moving ideas from development to translation.

  9. Research advances in traditional Chinese medicine syndromes in cancer patients.

    Ji, Qing; Luo, Yun-quan; Wang, Wen-hai; Liu, Xuan; Li, Qi; Su, Shi-bing


    Traditional Chinese medicine (TCM) syndrome, also known as TCM ZHENG or TCM pattern, is an integral and essential part of TCM theory that helps to guide the design of individualized treatments. A TCM syndrome, in essence, is a characteristic profile of all clinical manifestations in one patient that can be readily identified by a TCM practitioner. In this article, the authors reviewed the presentations of TCM syndromes in seven common malignancies (liver, lung, gastric, breast, colorectal, pancreatic and esophageal cancers), the objectivity and the standardization of TCM syndrome differentiation, the evaluation of TCM syndrome modeling in cancer research, and syndrome differentiation-guided TCM treatment of cancers. A better understanding of TCM syndrome theory, as well as its potential biological basis, may contribute greatly to the clinical TCM diagnosis and the treatment of cancer.

  10. Advances in Cancer Therapy

    Jordan BF, Sonveaux P


    The book "Advances in Cancer Therapy" is a new addition to the Intech collection of books and aims at providing scientists and clinicians with a comprehensive overview of the state of current knowledge and latest research findings in the area of cancer therapy. For this purpose research articles, clinical investigations and review papers that are thought to improve the readers' understanding of cancer therapy developments and/or to keep them up to date with the most recent advances in this fi...

  11. Biomimetic tissue-engineered systems for advancing cancer research: NCI Strategic Workshop report.

    Schuessler, Teresa K; Chan, Xin Yi; Chen, Huanhuan Joyce; Ji, Kyungmin; Park, Kyung Min; Roshan-Ghias, Alireza; Sethi, Pallavi; Thakur, Archana; Tian, Xi; Villasante, Aranzazu; Zervantonakis, Ioannis K; Moore, Nicole M; Nagahara, Larry A; Kuhn, Nastaran Z


    Advanced technologies and biomaterials developed for tissue engineering and regenerative medicine present tractable biomimetic systems with potential applications for cancer research. Recently, the National Cancer Institute convened a Strategic Workshop to explore the use of tissue biomanufacturing for development of dynamic, physiologically relevant in vitro and ex vivo biomimetic systems to study cancer biology and drug efficacy. The workshop provided a forum to identify current progress, research gaps, and necessary steps to advance the field. Opportunities discussed included development of tumor biomimetic systems with an emphasis on reproducibility and validation of new biomimetic tumor models, as described in this report.

  12. Conducting Biobehavioral Research in Patients With Advanced Cancer: Recruitment Challenges and Solutions.

    Gilbertson-White, Stephanie; Bohr, Nicole; Wickersham, Karen E


    Despite significant advances in cancer treatment and symptom management interventions over the last decade, patients continue to struggle with cancer-related symptoms. Adequate baseline and longitudinal data are crucial for designing interventions to improve patient quality of life and reduce symptom burden; however, recruitment of patients with advanced cancer in longitudinal research is difficult. Our purpose is to describe challenges and solutions to recruitment of patients with advanced cancer in two biobehavioral research studies examining cancer-related symptoms. Study 1: Symptom data and peripheral blood for markers of inflammation were collected from newly diagnosed patients receiving chemotherapy on the first day of therapy and every 3-4 weeks for up to 6 months. Study 2: Symptom data, blood, and skin biopsies were collected from cancer patients taking epidermal growth factor receptor inhibitors at specific time points over 4 months. Screening and recruitment results for both studies are summarized. Timing informed consent with baseline data collection prior to treatment initiation was a significant recruitment challenge for both the studies. Possible solutions include tailoring recruitment to fit clinic needs, increasing research staff availability during clinic hours, and adding recruitment sites. Identifying solutions to these challenges will permit the conduct of studies that may lead to identification of factors contributing to variability in symptoms and development of tailored patient interventions for patients with advanced cancer.

  13. The latest advances of experimental research on targeted gene therapy for prostate cancer

    Dongliang Pan; Lianchao Jin; Xianghua Zhang


    The absence of ef ective therapies for castration-resistant prostate cancer (CRPC) establishes the need to de-velop novel therapeutic modality, such as targeted gene therapy, which is ideal for the treatment of CRPC. But its application has been limited due to lack of favorable gene vector and the reduction of“bystander ef ect”. Consequently, scientists al over the world focus their main experimental research on the fol owing four aspects:targeted gene, vector, transfer means and comprehensive therapy. In this paper, we reviewed the latest advances of experimental research on targeted gene therapy for prostate cancer .

  14. Research Donor Program Needs Your Help to Advance Cancer and AIDS Research | Poster

    NCI at Frederick employees have a unique opportunity to contribute directly to cancer and AIDS research by donating blood, saliva, and other samples through the Research Donor Program (RDP). Donors are compensated for their time, which is typically between 10 and 30 minutes. The RDP, which is administered by Occupational Health Services (OHS), Leidos Biomedical Research, provides samples from healthy donors for use in in vitro research conducted at NCI at Frederick and Fort Detrick. Samples are provided anonymously to researchers.

  15. Advances in the research and development of natural health products as main stream cancer therapeutics.

    Ovadje, Pamela; Roma, Alessia; Steckle, Matthew; Nicoletti, Leah; Arnason, John Thor; Pandey, Siyaram


    Natural health products (NHPs) are defined as natural extracts containing polychemical mixtures; they play a leading role in the discovery and development of drugs, for disease treatment. More than 50% of current cancer therapeutics are derived from natural sources. However, the efficacy of natural extracts in treating cancer has not been explored extensively. Scientific research into the validity and mechanism of action of these products is needed to develop NHPs as main stream cancer therapy. The preclinical and clinical validation of NHPs would be essential for this development. This review summarizes some of the recent advancements in the area of NHPs with anticancer effects. This review also focuses on various NHPs that have been studied to scientifically validate their claims as anticancer agents. Furthermore, this review emphasizes the efficacy of these NHPs in targeting the multiple vulnerabilities of cancer cells for a more selective efficacious treatment. The studies reviewed here have paved the way for the introduction of more NHPs from traditional medicine to the forefront of modern medicine, in order to provide alternative, safer, and cheaper complementary treatments for cancer therapy and possibly improve the quality of life of cancer patients.

  16. Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer

    Haibo ZHU


    Full Text Available At present, in the treatment of non-small cell lung cancer (NSCLC, targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs, crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC. Phase I and II clinical trials prove that crizotinib is effective for treatment of activating EML4-ALK mutation in advanced NSCLC patients, little side-effect, and well tolerated. Recently, crizotinib can inhibit ROS1 receptor tyrosine kinase and show extraordinary significant antitumor activity in ROS1-rearranged NSCLC. Drug resistance also exists in crizotinib. The mechanism of drug resistance needs further research. In this study, a review is performed in the mechanism and pharmacokinetics of crizotinib, and the clinical progress of treatment in advanced NSCLC.

  17. 肿瘤干细胞研究进展%Research advances on cancer stem cells



    利用特异性的细胞表面标记分子已经从各类肿瘤组织中分离到了肿瘤干细胞,包括骨髓瘤、肺癌、结肠癌、前列腺癌和胰腺癌.但存在细胞表面标记分子专属性差以及异种移植问题.从临床应用角度来看,将肿瘤干细胞作为肿瘤治疗的靶点,寻找肿瘤干细胞与肿瘤发生的密切关系,选择性地杀伤肿瘤干细胞,为临床根治肿瘤和防止肿瘤复发与转移提供了新的思路.%Certain specific cancer stem cell subpopulation has been isolated from many kinds of tumors by some specified cell surface maker, including myeloma, lung carcinoma, colon cancer, prostate cancer and pancreatic carcinoma. However, poor individual specificity of cell surface maker molecules and heterograft-related problems provoke more researchers to find more specified cell surface makers and establish humanized mice receptor model in the future. From a clinical perspective, tumor stem cells are considered to be the potential target for curing cancer. Research advances in tumor stem cells can help us to elucidate the close relationship between tumor stem cells and tumorigenesis and provide new ideas and alternative pathways for us to conquer the tumor and avoid tumor recurrence and metastasis.

  18. Antisense Oligonucleotide Therapy for Patients with Advanced Cancer | Center for Cancer Research

    Colorectal cancer (CRC) is the second leading cause of cancer-related death in the U.S. Improvements in therapy have increased the survival of patients with CRC from 10 months to two years, but for patients who stop responding to treatments, such as irinotecan, options for additional therapy are limited. Antisense oligonucleotides (ASOs) may offer advantages over traditional therapies if an appropriate target can be identified.

  19. Advancement in research of anti-cancer effects of toad venom (ChanSu) and perspectives

    Miao Liu; Li-Xing Feng; Li-Hong Hu; Xuan Liu; De-An Guo


    Toad venom, called as ChanSu in China, is a widely used traditional Chinese medicine (TCM) whose active components are mainly bufadienolides. ChanSu could exhibit cardiotonic, anti-microbial, anti-inflammatory and, most importantly, anti-cancer effects. In the present review, reports about the in vitro, in vivo and clinical anti-cancer effects of ChanSu or its representative component, bufalin, were summarized. And, reported anti-cancer mechanisms of cardenolides, structure analogues of bufadienolides, were also introduced. Based on the results got from research of ChanSu/bufalin and the results from cardenolides, possible signal network related to the anti-cancer effects of ChanSu/bufalin was predicted. Furthermore, future potential use of ChanSu in anti-cancer therapy was discussed.

  20. Advancing Ethical Neuroscience Research.

    Borah, B Rashmi; Strand, Nicolle K; Chillag, Kata L


    As neuroscience research advances, researchers, clinicians, and other stakeholders will face a host of ethical challenges. The Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) has published two reports that provide recommendations on how to advance research endeavors ethically. The commission addressed, among other issues, how to prioritize different types of neuroscience research and how to include research participants who have impaired consent capacity. The Bioethics Commission's recommendations provide a foundation for ethical guidelines as neuroscience research advances and progresses.

  1. 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research | Division of Cancer Prevention

    The NIH Pain Consortium will convene the 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research, featuring keynote speakers and expert panel sessions on Innovative Models and Methods. The first keynote address will be delivered by David J. Clark, MD, PhD, Stanford University entitled “Challenges of Translational Pain Research: What Makes a Good Model?” |

  2. Advanced Research of Fibroblast Growth Factor Receptor 
in Non-small Cell Lung Cancer

    Dan PU


    Full Text Available Lung cancer is severely threatening human health. In recent years, the treatment for lung adenocarcinoma has made a great progress, targeted therapy has been widely applied in clinic, and benefits amount of patients. However, in squamous cell lung cancer, the incidence of epidermal growth factor receptor (EGFR gene mutant and ALK fusion gene are low,and targeted therapy like Tarceva and crizotinib, can hardly work. Since the fibroblast growth factors (fibroblast growth factor, FGF pathway is considered to be related to tumor cell proliferation, metastasis and angiogenesis, more and more researches proved the amplification of fibroblast growth factor receptor (FGFR in squamous cell lung cancer. Experiments in vivo and in vitro found that blocking FGF pathway could reduce the proliferation of tumor cells and inhibit metastasis. The FGF pathway might be a new target for treatment of squamous cell lung cancer. This article reviews the effect of FGFR in tumorigenesis,as well as the prospect as a therapeutic target in non-small cell lung cancer.

  3. Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer

    Xu LI


    Full Text Available Background and objective Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA to improve the efficacy of paclitaxel and reduce its adverse reactions. The aim of this retrospective study is to observe the efficacy and safety of albumin-bound paclitaxel-based therapy in the treatment of lung cancer. Methods We have enrolled 50 patients with advanced or unresectable retreatment lung cancer who were admitted from November 2011 to December 2014. All patients were treated with albumin-bound paclitaxel-based therapy with a 21 day cycle (albumin-bound paclitaxel weekly by intravenous dose of 130 mg/m2 on day 1 and day 8. Efficacy was evaluated every two cycles according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1 and side effects were observed during each cycle. All patients were evaluated. Results The total objective response rate (ORR of albumin-bound paclitaxel-based therapy was 20%, disease control rate (DCR was 68%. In the subgroup analysis, in squamous non-small-cell lung carcinoma groups, ORR and DCR were 26.7% and 80% respectively. Albumin-bound paclitaxel based chemotherapy combined anti-angiogenesis therapy had a promising overall response rate 36.4%. In the patients who had been previously treated with≥4 lines of chemotherapy DCR also reached 69.2%. The most common adverse reactions were hematologic toxicities and were all manageable, no hypersensitivity reactions or treatment-related grade 4 adverse events were reported. Conclusion Weekly albumin-bound paclitaxel is effective and well tolerated in the treatment of advanced lung cancer including all histological subtypes. Albumin-bound paclitaxel was associated with superior efficacy in patients with squamous (SCC histology and combined with anti-angiogenesis therapy. Albumin-bound paclitaxel shown to be an effective and safe regimen for elderly or previous heavily treated patients.

  4. [Therapeutic advances in breast cancer].

    Pestalozzi, B C


    The treatment of breast cancer has made significant improvements during the past ten years. For early breast cancer with a clinically negative axilla sentinel node biopsy has become the preferred approach. For endocrine therapy of postmenopausal patients the selective aromatase inhibitors have become standard in metastatic as well as in early breast cancer. Trastuzumab (Herceptin) plays an important role in the treatment of HER2-positive breast cancer in the metastatic and since 2005 also in the adjuvant setting. When chemotherapy is used to treat metastatic breast cancer drug combinations are superior to monotherapy only in terms of response rates. By contrast, in the adjuvant setting combination drug therapy is the standard. New methods of tissue analysis including expression patterns of mRNA and proteins are promising research strategies to further advance the field.

  5. Basic research in kidney cancer

    Oosterwijk, E.; Rathmell, W.K.; Junker, K.; Brannon, A.R.; Pouliot, F.; Finley, D.S.; Mulders, P.F.A.; Kirkali, Z.; Uemura, H.; Belldegrun, A.


    CONTEXT: Advances in basic research will enhance prognosis, diagnosis, and treatment of renal cancer patients. OBJECTIVE: To discuss advances in our understanding of the molecular basis of renal cancer, targeted therapies, renal cancer and immunity, and genetic factors and renal cell carcinoma (RCC)

  6. Engagement of Patients With Advanced Cancer


    End of Life; Advanced Cancer; Lung Neoplasm; Gastric Cancer; Colon Cancer; Glioblastoma Multiforme; Head and Neck Neoplasms; Rectum Cancer; Melanoma; Kidney Cancer; Prostate Cancer; Testicular Neoplasms; Liver Cancer; Cancer of Unknown Origin

  7. Animal Production Research Advances

    Animal Production Research Advances is a peer-review journal established expressly to ... and wildlife, minilivestock, livestock farming systems and other disciplines. ... Selenium and tocopherol effects on parasitaemia, organ weights and ...

  8. Advancing treatment of metastatic cancers: from research to communication--where do we need to go?

    Zetter, Bruce; Lake, Francesca


    Bruce Zetter* speaks to Francesca Lake, Managing Commissioning Editor: Bruce Zetter is the Charles Nowiszewski Professor of Cancer Biology at Harvard Medical School in Boston (MA, USA). Dr Zetter received a BA degree in anthropology from Brandeis University in Waltham (MA, USA) and a PhD from the University of Rhode Island in Kingston (RI, USA). He completed fellowships at Massachusetts Institute of Technology in Cambridge (MA, USA) and at the Salk Institute in San Diego (CA, USA). Subsequently, he was an assistant research biochemist at the University of California in San Francisco (CA, USA) before joining the faculty at Harvard Medical School. At Harvard, he directed the course in human physiology taken by all medical students. He further served as the Chief Scientific Officer at Boston Children's Hospital (MA, USA), where he directed the research efforts for the hospital. Dr Zetter has made major discoveries on the mechanisms underlying tumor metastasis and on the detection and treatment of late-stage tumors. As an internationally recognized expert in the field of tumor metastasis, Dr Zetter has chaired multiple international research conferences and grant review panels for agencies such as the US NIH and the US Department of Defense. He also chaired the NASA committee that selects scientific projects for the space shuttle. Dr Zetter has a strong interest in the interactions of academic and corporate institutions and has served as an advisor to more than 30 biotechnology and pharmaceutical companies, as well as to venture firms and investment companies.

  9. Types of Cancer Research

    An infographic from the National Cancer Institute (NCI) describing the four broad categories of cancer research: basic research, clinical research, population-based research, and translational research.

  10. Translational research on advanced therapies.

    Belardelli, Filippo; Rizza, Paola; Moretti, Franca; Carella, Cintia; Galli, Maria Cristina; Migliaccio, Giovanni


    Fostering translational research of advanced therapies has become a major priority of both scientific community and national governments. Advanced therapy medicinal products (ATMP) are a new medicinal product category comprising gene therapy and cell-based medicinal products as well as tissue engineered medicinal products. ATMP development opens novel avenues for therapeutic approaches in numerous diseases, including cancer and neurodegenerative and cardiovascular diseases. However, there are important bottlenecks for their development due to the complexity of the regulatory framework, the high costs and the needs for good manufacturing practice (GMP) facilities and new end-points for clinical experimentation. Thus, a strategic cooperation between different stakeholders (academia, industry and experts in regulatory issues) is strongly needed. Recently, a great importance has been given to research infrastructures dedicated to foster translational medicine of advanced therapies. Some ongoing European initiatives in this field are presented and their potential impact is discussed.

  11. Translational research on advanced therapies

    Filippo Belardelli


    Full Text Available Fostering translational research of advanced therapies has become a major priority of both scientific community and national governments. Advanced therapy medicinal products (ATMP are a new medicinal product category comprising gene therapy and cell-based medicinal products as well as tissue engineered medicinal products. ATMP development opens novel avenues for therapeutic approaches in numerous diseases, including cancer and neurodegenerative and cardiovascular diseases. However, there are important bottlenecks for their development due to the complexity of the regulatory framework, the high costs and the needs for good manufacturing practice (GMP facilities and new end-points for clinical experimentation. Thus, a strategic cooperation between different stakeholders (academia, industry and experts in regulatory issues is strongly needed. Recently, a great importance has been given to research infrastructures dedicated to foster translational medicine of advanced therapies. Some ongoing European initiatives in this field are presented and their potential impact is discussed.

  12. Breast Cancer Research Update

    ... JavaScript on. Feature: Breast Cancer Breast Cancer Research Update Winter 2017 Table of Contents National Cancer Institute ... Addressing Breast Cancer's Unequal Burden / Breast Cancer Research Update Winter 2017 Issue: Volume 11 Number 4 Page ...

  13. Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care

    Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care, a 2010 workshop sponsored by the Epidemiology and Genomics Research Program.

  14. Architecture for an advanced biomedical collaboration domain for the European paediatric cancer research community (ABCD-4-E).

    Nitzlnader, Michael; Falgenhauer, Markus; Gossy, Christian; Schreier, Günter


    Today, progress in biomedical research often depends on large, interdisciplinary research projects and tailored information and communication technology (ICT) support. In the context of the European Network for Cancer Research in Children and Adolescents (ENCCA) project the exchange of data between data source (Source Domain) and data consumer (Consumer Domain) systems in a distributed computing environment needs to be facilitated. This work presents the requirements and the corresponding solution architecture of the Advanced Biomedical Collaboration Domain for Europe (ABCD-4-E). The proposed concept utilises public as well as private cloud systems, the Integrating the Healthcare Enterprise (IHE) framework and web-based applications to provide the core capabilities in accordance with privacy and security needs. The utility of crucial parts of the concept was evaluated by prototypic implementation. A discussion of the design indicates that the requirements of ENCCA are fully met. A whole system demonstration is currently being prepared to verify that ABCD-4-E has the potential to evolve into a domain-bridging collaboration platform in the future.

  15. The Clinical Research in Advanced Stage Gastric Cancer Accompanying Hemorrhage with EHLF Chemotherapy and Thrombin to Take Orally

    Chen Huoguo


    Purpose:Study therapeutic effectiveness about EHLF chemotherapy and thrombin to take orally in advanced stage gastriccancer accompanying hemorrhage.Methods:76 cases were divided into two groups at random,that were diagnosed by pathology andclinical. Research group included medicine:(etoposide)VP-16,100 mg intravenous drip,d1~3;(hydroxycamptothecin)HCPT, 10mg,ivtravenous drip,d1~5;(calciumfolinate)CF, 100 mg,intravenous drip,d1~5;(fluorouracil)5-Fu,0.5,intravenous drip,d1~5;thrombin,5oou,oral administration,three times in a day, d1~7.Matched control:normal regulation to medicine in gastric hemorrhye.Results:Effective rate in research group was 78.4%,obvious better than one in matched control 28.2%(P<0.01),bad reaction wasslight, life quantity was obvious exaltation.Conclusion:EHLF chemotherapy and thrombin to take orally was used as treatment project inadranced stage gastric cancer accompanying hemorrhage,good result in research group. It is worthy to deserve further reseach.

  16. Advanced Cancer Detection Center


    Coeur d’Alene, ID IASLC 9th World Conference on Lung Cancer, Cellular Targeting in the Molecular Diagnosis of Lung Cancer, Tokyo, Japan The...World Conference on Lung Cancer, Cellular Targeting in the Molecular Diagnosis of Lung Cancer, Tokyo, Japan The first International Conference on

  17. Next-Generation Entrepreneurs Ready to Advance Breast Cancer Research Innovations | Poster

    By Michele Newton and Thomas Stackhouse, Contributing Writers, and Rosemarie Truman, Guest Writer Editor’s note: In May 2014, the Breast Cancer Start-Up Challenge was named one of six finalists in the HHS Innovates Award Competition. This award celebrates innovations developed by employees of the U.S. Department of Health and Human Services (HHS) to support the mission of HHS. In the final phase of the competition, the public will be invited to help select “The People’s Choice” winner; public voting takes place May 29 through June 6, 2014.

  18. Nausea and vomiting in advanced cancer.

    Gordon, Pamela; LeGrand, Susan B; Walsh, Declan


    Nausea and vomiting are very common symptoms in cancer both treatment and non-treatment related. Many complications of advanced cancer such as gastroparesis, bowel and outlet obstructions, and brain tumors may have nausea and vomiting or either symptom alone. In a non-obstructed situation, nausea may be more difficult to manage and is more objectionable to patients. There is little research on management of these symptoms except the literature on chemotherapy induced nausea where guidelines exist. This article will review the etiologies of nausea and vomiting in advanced cancer and the medications which have been used to treat them. An etiology based protocol to approach the symptom is outlined.

  19. Cancer Research Advance in CKLF-like MARVEL Transmembrane Domain Containing Member Family (Review).

    Lu, Jia; Wu, Qian-Qian; Zhou, Ya-Bo; Zhang, Kai-Hua; Pang, Bing-Xin; Li, Liang; Sun, Nan; Wang, Heng-Shu; Zhang, Song; Li, Wen-Jian; Zheng, Wei; Liu, Wei


    CKLF-like MARVEL transmembrane domain-containing family (CMTM) is a novel family of genes first reported at international level by Peking University Human Disease Gene Research Center. The gene products are between chemokines and the transmembrane-4 superfamily. Loaceted in several human chromosomes, CMTMs, which are unregulated in kinds of tumors, are potential tumor suppressor genes consisting of CKLF and CMTM1 to CMTM8. CMTMs play important roles in immune, male reproductive and hematopoietic systems. Also, it has been approved that CMTM family has strong connection with diseases of autoimmunity, haematopoietic system and haematopoietic system. The in-depth study in recent years found the close relation between CMTMs and umorigenesis, tumor development and metastasis. CMTM family has a significant clinical value in diagnosis and treatment to the diseases linking to tumor and immune system.

  20. Dyspnea during Advanced Cancer

    ... by chemotherapy. Conditions that are not related to cancer: Chronic obstructive pulmonary disease (COPD), such as chronic bronchitis or emphysema . ... depends on the type and stage of the cancer being treated. Laser therapy for tumors inside large ... Postradiation bronchiolitis obliterans Steroid ...

  1. Management of Advanced Laryngeal Cancer

    Patrick Sheahan


    Full Text Available Squamous cell carcinoma of the larynx continues to be the commonest head and neck cancer in many Western countries. The larynx plays a key role for many essential functions, including breathing, voice production, airway protection, and swallowing. The goals of laryngeal cancer treatment are thus to provide best possible oncologic control, while optimizing functional outcomes. In recent decades, the treatment paradigm for advanced laryngeal cancer has shifted from one of primary surgery (total laryngectomy as gold standard, toward non-surgical organ-preserving treatment using radiotherapy or chemoradiotherapy. However, concerns have emerged regarding functional outcomes after chemoradiotherapy, as well as possible decreased overall survival in patients with laryngeal cancer. The purpose of the present review is to review surgical and non-surgical options for treatment of advanced laryngeal cancer, as well as the evidence supporting each of these.

  2. Coping with Advanced Cancer

    ... Resources Conducting Clinical Trials Statistical Tools and Data Terminology Resources NCI Data Catalog Cryo-EM NCI's Role ... Contacts Other Funding Find NCI funding for small business innovation, technology transfer, and contracts Training Cancer Training ...

  3. Advances in cancer research

    Klein, G. (Dept. of Tumor Biology, Karolinska Institute, Stockholm, (SE)) Weinhouse, S. (Fels Research Institute, Temples Univ. Medical School, Philadelphia, PA (US))


    This book contains the following 10 chapters: Interactions of Retroviral Oncogenes with the Differentiation Program of Myogenic Cells; The fos Oncogene; Role of the abl Oncogene in Chronic Myelogenous Leukemia; The Epstein-Barr Virus and the Immune System; The Use of Cell Markers in the Study of Human Hematopoietic Neoplasia; Multistage Model of Natural Killer Cell-Mediated Cytotoxicity Involving NKCF as Soluble Cytotoxic Mediators; Shedding of Human Tumor-Associated Antigens in Vitro and in Vivo; New Classes of Tumor Promoters: Teleocidin, Aplysiatoxin and Palytoxin; Anticarcinogenic Action of Protease Inhibitors; and On the Epidemiology of Oral Contraceptives and Disease.

  4. Advanced Cancer Detection Center


    to support study investigators and research staff to code clinical research data using SNOMED CT at the point of research. This tool is customized...No significant level of agreement among the experts was found. Conclusion: There is little semantic agreement in coding of clinical research data items... Research Data : A Semantic Characterization of Data Items on Case Report Forms in Vasculitis Research. JAMIA 2006; 13:536-546. Andrews JE, Richesson RL

  5. Research Rrogress of Treating Advanced Cervical Cancer%中晚期宫颈癌治疗研究进展

    王艳丽; 李国文; 韩新巍


    Cervical cancer of treatment mode was mainly based on the instalment and stratification. The treatment of advanced cervical cancer was mainly based on radiation therapy of comprehensive treatment. However,as concurrent chemoradiotherapy,intervention treatment,gene therapy,biological target therapy,heat treatment of new therapy method are constantly emerging,for localy advanced cervical cancer treatment mode and concept to provide some new ideas and methods.%宫颈癌的治疗模式主要以分期为基础,实施分层治疗。中晚期宫颈癌的治疗是以放射治疗为主的综合治疗,但是,随着同步放化疗、介入治疗、基因治疗、生物靶向治疗、热疗等新的治疗手段的不断涌现,为中晚期宫颈癌治疗模式和理念提供一些新的思路和方法。

  6. The eighth Asia cancer forum: seeking to advance the outcomes of the UN summit: 'global health as the key to a new paradigm in cancer research'.

    Kawahara, Norie; Akaza, Hideyuki; Roh, Jae Kyung; Shibuya, Kenji; Inoue, Hajime; Takemi, Keizo; Nozaki, Shinjiro; Kawakami, Koji; Iwasaki, Masaru


    To date, the Asia Cancer Forum has focused its efforts on creating a common concept for collaborative efforts in international cancer research with a focus on Asia, where cancer incidence is rising dramatically, and also sharing information and knowledge among cancer specialists about the importance of cancer as a global health agenda issue. The Eighth Asia Cancer Forum was held following the historic outcome of the High-level Meeting of the United Nations General Assembly on the Prevention and Control of Non-communicable Diseases held in New York in September 2011, at which cancer was duly recognized as a global health agenda issue. Despite this significant development, however, the issue of cancer, one of the most intractable of all non-communicable diseases, still faces a variety of challenges if it is to be addressed on the global level. The Eighth Asia Cancer Forum sought to address these various issues, seeking ways to capitalize on the outcomes of the UN Meeting and take global collaborative studies and alliances in the field of cancer further. It was recognized that one of the main challenges for the Asia Cancer Forum is to formulate a proposal that demonstrates how middle-income countries can provide a good level of care using only their own limited medical resources. Given that the Asia Cancer Forum is one of the organizations that can provide assistance in working to further boost awareness about cancer research and the situation relating to cancer in Asian countries, discussion also focused on how to concretize activities in the future.

  7. Advanced Cancer Detection Center


    Neurocognitive Deficits in Children who Received Cancer Treatment Affecting the Central Nervous System (HLMCC 0707) • Melatonin and sleep hygiene...Environmental Determinants of Diabetes in the Young. (PI: Jeffrey Krischer, Ph.D.) The aetiology of type 1 diabetes (T1D) remains unknown, however...progression to diabetes . To test these hypotheses, large groups of young children at risk for T1D must be followed prospectively with collection of

  8. Using Phenomenology to Examine the Experiences of Family Caregivers of Patients with Advanced Head and Neck Cancer: Reflections of a Novice Researcher

    Jamie L. Penner RN, BN, BPE


    Full Text Available Faced with a number of research methods, astute researchers carefully choose the method of research most appropriate for their inquiry. Even when there is a goodness of fit between the research design selected to conduct the study and the topic of interest, all designs pose challenges for investigators that need to be considered and addressed. This paper represents the reflections of a novice researcher regarding the issues and decisions made in the course of selecting a phenomenological approach to conduct research examining family caregivers' experiences caring for tube feeding–dependent patients with advanced head and neck cancer. As such, the article is aimed at sensitizing other novice investigators about things to consider in selecting a phenomenological perspective to answer their own research questions.

  9. New possibilities for cancer therapy with advances in cancer immunology.

    MacLean, G D; Longenecker, B M


    There has been progress over the last decade in addressing three questions: Are there cancer-associated antigens that could be targets for immunotherapy? Can the human immune system recognize cancer-associated antigens? Can an anti-cancer immune response affect cancer cells and lead to increased survival? Results from animal model studies have been interpreted by optimists as encouraging, and by pessimists as being irrelevant to human cancer. Earlier studies on "cancer vaccines" utilized heterogeneous cell extracts of cell components. Monoclonal antibodies have enabled identification of relevant cancer-associated antigens or epitopes, such as the ganglioside GM2, the carbohydrates TF and STn, and the peptide sequences of MUC-1. In parallel with research on immune adjuvants and measures designed to inhibit suppressor activity, these epitopes are being tested for their potential in the immunotherapy of solid tumors. It is clear that some of these cancer-associated epitopes are immunogenic in humans. Mixed responses may relate to cancer heterogeneity and may indicate the importance of multi-epitopic vaccines. Responses are encouraging, but are they relevant? Prolonged disease stability challenges us to re-think the goals of cancer therapy. Recent advances in the knowledge of the effect of cytokines on tumor antigen expression and the regulation of the immune response, coupled with advances in active specific immunotherapy, provide hope that biomodulation may become an important part of the therapy of solid tumors in the next century.

  10. Advances in cancer immunology and cancer immunotherapy.

    Voena, Claudia; Chiarle, Roberto


    After decades of setbacks, cancer immunology is living its Golden Age. Recent advances in cancer immunology have provided new therapeutic approaches to treat cancer. The objective clinical response observed in patients treated with antibodies that block the immune checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) pathways, has led to their FDA approval for the treatment of melanoma in 2011 and in 2014, respectively. The anti-PD-1 antibody nivolumab has received the FDA-approval in March 2015 for squamous lung cancer treatment. In addition, antibodies targeting PD-1 or PD-L1 have demonstrated their efficacy and safety in additional tumors, including non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin's lymphoma. Almost at the same time, the field of adoptive cell transfer has exploded. The chimeric antigen receptor (CAR) T technology has provided strong evidence of efficacy in the treatment of B cell malignancies, and different T cell based treatments are currently under investigation for different types of tumors. In this review we will discuss the latest advances in cancer immunology and immunotherapy as well as new treatments now under development in the clinic and potential strategies that have shown promising results in preclinical models.

  11. Treatment of locally advanced rectal cancer

    Klaassen, RA; Nieuwenhuijzen, GAP; Martijn, H; Rutten, HJT; Hospers, GAP; Wiggers, T


    Historically, locally advanced rectal cancer is known for its dismal prognosis. The treatment of locally advanced rectal cancer is subject to continuous change due to development of new and better diagnostic tools, radiotherapeutic techniques, chemotherapeutic agents and understanding of the

  12. Advanced Prostate Cancer

    ... CareBlog Make a Difference Planned Giving Cause-Related Marketing Research Quick Links Urologic Conditions Financials & Annual Report Leadership Privacy Statement Link Policy American Urological Association © 2017 Urology Care Foundation | All Rights Reserved.

  13. Interdisciplinary Research Training in Breast Cancer


    University. An Internet-Based Low- Literacy Cancer Communication Intervention. $1,500, funded. * 2004- Pfizer Clear Health Communication Program. An...Internet-Based Low- Literacy Cancer Communication Intervention. $195,000, not funded. 0 2004- DOD Breast Cancer Research Program, Multidisciplinary...of Connecticut and Yale University. While providing didactic experience in advanced research, methodology, it allows the candidate to have sustained

  14. Recent advances in the research for the homolog of breast cancer associated gene AtROW1 in higher plants.

    Jiao, Yue; Zhang, Yuzhou; Zhu, Yu-Xian


    BARD1 (BRCA1 associated RING domain protein 1), as an important animal tumor suppressor gene associated with many kinds of cancers, has been intensively studied for decades. Surprisingly, homolog of BARD1 was found in plants and it was renamed AtROW1 (repressor of Wuschel-1) according to its extremely important function with regard to plant stem cell homeostasis. Although great advances have been made in human BARD1, the function of this animal tumor-suppressor like gene in plant is not well studied and need to be further elucidated. Here, we review and summarize past and present work regarding this protein. Apart from its previously proposed role in DNA repair, recently it is found essential for shoot and root stem cell development and differentiation in plants. The study of AtROW1 in plant may provide an ideal model for further elucidating the functional mechanism of BARD1 in mammals.

  15. Current Research on Consolidation Therapy and Follow-up Health Care in Advanced Non-small Cell Lung Cancer Patients

    Runbo Zhong; Baohui Han; Bo Jin


    ABSTRACT Following concurrent radio-chemotherapy or first-line chemotherapy for advanced non-small cell lung cancer(NSCLC), continuous maintenance therapy given to patients with stable disease (SD) and follow-up treatment is called consolidation therapy. Concerning NSCLC patients with a non-operable dry Stage-ⅢB (N3) disease, I.e. Contra-lateral mediastinal and hilar lymph node, or homolateral/contra-lateral scalene and Troisier sign, a 2 or 3-course of standard-dosage Taxotere consolidation therapy can be performed after concurrent radio-chemotherapy. In pursuance of evidence-based medicine (EBM), low-dose Taxoteremaintenance therapy, and biological targeted therapy of patients with appropriate symptoms are suitable for second-line therapy for moist of the Stage-ⅢB (malignant pleural effusion) and Ⅳpatients.

  16. [Research advances in dendrochronology].

    Fang, Ke-Yan; Chen, Qiu-Yan; Liu, Chang-Zhi; Cao, Chun-Fu; Chen, Ya-Jun; Zhou, Fei-Fei


    Tree-ring studies in China have achieved great advances since the 1990s, particularly for the dendroclimatological studies which have made some influence around the world. However, because of the uneven development, limited attention has been currently paid on the other branches of dendrochronology. We herein briefly compared the advances of dendrochronology in China and of the world and presented suggestions on future dendrochronological studies. Large-scale tree-ring based climate reconstructions in China are highly needed by employing mathematical methods and a high quality tree-ring network of the ring-width, density, stable isotope and wood anatomy. Tree-ring based field climate reconstructions provide potentials on explorations of climate forcings during the reconstructed periods via climate diagnosis and process simulation.

  17. Marine biomass research advances

    Bender, E.


    This paper reports on research in California, New York and elsewhere into marine biomass. A manmade marine farm moored four miles off the coast of southern California pumps deep water up a 450 m pipe to fertilize giant kelp. After harvesting and chopping by existing commercial methods, the kelp would be converted, by either anaerobic bacteria or thermal processes, into methane and other products.

  18. Advancing vector biology research

    Kohl, Alain; Pondeville, Emilie; Schnettler, Esther; Crisanti, Andrea; Supparo, Clelia; Christophides, George K.; Kersey, Paul J.; Maslen, Gareth L.; Takken, Willem; Koenraadt, Constantianus J.M.; Oliva, Clelia F.; Busquets, Núria; Abad, F.X.; Failloux, Anna Bella; Levashina, Elena A.; Wilson, Anthony J.; Veronesi, Eva; Pichard, Maëlle; Arnaud Marsh, Sarah; Simard, Frédéric; Vernick, Kenneth D.


    Vector-borne pathogens impact public health, animal production, and animal welfare. Research on arthropod vectors such as mosquitoes, ticks, sandflies, and midges which transmit pathogens to humans and economically important animals is crucial for development of new control measures that target t

  19. Advances in energy research

    Acosta, Morena J


    This book presents a comprehensive review of energy research studies from authors around the globe, including recent research in new technologies associated with the construction of nuclear power plants; oil disperse systems study using nuclear magnetic resonance relaxometry (NMRR); low energy consumption for cooling and heating systems; experimental investigation of the performance of a ground-source heat pump system for buildings heating and cooling; sustainable development of bioenergy from agricultural wastes and the environment; hazard identification and parametric analysis of toxic pollutants dispersion from large liquid hydrocarbon fuel-tank fires; maintenance benchmarking in petrochemicals plants by means of a multicriteria model; wind energy development innovation; power, people and pollution; nature and technology of geothermal energy and clean sustainable energy for the benefit of humanity and the environment; and soil thermal properties and the effects of groundwater on closed loops.

  20. Advances in nanotheranostics II cancer theranostic nanomedicine


    This book surveys recent advances in theranostics based on magnetic nanoparticles, ultrasound contrast agents, silica nanoparticles and polymeric micelles. It presents magnetic nanoparticles, which offer a robust tool for contrast enhanced MRI imaging, magnetic targeting, controlled drug delivery, molecular imaging guided gene therapy, magnetic hyperthermia, and controlling cell fate. Multifunctional ultrasound contrast agents have great potential in ultrasound molecular imaging, multimodal imaging, drug/gene delivery, and integrated diagnostics and therapeutics. Due to their diversity and multifunctionality, polymeric micelles and silica-based nanocomposites are highly capable of enhancing the efficacy of multimodal imaging and synergistic cancer therapy. This comprehensive book summarizes the main advances in multifunctional nanoprobes for targeted imaging and therapy of gastric cancer, and explores the clinical translational prospects and challenges. Although more research is needed to overcome the substan...

  1. PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation.

    Yoon, Jung Won; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae; Kang, Won Jun; Nam, Eun Ji


    To investigate whether the ratio of SUVs measured with F-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. F-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by F-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). In total, 142 patients receiving chemoradiation showed radiologic responses (median 56% decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73% decrease in SUVmax; 48% decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.

  2. Responses to advanced cancer: Chinese-Australians.

    Chui, Ying-Yu; Donoghue, Judith; Chenoweth, Lynn


    This paper describes a study identifying the impact of key aspects of Chinese culture on the responses of mid-aged Chinese-Australians to their advanced cancer in order to make recommendations about their care within the health system. Studies conducted in the 1960s and 1970s focused on understanding people's psychological responses to their experiences of terminal illness, but the issue of culture was not addressed. In recent years, a few studies have been conducted with Chinese-Australians, but were limited to issues related to their information needs and the disclosure of a cancer diagnosis. There is a lack of understanding of the impact of Chinese culture on the experiences of these patients. A grounded theory approach was used to generate a substantive theory to explain how mid-aged Chinese-Australians respond to advancing cancer. Eleven participants were recruited and data were collected from face-to-face interviews, telephone contacts, observation and researcher field notes. Data generation occurred between 1997 and 1999. Four modes of response to advanced cancer were identified: acute crisis, combat, despondency and waiting for death. This paper deals particularly with the combat mode which incorporated five culturally specific strategies used by participants in their struggle against advanced cancer. These were traditional Chinese medicine, traditional Chinese beliefs on the use of food for health maintenance, qi gong (a form of exercise), feng shui (which involves paying attention to spatial organization) and the worship of ancestors and gods. Deeply entrenched within these responses is the influence of Chinese culture, rooted in the beliefs and practices of traditional Chinese medicine and the philosophy of harmony and balance of yin and yang and qi. Health care professionals need to be aware of the cultural practices and beliefs of the different ethnic groups for whom they care, and of the importance of accommodation to and negotiation about these




    The activities of the Advanced Gas Turbine Systems Research (AGTSR) program for this reporting period are described in this quarterly report. The report is divided into discussions of Membership, Administration, Technology Transfer (Workshop/Education), Research and Miscellaneous Related Activity. Items worthy of note are presented in extended bullet format following the appropriate heading.




    The activities of the Advanced Gas Turbine Systems Research (AGTSR) program for this reporting period are described in this quarterly report. The report is divided into discussions of Membership, Administration, Technology Transfer (Workshop/Education), Research and Miscellaneous Related Activity. Items worthy of note are presented in extended bullet format following the appropriate heading.

  5. Genetically Engineered Immunotherapy for Advanced Cancer

    In this trial, doctors will collect T lymphocytes from patients with advanced mesothelin-expressing cancer and genetically engineer them to recognize mesothelin. The gene-engineered cells will be multiplied and infused into the patient to fight the cancer

  6. New treatment modalities in advanced thyroid cancer.

    Kapiteijn, E.; Schneider, T.C.; Morreau, H.; Gelderblom, H.; Nortier, J.W.; Smit, J.W.A.


    BACKGROUND: Thyroid cancer is a heterogeneous disease that is classified into differentiated thyroid carcinoma (DTC), undifferentiated/anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma. Results of conventional treatment modalities in advanced thyroid cancer have been disappointing a

  7. Common symptoms in advanced cancer.

    Lagman, Ruth L; Davis, Mellar P; LeGrand, Susan B; Walsh, Declan


    The key points of this article are anorexia and cachexia are: A major cause of cancer deaths. Several drugs are available to treat anorexia and cachexia. Dyspnea in cancer usually is caused by several factors. Treatment consists of reversing underlying causes, empiric bronchodilators, cortico-steroids--and in the terminally ill patients-opioids, benzodiazepines,and chlorpromazine. Delirium is associated with advanced cancer. Empiric treatment with neuroleptics while evaluating for reversible causes is a reasonable approach to management. Nausea and vomiting are caused by extra-abdominal factors (drugs,electrolyte abnormalities, central nervous system metastases) or intra-abdominal factors (gastroparesis, ileus, gastric outlet obstruction, bowel obstruction). The pattern of nausea and vomiting differs depending upon whether the cause is extra- or intra-abdominal. Reversible causes should be sought and empiric metoclopramide or haloperidol should be initiated. Fatigue may be caused by anemia, depression, endocrine abnormalities,or electrolyte disturbances that should be treated before using empiric methylphenidate. Constipation should be treated with laxatives and stool softeners. Both should start with the first opioid dose.

  8. [Innovation in Surgery for Advanced Lung Cancer].

    Nakano, Tomoyuki; Yasunori, Sohara; Endo, Shunsuke


    Thoracoscopic surgery can be one of less invasive surgical interventions for early stage lung cancer. Locally advanced lung cancer, however, cannot avoid aggressive procedures including pneumonectomy and/or extended combined resection of chest wall, aorta, esophagus, etc. for complete resection. Surgical approach even for advanced lung cancer can be less invasive by benefit from new anti-cancer treatment, innovated manipulations of bronchoplasty and angioplasty, and bench surgery( lung autotransplantation technique). We herein reviewed the strategy to minimize invasive interventions for locally advanced lung cancer, introducing 2 successful cases with advanced lung cancer. The 1st patient is a 62-year old man with centrally advanced lung cancer invading to mediastinum. Right upper sleeve lobectomy with one-stoma carinoplasty following induction chemoradiation therapy was successful. The operation time was 241 minutes. The performance status is good with no recurrence for 60 months after surgery. The 2nd is a 79-year old man with advanced lung cancer invading to the distal aortic arch. Left upper segmentectomy following thoracic endovascular aortic repair with stentgraft was successful with no extracorporeal circulation. The operation time was 170 minutes. The performance status is good with no recurrence for 30 months after surgery. The invasiveness of surgical interventions for local advanced lung cancer can be minimized by innovated device and new anti-cancer drugs.

  9. 三阴乳腺癌研究进展%Research advancement on triple negative breast cancer



    三阴乳腺癌是指雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(Her-2)均不表达的乳腺癌,是乳腺癌的一种特殊亚型,有着特殊的生物学特性和临床病理特征,对内分泌治疗及针对Her-2的靶向药物赫赛汀无效,对化疗敏感,但是远期疗效不佳.三阴乳腺癌的特点,以及治疗方案的选择,是近年研究的热点.%Triple negative breast cancer(TNBC) is defined by the lack of estrogen receptor (ER) , progesterone receptor (PR) and human epidermal growth factor receptor-2 ( Her-2) expression. It is a subtype of tumor with distinct clinical and pathologic features and lacks effective targeted therapies. It is non - sensitive to endocrine therapy and targeted therapy drug herceptin, leaving chemotherapy as the mainstay of treatment The feature and the treatment of TNBC is the hotspot of resent research.

  10. ISAAC Advanced Composites Research Testbed

    Wu, K. Chauncey; Stewart, Brian K.; Martin, Robert A.


    The NASA Langley Research Center is acquiring a state-of-art composites fabrication capability to support the Center's advanced research and technology mission. The system introduced in this paper is named ISAAC (Integrated Structural Assembly of Advanced Composites). The initial operational capability of ISAAC is automated fiber placement, built around a commercial system from Electroimpact, Inc. that consists of a multi-degree of freedom robot platform, a tool changer mechanism, and a purpose-built fiber placement end effector. Examples are presented of the advanced materials, structures, structural concepts, fabrication processes and technology development that may be enabled using the ISAAC system. The fiber placement end effector may be used directly or with appropriate modifications for these studies, or other end effectors with different capabilities may either be bought or developed with NASA's partners in industry and academia.

  11. Global cancer research initiative

    Richard R Love


    Full Text Available Richard R LoveThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USAAbstract: Cancer is an increasing problem for low- and middle-income countries undergoing an epidemiologic transition from dominantly acute communicable disease to more frequent chronic disease with increased public health successes in the former domain. Progress against cancer in high-income countries has been modest and has come at enormous expense. There are several well-conceived global policy and planning initiatives which, with adequate political will, can favorably impact the growing global cancer challenges. Most financial resources for cancer, however, are spent on diagnosis and management of patients with disease in circumstances where specific knowledge about effective approaches is significantly limited, and the majority of interventions, other than surgery, are not cost-effective in resource-limited countries by global standards. In summary, how to intervene effectively on a global scale for the majority of citizens who develop cancer is poorly defined. In contrast to technology-transfer approaches, markedly increased clinical research activities are more likely to benefit cancer sufferers. In these contexts, a global cancer research initiative is proposed, and mechanisms for realizing such an effort are suggested.Keywords: breast cancer, research, global, international, low-income, middle-income

  12. Advanced research in data privacy

    Torra, Vicenç


    This book provides an overview of the research work on data privacy and privacy enhancing technologies carried by the participants of the ARES project. ARES (Advanced Research in Privacy an Security, CSD2007-00004) has been one of the most important research projects funded by the Spanish Government in the fields of computer security and privacy. It is part of the now extinct CONSOLIDER INGENIO 2010 program, a highly competitive program which aimed to advance knowledge and open new research lines among top Spanish research groups. The project started in 2007 and will finish this 2014. Composed by 6 research groups from 6 different institutions, it has gathered an important number of researchers during its lifetime. Among the work produced by the ARES project, one specific work package has been related to privacy. This books gathers works produced by members of the project related to data privacy and privacy enhancing technologies. The presented works not only summarize important research carried in the proje...

  13. Nanotechnology in Cancer Research

    The NCI Office of Cancer Nanotechnology Research has had a major impact on bringing novel nano-enabled solutions through the pre-clinical space. The strategic framework of this effort is presented here.

  14. Profiles in Cancer Research

    These articles put a face to some of the thousands of individuals who contribute to NCI’s cancer research efforts. The profiles highlight the work of scientists and clinicians and describe the circumstances and motivation behind their work.

  15. Surgery for advanced epithelial ovarian cancer.

    Hacker, Neville F; Rao, Archana


    Cytoreductive surgery for patients with advanced epithelial ovarian cancer has been practised since the pioneering work of Tom Griffiths in 1975. Further research has demonstrated the prognostic significance of the extent of metastatic disease pre-operatively, and of complete cytoreduction post-operatively. Patients with advanced epithelial ovarian cancer should be referred to high volume cancer units, and managed by multidisciplinary teams. The role of thoracoscopy and resection of intrathoracic disease is presently investigational. In recent years, there has been increasing use of neoadjuvant chemotherapy and interval cytoreductive surgery in patients with poor performance status, which is usually due to large volume ascites and/or large pleural effusions. Neoadjuvant chemotherapy reduces the post-operative morbidity, but if the tumour responds well to the chemotherapy, the inflammatory response makes the surgery more difficult. Post-operative morbidity is generally tolerable, but increases in older patients, and in those having multiple, aggressive surgical procedures, such as bowel resection or diaphragmatic stripping. Primary cytoreductive surgery should be regarded as the gold standard for most patients until a test is developed which would allow the prediction of platinum resistance pre-operatively.

  16. Extended resection for locally advanced colorectal cancer

    WANG Jian-ping; SONG Xin-ming


    @@ Colorectal cancer is a common cause of cancer-related mortality.1 In China, it is one of eight cancers in the cancer control blueprint, which are suggested to have comprehensive treatment.Some patients with colorectal cancer presented no symptoms when they were diagnosed, yet the tumor had already penetrated the intestinal wall and involved adjacent organs. If the tumor is localized at time of diagnosis without distant metastases, it is termed locally advanced colorectal cancer (LACC)regardless of whether there is lymph node metastasis. LACC commonly encountered in clinical practice accounts for 5%-10% of all colorectal cancers.2

  17. Bioprinting for cancer research.

    Knowlton, Stephanie; Onal, Sevgi; Yu, Chu Hsiang; Zhao, Jean J; Tasoglu, Savas


    Bioprinting offers the ability to create highly complex 3D architectures with living cells. This cutting-edge technique has significantly gained popularity and applicability in several fields. Bioprinting methods have been developed to effectively and rapidly pattern living cells, biological macromolecules, and biomaterials. These technologies hold great potential for applications in cancer research. Bioprinted cancer models represent a significant improvement over previous 2D models by mimicking 3D complexity and facilitating physiologically relevant cell-cell and cell-matrix interactions. Here we review bioprinting methods based on inkjet, microextrusion, and laser technologies and compare 3D cancer models with 2D cancer models. We discuss bioprinted models that mimic the tumor microenvironment, providing a platform for deeper understanding of cancer pathology, anticancer drug screening, and cancer treatment development.

  18. Sipuleucel-T for the treatment of advanced prostate cancer.

    Frohlich, Mark W


    Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.

  19. Recent advances in shoulder research

    Killian, Megan L; Cavinatto, Leonardo; Galatz, Leesa M.; Thomopoulos, Stavros


    Shoulder pathology is a growing concern for the aging population, athletes, and laborers. Shoulder osteoarthritis and rotator cuff disease represent the two most common disorders of the shoulder leading to pain, disability, and degeneration. While research in cartilage regeneration has not yet been translated clinically, the field of shoulder arthroplasty has advanced to the point that joint replacement is an excellent and viable option for a number of pathologic conditions in the shoulder. R...

  20. 晚期癌症病人家庭临终护理的研究进展%Research progress on family palliative care of advanced cancer patients

    朱雅铃; 汪苗


    综述近年来国内外晚期癌症病人家庭护理模式的研究进展,探讨我国开展晚期癌症病人家庭临终护理存在的问题和解决方法,指出未来应着重培养专业的家庭临终医护人员,健全家庭临终护理的模式,从而为病人和家属提供全面、专业的照护与支持;逐步将家庭临终护理加入医保范围,加大对家庭临终护理的政策和财力支持,普及和推广家庭临终护理;加大宣传,帮助人们更新思想观念,关注人的基本权利。%It reviewed the research progress on home care of domestic and foreign advanced cancer patients in recent years.It probe into the existing problems and solutions of family palliative care of advanced cancer pa-tients,and pointed out the future should focus on the training of health care professional family palliative carer, improve the family palliative care model,and then to provide comprehensive and professional care and support for patients and their families;Family palliative care was gradually added into medicare,and the policy and fi-nancial support for family palliative care were increased,to popularize and promote the family palliative care;in-crease publicity and help people to update ideas and concern about the fundamental rights of human.

  1. Research advance in microRNAs and breast cancer.%MicroRNA与乳腺癌研究进展

    卞国奉; 陈爱军


    MicroRNAs (miRNAs) are a major class of small endogenous RNA molecules that post-transcription-ally regulate gene expression. Several miRNAs have been proved to be related to human cancers, including breast cancer. The loss of several tumor suppressor miRNAs and the overexpression of certain oncogenic miRNAs have been observed in breast cancers. Here we describe the relationship of miRNA with the tumorigenesis and metastasis of breast cancer.%MicroRNAs (miRNAs)是一种内源性的小RNA分子,在基因的转录后能调节其表达.许多MicroRNAs被证实与各种肿瘤相关,包括乳腺癌.某些抑癌性MicroRNAs的缺失和致癌性MicroRNAs的过表达已经在许多乳腺癌中被发现.本文就MicroRNAs与乳腺癌发生发展之间的联系以及与一些乳腺癌相关的MicroRNA及其作用作一综述.

  2. Bioenergy research advances and applications

    Gupta, Vijai G; Kubicek, Christian P; Saddler, Jack; Xu, Feng


    Bioenergy Research: Advances and Applications brings biology and engineering together to address the challenges of future energy needs. The book consolidates the most recent research on current technologies, concepts, and commercial developments in various types of widely used biofuels and integrated biorefineries, across the disciplines of biochemistry, biotechnology, phytology, and microbiology. All the chapters in the book are derived from international scientific experts in their respective research areas. They provide you with clear and concise information on both standard and more recent bioenergy production methods, including hydrolysis and microbial fermentation. Chapters are also designed to facilitate early stage researchers, and enables you to easily grasp the concepts, methodologies and application of bioenergy technologies. Each chapter in the book describes the merits and drawbacks of each technology as well as its usefulness. The book provides information on recent approaches to graduates, post...

  3. Advances in stem cell research


    @@In 1998, biologists Thomson and Gearhart successfully derived stem cells from human embryos. One year later, several researchers discovered that adult stem cells still retain the ability to be differentiated into unrelated types of cells. Advances in stem cell research open a promising direction for applied medical science. Moreover, it may also force scientists to reconsider the fundamental theory about how cells grow up. Stem cell research was considered by Science as the top of the ten breakthroughs of science of the year[1]. This paper gives a survey of recent advances in stem cell research. 1 Overview In the 1980s, embryonic stem cell and/or embryonic germ cell line (ES cell line, EG cell line) of multifarious mammalian animals, especially those of non-human pri-mates, had been established. In 1998, Thomson and Shamblott obtained ES, EG cell lines from human blasto-cysts and gonad ridges of early human embryos, respec-tively. Their research brought up an ethical debate about whether human embryos can be used as experimental materials. It was not appeased until 1999 when research-ers discovered that stem cells from adults still retain the ability to become different kinds of tissue cells. For in-stance, brain cells can become blood cells[2], and cells from bone marrow can become cells in liver. Scientists believe, for a long time, that cells can only be developed from early pluripotent embryo cells; the differentiation potential of stem cells from mature tissues is restricted to only one of the cell types of the tissue where stem cells are obtained. Recent stem cell researches, however, sub-verted the traditional view of stem cells. These discoveries made scientists speed ahead with the work on adult stem cells, hoping to discover whether their promise will rival that of ES cells.

  4. Advances on Active Tectonics Research

    Chen Yong; Chen Qifu; Li Juan


    The tectonic movement at human scale has not been fully understood yet, especially for active tectonics, although it is the basis to study natural hazards and environmental variations. Many national and international scientific plans related closely to active tectonics research have been made in the past ten years. This paper briefly summarized the background of the undertaking of active tectonics research, its advances and existing problems, and the key points in its future studies are also pointed out. The emerging of new technologies like the Earth Observing Sys tem, Digital Seismology and so on provides unusual opportunities for tectonic research. It is emphasized, however, that careful analyses and building up of new theoretical frame are sill the key problems for studies of active tectonics, especially for active tectonics in China' s conti nent.

  5. How to research cancer

    ... summaries on pediatric cancer treatment -- American Cancer Society -- . The American Cancer Society (ACS) ...

  6. Advancing musculoskeletal research with nanoscience.

    Brown, Cameron P


    Nanoscience has arrived. Biological applications of nanoscience are particularly prominent and can be useful in a range of disciplines. Advances in nanoscience are underpinning breakthroughs in biomedical research and are beginning to be adopted by the rheumatology and musculoskeletal science communities. Within these fields, nanoscience can be applied to imaging, drug delivery, implant development, regenerative medicine, and the characterization of nanoscale features of cells, matrices and biomaterials. Nanoscience and nanotechnology also provide means by which the interaction of cells with their environment can be studied, thereby increasing the understanding of disease and regenerative processes. Although its potential is clear, nanoscience research tends to be highly technical, generally targeting an audience of physicists, chemists, materials scientists and engineers, and is difficult for a general audience to follow. This Review aims to step back from the most technical aspects of nanoscience and provide a widely accessible view of how it can be applied to advance the field of rheumatology, with an emphasis on technologies that can have an immediate impact on rheumatology and musculoskeletal research.

  7. Research on advanced transportation systems

    Nagai, Hirokazu; Hashimoto, Ryouhei; Nosaka, Masataka; Koyari, Yukio; Yamada, Yoshio; Noda, Keiichirou; Shinohara, Suetsugu; Itou, Tetsuichi; Etou, Takao; Kaneko, Yutaka


    An overview of the researches on advanced space transportation systems is presented. Conceptual study is conducted on fly back boosters with expendable upper stage rocket systems assuming a launch capacity of 30 tons and returning to the launch site by the boosters, and prospect of their feasibility is obtained. Reviews are conducted on subjects as follows: (1) trial production of 10 tons sub scale engines for the purpose of acquiring hardware data and picking up technical problems for full scale 100 tons thrust engines using hydrocarbon fuels; (2) development techniques for advanced liquid propulsion systems from the aspects of development schedule, cost; (3) review of conventional technologies, and common use of component; (4) oxidant switching propulsion systems focusing on feasibility of Liquefied Air Cycle Engine (LACE) and Compressed Air Cycle Engine (CACE); (5) present status of slosh hydrogen manufacturing, storage, and handling; (6) construction of small high speed dynamometer for promoting research on mini pump development; (7) hybrid solid boosters under research all over the world as low-cost and clean propulsion systems; and (8) high performance solid propellant for upper stage and lower stage propulsion systems.

  8. Intermediate/Advanced Research Design and Statistics

    Ploutz-Snyder, Robert


    The purpose of this module is To provide Institutional Researchers (IRs) with an understanding of the principles of advanced research design and the intermediate/advanced statistical procedures consistent with such designs

  9. Advancing Concentrating Solar Power Research (Fact Sheet)


    Researchers at the National Renewable Energy Laboratory (NREL) provide scientific, engineering, and analytical expertise to help advance innovation in concentrating solar power (CSP). This fact sheet summarizes how NREL is advancing CSP research.

  10. Research advancement of lung cancer stem cells%肺癌干细胞的研究进展



    肺癌干细胞(lung cancer stem cell,LCSC)是肺癌组织中一小群具有自我更新及分化潜能,并且具有耐药性的特殊细胞.LCSC是目前肺癌研究中的热点.研究者通过对肺癌中CD133阳性细胞侧群(side population,SP)细胞及耐药存活细胞(drug surviving cell,DSC)的研究,证实了LCSC的存在;而乙醛脱氢酶Ⅰ(aldehyde dehydrogenase 1,ALDH1)、八聚体结合转录因子-4(octamer-binding transcription factor 4,Oct-4)及CD44可能是鉴定LCSC的新标志物.Notch、Wnt及Hedgehog信号通路与LCSC的发生及维持关系密切,靶向组断这些信号通路可以减少肺癌组织中LCSC的比例,可能成为肺癌靶向治疗的新策略.

  11. Lysyl oxidase in cancer research.

    Perryman, Lara; Erler, Janine T


    Metastasis is the main reason for cancer-associated deaths and therapies are desperately needed to target the progression of cancer. Lysyl oxidase (LOX) plays a pivotal role in cancer progression, including metastasis, and is therefore is an attractive therapeutic target. In this review we will breakdown the process of cancer progression and the various roles that LOX plays has in the advancement of cancer. We will highlight why LOX is an exciting therapeutic target for the future.

  12. miRNA与卵巢癌的研究进展%Advances in research of miRNA and ovarian cancer



    MicroRNA(miRNA)constitute a large family of small,approximately 21 to 23 nucleotide-long,non-coding RNA that is a key post-transcriptional regulators of gene expression.By base pairing to mRNA,miRNA mediate translational repression or miRNA degradation.The recent study find that miRNA play an important role in carcinogenesis.Here is a reviews of the research advances of miRNA and ovarian cancer.%微小RNA(micro-RNA,即miRNA)是长约21~23nt的非编码短链RNA,是基因表达的转录后调节因子,通过与靶miRNA特异的碱基配对,引起靶miRNA降解或翻译抑制.近年研究表明miRNA在肿瘤的发生和发展中起着重要作用.

  13. Advances in personalized cancer immunotherapy.

    Kakimi, Kazuhiro; Karasaki, Takahiro; Matsushita, Hirokazu; Sugie, Tomoharu


    There are currently three major approaches to T cell-based cancer immunotherapy, namely, active vaccination, adoptive cell transfer therapy and immune checkpoint blockade. Recently, this latter approach has demonstrated remarkable clinical benefits, putting cancer immunotherapy under the spotlight. Better understanding of the dynamics of anti-tumor immune responses (the "Cancer-Immunity Cycle") is crucial for the further development of this form of treatment. Tumors employ multiple strategies to escape from anti-tumor immunity, some of which result from the selection of cancer cells with immunosuppressive activity by the process of cancer immunoediting. Apart from this selective process, anti-tumor immune responses can also be inhibited in multiple different ways which vary from patient to patient. This implies that cancer immunotherapy must be personalized to (1) identify the rate-limiting steps in any given patient, (2) identify and combine strategies to overcome these hurdles, and (3) proceed with the next round of the "Cancer-Immunity Cycle". Cancer cells have genetic alterations which can provide the immune system with targets by which to recognize and eradicate the tumor. Mutated proteins expressed exclusively in cancer cells and recognizable by the immune system are known as neoantigens. The development of next-generation sequencing technology has made it possible to determine the genetic landscape of human cancer and facilitated the utilization of genomic information to identify such candidate neoantigens in individual cancers. Future immunotherapies will need to be personalized in terms of the identification of both patient-specific immunosuppressive mechanisms and target neoantigens.

  14. Sipuleucel-T: immunotherapy for advanced prostate cancer

    Olson BM


    Full Text Available Brian M Olson, Douglas G McNeelUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USAAbstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.Keywords: sipuleucel-T, prostatic acid phosphatase, granulocyte-macrophage colonystimulating factor

  15. Cancer Biotechnology | Center for Cancer Research

    Biotechnology advances continue to underscore the need to educate NCI fellows in new methodologies. The Cancer Biotechnology course will be held on the NCI-Frederick campus on January 29, 2016 (Bldg. 549, Main Auditorium) and the course will be repeated on the Bethesda campus on February 9, 2016 (Natcher Balcony C). The latest advances in DNA, protein and image analysis will be presented. Clinical and postdoctoral fellows who want to learn about new biotechnology advances are encouraged to attend this course.

  16. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.

    Smithers, B Mark; Thomson, Iain


    In patients with operable esophageal cancer, there is evidence supporting the use of preoperative chemotherapy or preoperative chemoradiation. The addition of radiotherapy to chemotherapy seems more relevant for the more locally advanced cancers. There is a need to examine in trials more modern chemotherapy combinations with and without concurrent radiation and for research into assessing methods for predicting outcomes from neoadjuvant therapy as part of the paradigm of therapy for this disease.

  17. Research and comprehensive cancer control coalitions.

    Vinson, Cynthia; La Porta, Madeline; Todd, William; Palafox, Neal A; Wilson, Katherine M; Fairley, Temeika


    The goal of cancer control research is "to generate basic knowledge about how to monitor and change individual and collective behavior and to ensure that knowledge is translated into practice and policy rapidly, effectively, and efficiently" (Division of Cancer Control and Population Sciences in Cancer control framework and synthese rationale, 2010). Research activities span the cancer control continuum from prevention to early detection and diagnosis through treatment and survivorship (Division of Cancer Control and Population Sciences in Cancer control framework and synthese rationale, 2010). While significant advancements have been made in understanding, preventing and treating cancer in the past few decades, these benefits have yielded disproportionate results in cancer morbidity and mortality across various socioeconomic and racial/ethnic subgroups (Ozols et al in J Clin Oncol, 25(1):146-1622, 2007). It has been a high priority since the beginning of the Comprehensive Cancer Control (CCC) movement to utilize research in the development and implementation of cancer plans in the states, tribes and tribal organizations, territories and US Pacific Island Jurisdictions. Nevertheless, dissemination and implementation of research in coalition activities has been challenging for many programs. Lessons learned from programs and coalitions in the implementation and evaluation of CCC activities, as well as resources provided by national partners, can assist coalitions with the translation of research into practice.

  18. 32 CFR 37.1210 - Advanced research.


    ... 32 National Defense 1 2010-07-01 2010-07-01 false Advanced research. 37.1210 Section 37.1210... research. Research that creates new technology or demonstrates the viability of applying existing technology to new products and processes in a general way. Advanced research is most closely analogous...

  19. Cancer and Radiation Therapy: Current Advances and Future Directions

    Rajamanickam Baskar, Kuo Ann Lee, Richard Yeo, Kheng-Wei Yeoh


    Full Text Available In recent years remarkable progress has been made towards the understanding of proposed hallmarks of cancer development and treatment. However with its increasing incidence, the clinical management of cancer continues to be a challenge for the 21st century. Treatment modalities comprise of radiation therapy, surgery, chemotherapy, immunotherapy and hormonal therapy. Radiation therapy remains an important component of cancer treatment with approximately 50% of all cancer patients receiving radiation therapy during their course of illness; it contributes towards 40% of curative treatment for cancer. The main goal of radiation therapy is to deprive cancer cells of their multiplication (cell division potential. Celebrating a century of advances since Marie Curie won her second Nobel Prize for her research into radium, 2011 has been designated the Year of Radiation therapy in the UK. Over the last 100 years, ongoing advances in the techniques of radiation treatment and progress made in understanding the biology of cancer cell responses to radiation will endeavor to increase the survival and reduce treatment side effects for cancer patients. In this review, principles, application and advances in radiation therapy with their biological end points are discussed.

  20. Palbociclib for Advanced Breast Cancer

    An interim analysis of the PALOMA3 trial shows that women with hormone receptor-positive metastatic breast cancer who received palbociclib plus fulvestrant had longer progression-free survival rates than women who received a placebo plus fulvestrant.

  1. Adjuvant chemotherapy for advanced endometrial cancer.

    Galaal, Khadra; Al Moundhri, Mansour; Bryant, Andrew; Lopes, Alberto D; Lawrie, Theresa A


    research is needed to determine which chemotherapy regimen(s) are the most effective and least toxic, and whether the addition of radiotherapy further improves outcomes. A large trial evaluating the benefits and risks of adjuvant chemoradiation versus chemotherapy in advanced endometrial cancer is ongoing.

  2. Sipuleucel-T: immunotherapy for advanced prostate cancer.

    Olson, Brian M; McNeel, Douglas G


    Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.

  3. Management of patients with advanced prostate cancer

    Gillessen, S; Omlin, A; Attard, G


    The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration......, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed...

  4. Cytogenomics of Feline Cancers: Advances and Opportunities

    Rachael Thomas


    Relative to the dog, integration of the cat into the “One Health” concept has been more restricted, particularly in the field of molecular oncology. Beyond the continual need to enhance the sophistication of feline healthcare per se, the unique spectrum of naturally-occurring cancers in the cat offers tremendous opportunities for comparative and translational advances that may have mutual benefit for human and veterinary medicine. The study of feline cancers additionally may generate new insi...

  5. Strategies for advancing cancer nanomedicine

    Chauhan, Vikash P.; Jain, Rakesh K.


    Cancer nanomedicines approved so far minimize toxicity, but their efficacy is often limited by physiological barriers posed by the tumour microenvironment. Here, we discuss how these barriers can be overcome through innovative nanomedicine design and through creative manipulation of the tumour microenvironment.

  6. Current Research and Management of Ovarian Cancer in China

    GUMeijiao; SHIWei


    Ovarian cancer is ne of the most lethal malignant tumors in China,represents the third most common cancer after cervical cancer and endometrial cancer,and the first leading cause of death from hynaecological cancers.Due to the lack of effective screening strategies and the absence of symptoms in early-stage of disease,over 70% of patients present at an advanced stage.Despite the advances in surgical techniques and conventional chemotheraphy,the prognosis of ovarian cancer has not been improved significantly,and indeed the long-term survival for patients with advanced disease does not exceed 20%.The aetiology of ovarian cancer temains poorly understood.In China,the major focus of research is to clarify the mechanism underlying ovarian cancer,develop more effective life-saving diagnostic and therapeutic measures,and undertake more population-based studies.This article summarizes current research,diagnosis and management of ovarian cancer in China.

  7. Breast cancer. Part 3: advanced cancer and psychological implications.

    Harmer, Victoria

    This is the last article in this 3-part series on breast cancer. The previous two articles have outlined the principles behind breast awareness and breast health, detailing common benign breast diseases, types of breast cancer and staging, and treatment for breast cancer, including surgery, chemotherapy, radiotherapy and endocrine treatment. The series concludes by giving information on advanced disease, including when a patient presents late with a fungating breast lesion, or if the disease has metastasized from the breast to other organs. Lymphoedema is also described and discussed, and the latter half of this article discusses psychological implications of breast cancer, from diagnosis through the individual treatments.

  8. Fostering Cooperation in Cancer Research

    Thursday, June 25, 2015 Memorandum of Understanding (MoU) was signed between US National Cancer Institute and three agencies of the Indian government - the Department of Biotechnology, the Indian Council of Medical Research, and the Indian National Cancer Institute, a part of the All India Institute of Medical Sciences to foster cooperation in cancer research.

  9. Understanding Cancer Prognosis

    Full Text Available ... about Advanced Cancer Research Managing Cancer Care Finding Health Care Services Costs & Medical Information Advance Directives Using ... Cancer Advanced Cancer & Caregivers Managing Cancer Care Finding Health Care Services Managing Costs and Medical Information Advance ...

  10. Understanding Cancer Prognosis

    Full Text Available ... about Advanced Cancer Research Managing Cancer Care Finding Health Care Services Costs & Medical Information Advance Directives Using ... Cancer Advanced Cancer & Caregivers Managing Cancer Care Finding Health Care Services Managing Costs and Medical Information Advance ...

  11. Management of locally advanced prostate cancer

    Heather Payne


    The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines.Despite prostate-specific antigen (PSA) testing,the presentation of prostate cancer at a locally advanced stage is common in the UK,accounting for one-third of all new cases.There is no universally accepted definition of locally advanced prostate cancer;the term is loosely used to encompass a spectrum of disease profiles that show high-risk features.Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated.High-risk patients,including those with locally advanced disease,present two specific challenges.There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression.The optimal treatment approach will therefore often necessitate multiple modalities.The exact combinations,timing and intensity of treatment continue to be strongly debated.Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists,oncologists,radiologists,pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances.This article reviews the current therapy options.

  12. Advancing Service-Learning at Research Universities.

    Furco, Andrew


    Offers three strategies for overcoming the challenges of advancing and institutionalizing service learning at research universities. The strategies address making service learning integral to faculty research, the university mission, and the disciplines. (EV)

  13. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer

    Ratosa Ivica


    Full Text Available Background. To purpose of the study was to analyze the results of preoperative radiochemotherapy in patients with unresectable gastric or locoregionally advanced gastroesophageal junction (GEJ cancer treated at a single institution.

  14. Afatinib in Advanced Refractory Urothelial Cancer


    Distal Urethral Cancer; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Urethral Cancer; Stage III Bladder Cancer; Stage III Urethral Cancer; Stage IV Bladder Cancer; Stage IV Urethral Cancer; Ureter Cancer

  15. Respiratory problems in advanced cancer.

    Ripamonti, Carla; Fusco, Flavio


    Respiratory problems are an important issue in the palliative care setting, not only from a diagnostic and therapeutic point of view but also from emotion-related aspects involving both the patients and their families and also caregivers. In this paper we consider some of the most common respiratory problems, such as dyspnea, infections, hemoptysis, hiccup. A review of the literature was performed with reference to the frequency, diagnosis and management of the above respiratory problems in patients in advanced and terminal stages of the disease. Particular emphasis was given to the importance of communication with the patients and their families, which is considered a crucial point in the care and the cure of such patients.

  16. Clinical Research on Use of Oxaliplcrtin in Combination with HCPT, LV and 5FU in a Regimen for Advanced Gastric Cancer

    GuoqingHu; QiangFu; MaolinJin; JieLi; LiangxiPan; YuxianBai; HuaijinWang; JianweiZhang; DingYu


    OBJECTIVE To observe the effects and adverse reactions of a OXA-HCPT LV/5FU 3 regimen for patients with advanced gastric cancer.METHODS OHLF3 regimen: OXA 130 mg/m2iv d 1, HCPT6 mg/m2, iv d 1-5, LV 200 mg/m2iv 2 h followed by a 5FU 400 mg/m2 iv bolus and 5FU 600mg/m2 iv d 1-3, were given, every 21 days as 1 cycle. Assessment of the tumor was conducted after 3 cycles and the effective cases were confirmed after 4 weeks.RESULTS Among 39 patients, 36 were actually evaluable. Overall response rates (CR + PR} were 50%' the major adverse reactions were mild hematological toxicity, nausea and vomiting and peripheral nerve abnormalities.CONCLUSION The OHLF 3 regimen using OXA and HCPT is effective and results in mild toxicity when used in combined chemotherapy for advanced gastric cancer.

  17. Important drugs for cough in advanced cancer.

    Homsi, J; Walsh, D; Nelson, K A


    Cough is a defense mechanism that prevents the entry of noxious materials into the respiratory system and clears foreign materials and excess secretions from the lungs and respiratory tract. In advanced cancer, it is a common symptom that interferes with the patient's daily activity and quality of life. Empiric treatment with antitussive agents is often needed. Two classes of antitussive drugs are available: (1) centrally acting: (a) opioids and (b) non-opioids; (2) peripherally acting: (a) directly and (b) indirectly. Antitussive availability varies widely around the world. Many antitussives, such as benzonatate, codeine, hydrocodone, and dextromethorphan, were extensively studied in the acute and chronic cough settings and showed relatively high efficacy and safety profiles. Benzonatate, clobutinol, dihydrocodeine, hydrocodone, and levodropropizine were the only antitussives specifically studied in cancer and advanced cancer cough. They all have shown to be effective and safe in recommended daily dose for cough. In advanced cancer the patient's current medications, previous antitussive use, the availability of routes of administration, any history of drug abuse, the presence of other symptoms and other factors, all have a role in the selection of antitussives for prescription. A good knowledge of the pharmacokinetics, dosage, efficacy, and side effects of the available antitussives provides for better management.

  18. Prostate Cancer Stem-Like Cells | Center for Cancer Research

    Prostate cancer is the third leading cause of cancer-related death among men, killing an estimated 27,000 men each year in the United States. Men with advanced prostate cancer often become resistant to conventional therapies. Many researchers speculate that the emergence of resistance is due to the presence of cancer stem cells, which are believed to be a small subpopulation of tumor cells that can self-renew and give rise to more differentiated tumor cells. It is thought that these stem cells survive initial therapies (such as chemotherapy and hormone therapy) and then generate new tumor cells that are resistant to these standard treatments. If prostate cancer stem cells could be identified and characterized, it might be possible to design treatments that prevent resistance.

  19. Advanced research reactor fuel development

    Kim, Chang Kyu; Pak, H. D.; Kim, K. H. [and others


    The fabrication technology of the U{sub 3}Si fuel dispersed in aluminum for the localization of HANARO driver fuel has been launches. The increase of production yield of LEU metal, the establishment of measurement method of homogeneity, and electron beam welding process were performed. Irradiation test under normal operation condition, had been carried out and any clues of the fuel assembly breakdown was not detected. The 2nd test fuel assembly has been irradiated at HANARO reactor since 17th June 1999. The quality assurance system has been re-established and the eddy current test technique has been developed. The irradiation test for U{sub 3}Si{sub 2} dispersed fuels at HANARO reactor has been carried out in order to compare the in-pile performance of between the two types of U{sub 3}Si{sub 2} fuels, prepared by both the atomization and comminution processes. KAERI has also conducted all safety-related works such as the design and the fabrication of irradiation rig, the analysis of irradiation behavior, thermal hydraulic characteristics, stress analysis for irradiation rig, and thermal analysis fuel plate, for the mini-plate prepared by international research cooperation being irradiated safely at HANARO. Pressure drop test, vibration test and endurance test were performed. The characterization on powders of U-(5.4 {approx} 10 wt%) Mo alloy depending on Mo content prepared by rotating disk centrifugal atomization process was carried out in order to investigate the phase stability of the atomized U-Mo alloy system. The {gamma}-U phase stability and the thermal compatibility of atomized U-16at.%Mo and U-14at.%Mo-2at.%X(: Ru, Os) dispersion fuel meats at an elevated temperature have been investigated. The volume increases of U-Mo compatibility specimens were almost the same as or smaller than those of U{sub 3}Si{sub 2}. However the atomized alloy fuel exhibited a better irradiation performance than the comminuted alloy. The RERTR-3 irradiation test of nano

  20. 宫颈癌治疗性疫苗研究进展%Advances in the research of therapeutic vaccines against cervical cancer

    邓玲; 刘金辉; 施桥发


    宫颈癌为妇女最常见的恶性肿瘤之一,其与人乳头瘤病毒(human papillomavirus,HPV)感染密切相关.随着对HPV及其致病机理研究的深入和免疫学的发展,利用免疫学方法治疗HPV引发的疾病显示良好的前景.目前,有关HPV治疗性疫苗的研究已取得较大进展,这些疫苗包括病毒/细菌载体疫苗、肽疫苗、蛋白疫苗、DNA疫苗、细胞疫苗等.此文就HPV治疗性疫苗的研究进展做一综述.%Cervical cancer, one of the most common cancers in women, is closely associated with human papillomavirus (HPV) infection.Along with development of immunology as well as study on HPV and its pathogenic mechanism, the treatment of HPV-related diseases by immunological methods has showed excellent prospect.Great advances in therapeutic vaccines-including viral and bacterial vector vaccines, peptide and protein vaccines, nucleic acid or DNA vaccines, and cell-based vaccines- against cervical cancer have been achieved in recent years.The progress in study on therapeutic vaccines against HPV is reviewed in this paper.

  1. New Advances in Brain Research.

    Seita, Lori Perkins


    Recent findings in brain research suggest the implementation of contemporary instructional practices is in order for base practices. Incorporating best practice research is critical for students to be competitive in a global market. This article provides a brief overview of educational philosophy, recent findings on brain research and language…


    Maura Gabriela FELEA


    Full Text Available Negative emotions (distress are recognized as part of the psychological profile of patients diagnosed with advanced stage cancer. However, most patients are not accustomed to verbalize feelings towards their physician, and generally towards family and medical care personnel. The purpose of this paper is to analyze the expression of emotions by patients in advanced stages of cancer, respectively the means by which they get to express emotions. To this respect, we identified the most common types of emotions expressed, or metaphors used by patients to describe their emotions and topics that trigger emotions. Words and phrases most commonly used are in relation to: fear, anxiety, depression, guilt, negligence, concern. They are uttered in order to depict the network created between disclosed emotions and topics on health status, symptoms, adverse effects and therapeutic choice, patient privacy, and social and family issues.

  3. Advanced strategies in liposomal cancer therapy

    Andresen, Thomas Lars; Jensen, Simon Skøde; Jørgensen, Kent


    , none of them have yet led to marketed drugs and are still far from achieving this goal. The most advanced and prospective technologies are probably the prodrug strategies where nontoxic drugs are carried and activated specifically in the malignant tissue by overexpressed enzymes. In the second part......Tumor specific drug delivery has become increasingly interesting in cancer therapy, as the use of chemotherapeutics is often limited due to severe side effects. Conventional drug delivery systems have shown low efficiency and a continuous search for more advanced drug delivery principles...... is therefore of great importance. In the first part of this review, we present current strategies in the drug delivery field, focusing on site-specific triggered drug release from liposomes in cancerous tissue. Currently marketed drug delivery systems lack the ability to actively release the carried drug...

  4. Technological advances in radiotherapy for esophageal cancer

    Milan; Vosmik; Jiri; Petera; Igor; Sirak; Miroslav; Hodek; Petr; Paluska; Jiri; Dolezal; Marcela; Kopacova


    Radiotherapy with concurrent chemotherapy and surgery represent the main treatment modalities in esophageal cancer.The goal of modern radiotherapy approaches,based on recent technological advances,is to minimize post-treatment complications by improving the gross tumor volume definition (positron emission tomography-based planning),reducing interfraction motion (image-guided radiotherapy) and intrafraction motion (respiratory-gated radiotherapy),and by better dose delivery to the precisely defined planning ...

  5. Optimal cytoreduction for advanced epithelial ovarian cancer

    N. G. Kormosh


    Full Text Available This article is review of literature on role of surgery in the initial management of advanced stage ovarian cancer, focusing on the definition of optimum surgical cytoreduction, assessment of resectability, estimation of the risk of postoperative complications. Analyze of published scien- tific data suggest that removal of all evidence of macroscopic disease should be the goal of primary or interval cytoreductive surgery.

  6. 微小RNA在胰腺癌中的研究进展%Research Advancement of MicroRNA on Pancreatic Cancer

    姚汝铖; 郑军; 邢荣春


    Objective To summarize the domestic and abroad articles related to the research on the relation between microRNA (miRNA) and pancreatic cancer, and explore the important effects of miRNA expression patterns in diagnosis of pancreatic cancer. Methods "microRNA and pancreatic cancer" were searched as key words by PubMed and CNKI series full-text database retrieval systems from 2000 to 2012. Totally 60 English papers and 15 Chinese papers were obtained. Choice criteria: the basic research of miRNA and pancreatic cancer, the clinical research of miRNA and pancreatic cancer, and the prospect of miRNA in pancreatic cancer diagnosis and treatment. According to the choice criteria, 31 papers were finally analyzed. Results The miRNA expression spectrum and specific miRNA expression such as miR-21, miR-34, miR-217, miR-196a, miR-l0a, miR-155, miR-221, miR-222, miR-181a, miR-181b, miR-181d, and the family members of miR-200 and let-7 might be used as rumor markers to differentiate pancreatic cancer from normal pancreas, chronic pancreatitis or pancreatic endocrine tumors, and might be used as prognostic factor to predict the outcome. Conclusions miRNA expression spectrum are not only related to diagnosis of pancreatic cancer, but also have provided a new research direction and method for gene therapy of pancreatic cancer.%目的 总结微小RNA (microRNA,miRNA)与胰腺癌之间关系的研究现状,探讨其表达谱在胰腺癌诊断中的重要作用.方法 应用PubMed及CNKI期刊全文数据库检索系统,以“microRNA、胰腺癌”等为关键词,检索2000~2012年的相关文献,共检索到英文文献60篇和中文文献15篇.纳入标准为:miRNA与胰腺癌的基础与临床研究以及miRNA在胰腺癌诊治中的前景.根据纳入标准,纳入31篇文献.结果 研究发现,miRNA表达谱如miR-21、miR-34、miR-217、miR-196a、miR- 10a、miR-155、miR-221、miR-222、miR-181a、miR-181b、miR-181d、miR-200、let-7等家族成员可作为肿瘤标志物

  7. Understanding Cancer Prognosis

    Full Text Available ... Information Advance Directives Using Trusted Resources Cancer Types Adolescents and Young Adults with Cancer Reports, Research, and ... of Cancers Cancers by Body Location Childhood Cancers Adolescent & Young Adult Cancers Metastatic Cancer Recurrent Cancer Research ...

  8. Understanding Cancer Prognosis

    Full Text Available ... Information Advance Directives Using Trusted Resources Cancer Types Adolescents and Young Adults with Cancer Reports, Research, and ... of Cancers Cancers by Body Location Childhood Cancers Adolescent & Young Adult Cancers Metastatic Cancer Recurrent Cancer Research ...

  9. Locally advanced rectal cancer: management challenges

    Kokelaar RF


    Full Text Available RF Kokelaar, MD Evans, M Davies, DA Harris, J Beynon Department of Colorectal Surgery, Singleton Hospital, Swansea, UK Abstract: Between 5% and 10% of patients with rectal cancer present with locally advanced rectal cancer (LARC, and 10% of rectal cancers recur after surgery, of which half are limited to locoregional disease only (locally recurrent rectal cancer. Exenterative surgery offers the best long-term outcomes for patients with LARC and locally recurrent rectal cancer so long as a complete (R0 resection is achieved. Accurate preoperative multimodal staging is crucial in assessing the potential operability of advanced rectal tumors, and resectability may be enhanced with neoadjuvant therapies. Unfortunately, surgical options are limited when the tumor involves the lateral pelvic sidewall or high sacrum due to the technical challenges of achieving histological clearance, and must be balanced against the high morbidity associated with resection of the bony pelvis and significant lymphovascular structures. This group of patients is usually treated palliatively and subsequently survival is poor, which has led surgeons to seek innovative new solutions, as well as revisit previously discarded radical approaches. A small number of centers are pioneering new techniques for resection of beyond-total mesorectal excision tumors, including en bloc resections of the sciatic notch and composite resections of the first two sacral vertebrae. Despite limited experience, these new techniques offer the potential for radical treatment of previously inoperable tumors. This narrative review sets out the challenges facing the management of LARCs and discusses evolving management options. Keywords: rectal cancer, exenteration, pelvic sidewall, sacrectomy

  10. Bringing Advanced Computational Techniques to Energy Research

    Mitchell, Julie C


    Please find attached our final technical report for the BACTER Institute award. BACTER was created as a graduate and postdoctoral training program for the advancement of computational biology applied to questions of relevance to bioenergy research.

  11. Advances and Implications in Nanotechnology for Lung Cancer Management.

    Sarkar, Sana; Osama, Khwaja; Jamal, Qazi Mohammad Sajid; Kamal, Mohammad Amjad; Sayeed, Usman; Khan, M Kalim A; Siddiqui, Mohd Haris; Akhtar, Salman


    Lung cancer is one of the most important chronic diseases in the field of respiratory medicine. Conventional treatment strategies for lung cancer include chemotherapy, surgery and radiation therapy. These current therapies lack specificity and are limited by undesirable toxicities in normal cells, as well as a high rate of recurrence.Nanotechnological intervention has greatly revolutionized the therapy of lung cancer by surmounting the current limitations in conventional therapies. Nanoparticles (NPs) achieve preferential accumulation in the tumor cells by employing two mechanisms: passive and active targeting. Several nanoscale drug delivery systems for lung cancer treatment are currently in clinical trials and few of them are already commercially available. Recently, the interest to develop pulmonary delivery system of nano-based drug formulations suitable for lung cancer has been also increased which have resulted in more effective and advanced treatment of Lung cancer. However, although nanotechnology based drug carriers for lung cancer treatment have established outstanding therapeutic potential at both preclinical and clinical Phases, but there are still many limitations to be solved. This review details the till date drug nanocarriers researches performed for lung cancer therapy.

  12. Lipoxygenase metabolism and lung cancer:research advances%脂氧合酶代谢与肺癌研究进展

    杨玉花; 魏晓莉; 郑建全


    脂氧合酶(LOX)是非血红素铁双加氧酶,能催化底物生成各种类花生酸物质,在肺癌预防和治疗中发挥重要作用,有望成为新的抗肺癌药物作用靶点.根据氧分子插入底物的位点不同,人类LOX主要分为5-LOX、12-LOX和15-LOX,5-LOX和12-LOX具有促进肺癌细胞生长和肿瘤转移的作用,而15-LOX的两种亚型15-LOX-1和15-LOX-2主要具有抗肺癌的作用.本文主要综述了各种LOX代谢通路在肺癌发生发展中的作用特点.此外,还介绍了LOX依赖氧化应激、过氧化物酶体增殖物活化受体和P53的抗肺癌机制及其作为肺癌药物作用靶点的研究进展.%Lipoxygenases constitute a family of non-heme iron dioxygenases that catalize substrates to generate various biologically active eicosanoids. Their roles in chemoprevention and treatment of lung cancer in recent years have become a hot research spot and lipoxygenases have the potential to become a new action spots of anti-lung cancer drugs. The human lipoxygenases are classified into 5-, 12-, and 15-lipoxygenase according to the positional specificity of the introduction of molecular oxygen in the substrates. 5-, and 12-lipoxygenases have the effects of promoting lung cancer cell growth and metastasis, but 15-lipoxygenase-l and -2 (two isoforms of 15-lipoxygenase) possess the anti-lung cancer effect. In this review we focus on action features of lipoxygenase pathways in lung cancers and introduce the anti-lung cancer mechanisms of lipoxygenase pathways by oxidative stress, peroxisome proliferator-activated receptors and P53, as well as their prospects as lung cancer pharmacology targets.

  13. Research in Danish cancer rehabilitation

    Høybye, Mette Terp; Dalton, Susanne Oksbjerg; Christensen, Jane


    Worldwide, the number of cancer survivors is increasing, owing to improvements in cancer therapy, resulting in an increased need to address the physical and mental sequelae of cancer. This paper introduces a Danish psychosocial cancer intervention and presents the baseline characteristics...... of the cancer survivors with respect to cancer site, sociodemographic variables, social network, lifestyle, self-rated health and the prevalence of cancer-related late effects. The study is part of the FOCARE research project, in which the long-term effects of the rehabilitation programme are evaluated...... systematically. The study is based on data from a self-administered baseline questionnaire filled in by 2 174 cancer survivors who registered for a 1-week, publicly paid rehabilitation retreat and were invited to participate in the FOCARE study in the period 25 November 2002 to 31 December 2005. The response...

  14. Current concepts in cancer research

    Ivan Kok Seng Yap


    Full Text Available Cancer research is an extremely broadtopic covering many scientific disciplines includingbiology (e.g. biochemistry and signal transduction,chemistry (e.g. drug discover and development,physics (e.g. diagnostic devices and even computerscience (e.g. bioinformatics. Some would argue thatcancer research will continue in much the same wayas it is by adding further layers of complexity to thescientific knowledge that is already complex and almostbeyond measure. But we anticipate that cancer researchwill undergo a dramatic paradigm shift due to therecent explosion of new discoveries in cancer biology.This review article focuses on the latest horizons incancer research concerning cancer epigenetics, cancerstem cells, cancer immunology and cancer metabolism.

  15. Nontraditional machining processes research advances


    Nontraditional machining employs processes that remove material by various methods involving thermal, electrical, chemical and mechanical energy or even combinations of these. Nontraditional Machining Processes covers recent research and development in techniques and processes which focus on achieving high accuracies and good surface finishes, parts machined without burrs or residual stresses especially with materials that cannot be machined by conventional methods. With applications to the automotive, aircraft and mould and die industries, Nontraditional Machining Processes explores different aspects and processes through dedicated chapters. The seven chapters explore recent research into a range of topics including laser assisted manufacturing, abrasive water jet milling and hybrid processes. Students and researchers will find the practical examples and new processes useful for both reference and for developing further processes. Industry professionals and materials engineers will also find Nontraditional M...

  16. Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer

    WANG Xiao-yan; ZHOU Er-xi


    Objective:To explore the significance of epidermal growth factor receptor (EGFR) gene mutations in targeted therapy for patients with advanced non-small cell lung cancer (NSCLC). Methods:One hundred and seventeen patients with advanced NSCLC admitted in Maternal and Child Health Care Center of Zibo City from Jan., 2011 to Jan., 2014 were performed with EGFR gene detection and then divided into 3 groups according to the detecting results. Patients in group A and group B were given oral geiftinib, 250 mg/d while patients in Group C with docetaxel, 75 mg/m2. Chemotherapy for 3 groups was discontinued until severe adverse reactions or disease progression occurred, or continuous treatment was considered to be unfavorable by the doctors, or patients asked for withdrawal from the study. The relationship between clinicopathological features and EGFR mutations were analyzed. The short-term and long-term efifcacy and adverse reactions of 3 groups were observed. Results:Of the 31 cases with EGFR mutations, there were 16 cases (51.6%) of mutations in exon 19, 14 (45.2%) in exon 21 and 2 (6.45%) in exon 18. No EGFR mutation was found in exon 20. EGFR mutations were associated with histological types of tumors and whether patients were smoking. The median follow-up time was 26 months and 62 patients were dead. None of CR was in 3 groups. The disease control rate (DCR) in group A was obviously higher than that in group B (χ2=9.382,P=0.002), which was also higher in group C than that in group B (χ2=4.674,P=0.031). The 1-year survival rate in group A was obviously higher than that in group B and group C (P Conclusion:EGFR mutations are the main indicators for guiding the targeted therapy for patients with advanced NSCLC.

  17. Advances in Qualitative Research about Psychosocial Experiences of Breast Cancer%乳腺癌心理体验质性研究进展

    李艳敏; 齐玉龙; 朱宁宁


    This article reviewed 119 qualitative research reporters about the psychosocial experiences of breast cancer from CNKI and Pubmed databases( Jan. 2000 to Dec. 2010). There was no significant distinction in the ages of the study objects, but there was obvious difference in the study object, methods, angle and depth in these references. There was a difference in emphasis on the psychosocial experiences between domestic papers and international papers;the domestic researches were almost the single research :the object focused on breast cancer patients himself, the main methods were phenomenological research, the angle foeused on clinical phase,the depth was limited to research on the influencing factors;while the abroad qualitative researches of breast cancer mental experience were much more diversified :the sample covers from the breast cancer patients to the families of the patients and the ordinary person, the research methods was from the simple qualitative research to the combination of the qualitative research and quantitative research, the research angle much more focused on the aspects of the social and cultural, the study in depth was from the influencing factors to the interfere study.%本文分析了2000~2010年中国知网、Pubmed上与乳腺癌有关的心理体验的质性研究119篇,发现这些文献在调查对象的年龄选取上无明显差异,但在研究对象、研究方法、研究角度、研究深度上有较大差别,且国内外研究侧重点不同,国内乳腺癌心理体验的质性研究较单一:研究对象主要侧重于乳腺癌患者本人,研究方法主要为质性研究中的现象学方法,研究角度侧重于临床阶段,研究深度上仅限于影响因素研究;国外乳腺癌心理体验的质性研究较为多样化:研究对象从乳腺癌患者延伸到乳腺癌患者家属及一般人群,研究方法从单纯的质性研究到质性研究与量性研究相结合,研究角度更侧重于从社会、文化等方面

  18. Advanced Construction Technology Center Research


    M.S., Ceramic Engineering, May 1989 RESEARCH ASSISTANTS: 1 J.M. Bukowski Ph.D., Ceramic Engineering, August 1993* Hung-Yuan Hsieh M.S., Civil...Parallel Processing (St. Charles , IL, August 1988) 204-211 (1988). 97 U LO, T.M. Data modeling of three-dimensional objects. M.S. thesis, J. Liu, advisor U

  19. Research advances in industrial engineering


    This book provides discussions and the exchange of information on principles, strategies, models, techniques, methodologies and applications of industrial engineering. It communicates the latest developments and research activity on industrial engineering and is useful for all those interested in the technological challenges in the field.

  20. Advances in Translational Medical Research


    Reviewed Orthopaedic Spinal Cord Injury Research Program 1996 1997 1999 2007 2011 MHS Conference Scope of CDMRP Funds and Awards 4 Proposals Received...of many NF1- and NF2-associated tumors:  Plexiform Neurofibroma  Malignant Peripheral Nerve Sheath Tumor  Glioma  Meningioma  Myeloid

  1. Advances in developmental prosopagnosia research.

    Susilo, Tirta; Duchaine, Bradley


    Developmental prosopagnosia (DP) refers to face recognition deficits in the absence of brain damage. DP affects ∼2% of the population, and it often runs in families. DP studies have made considerable progress in identifying the cognitive and neural characteristics of the disorder. A key challenge is to develop a valid taxonomy of DP that will facilitate many aspects of research.




    The activities of the AGTSR Program during this reporting period are described in this quarterly report. The report text is divided into discussions on Membership, Administration, Technology Transfer (Workshop/Education) and Research. Items worthy of note are highlighted below with additional detail following in the text of the report.

  3. Cytogenomics of Feline Cancers: Advances and Opportunities

    Rachael Thomas


    Full Text Available Relative to the dog, integration of the cat into the “One Health” concept has been more restricted, particularly in the field of molecular oncology. Beyond the continual need to enhance the sophistication of feline healthcare per se, the unique spectrum of naturally-occurring cancers in the cat offers tremendous opportunities for comparative and translational advances that may have mutual benefit for human and veterinary medicine. The study of feline cancers additionally may generate new insight into underexplored aspects of tumor biology that are less accessible in other species, such as the relationship between chronic inflammation and neoplasia, and the role of viruses in malignant transformation. Several factors that have hindered molecular studies of feline cancers have now been surmounted, with the most fundamental step forward coming from the development of a high-quality reference genome sequence assembly for the cat. This article reviews landmark studies that have led to our current appreciation of feline genome architecture, and outlines techniques used in cancer cytogenomics, from conventional karyotyping analysis through to the development of genomic microarrays and beyond. A summary of progress in the identification and characterization of chromosomal aberrations in feline cancers is provided using examples from studies of injection-site sarcomas, lymphomas and mammary tumors.

  4. Advances in Activity Cliff Research.

    Dimova, Dilyana; Bajorath, Jürgen


    Activity cliffs, i.e. similar compounds with large potency differences, are of interest from a chemical and informatics viewpoint; as a source of structure-activity relationship information, for compound optimization, and activity prediction. Herein, recent highlights of activity cliff research are discussed including studies that have further extended our understanding of activity cliffs, yielded unprecedented insights, or paved the way for practical applications.

  5. PIVKA-II-producing advanced gastric cancer.

    Takano, Shigetsugu; Honda, Ichiro; Watanabe, Satoshi; Soda, Hiroaki; Nagata, Matsuo; Hoshino, Isamu; Takenouchi, Toshinao; Miyazaki, Masaru


    We describe the case of a 68-year-old man with primary advanced adenocarcinoma of the stomach, who displayed extremely high plasma levels of protein induced by vitamin K antagonist (PIVKA)-II (15 600 mAU/ml) and normal levels of alphafetoprotein (AFP) (4 ng/ml). Ultrasonography and dynamic computed tomography ruled out hepatocellular carcinoma (HCC) or liver metastasis. After preoperative chemotherapy, pancreatico-spleno total gastrectomy with D2 lymphadenectomy was performed. Postoperatively, plasma levels of PIVKA-II returned to within the normal range (29 mAU/ml). Microscopic examination revealed stomach adenocarcinoma showing various histological types, such as moderately to poorly differentiated mucinous adenocarcinoma, but hepatoid differentiation of gastric adenocarcinoma was not detected. Localization of PIVKA-II and AFP within tumor cells was demonstrated by immunohistochemical staining using monoclonal antibodies. These results indicate that tumor cells from gastric cancer may produce PIVKA-II. Some cases of PIVKA-II- and AFP-producing advanced gastric cancer with liver metastasis have been reported, but this is the first report of gastric cancer without liver metastasis producing PIVKA-II alone.

  6. Treatment of locally advanced prostatic cancer

    Marušić Goran


    Full Text Available Introduction. A locally advanced prostate cancer is defined as a malignant process spreading beyond the prostate capsule or in seminal vesicles but without distant metastasis or regional lymph nodes invasion. Clinical classification, prediction and treatment of prostate cancer. An exact staging of clinical T3 stadium is usually difficult because of the frequent over and under staging. The risk prognostic stratification is performed through nomograms and ANN (artificial neural networks. The options for treatment are: radical prostatectomy, external radiotherapy and interstitial implantation of radioisotopes, hormonal therapy by androgen blockade. Radical prostatectomy is considered in patients with T3 stage but extensive dissection of lymph nodes, dissection of neurovascular bundle (on tumor side, total removal of seminal vesicle and sometimes resection of bladder neck are obligatory. Postoperative radiotherapy is performed in patients with invasion of seminal vesicles and capsular penetration or with prostate specific antigen value over 0.1 ng/ml, one month after the surgical treatment. Definitive radiotherapy could be used as the best treatment option considering clinical stage, Gleason score, age, starting prostate specific antigen (PSA value, concomitant diseases, life expectancy, quality of life, through multidisciplinary approach (combined with androgen deprivation. Hormonal therapy in intended for patients who are not eligible for surgical treatment or radiotherapy. Conclusion. Management of locally advanced prostate cancer is still controversial and studies for better diagnosis and new treatment modalities are ongoing.

  7. [Research advancement about lactose intolerance].

    Yu, Qing; Yin, Shi-An


    Lactose intolerance associated with nutrition and health of human especially infant period of time and effect milk product intake. It is important significance to maintain health and cut down the aged risk of osteoporosis because lactose intolerance was understand about grouping, clinical symptom and diagnose. There are extensive perspective for understand prevent and control lactose intolerance for lactose gene polymorphism. It is effective method for earlier period detection gene screen with lactose typing for osteoporosis, however there are carry out multiplicity research in many ways to improve and control lactose intolerance

  8. [Research advances in porcine bocavirus].

    Zhai, Shao-Lun; Chen, Sheng-Nan; Wei, Wen-Kang


    Porcine bocavirus (PBoV) was considered as a new member of the genus Bocavirus of the subfamily Parvovirinae of the family Parvoviridae, which was discovered in Swedish swine herds with postweaning multisystemic wasting syndrome (PMWS) in 2009. At present, as an emerging pathogen, it was paid great attention by researchers at home and abroad. This paper referred to some published literatures and reviewed several aspects of PBoV including its finding, classification, genome structure and replication, epidemiology, associativity with diseases, cultural and diagnostic methods.

  9. Navigating the evolving therapeutic landscape in advanced prostate cancer.

    Crawford, E David; Petrylak, Daniel; Sartor, Oliver


    Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year. The overall 5-year survival rate for prostate cancer is very high. Up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop castration-resistant prostate cancer (CRPC) within 5 years, with median survival for those with metastatic CRPC ranging from approximately 15 to 36 months in recent studies. With the advent of several new drugs in the past 5 years to treat CRPC, the challenge facing clinicians is how to best sequence or combine therapies or both to optimize outcomes. A better understanding of the disease process and the role of the androgen receptor as a target for both therapy and resistance have led to the consideration of biomarkers as an approach to aid in selecting the appropriate agent for a given patient as patients respond to or tolerate different drugs differently. Research to identify new prognostic biomarkers, which are associated with outcome measures, as well as predictive biomarkers, which predict response or resistance to therapy is ongoing. The treatment of advanced prostate cancer and the research related to biomarkers are discussed.

  10. Advanced prostate cancer: Every Voice Matters.

    Payne, Heather; Westcott, Gemma


    Heather Payne speaks to Gemma Westcott, Commissioning Editor: Heather Payne was appointed as a consultant in Clinical Oncology at University College Hospital (London, UK) in 1997. Following her training at St Mary's Hospital London Medical School and after qualifying, she spent time working in general medicine in both London and Haiti. Currently, she specializes in the management of urological malignancies, and is actively involved in clinical research as well as being the principal investigator in a number of international multicenter and local studies. She enjoys helping patients with quality of life and decision-making issues with regard to their treatment options. In addition, she is the chairman of the British Uro-oncology Group, and is a member of the Department of Health Prostate Cancer Advisory Group. Further to this, she is a trustee of the Prostate Cancer Research Centre and clinical lead for the National Prostate Cancer Audit.

  11. [Advances of molecular targeted therapy in squamous cell lung cancer].

    Ma, Li; Zhang, Shucai


    Squamous cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lung adenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, the discoidin domain receptor 2 (DDR2) gene mutation as potential novel targets for the treatment of SQCLCs. Researchers find that there are many specific molecular targeted genes in the genome of squamous-cell lung cancer patients. These changes play a vital role in cell cycle regulation, oxidative stress, cell apoptosis, squamous epithelium differentiation, may be the candidate targeted moleculars in SQCLCs. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lung cancer assessing the value of novel therapeutics addressing these targets.

  12. 蛋白激酶B与乳腺癌的最新研究进展%The latest research advances in protein kinase B and breast cancer

    张超; 孙治君


    丝氨酸/苏氨酸蛋白激酶即蛋白激酶B(protein kinase B,PKB/Akt)是细胞内最重要的激酶之一,它能够通过接受整合多种细胞外信号产生多种生物学效应,包括对细胞增殖、迁徙、生长、周期、能量代谢、死亡等多方面的影响.Akt在乳腺癌发展过程中的作用成为研究热点.现就近两年来Akt与乳腺癌的重要研究成果予以综述.%The protein serine/threonine kinase Akt, also known as protein kinase B ( PKB ), is one of the most important kinases in cell. Akt integrates a plethora of extracellular signals to generate diverse outcomes, including proliferation, motility, growth, cell cycle, glucose homeostasis, and cell death. What is the role of Akt in the breast cancer has become a research focus. In this review, we will show the most important and latest research about Akt with breast cancer.

  13. 进展期胃癌腹腔镜淋巴结清扫的研究进展%Research progress of laparoscopic-assisted lymphadenectomy in patients with advanced gastric cancer



    The diagnosis rate of early gastric cancer in China is low,most patients seeing the doctor are already in advanced period.Lymphadenectomy is the key factor affecting the tumor treatment and prognosis.With the depth of the research on tumor immunology,the function of lymph nodes in tumor immunity has been gradually paid more and more attention.The role of lymphadenectomy according to the rule of the lymph nodes metastasis has become the research point of the radical gastrectomy.Gastrectomy with D2 lymphadenectomy is the standard surgical treatment for advanced cancer.Laparoscopic-assisted gastrectomy with D3 lymphadenectomy is also in active exploring.In this article,the application of laparoscopy in advanced gastric cancer of current status,near-term efficacy,long-term outcome and complications are reviewed.%中国早期胃癌诊断率低,大部分患者就诊时已处于进展期.随着肿瘤免疫学研究的深入,淋巴结在肿瘤免疫中的作用逐渐受到重视.根据淋巴结转移规律进行淋巴结清扫已成为胃癌根治术研究的重点.D2根治术是治疗进展期胃癌的标准术式,而腹腔镜下D3根治术目前亦在积极探索之中.就腹腔镜在进展期胃癌淋巴结清扫应用中的现状、近期和远期疗效等进行综述.

  14. 肿瘤干细胞与滑膜肉瘤相关研究进展%Research advances related with cancer stem cells and synovial sarcoma

    刘爱国; 谷文光


    Cancer stem cells (CSCs) are identified and characterized as a unique stem cell in many types of cancer. Although there is no consensus regarding CSCs phenotype from different tumor types, CSCs from different cancers share a primitive undifferentiated nature. Current CSCs studies have provided many new insights into the complexities of cancer therapy: tumor initiation, self-renewal, multi-potential differentiation, high tumorigenicity, resistance to therapy and prediction of clinical course. There are 3 possible methodologies to isolate or identify cancer stem cells: the use of a magnetic activated cell sorting (MACS), flowcytometry (FCM) identifying, or the measurement of aldehyde dehydrogenase (ALDH). The novel promising therapies against cancer stem cells are considered, including targeting signal transduction pathways, surface molecular markers as well as differentiation-inducing therapy. Synovial sarcoma (SS) is a malignant soft tissue tumor characterized by its unique chromosomal translocation leading to the formation of the SS18-SSX fusion gene. However, the cellular origin of SS is highly debated. It has established 2 novel human SS cell lines, named Yamato-SS and Aska-SS. Their biological properties were investigated and the self-renewal ability of these cells to generate sarcospheres was found. SS traditionally has been considered to have a poor prognosis, however, not all SS shares the same dismal outcome. Additonally, cytogenetics has proven that certain molecular genetic features are related to the course of the disease and thus may be used as a prognostic indicator. Although primary therapy is predicated on surgical resection with an adequate margin and maximal preservation of function, adjuvant radiation and/or chemotherapy may be beneficial, particularly in high risk patients, whereas adjuvant chemotherapy, for localized respectable SS in adults. In this review, we discuss the current evidence regarding the identification and microenvironmental

  15. American Institute for Cancer Research

    ... About Cancer By Cancer Site What Is Cancer Foods That Fight Cancer Tools You Can Use Cancer Infographics & Multimedia Studying ... About Cancer By Cancer Site What Is Cancer Foods That Fight Cancer Tools You Can Use Cancer Infographics & Multimedia Studying ...

  16. Traditional machining processes research advances


    This book collects several examples of research in machining processes. Chapter 1 provides information on polycrystalline diamond tool material and its emerging applications. Chapter 2 is dedicated to the analysis of orthogonal cutting experiments using diamond-coated tools with force and temperature measurements. Chapter 3 describes the estimation of cutting forces and tool wear using modified mechanistic models in high performance turning. Chapter 4 contains information on cutting under gas shields for industrial applications. Chapter 5 is dedicated to the machinability of magnesium and its alloys. Chapter 6 provides information on grinding science. Finally, chapter 7 is dedicated to flexible integration of shape and functional modelling of machine tool spindles in a design framework.    

  17. Understanding Cancer Prognosis

    Full Text Available ... Caregivers Questions to Ask about Advanced Cancer Research Managing Cancer Care Finding Health Care Services Costs & Medical ... Feelings Planning for Advanced Cancer Advanced Cancer & Caregivers Managing Cancer Care Finding Health Care Services Managing Costs ...

  18. Advanced Merkel cell cancer and the elderly.

    Bird, B R


    BACKGROUND: Merkel cell cancer (MCC) is an uncommon neuroendocrine skin cancer occurring predominantly in elderly Caucasians. It tends to metastasize to regional lymph nodes and viscera and is sensitive to chemotherapy but recurs rapidly. AIM: To report one such case, its response to chemotherapy and briefly review the literature. METHODS: A 73-year-old male with a fungating primary lesion on his left knee and ulcerated inguinal lymph nodes was diagnosed with MCC and treated with chemotherapy. The two largest case series and reviews of case reports were summarised. RESULTS: His ulcer healed after two cycles of carboplatin and etoposide with improvement in quality of life. Overall response rates of nearly 60% to chemotherapy are reported but median survival is only nine months with metastatic disease. CONCLUSIONS: Chemotherapy should be considered for fit elderly patients with MCC who have recurrent or advanced disease.

  19. Advances in Radiotherapy Management of Esophageal Cancer

    Verma, Vivek; Moreno, Amy C.; Lin, Steven H.


    Radiation therapy (RT) as part of multidisciplinary oncologic care has been marked by profound advancements over the past decades. As part of multimodality therapy for esophageal cancer (EC), a prime goal of RT is to minimize not only treatment toxicities, but also postoperative complications and hospitalizations. Herein, discussion commences with the historical approaches to treating EC, including seminal trials supporting multimodality therapy. Subsequently, the impact of RT techniques, including three-dimensional conformal RT, intensity-modulated RT, and proton beam therapy, is examined through available data. We further discuss existing data and the potential for further development in the future, with an appraisal of the future outlook of technological advancements of RT for EC. PMID:27775643

  20. Concurrent radiochemotherapy in advanced hypopharyngeal cancer

    Lukarski Dusko


    Full Text Available Abstract Background Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer. Methods A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week. In dependence of the period when radiotherapy was realized, two different treatment techniques were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m2 given on a weekly basis. Results The median age was 52 years (range 29-70. Stage IV disease was recognized in 73.2% of the patients. Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively. A complete composite response was present in 27 patients (65.9%. Median follow-up was 13 months (range 7-36. Distant metastases as initial failure occurred in 7 patients (46.7%. The 2-year local relapse-free survival and regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The median weight loss at the end of treatment was 12% (range 5-21. The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue. Conclusions Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy

  1. Prostate Cancer Research Training Program


    evaluate medication safety. Examples of HERCe research include recent publications on breast cancer treatments, complications of chemotherapy for...with specific interest in minimally invasive procedures, new techniques, and outcomes. Dr. Brown initiated many of the laparoscopic and robotic ... surgery as it is one of the main areas of his clinical expertise. Currently, he performs more prostate cancer surgery than any other physician in

  2. Research advances of treatment planning of thermal ablation for liver cancer%肝癌热消融治疗规划的研究进展

    刘方义; 梁萍


    随着热消融技术的发展,热消融技术已成为肝癌根治性方法之一.术前治疗规划作为整个消融治疗过程的第一步,其核心目的是在并发症较低的前提下,保证消融后有安全的无瘤边缘,提高患者中长期生存率.术前治疗规划的好坏直接决定着术后疗效的优劣,对提高热消融治疗的科学性及准确性具有重要意义.因此,肝癌热消融治疗规划问题亦成为热消融领域研究热点之一.本文就近年来国内外关于影像引导下肝癌热消融治疗规划研究进展进行了综述.%With the development of thermal ablation techniques,thermal ablation has been a curative method in the treatment of liver cancer.Preoperative treatment planning as the first step in the thermal ablation process,its core purpose is to lower the complications,ensure tumor-free safety margin after ablation and improve patients' long-term survival.Preoperative treatment planning determines directly the effect of thermal ablation therapy.Preoperative treatment planning is significant to improve the accuracy and sci entific of thermal ablation therapy.Therefore,preoperative treatment planning of thermal ablation for liver cancer has become one of the research focuses in the thermal ablation fields.This review focuses on the treatment planning studies of image-guided thermal ablation for liver cancer in recent years.

  3. The research of dying emotional experience of patients with advanced cancer%晚期癌症患者临终情感体验的研究

    向克兰; 王青丽; 赵凤; 彭翠香; 吕晓玲


    目的 探索和理解晚期癌症患者面l临死亡时内心世界的情感体验,以及他们在治疗护理过程中的真实心理感受.方法 用立意取样法取13例晚期癌症患者,运用深入访谈法收集资料,用Colaizzi法对采集资料进行分析.结果 找出与本研究相关的3个主题:①疾病本身带来的痛苦感受:癌痛无法控制的感受;对治疗护理丧失信心、缺乏舒适的感受.②对死亡态度的体验与感受:对死亡恐惧的感受;对死亡迫近的感受;心理落差的感受;心理负担的感受;被迫接受的感受.③情感支持的需求:情感支持的感受;寻找一种解脱的方式.结论 应重视患者的主观感受,用爱心去倾听,以共情去感受;临终患者需要临终关怀和有效的情感支持;临终患者需要对癌痛及癌痛控制方法的认知.帮助其提高舒适度,适时进行死亡教育.%Objective To explore and understand patients with advanced cancer faced with the death of the inner worid of emotional experience,as well as their real psychological feelings in the process of the treatment and nursing Methods To use purposive sampling method from 13 cases of patients with advanced cancer,using in-depth interviews with data collection,and Colaizzi method of collecting data for analysis.Results To identify related to our three themes:①the pain caused by the disease itself:the feeling of pain can not control;loss of confidence on the curative care;lack of a comfortable feeling.②experience on attitudes toward death and feelings:the feelings of fear of death;the feeling of imminent death;mind the feelings of difference;mind the feelings of burden;forcing to accept the feelings.③emotional support demands:the feeling of emotional support;looking for a free way.Conclusions We should attach importance to the subjective feeling of love,uge love to listen,to feel empathy;dying patients need hospice and effective emotional support;and they need for pain and cancer pain

  4. Multidimensional fatigue and its correlates in hospitalised advanced cancer patients.

    Echteld, M.A.; Passchier, J.; Teunissen, S.; Claessen, S.; Wit, R. de; Rijt, C.C.D. van der


    Although fatigue is a multidimensional concept, multidimensional fatigue is rarely investigated in hospitalised cancer patients. We determined the levels and correlates of multidimensional fatigue in 100 advanced cancer patients admitted for symptom control. Fatigue dimensions were general fatigue (

  5. What's New in Thyroid Cancer Research and Treatment?

    ... Thyroid Cancer About Thyroid Cancer What’s New in Thyroid Cancer Research and Treatment? Important research into thyroid cancer ... in Thyroid Cancer Research and Treatment? More In Thyroid Cancer About Thyroid Cancer Causes, Risk Factors, and Prevention ...

  6. What's New in Testicular Cancer Research and Treatment?

    ... Testicular Cancer About Testicular Cancer What’s New in Testicular Cancer Research and Treatment? Important research into testicular cancer ... in Testicular Cancer Research and Treatment? More In Testicular Cancer About Testicular Cancer Causes, Risk Factors, and Prevention ...

  7. Mouse models for cancer research

    Wei Zhang; Lynette Moore; Ping Ji


    Mouse models of cancer enable researchers to leamn about tumor biology in complicated and dynamic physiological systems. Since the development of gene targeting in mice, cancer biologists have been among the most frequent users of transgenic mouse models, which have dramatically increased knowledge about how cancers form and grow. The Chinese Joumnal of Cancer will publish a series of papers reporting the use of mouse models in studying genetic events in cancer cases. This editorial is an overview of the development and applications of mouse models of cancer and directs the reader to upcoming papers describing the use of these models to be published in coming issues, beginning with three articles in the current issue.

  8. Novel therapy for advanced gastric cancer

    Yue; Zhang; Shenhong; Wu


    Gastric cancer(GC) is a common lethal malignancy.Gastroesophageal junction and gastric cardia tumors are the fastest rising malignancies due to increasing prevalence of obesity and acid reflex in the United States.Traditional chemotherapy remains the main treatment with trastuzumab targeting human epidermal growth factor receptor 2 positive disease.The median overall survival(OS) is less than one year for advanced GC patients; thus,there is an urgent unmet need to develop novel therapy for GC.Although multiple targeted agents were studied,only the vascular endothelial growth factor receptor inhibitor ramucirumab was approved recently by the United States Food and Drug Administration because of its 1.4 mo OS benefit(5.2 mo vs 3.8 mo,P = 0.047) as a single agent; 2.2 mo improvement of survival(9.6 mo vs 7.4 mo,P = 0.017) when combined with paclitaxel in previously treated advanced GC patients.It is the first single agent approved for previously treated GC and the second biologic agent after trastuzumab.Even with limited success,targeted therapy may be improved by developing new biomarkers.Immune therapy is changing the paradigm of cancer treatment and is presently under active investigation for GC in clinical trials.More evidence supports GC stem cells existence and early stage studies are looking for its potential therapeutic possibilities.

  9. Palbociclib and Letrozole in Advanced Breast Cancer.

    Finn, Richard S; Martin, Miguel; Rugo, Hope S; Jones, Stephen; Im, Seock-Ah; Gelmon, Karen; Harbeck, Nadia; Lipatov, Oleg N; Walshe, Janice M; Moulder, Stacy; Gauthier, Eric; Lu, Dongrui R; Randolph, Sophia; Diéras, Véronique; Slamon, Dennis J


    Background A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. Methods In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. Results The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; PPfizer; PALOMA-2 number, NCT01740427 .).

  10. Proteomics in Pancreatic Cancer Research

    Ruihui Geng


    Full Text Available Pancreatic cancer is a highly aggressive malignancy with a poor prognosis and deeply affects the life of people. Therefore, the earlier diagnosis and better treatments are urgently needed. In recent years, the proteomic technologies are well established and growing rapidly and have been widely applied in clinical applications, especially in pancreatic cancer research. In this paper, we attempt to discuss the development of current proteomic technologies and the application of proteomics to the field of pancreatic cancer research. This will explore the potential perspective in revealing pathogenesis, making the diagnosis earlier and treatment.

  11. Nebraska Prostate Cancer Research Program


    Annual National Symposium on Prostate Cancer by CCRTD, CAU, March 16-19, 2014. 15. Appendix #15: Peer- reviewed scientific publication with inputs...and  Immunology Y. Tu CU Regulation of G‐Protein‐Coupled  Receptors in Prostate  Cancer     Acknowledgements: DOD CDMRP PCa Research Program PC121645...AWARD NUMBER: W81XWH-13-1-0264 TITLE: Nebraska Prostate Cancer Research Program PRINCIPAL INVESTIGATOR: Ming-Fong Lin, Ph.D

  12. Research progresses of targeted therapy on advanced non-small cell lung cancer%晚期非小细胞肺癌靶向治疗研究进展

    孙虎; 张俊萍


    肺癌恶性程度高,是目前发病率和死亡率居首位的恶性肿瘤,其中非小细胞肺癌约占肺癌的80%~85%,且多数患者在确诊时已属晚期。随着对肿瘤发病机制及其生物学行为研究的不断深入,以特异性高、不良反应轻为特点的分子靶向治疗成为目前关注的焦点,如针对 EGFR、KRAS及EML4-ALK融合基因等常见突变基因的靶向治疗。但是由于基因检测技术、组织标本获取困难等多种原因,致使大约70%以上的晚期非小细胞肺癌患者不能够接受基因靶向治疗,本文就晚期非小细胞肺癌靶向治疗进行综述。%Lung cancer is high malignant, with the most morbidity and mortality currently, including non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of lung cancer, and most patients are diagnosed at advanced stage. With the deepening research of tumor pathogenesis and biological behavior, molecular targeted therapy characterized by highspecificity and mild adverse reactions has become the focus of current concern, such as the therapy targeted at EGFR, KRAS, and EML4-ALK fusion genes mutations. However, due to genetic testing, tissue samples and other difficulties, resulting in over about 70% of advanced NSCLC patients can not accept targeted gene therapy. This article reviewed the targeted therapy of advanced NSCLC.

  13. Advancements in radiotherapy for lung cancer in China

    Lujun Zhao; Luhua Wang


    Lung cancer is the leading cause of death due to cancer in China. In recent years, great progress has been made in radiotherapy for lung cancer patients in China. The main advance-ments include the fol owing aspects:(1) stereotactic ablative radiotherapy for early stage non-smal cel lung cancer (NSCLC), (2) post-operative radiotherapy for NSCLC, (3) combined chemotherapy and radiotherapy for local y advanced NSCLC, (4) improved radiotherapy for advanced NSCLC, and 5) prediction of radiation-induced lung toxicity.

  14. Advances in structure research by diffraction methods

    Brill, R


    Advances in Structure Research by Diffraction Methods reviews advances in the use of diffraction methods in structure research. Topics covered include the dynamical theory of X-ray diffraction, with emphasis on Ewald waves in theory and experiment; dynamical theory of electron diffraction; small angle scattering; and molecular packing. This book is comprised of four chapters and begins with an overview of the dynamical theory of X-ray diffraction, especially in terms of how it explains all the absorption and propagation properties of X-rays at the Bragg setting in a perfect crystal. The next

  15. Beyond competence: advance directives in dementia research.

    Jongsma, Karin Rolanda; van de Vathorst, Suzanne


    Dementia is highly prevalent and incurable. The participation of dementia patients in clinical research is indispensable if we want to find an effective treatment for dementia. However, one of the primary challenges in dementia research is the patients' gradual loss of the capacity to consent. Patients with dementia are characterized by the fact that, at an earlier stage of their life, they were able to give their consent to participation in research. Therefore, the phase when patients are still competent to decide offers a valuable opportunity to authorize research, by using an advance research directive (ARD). Yet, the use of ARDs as an authorization for research participation remains controversial. In this paper we discuss the role of autonomous decision-making and the protection of incompetent research subjects. We will show why ARDs are a morally defensible basis for the inclusion of this population in biomedical research and that the use of ARDs is compatible with the protection of incompetent research subjects.

  16. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

    Bible, Keith C; Ryder, Mabel


    Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid cancer (MTC), and two agents (sorafenib and lenvatinib) for the treatment of radioactive- iodine refractory differentiated thyroid cancer (DTC) in both the USA and in the EU. The effects of these and other therapies on overall survival and quality of life among patients with thyroid cancer, however, remain to be more-clearly defined. When applied early in the disease course, intensive multimodality therapy seems to improve the survival outcomes of patients with anaplastic thyroid cancer (ATC), but salvage therapies for ATC are of uncertain benefit. Additional innovative, rationally designed therapeutic strategies are under active development both for patients with DTC and for patients with ATC, with multiple phase II and phase III randomized clinical trials currently ongoing. Continued effort is being made to identify further signalling pathways with potential therapeutic relevance in thyroid cancers, as well as to elaborate on the complex interactions between signalling pathways, with the intention of translating these discoveries into effective and personalized therapies. Herein, we summarize the progress made in molecular medicine for advanced-stage thyroid cancers of different histotypes, analyse how these developments have altered - and might further refine - patient care, and identify open questions for future research.

  17. Recent advances in the development of breast cancer vaccines

    Milani A


    Full Text Available Andrea Milani,1 Dario Sangiolo,1 Massimo Aglietta,1,2 Giorgio Valabrega1,2 1Department of Oncology, University of Torino, Torino, Italy; 2FPO, Candiolo Cancer Institute, IRCCS, Torino, Italy Abstract: The manipulation of the immune system through the administration of a vaccine to direct an effective and long-lasting immune response against breast cancer (BC cells is an attractive strategy. Vaccines would have several theoretical advantages over standard therapies, including low toxicities, high specificity, and long-lasting efficacy due to the establishment of immunological memory. However, BC vaccines have failed to demonstrate meaningful results in clinical trials so far. This reflects the intrinsic difficulty in breaking the complex immune-escaping mechanisms developed by cancer cells. New vaccines should be able to elicit complex immunologic response involving multiple immune effectors such as cytotoxic and antibody-secreting B cells, innate immunity effectors, and memory cells. Moreover, especially in patients with large tumor burdens and metastatic disease, combining vaccines with other strategies, such as systemic BC therapies, passive immunotherapy, or immunomodulatory agents, could increase the effectiveness of each approach. Here, we review recent advances in BC vaccines, focusing on suitable targets and innovative strategies. We report results of most recent trials investigating active immunotherapy in BC and provide possible future perspectives in this field of research. Keywords: breast cancer, cancer vaccines, cancer immunology, HER2, MUC-1, hTERT

  18. Advances of Molecular Targeted Therapy in Squamous Cell Lung Cancer

    Li MA


    Full Text Available Squamous cell lung cancer (SQCLC is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR inhibitors or anaplastic lymphoma kinase (ALK inhibitors that show exquisite activity in lungadenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 (FGFR1 gene, the discoidin domain receptor 2 (DDR2 gene mutation as potential novel targets for the treatment of SQCLCs. Researchers find that there are many specific molecular targeted genes in the genome of squamous-cell lung cancer patients. These changes play a vital role in cell cycle regulation, oxidative stress, cell apoptosis, squamous epithelium differentiation, may be the candidate targeted moleculars in SQCLCs. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lungcancer assessing the value of novel therapeutics addressing these targets.

  19. Preoperative chemoradiotherapy for locally advanced gastric cancer

    Pepek Joseph M


    Full Text Available Abstract Background To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT for gastric cancer. Methods Patients with gastroesophageal (GE junction (Siewert type II and III or gastric adenocarcinoma who underwent neoadjuvant CRT followed by planned surgical resection at Duke University between 1987 and 2009 were reviewed. Overall survival (OS, local control (LC and disease-free survival (DFS were estimated using the Kaplan-Meier method. Toxicity was graded according to the Common Toxicity Criteria for Adverse Events version 4.0. Results Forty-eight patients were included. Most (73% had proximal (GE junction, cardia and fundus tumors. Median radiation therapy dose was 45 Gy. All patients received concurrent chemotherapy. Thirty-six patients (75% underwent surgery. Pathologic complete response and R0 resection rates were 19% and 86%, respectively. Thirty-day surgical mortality was 6%. At 42 months median follow-up, 3-year actuarial OS was 40%. For patients undergoing surgery, 3-year OS, LC and DFS were 50%, 73% and 41%, respectively. Conclusions Preoperative CRT for gastric cancer is well tolerated with acceptable rates of perioperative morbidity and mortality. In this patient cohort with primarily advanced disease, OS, LC and DFS rates in resected patients are comparable to similarly staged, adjuvantly treated patients in randomized trials. Further study comparing neoadjuvant CRT to standard treatment approaches for gastric cancer is indicated.

  20. NATO Advanced Research Workshop on Molecular Engineering for Advanced Materials

    Schaumburg, Kjeld


    An important aspect of molecular engineering is the `property directed' synthesis of large molecules and molecular assemblies. Synthetic expertise has advanced to a state which allows the assembly of supramolecules containing thousands of atoms using a `construction kit' of molecular building blocks. Expansion in the field is driven by the appearance of new building blocks and by an improved understanding of the rules for joining them in the design of nanometer-sized devices. Another aspect is the transition from supramolecules to materials. At present no single molecule (however large) has been demonstrated to function as a device, but this appears to be only a matter of time. In all of this research, which has a strongly multidisciplinary character, both existing and yet to be developed analytical techniques are and will remain indispensable. All this and more is discussed in Molecular Engineering for Advanced Materials, which provides a masterly and up to date summary of one of the most challenging researc...

  1. Understanding Cancer Prognosis

    Full Text Available ... about Advanced Cancer Research Managing Cancer Care Finding Health Care Services Costs & Medical Information Advance Directives Using Trusted Resources Understanding Cancer What ...

  2. Breast Cancer Research Program


    tion of tumor cells with red indicating the highest density of tumor cells at the primary tumor (4th mammary fat pad ) and purple/blue showing the...Idea Award Elaine Hardman and Philippe Georgel “ Maternal Consumption of Omega 3 Fatty Acids to Reduce Breast Cancer Risk in Offspring” FY09

  3. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

    Burstein, Harold J; Krilov, Lada; Aragon-Ching, Jeanny B; Baxter, Nancy N; Chiorean, E Gabriela; Chow, Warren Allen; De Groot, John Frederick; Devine, Steven Michael; DuBois, Steven G; El-Deiry, Wafik S; Epstein, Andrew S; Heymach, John; Jones, Joshua Adam; Mayer, Deborah K; Miksad, Rebecca A; Pennell, Nathan A; Sabel, Michael S; Schilsky, Richard L; Schuchter, Lynn Mara; Tung, Nadine; Winkfield, Karen Marie; Wirth, Lori J; Dizon, Don S


    A MESSAGE FROM ASCO'S PRESIDENT I am pleased to present Clinical Cancer Advances 2017, which highlights the most promising advances in patient-oriented cancer research over the past year. The report gives us an opportunity to reflect on what an exciting time it is for cancer research and how swiftly our understanding of cancer has improved. One year ago, the White House announced the national Cancer Moonshot program to accelerate progress against cancer. This shared vision of progress has reinvigorated the research community, identified new areas of scientific collaboration, and raised our ambitions regarding what may be possible beyond the progress we have already made. When I entered the field 35 years ago, I could not have imagined where we would be today. We can now detect cancer earlier, target treatments more effectively, and manage adverse effects more effectively to enable patients to live better, more fulfilling lives. Today, two of three people with cancer live at least 5 years after diagnosis, up from roughly one of two in the 1970s. This progress has resulted from decades of incremental advances that have collectively expanded our understanding of the molecular underpinnings of cancer. There is no better current example of this than ASCO's 2017 Advance of the Year: Immunotherapy 2.0. Over the last year, there has been a wave of new successes with immunotherapy. Research has proven this approach can be effective against a wide range of hard-to-treat advanced cancers previously considered intractable. Researchers are now working to identify biologic markers that can help increase the effectiveness of treatment and determine who is most likely to benefit from immunotherapy. This knowledge will enable oncologists to make evidence-based decisions so as many patients as possible might benefit from this new type of treatment. Each successive advance builds on the previous hard work of generations of basic, translational, and clinical cancer researchers

  4. Progress in diagnosis of breast cancer: Advances in radiology technology

    J Mari Beth Linder


    Full Text Available Breast cancer is the leading cause of cancer in females between the ages of 15 and 54, and the second leading cause of cancer death in women in the United States. Diagnosis begins with detection by breast examination (clinical breast exam or breast self-exam or by radiologic studies, like mammography. Many advances in the diagnosis of breast cancer have taken place in recent years. This article will review the history of radiologic advances in the diagnosis of breast cancer. Use of technological advancements in digital breast tomosynthesis, magnetic resonance imaging, and ultrasound in breast cancer diagnosis will be presented. Advantages and disadvantages of these diagnostic interventions when compared to older, traditional X-ray films will be discussed. It is important for all nurses, including radiology and oncology nurses, to be well informed about these varied diagnostic modalities, and appreciate the fact that advances in radiologic imaging technologies can yield improved outcomes for breast cancer patients.

  5. [Advancement of research on polyamidoamine dendrimers].

    Xu, Jing; Zhang, Longzhen


    Polyamidoamine (PAMAM) dendrimers is synthesized by the American scientist, Tomalia, in 1985 and is now used widely in many fields such as gene carriers, photoelectric sensor, wastewater treatment, drug carriers and catalyst. The present paper mainly reviews the structure and methods of synthesis, celluar cytotoxicity, achievements of gene and drug carriers research, advancement and prospect of PAMAM as a carrier in glioma therapy. Besides, it also involves an outline for the future research of the radiotherapy for glioma.

  6. Advances in virus research. Volume 31

    Maramorosch, K.; Murphy, F.A.; Shatkin, A.J.


    This book presents topics in virus research and advances made in this field. Topics covered include: ambisense RNA genomes of arenaviruses and phleboviruses; the molecular basis of antigenic variation in influenza virus; epitope mapping of flavivirus glycoproteins; regulation of adenovirus mRNA formation; regulation of protein synthesis in virus infected animal cells; and antibody-dependent enhancement of vira infectivity.

  7. Gaps in nutritional research among older adults with cancer.

    Presley, Carolyn J; Dotan, Efrat; Soto-Perez-de-Celis, Enrique; Jatoi, Aminah; Mohile, Supriya G; Won, Elizabeth; Alibhai, Shabbir; Kilari, Deepak; Harrison, Robert; Klepin, Heidi D; Wildes, Tanya M; Mustian, Karen; Demark-Wahnefried, Wendy


    Nutritional issues among older adults with cancer are an understudied area of research despite significant prognostic implications for treatment side effects, cancer-specific mortality, and overall survival. In May of 2015, the National Cancer Institute and the National Institute on Aging co-sponsored a conference focused on future directions in geriatric oncology research. Nutritional research among older adults with cancer was highlighted as a major area of concern as most nutritional cancer research has been conducted among younger adults, with limited evidence to guide the care of nutritional issues among older adults with cancer. Cancer diagnoses among older adults are increasing, and the care of the older adult with cancer is complicated due to multimorbidity, heterogeneous functional status, polypharmacy, deficits in cognitive and mental health, and several other non-cancer factors. Due to this complexity, nutritional needs are dynamic, multifaceted, and dependent on the clinical scenario. This manuscript outlines the proceedings of this conference including knowledge gaps and recommendations for future nutritional research among older adults with cancer. Three common clinical scenarios encountered by oncologists include (1) weight loss during anti-cancer therapy, (2) malnutrition during advanced disease, and (3) obesity during survivorship. In this manuscript, we provide a brief overview of relevant cancer literature within these three areas, knowledge gaps that exist, and recommendations for future research.

  8. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

    M.E.L. van der Burg (Maria); M. van Lent; M. Buyse; A. Kobierska; N. Colombo; G. Favalli; A.J. Lacave; M. Nardi; J. Renard; S. Pecorelli (Sergio)


    textabstractBACKGROUND. Although the value of primary cytoreductive surgery for epithelial ovarian cancer is beyond doubt, the value of debulking surgery after induction chemotherapy has not yet been defined. In this randomized study we investigated the effect on surviv

  9. International Cancer Proteogenome Consortium | Office of Cancer Clinical Proteomics Research

    The International Cancer Proteogenome Consortium (ICPC), is a voluntary scientific organization that provides a forum for collaboration among some of the world's leading cancer and proteogenomic research centers.

  10. Advanced heat pump research and development

    Kuliasha, M. A.

    The Office of Building Energy Research and Development of the U.S. Department of Energy (DOE), has been funding R&D in advanced heat pumps and appliances since 1976. Much of that research has been managed for DOE by the Oak Ridge National Laboratory (ORNL). The objective of the Building Equipment Research (BER) program at ORNL has been to generate new concepts and develop a technology base for improving the energy efficiency and load characteristics of energy conversion equipment used in residential and commercial buildings. The research being pursued to achieve these objectives falls under three general areas: thermally activated heat pumps (TAHP), refrigeration systems, and building equipment systems. The TAHP work is concentrated on three technologies: (1) absorption heat pumps; (2) Stirling engine-driven heat pumps; and (3) internal combustion (IC) engine-driven heat pumps. Major project areas in refrigeration systems research include electric heat pumps, ground-coupled heat pumps, and refigerant mixtures. In the building equipment systems areas, project areas include advanced distribution systems, advanced insulation for appliances, and commercial building equipment.

  11. Predictors of cervical cancer being at an advanced stage at diagnosis in Sudan

    Ibrahim, Ahmed; Rasch, Vibeke; Pukkala, Eero


    of this cancer, but other factors potentially associated with advanced stages of cervical cancer at diagnosis are unknown. The purpose of this research was to investigate the relationship between age, marital status, ethnicity, health insurance coverage, residence in an urban vs a rural setting, and stage (at...

  12. Palliative Care Improves Survival, Quality of Life in Advanced Lung Cancer | Division of Cancer Prevention

    Results from the first randomized clinical trial of its kind have revealed a surprising and welcome benefit of early palliative care for patients with advanced lung cancer—longer median survival. Although several researchers said that the finding needs to be confirmed in other trials of patients with other cancer types, they were cautiously optimistic that the trial results could influence oncologists’ perceptions and use of palliative care. |

  13. Advances in structure research by diffraction methods

    Hoppe, W


    Advances in Structure Research by Diffraction Methods: Volume 5 presents discussions on application of diffraction methods in structure research. The book provides the aspects of structure research using various diffraction methods. The text contains 2 chapters. Chapter 1 reviews the general theory and experimental methods used in the study of all types of amorphous solid, by both X-ray and neutron diffraction, and the detailed bibliography of work on inorganic glasses. The second chapter discusses electron diffraction, one of the major methods of determining the structures of molecules in the

  14. Laparoscopic cytoreduction for primary advanced ovarian cancer.

    Fanning, James; Hojat, Rod; Johnson, Jil; Fenton, Bradford


    We evaluated the feasibility of laparoscopic cytoreduction for primary advanced ovarian cancer. All patients with presumed stage 3/4 primary ovarian cancer underwent attempted laparoscopic cytoreduction. All patients had CT evidence of omental metastasis and ascites. A 5-port (5-mm) transperitoneal approach was used. A bilateral salpingo-oophorectomy, supracervical hysterectomy, and omentectomy were performed with PlasmaKinetic (PK) cutting forceps. A laparoscopic 5-mm Argon-Beam Coagulator was used to coagulate tumor in the pelvis, abdominal peritoneum, intestinal mesentery, and diaphragm. Nine of 11 cases (82%) were successfully debulked laparoscopically without conversion to laparotomy. Median operative time was 2.5 hours, and median blood loss was 275 mL. All tumors were debulked to <2 cm and 45% had no residual disease. Stages were 1-3B, 7-3C, and 1-4. Median length of stay was one day. Median VAS pain score was 4 (discomforting). Two of 11 patients (18%) had postoperative complications. Laparoscopic cytoreduction was successful and resulted in minimal morbidity. Because of our small sample size, additional studies are needed.

  15. 胃癌靶向治疗的研究现状与进展%Research status quo and progression in targeted therapy for advanced gastric cancer

    冯睿; 张小田; 杨升


    随着对胃癌增殖生长与侵袭转移等恶性生物学行为机制研究深入,靶向治疗已成为胃癌领域研究热点。目前靶向药物研究的热门信号通路包括人类表皮生长因子受体(HER)家族信号通路、血管内皮生长因子(VEGF)信号通路、磷脂酰肌醇3激酶-蛋白激酶/哺乳动物雷帕霉素靶蛋白(PI3K/mTOR)信号通路和NF-κB信号通路等。HER家族信号通路相关靶向药物,包括针对HER-1的西妥昔单抗、尼妥珠单抗、马妥珠单抗、帕尼单抗和厄洛替尼,针对HER-2的曲妥珠单抗、帕妥珠单抗和 T-DM1,以及针对HER家族多靶点的拉帕替尼和阿法替尼。 VEGF信号通路相关靶向药物包括针对VEGF的贝伐珠单抗,抗VEGFR的雷莫芦单抗、阿帕替尼、索拉非尼、舒尼替尼及西地尼布,以及重组融合蛋白阿柏西普。此外,在胃癌治疗中具有潜力的PI3K/mTOR信号通路相关靶向药物包括LY294002、BEZ235和依维莫司,而硼替佐米为现有研究较多抑制NF-κB信号通路靶向药物。目前胃癌分子靶向治疗领域完成的Ⅲ期药物临床试验且成功的分子靶向药物主要有曲妥珠单抗、雷莫芦单抗及阿帕替尼。未来研究方向应关注针对多靶点的药物或应用针对不同靶点的药物联合治疗胃癌。本文收集国内外近期相关研究和临床试验报道,对胃癌靶向治疗的现状和进展做简要综述。%With the deeper research of the proliferation, invasion and metastasis mechanisms of the gastric cancer , targeted therapy has become a hot spot in this field. The exploration of targeted agents for gastric cancer is mainly concentrated upon the drugs that target human epidermal growth factor receptor (HER) family, the vascular endothelial growth factor (VEGF), the phosphatidylinositol 3-kinase-protein kinase/mammalian target of rapamycin (PI3K/mTOR) and the NF-κB signaling pathways. The targeted drugs relevant to

  16. 前列腺癌干细胞相关肿瘤标志物的研究进展*%Advanced research on prostate cancer stem cell-related tumor markers

    郝玉美(综述); 刘谦(综述); 宋娜玲(审校)


    前列腺癌(prostate cancer,PCa)是男性常见的恶性肿瘤。内分泌治疗是晚期前列腺癌的主要治疗方法,但该方法易使其发展成为激素难治性前列腺癌,且暂无切实有效的治疗方法。近年来的研究发现,前列腺癌干细胞在前列腺癌的发生、发展和转移中起着关键作用,因此前列腺癌干细胞的靶向治疗可能是根治前列腺癌的有效途径。靶向前列腺癌干细胞治疗需首先明确前列腺癌干细胞标志物,尤其是其特异标志物,才能更好地开展前列腺癌根治方案的研究。目前前列腺癌干细胞标志物的研究主要集中于CD44和CD133,但随着研究的不断深入其开始受到质疑,且发现了更多新的标志物,本文主要对前列腺癌干细胞领域研究较广和较新发现的肿瘤标志物进行综述。%Prostate cancer is one of the most common malignant tumors in males. Endocrine therapy is currently the main treatment for patients with advanced prostate cancer. Although this therapy frequently results in tumor shrinkage, it is not curative, and the majority of patients eventually develop hormone-refractory prostate cancer. Recent studies suggested that prostate cancer stem cells serve a key function in the occurrence, development, and metastasis of prostate cancer. Therefore, targeted therapy of prostate cancer stem cells may be effective for the treatment of prostate cancer. Prostate cancer stem cell markers must be identified to facilitate studies on prostate cancer radical treatment schemes, especially the specific markers of this disease. Previous research on prostate cancer stem cell markers mainly focus on CD44 and CD133. Along with in-depth studies, a substantial number of new markers have been found with research development. This review summarizes the widely studied and recently discovered markers found in the field of prostate cancer stem cells.

  17. What's New in Stomach Cancer Research and Treatment?

    ... Stomach Cancer About Stomach Cancer What’s New in Stomach Cancer Research and Treatment? Research is always being ... in Stomach Cancer Research and Treatment? More In Stomach Cancer About Stomach Cancer Causes, Risk Factors, and ...

  18. Research advancement in breast cancer risk evaluation models%乳腺癌风险评估模型的研究进展



    具有乳腺癌高危因素的女性可通过风险评估模型计算乳腺癌的发生风险,以BRCA基因突变检测为基础的基因模型准确性更高,经验模型也有其不可替代的优点而被广泛应用.%Women with high risk factors of breast cancer can been assessed their probabilities to devel-op breast cancer through the breast cancer risk evaluation models,such as experience models and gene models.The gene models basing on detection of BRCA genes are more accurate than the experience models when be used in women with breast cancer familial history.The experience models are widely used in women without fa-milial history and in many prevention trials of breast cancer.

  19. Advanced energy projects FY 1997 research summaries



    The mission of the Advanced Energy Projects (AEP) program is to explore the scientific feasibility of novel energy-related concepts that are high risk, in terms of scientific feasibility, yet have a realistic potential for a high technological payoff. The concepts supported by the AEP are typically at an early stage of scientific development. They often arise from advances in basic research and are premature for consideration by applied research or technology development programs. Some are based on discoveries of new scientific phenomena or involve exploratory ideas that span multiple scientific and technical disciplines which do not fit into an existing DOE program area. In all cases, the objective is to support evaluation of the scientific or technical feasibility of the novel concepts involved. Following AEP support, it is expected that each concept will be sufficiently developed to attract further funding from other sources to realize its full potential. Projects that involve evolutionary research or technology development and demonstration are not supported by AEP. Furthermore, research projects more appropriate for another existing DOE research program are not encouraged. There were 65 projects in the AEP research portfolio during Fiscal Year 1997. Eigheen projects were initiated during that fiscal year. This document consists of short summaries of projects active in FY 1997. Further information of a specific project may be obtained by contacting the principal investigator.

  20. New advances in virtual plant research


    Virtual plants are computer simulations of the growth, development and deployment of plants in a three-dimensional space. Over the past 20 years, significant pro-gress has been made in virtual plant modeling corresponding to the rapid advances in information technology. Virtual plant research has broad applications in agronomy, forestry, ecology, and remote sensing areas. In this review, we attempt to introduce the significance, modeling methodology, and main advances in virtual plant research and applications. The challenges associated with virtual plant modeling in agronomy applications, including the interaction mechanism between plant and environment and root system modeling, are also discussed. Insights into applications of virtual plants in agronomy are given in the areas of performing virtual experiments to accurately quantify the utilization of soil water and nutrients, to design crop ideotype on computers, and to improve crop planting.

  1. Research and Development of Advanced Gas Turbine


    The program “Advanced Gas Turbine” successfully completed in FY 1987, having been started in FY 1978 as a part of the “Moonlight Project”, the National research and development program for energy conservation promoted by the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry. The purpose of this program was to establish the technologies for the combined cycle power generation system, which has an overall thermal efficiency of 55% (LHV), by developing...

  2. Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer


    AWARD NUMBERS: W81XWH-14-1-0554 TITLE: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer PRINCIPAL INVESTIGATOR...Dr. Nora M. Navone (Initiating PI) RECIPIENT: The University of Texas MD Anderson Cancer Center Houston, TX 77030 REPORT DATE: TYPE OF...21Sep2016 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER N/A Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer 5b. GRANT

  3. Research Institute for Advanced Computer Science

    Gross, Anthony R. (Technical Monitor); Leiner, Barry M.


    The Research Institute for Advanced Computer Science (RIACS) carries out basic research and technology development in computer science, in support of the National Aeronautics and Space Administration's missions. RIACS is located at the NASA Ames Research Center. It currently operates under a multiple year grant/cooperative agreement that began on October 1, 1997 and is up for renewal in the year 2002. Ames has been designated NASA's Center of Excellence in Information Technology. In this capacity, Ames is charged with the responsibility to build an Information Technology Research Program that is preeminent within NASA. RIACS serves as a bridge between NASA Ames and the academic community, and RIACS scientists and visitors work in close collaboration with NASA scientists. RIACS has the additional goal of broadening the base of researchers in these areas of importance to the nation's space and aeronautics enterprises. RIACS research focuses on the three cornerstones of information technology research necessary to meet the future challenges of NASA missions: (1) Automated Reasoning for Autonomous Systems. Techniques are being developed enabling spacecraft that will be self-guiding and self-correcting to the extent that they will require little or no human intervention. Such craft will be equipped to independently solve problems as they arise, and fulfill their missions with minimum direction from Earth; (2) Human-Centered Computing. Many NASA missions require synergy between humans and computers, with sophisticated computational aids amplifying human cognitive and perceptual abilities; (3) High Performance Computing and Networking. Advances in the performance of computing and networking continue to have major impact on a variety of NASA endeavors, ranging from modeling and simulation to data analysis of large datasets to collaborative engineering, planning and execution. In addition, RIACS collaborates with NASA scientists to apply information technology research to a

  4. Research Advancement of Relationship between Human Papillomavirus and Cervical Cancer%人乳头瘤病毒感染与宫颈癌的研究进展

    刘英华; 陈瑛


    宫颈癌是一种严重危害女性健康的恶性肿瘤,其发病率较高,位居女性恶性肿瘤的第二位,仅次于乳腺癌.流行病学治疗显示,99%的宫颈癌患者均感染高危型人乳头瘤病毒(Human papillomavirus,HPV),HPV是宫颈癌的首要病因.近年来,HPV分型检测技术的发展十分迅速,在宫颈癌筛查中与细胞学检测联合应用,对子宫颈病变的早期发现和预防有很重要的意义,可以提高诊断的敏感性,预防宫颈癌的发生和改善宫颈癌患者的预后.本文拟对HPV感染的检测方法与宫颈癌的研究进展做一综述.%Cervical cancer is a malignant tumor, and it has relatively high incidence, second only to breast cancer. Epidemiological treatment study showed that, 99% of the patients with cervical cancer are all infected with high-risk human papillomavirus which is the primary cause of cervical cancer. The HPV genotyping technology has developed rapidly in recent years, HPV detecting and genotyping combined with cytology in the cervical cancer screening is very important for early detection and prevention of cervical lesions, which not only can improve the sensitivity, but also can greatly prevent the incidence of cervical cancer and improve the prognosis of patient with cervical cancer. We briefly review the detection methods of HPV infection and the progress of cervical cancer.

  5. UZIG USGS research: Advances through interdisciplinary interaction

    Nimmo, J.R.; Andraski, B.J.; Rafael, M.-C.


    Because vadose zone research relates to diverse disciplines, applications, and modes of research, collaboration across traditional operational and topical divisions is especially likely to yield major advances in understanding. The Unsaturated Zone Interest Group (UZIG) is an informal organization sponsored by the USGS to encourage and support interdisciplinary collaboration in vadose or unsaturated zone hydrologic research across organizational boundaries. It includes both USGS and non-USGS scientists. Formed in 1987, the UZIG operates to promote communication, especially through periodic meetings with presentations, discussions, and fi eld trips. The 10th meeting of the UZIG at Los Alamos, NM, in August 2007 was jointly sponsored by the USGS and Los Alamos National Laboratory. Presentations at this meeting served as the initial basis for selecting papers for this special section of Vadose Zone Journal, the purpose of which is to present noteworthy cuting-edge unsaturated zone research promoted by, facilitated by, or presented in connection with the UZIG. ?? Soil Science Society of America.

  6. Locally advanced rectal cancer: the importance of a multidisciplinary approach.

    Berardi, Rossana; Maccaroni, Elena; Onofri, Azzurra; Morgese, Francesca; Torniai, Mariangela; Tiberi, Michela; Ferrini, Consuelo; Cascinu, Stefano


    Rectal cancer accounts for a relevant part of colorectal cancer cases, with a mortality of 4-10/100000 per year. The development of locoregional recurrences and the occurrence of distant metastases both influences the prognosis of these patients. In the last two decades, new multimodality strategies have improved the prognosis of locally advanced rectal cancer with a significant reduction of local relapse and an increase in terms of overall survival. Radical surgery still remains the principal curative treatment and the introduction of total mesorectal excision has significantly achieved a reduction in terms of local recurrence rates. The employment of neoadjuvant treatment, delivered before surgery, also achieved an improved local control and an increased sphincter preservation rate in low-lying tumors, with an acceptable acute and late toxicity. This review describes the multidisciplinary management of rectal cancer, focusing on the effectiveness of neoadjuvant chemoradiotherapy and of post-operative adjuvant chemotherapy both in the standard combined modality treatment programs and in the ongoing research to improve these regimens.

  7. Managing occupations in everyday life for people with advanced cancer living at home

    Peoples, Hanne; Brandt, Åse; Wæhrens, Eva Elisabet Ejlersen


    limited research that specifically explores how these occupational difficulties are managed. Objective: To describe and explore how people with advanced cancer manage occupations when living at home. Material and methods: A sub-sample of 73 participants from a larger occupational therapy project took part......Background: People with advanced cancer are able to live for extended periods of time. Advanced cancer can cause functional limitations influencing the ability to manage occupations. Although studies have shown that people with advanced cancer experience occupational difficulties, there is only...... in the study. The participants were consecutively recruited from a Danish university hospital. Qualitative interviews were performed at the homes of the participants. Content analysis was applied to the data. Results: Managing occupations were manifested in two main categories; 1) Conditions influencing...

  8. Psychotherapy for depression among patients with advanced cancer.

    Akechi, Tatsuo


    Cancer causes profound suffering for patients, and previous reports have demonstrated that psychological distress, particularly depression, is frequently observed in advanced and/or terminally ill cancer patients. Such depression can lead to serious and far-reaching negative consequences in patients with advanced cancer: reducing their quality of life and causing severe suffering, a desire for early death, and suicide, as well as psychological distress in family members. For the management of their distress, cancer patients are more likely to prefer psychotherapeutic interventions to pharmacotherapy, and psychotherapy is known to be effective for the management of depression among advanced cancer patients. Hence, psychotherapy is an important treatment strategy for alleviating their depression. Furthermore, patients with advanced and/or terminal cancer suffer from various physical symptoms and are forced to face a continuous decline in physical function. In addition, psychological defense mechanisms such as denial are frequently observed in these patients. Hence, an individually tailored and careful psychotherapeutic approach should be followed, which considers the specific nature of the advanced and/or terminal cancer. This review focuses on psychological interventions that can be utilized in the clinical oncology practice to ameliorate depression among advanced and/or terminally ill cancer patients, rather than focusing on the level of evidence for each intervention. In addition, the current review introduces some novel therapeutic strategies that have not yet been proved to be effective but show promise for future studies.

  9. Physical activity in patients with advanced-stage cancer: a systematic review of the literature.

    Albrecht, Tara A; Taylor, Ann Gill


    The importance of physical activity for chronic disease prevention and management has become generally well accepted. The number of research interventions and publications examining the benefits of physical activity for patients with cancer has been rising steadily. However, much of that research has focused on the impact of physical activity either prior to or early in the cancer diagnosis, treatment, and survivorship process. Research focusing on the effects of physical activity, specifically for patients with advanced-stage cancer and poorer prognostic outcomes, has been addressed only recently. The purpose of this article is to examine the state of the science for physical activity in the advanced-stage disease subset of the cancer population. Exercise in a variety of intensities and forms, including yoga, walking, biking, and swimming, has many health benefits for people, including those diagnosed with cancer. Research has shown that, for people with cancer (including advanced-stage cancer), exercise can decrease anxiety, stress, and depression while improving levels of pain, fatigue, shortness of breath, constipation, and insomnia. People diagnosed with cancer should discuss with their oncologist safe, easy ways they can incorporate exercise into their daily lives.

  10. A Grounded Theory Approach to Physical Activity and Advanced Cancer

    Sonya S. Lowe


    Full Text Available Background: Physical activity has demonstrated benefits in cancer-related fatigue and physical functioning in early-stage cancer patients, however the role of physical activity at the end stage of cancer has not been established. To challenge positivist–empiricist assumptions, I am seeking to develop a new theoretical framework that is grounded in the advanced cancer patient’s experience of activity. Aim: To gain an in-depth understanding of the experience of activity and quality of life in advanced cancer patients. Objectives: (1 To explore the meaning of activity for advanced cancer patients in the context of their day-to-day life, (2 to elicit advanced cancer patients’ perceptions of activity with respect to their quality of life, and (3 to elicit advanced cancer patients’ views of barriers and facilitators to activity in the context of their day-to-day life. Study Design: A two-phase, cross-sectional, qualitative study will be conducted through the postpositivist lens of subtle realism and informed by the principles of grounded theory methods. Study Methods: Advanced cancer patients will be recruited through the outpatient department of a tertiary cancer center. For Phase one, participants will wear an activPAL™ activity monitor and fill out a daily record sheet for seven days duration. For Phase two, the activity monitor output and daily record sheets will be used as qualitative probes for face-to-face, semistructured interviews. Concurrent coding, constant comparative analysis, and theoretical sampling will continue with the aim of achieving as close as possible to theoretical saturation. Ethics and Discussion: Ethical and scientific approval will be obtained by all local institutional review boards prior to study commencement. The findings will generate new mid-level theory about the experience of activity and quality of life in advanced cancer patients and aid in the development of a new theoretical framework for designing

  11. Advances in geochemical research on nanometer materials


    Important advances have been made in the field of geochemistry since nanometer science and technology were introduced into the field of geoscience. The nanometer particulates have been discovered in naturally-occurring ore deposits, volcano-eruptive materials and geo-gases, and a more detailed exploration of the metallogenic mechanism of endogenic metallic ore deposits has been conducted. It is considered that some ore-forming metals may transport in the form of native particulates. Because they have very strong capabilities of adsorption, adsorption is always regarded as an important mechanism of metallogenesis under supergenic and low temperature conditions.Therefore, a new technology of ore exploration has also been developed. This paper attempts to review the new advances in geochemical research on nanometer materials, as well as its perspectivess.

  12. Advances and Prospects in Cancer Immunotherapy

    Juhua Zhou


    Full Text Available Cancer immunotherapy is a promising and effective treatment modality for patients with cancers. Cytokine, anticytokine, and antibody therapies appear to be effective in treating various forms of cancer. The human papillomavirus vaccine is protective for cervical cancer, and this discovery has paved the way to the development of cancer vaccines for other forms of virus-associated cancers such as liver cancer and Merkel cell carcinoma. Clinical trials have demonstrated that adoptive cell therapy using tumor-infiltrating lymphocytes can induce tumor regression in approximately 75% of metastatic melanoma patients, suggesting the possibility of using similar technique to effectively treat breast, lung, and renal cancers in the near future. Besides, genetically engineered T cells transduced with genes encoding specific T cell receptors and chimeric antigen receptors have been shown effective in the treatment of cancer patients. These studies suggest that combination therapies are superior choices in cancer immunotherapy for patients.

  13. Multimodality approach for locally advanced esophageal cancer

    Khaldoun Almhanna; Jonathan R Strosberg


    Carcinoma of the esophagus is an aggressive and lethal malignancy with an increasing incidence world-wide.Incidence rates vary internationally,with the highest rates found in Southern and Eastern Africa and Eastern Asia,and the lowest in Western and Middle Africa and Central America.Patients with locally advanced disease face a poor prognosis,with 5-year survival rates ranging from 15%-34%.Recent clinical trials have evaluated different strategies for management of locoregional cancer; however,because of stage migration and changes in disease epidemiology,applying these trials to clinical practice has become a daunting task.We searched Medline and conference abstracts for randomized studies published in the last 3 decades.We restricted our search to articles published in English.Neoadjuvant chemoradiotherapy followed by surgical resection is an accepted standard of care in the United States.Esophagectomy remains an essential component of treatment and can lead to improved overall survival,especially when performed at high volume institutions.The role of adjuvant chemotherapy following curative resection is still unclear.External beam radiation therapy alone is considered palliative and is typically reserved for patients with a poor performance status.

  14. [Advances in genetic research of cerebral palsy].

    Wang, Fang-Fang; Luo, Rong; Qu, Yi; Mu, De-Zhi


    Cerebral palsy is a group of syndromes caused by non-progressive brain injury in the fetus or infant and can cause disabilities in childhood. Etiology of cerebral palsy has always been a hot topic for clinical scientists. More and more studies have shown that genetic factors are closely associated with the development of cerebral palsy. With the development and application of various molecular and biological techniques such as chromosome microarray analysis, genome-wide association study, and whole exome sequencing, new achievements have been made in the genetic research of cerebral palsy. Chromosome abnormalities, copy number variations, susceptibility genes, and single gene mutation associated with the development of cerebral palsy have been identified, which provides new opportunities for the research on the pathogenesis of cerebral palsy. This article reviews the advances in the genetic research on cerebral palsy in recent years.

  15. Exercise and relaxation intervention for patients with advanced lung cancer

    Adamsen, Lis; Stage, M; Laursen, J


    Lung cancer patients experience loss of physical capacity, dyspnea, pain, reduced energy and psychological distress. The aim of this study was to explore feasibility, health benefits and barriers of exercise in former sedentary patients with advanced stage lung cancer, non-small cell lung cancer ...... patients with advanced stages of disease, during treatment. The patients experienced physical, functional and emotional benefits. This study confirmed that supervised training in peer-groups was beneficial, even in a cancer population with full-blown symptom burden and poor prognosis....

  16. Improving Cancer Care Through Nursing Research.

    Mayer, Deborah K


    Nursing research and nurse researchers have been an integral and significant part of the Oncology Nursing Society's (ONS's) history, as evidenced by the development of the Nursing Research Committee within a few years of ONS's establishment. Ruth McCorkle, PhD, RN, FAAN, was the committee's first chairperson in 1979. This was followed by the creation of the Advanced Nursing Research Special Interest Group in 1989 under the leadership of Jean Brown, PhD, RN, FAAN. ONS also began to recognize nurse researchers in 1994 by creating the annual ONS Distinguished Researcher Award to recognize the contributions of a member who has conducted or promoted research that has enhanced the science and practice of oncology nursing. The list of recipients and of their work is impressive and reflects the wide range of our practice areas (see for the recipient list). In addition, the ONS Foundation began funding research in 1981 and has distributed more than $24 million in research grants, research fellowships, and other scholarships, lectures, public education projects, and career development awards (ONS Foundation, 2015). And, in 2006, the Putting Evidence Into Practice resource was unveiled, which provides evidence-based intervention reviews for the 20 most common problems experienced by patients with cancer and their caregivers (www.ons

  17. What`s New in Cervical Cancer Research and Treatment?

    ... Cervical Cancer About Cervical Cancer What's New in Cervical Cancer Research and Treatment? New ways to prevent and ... in Cervical Cancer Research and Treatment? More In Cervical Cancer About Cervical Cancer Causes, Risk Factors, and Prevention ...

  18. What's New in Ovarian Cancer Research and Treatment?

    ... Ovarian Cancer About Ovarian Cancer What's New in Ovarian Cancer Research and Treatment? Risk factors and causes Scientists ... in Ovarian Cancer Research and Treatment? More In Ovarian Cancer About Ovarian Cancer Causes, Risk Factors, and Prevention ...

  19. What's New in Liver Cancer Research and Treatment?

    ... Liver Cancer About Liver Cancer What's New in Liver Cancer Research and Treatment? Because there are only a ... in Liver Cancer Research and Treatment? More In Liver Cancer About Liver Cancer Causes, Risk Factors, and Prevention ...

  20. Research Advances in the Hedgehog Signaling Pathway in Gastric Cancer%Hedgehog信号通路在胃癌中的研究进展



    Hedgehog信号通路是来自内胚层的信号分子之一,在个体胚胎发育诱导、模式的形成和细胞命运的决定中起着关键的作用,信号紊乱会导致各种组织器官畸形.在个体发育成熟后,Hedgehog信号通路只在特定的部位表达,与器官正常功能的维持、机体内环境的稳定有着密切的关系.然而,越来越多的研究显示Hedgehog信号通路与肿瘤的发生发展有着密切的关联.已有研究报道胃癌中也明显存在Hedgehog信号通路的异常活化.本文从Hedgehog信号通路过度表达的机制、成员突变、非经典Hedgehog信号通路、胃癌干细胞、上皮间质转化等方面出发,将近几年来Hedgehog信号通路与胃癌发生发展关联方面的研究进展进行报道.%The Hedgehog signaling pathway involves cells originaing from the endoderm. It plays a crucial role in embryonic development, pattern formation and cell fate. Its mutation or abnormal expression can result in malformations of various tissues and organs. After maturation of the individual, the Hedgehog signaling pathway is either not expressed, has low expression or is only expressed in a few specific parts. This pathway is important for maintaining normal organ function and a stable internal environment.However, many studies have revealed that abnormal expression of the Hedgehog signaling pathway is found in carcinogenesis. These studies also determined that this pathway can be activated by mutations or other mechanisms, leading to abnomal expression in adult tissue. It appears to play a crucial role in the development of tumors, including basal cell cancer, lung cancer, prostate cancer, colorectal cancer, and pancreatic cancer A special inhibitor of the Hedgehog signaling pathway can inhibit the proliferation of these tumor cells.Gastric cancer is a significant threat to human health; as a malignant disease, it ranks second worldwide and first in China in incidence and mortality, It has been reported

  1. Advancing research transdisciplinarity within our discipline.

    Sadovsky, Yoel; Esplin, M Sean; Garite, Thomas J; Nelson, D Michael; Parry, Samuel I; Saade, George R; Socol, Michael L; Spong, Catherine Y; Varner, Michael W; D'Alton, Mary E


    Advancing biomedical knowledge is crucial to the understanding of disease pathophysiology, diagnosis, treatment, and the maintenance of health. Whereas collaborative pursuits among basic and translational scientists, clinical researchers, and clinicians should advance biomedical progress and its translation to better medicine. The field of obstetrics and gynecology and its subspecialties has not escaped this problem. Obstetrics and gynecology specialists and subspecialists have limited opportunities to interact with translational or basic investigators, and cross-fertilization and collaborations are further challenged by the current healthcare and funding climate. This opinion manuscript focuses on the field of maternal-fetal medicine, serving as an example that illustrates the risks and opportunities that might exist within our obstetrics and gynecology academic community. A Pregnancy Task Force recently sought to identify ways to overcome hurdles related to research training, and ensure a sufficient pool of physician-scientists pursuing pertinent questions in the field. The group discussed strategies to promote a culture of intellectual curiosity and research excellence, securing additional resources for trainees, and attracting current and next generation basic, translational, and clinical scholars to our field. Recommendations encompassed activities within annual academic meetings, training initiatives, and additional funding opportunities. Inferences from these discussions can be made to all obstetrics and gynecology subspecialty areas. Copyright © 2014 Mosby, Inc. All rights reserved.

  2. Advanced Breast Cancer as Indicator of Quality Mammography

    Gaona, Enrique


    Breast cancer is the most frequently diagnosed cancer and is the second leading cause of cancer death among women in the Mexican Republic. Mammography is the more important screening tool for detecting early breast cancer. Screening mammography involves taking x-rays from two views from each breast, typically from above (cranial-caudal view, CC) and from an oblique or angled view (mediolateral-oblique, MLO). The purpose of this study was to carry out an exploratory survey of the issue of patients with advanced breast cancer who have had a screening mammography. A general result of the survey is that 22.5% of all patients (102) with advanced breast cancer that participated in the study had previous screening mammography. But we should consider that 10% of breast cancers are not detected by mammography. Only 70% of the family doctors prescribed a diagnostic mammography when the first symptoms were diagnosed.

  3. Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

    Xiaoyu Hou


    Full Text Available Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT. The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC remains the key roadblock in successful long-term management of prostate cancer. New advancements in medical therapy for prostate cancer have added to the hormonal therapy armamentarium. These new therapeutic agents not only provide a survival benefit but also show potential for reversing hormonal resistance in metastatic CRPC, and thus redefining hormonally sensitive disease.

  4. Frederick National Laboratory for Cancer Research

    Federal Laboratory Consortium — Among the many cancer research laboratories operated by NCI, the Frederick National Laboratory for Cancer Research(FNLCR) is unique in that it is a Federally Funded...

  5. Center for Herbal Research on Colorectal Cancer

    Federal Laboratory Consortium — Research Area: Herbs Program:Centers of Excellence for Research on CAM Description:Colorectal cancer is the third most common cancer and the third leading cause of...

  6. Gene-Environment Research and Cancer Epidemiology

    The Epidemiology and Genomics Research Program supports extramural research that investigates both genetic and environmental factors that may contribute to the etiology of cancer and/or impact cancer outcomes.

  7. Advancing Cancer Prevention and Behavior Theory in the Era of Big Data.

    Atienza, Audie A; Serrano, Katrina J; Riley, William T; Moser, Richard P; Klein, William M


    The era of "Big Data" presents opportunities to substantively address cancer prevention and control issues by improving health behaviors and refining theoretical models designed to understand and intervene in those behaviors. Yet, the terms "model" and "Big Data" have been used rather loosely, and clarification of these terms is required to advance the science in this area. The objectives of this paper are to discuss conceptual definitions of the terms "model" and "Big Data", as well as examine the promises and challenges of Big Data to advance cancer prevention and control research using behavioral theories. Specific recommendations for harnessing Big Data for cancer prevention and control are offered.

  8. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

    Bridgewater, J; Lopes, A; Wasan, H


    BACKGROUND: Biliary tract cancer is an uncommon cancer with a poor outcome. We assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 international studies to determine prognostic outcome characteristics for patients with advanced disease. METHODS: Multivariable...... associated with PFS and OS. ROC analysis suggested the models generated from the ABC-02 study had a limited prognostic value [6-month PFS: area under the curve (AUC) 62% (95% CI 57-68); 1-year OS: AUC 64% (95% CI 58-69)]. CONCLUSION: These data propose a set of prognostic criteria for outcome in advanced...

  9. A review of tasquinimod in the treatment of advanced prostate cancer

    Williamson SC


    Full Text Available Stuart Charles Williamson, Alice Elizabeth Hartley, Rakesh HeerNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UKAbstract: Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival. Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.Keywords: prostate cancer, castration resistant prostate cancer, antiangiogenesis, S100A9, HDAC4, ABR-215050, quinoline-3-carboximide

  10. Immunotherapy: A breakthrough in cancer research

    Editorial Office


    a mixed population. The clinical benefit of the fixed dose of pembrolizumab in the first and second line treatment of recurrent/metastatic head and neck cancer is being evaluated head-to-head with standard of care chemotherapy in phase 3 trials around the world, including Asia Pacific.” Meanwhile, another research paper on immunotherapy presented at the ESMO Asia 2016 was by Dr. Herbert Loong, Clinical Assistant Professor at the Department of Clinical Oncology of the Chinese University of Hong Kong, who discussed about the cost-effectiveness of immunotherapy with pembrolizumab for advanced melanoma patients in Hong Kong. Dr. Loong said, “We have determined that whilst pembrolizumab is expensive, the increase in quality adjusted life years (QALYs compared with standard cytotoxic chemotherapy, and even so with ipilimumab, qualifies it as a cost-effective approach.” Commenting on the results of the research by Dr. Loong and his colleagues, Dr. Mark Tang – a senior consultant dermatologist said, “Given the high costs of these new treatment options, cost effectiveness studies such as this one are timely and useful as further evidence for the use of pembrolizumab in the treatment of advanced melanoma. This is particularly important in an Asian context where, although rare, acral melanoma has unfortunately been known to present late advanced disease.” Taking all these exciting discoveries into account, a good number of studies have repeatedly shown that progress in cancer immunotherapy has accelerated and resulted in the development of several effective and promising therapies for multiple forms of cancer. At this critical juncture, oncological organizations such as ESMO provide an important knowledge transfer platform for the sharing of expertise and interaction between regional and international experts in the area of onco-immunology. Moving forward, immunotherapy and targeted medicine are expected to remain in the spotlight and will be an indispensable

  11. 转移相关基因在肿瘤中的研究进展%The advance of research of metastasis-associated gene in human cancer

    曹磊; 任华


    MTA is a gene family closely related with carcinogenesis and cancer progression. According to many recent studies, the member of MTA overexpressed in a wide range of human cancers and was involved in invasion, metastasis and angiogenesis. MTA may be one of main regulatory molecules family in the procession of carcinogenesis and progression.%转移相关基因(MTA)是一个与肿瘤发生和进展密切相关的基因家族.最近的研究表明,MTA家族成员在多种人类肿瘤组织中表达异常升高,并通过多种机制参与肿瘤的侵袭、转移及血管生成.MTA可能是多种恶性肿瘤发生与进展相关的主要调节分子家族之一.

  12. Crizotinib for Advanced Non-Small Cell Lung Cancer

    A summary of results from an international phase III clinical trial that compared crizotinib versus chemotherapy in previously treated patients with advanced lung cancer whose tumors have an EML4-ALK fusion gene.

  13. Drug Extends Lives of Patients with Advanced Prostate Cancer: Studies

    ... for all the advanced prostate cancer patients, James said. "We think this is one of the biggest survival gains ever reported in a trial in adults with solid tumor," he said. Both studies reported side effects in abiraterone similar ...

  14. Herbal therapy for advanced breast cancer. Personal experience ...

    Box 2234, Eldoret-KENYA. Key words: ... Results: Herbal therapy given in advanced breast cancer was found to produce remarkable ... in females in Rift valley region of Kenya next to ... metastases in bone, liver and lungs were destroyed.

  15. Bevacizumab improves survival for patients with advanced cervical cancer

    Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis

  16. Blocking DNA Repair in Advanced BRCA-Mutated Cancer

    In this trial, patients with relapsed or refractory advanced cancer and confirmed BRCA mutations who have not previously been treated with a PARP inhibitor will be given BMN 673 by mouth once a day in 28-day cycles.

  17. Combination Therapy Shows Promise for Treating Advanced Breast Cancer

    Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.

  18. What's New in Research and Treatment for Thymus Cancer?

    ... Cancer What’s New in Research and Treatment for Thymus Cancer? There is always research going on in ... Research and Treatment for Thymus Cancer? More In Thymus Cancer About Thymus Cancer Causes, Risk Factors, and ...

  19. Research advances of the bone metastasis of the colorectal cancer%结直肠癌骨转移研究进展

    赵亮; 苏佳灿


    As one of the most common malignant tumors, the colorectal cancer showed an increasing morbidity and mortality in recent years. Bone metastasis was the terminal manifestation of the colorectal cancer with low metastasis rate. It commonly occurred in multiple bones, leading severe pain, hypercalcemia, pathologic fracture and so on. Appropriate imaging examinations such as X-ray, CT, MRI and ECT and laboratory parameters such as CEA could provide help in the diagnose of the bone metastasis of the colorectal cancer. The mechanism of the bone metastasis of the colorectal cancer was still not clear now, however studies showed that metastasis promoting genes and metastasis suppressing genes might play important roles. The treatment of the bone metastasis included 2 aspects: the systemic treatment including radionuclide therapy, chemotherapy and bone resorption inhibitor therapy and the local treatment including operation and radiotherapy. The bone metastasis of the colorectal cancer was usually ignored in clinic and there were still a lot of problems remaining to be studied in the future.%@@ 结直肠癌是常见恶性肿瘤之一.流行病学资料刘放等[6] 分析了191例结直肠癌术后骨转移的患者,显示,2000年全世界有70万人患结直肠癌,占全部占同期治疗3454例结直肠癌的5.5%,其中结肠癌骨癌症新发病例数的9.4%;50万人死于结直肠癌,占转移率为2.9%,直肠癌转移率为7.5%,结、直肠癌癌症死亡数的7.9%[1-2] .在过去的20多年中,结直转移率差异具有显著的统计学意义.可见,结直肠肠癌的发病数和死亡数在世界大多数国家和地区都癌骨转移率虽然较低,但总体呈上升趋势,且直肠呈上升趋势.

  20. Current research and advances in cancer breakthrough pain%癌症爆发痛的现状和研究进展

    李华; 刘巍


    虽然癌症患者的基础疼痛控制相当稳定,但也可能会遭受短暂的疼痛加重,即癌症爆发痛.典型的爆发痛有快速发作和持续时间短等临床特征,这种疼痛对患者生活质量和卫生资源的不良影响显而易见.即释型口服阿片类药物目前已广泛用于爆发痛的治疗,但其起效时间及作用持续时间长的特点并不适合治疗大部分的爆发痛.相比之下一些芬太尼制剂,如芬太尼透黏膜口含剂(oral transmucosal fentanyl citrate,OTFC)、芬太尼口腔泡腾片(fentanyl buccal tablet,FBT)、芬太尼舌下含片(sublingual fentanyl citrate,SLF)和芬太尼鼻喷雾剂(intranasal fentanyl spray,INFS)等,为癌症爆发痛的治疗带来了令人欣慰的疗效.另外,国内对布托啡诺鼻喷剂治疗癌症爆发痛也已有一定的研究.%Although the control of background pain is satisfying, the patients may also suffer from transient exacerbation of pain, which is known as cancer breakthrough pain (BTP). A typical episode of BTP has a fast onset and a short duration. The BTP can apparently affect the quality of life and may also have an adverse impact on healthcare resources. Normal-release oral opioids have been applied in the treatment of cancer BTP, but the late onset and long duration of action of oral opioids may not appropriate for controlling a typical cancer BTP. Some formulations of fentanyl provide more favourable efficacy in the control of cancer BTP, such as oral transmucosal fentanyl citrate (OTFC), buccal fentanyl citrate (FBT), sublingual fentanyl citrate (SLF), and intranasal fentanyl spray (INFS). In addition, some studies have focused on the treatment of cancer BTP with transnasal butorphanol.

  1. Advanced Energy Projects FY 1996 research summaries



    The mission of the Advanced Energy Projects Division (AEP) is to explore the scientific feasibility of novel energy-related concepts. These concepts are typically at an early stage of scientific development and, therefore, are premature for consideration by applied research or technology development programs. The portfolio of projects is dynamic, but reflects the broad role of the Department in supporting research and development for improving the Nation`s energy posture. Topical areas presently receiving support include: alternative energy sources; innovative concepts for energy conversion and storage; alternate pathways to energy efficiency; exploring uses of new scientific discoveries; biologically-based energy concepts; renewable and biodegradable materials; novel materials for energy technology; and innovative approaches to waste treatment and reduction. Summaries of the 70 projects currently being supported are presented. Appendices contain budget information and investigator and institutional indices.

  2. Advanced Scientific Computing Research Network Requirements

    Bacon, Charles; Bell, Greg; Canon, Shane; Dart, Eli; Dattoria, Vince; Goodwin, Dave; Lee, Jason; Hicks, Susan; Holohan, Ed; Klasky, Scott; Lauzon, Carolyn; Rogers, Jim; Shipman, Galen; Skinner, David; Tierney, Brian


    The Energy Sciences Network (ESnet) is the primary provider of network connectivity for the U.S. Department of Energy (DOE) Office of Science (SC), the single largest supporter of basic research in the physical sciences in the United States. In support of SC programs, ESnet regularly updates and refreshes its understanding of the networking requirements of the instruments, facilities, scientists, and science programs that it serves. This focus has helped ESnet to be a highly successful enabler of scientific discovery for over 25 years. In October 2012, ESnet and the Office of Advanced Scientific Computing Research (ASCR) of the DOE SC organized a review to characterize the networking requirements of the programs funded by the ASCR program office. The requirements identified at the review are summarized in the Findings section, and are described in more detail in the body of the report.

  3. Advanced cyberinfrastructure for research in Geodynamics

    Manea, Marina; Constantin Manea, Vlad


    Today's scientists need access to new information technology capabilities, able to perform high-resolution complex computing simulations in a reasonable time frame. Sophisticated simulation tools allow us to study phenomena that can never be observed or replicated by standard laboratory experiments. Modeling complex natural processes in general, and numerical computation in particular, represents today an essential need of research, and all modern research centers benefit from a computing center of one form or another. The combined power of hardware and sophisticated software, visualization tools, and scientific applications produced and used by interdisciplinary research teams make possible nowadays to advance the frontiers of science and to pose new key scientific questions. Cyberinfrastructure integrates hardware for high speed computing, a collection of highly specialized software and tools, and a powerful visualization tool. A new interdisciplinary research domain is emerging at the interface of geosciences and computing with essential inputs from geology and geophysics. In this study we show how to rapidly deploy a low-cost high-performance computing cluster (HPCC) and a 3D visualization system that can be used both in teaching and research in geosciences. Also, we present several geodynamic simulations performed with such systems.

  4. Tumor Microenvironment Inflammation and Obesity in Advanced Prostate Cancer


    AWARD NUMBER: W81XWH-14-1-0064 TITLE: Tumor Microenvironment Inflammation and Obesity in Advanced Prostate Cancer PRINCIPAL INVESTIGATOR...1 Apr 2014 - 31 Mar 2015 4. TITLE AND SUBTITLE Tumor Microenvironment Inflammation and Obesity in Advanced 5a. CONTRACT NUMBER Prostate Cancer 5b...Background: The goal of this pilot study was to examine the relationship between inflammation markers in the tumor microenvironment and PCa outcomes by

  5. Role of chemoradiation in advanced cervical cancer

    Singh T


    Full Text Available A prospective randomized study was conducted in our department of Radiotherapy, Regional Institute of Medical Sciences, Imphal to evaluating the role of chemoradiation in the management of advanced inoperable cervical cancer (stage IIB-IIIB taking only radiation treatment as control spanning the period 1996-1999. Of the fifty patients accumulated in the study group, three patients did not complete treatment, one expired due to other causes and three were lost to follow up. Likewise, of the forty-six patients in the control group, one patient did not complete treatment and 4 were lost to follow up. Thus only 43 and 41 patients were available for the result analysis for the study and control groups respectively. The early treatment response as assessed after two months of treatment conclusion were 79.1%, 13.9%, 93.0% and 58.5%, 31.7%, 90.2% as complete response (CR, partial response (PR, and total response (TR respectively for the study and control groups. Our patients included in this study had a median follow up of 35 months and 33 months for study and control groups respectively. For this follow up, the disease-free survival, survival with disease and overall survival were 67.4%, 7.0%, 74.4% and 43.9%, 12.2%, 56.1% for study and control groups respectively. There was an increase in early side-effects in the chemoradiation group but the difference was not significant. Because of the early side effects, treatment delays ensued in 7 patients (16.3% and in 3 patients (7.3% in the study and control groups respectively. There was no significant increase in the late treatment toxicities in both the groups.

  6. Geysers advanced direct contact condenser research

    Henderson, J.; Bahning, T.; Bharathan, D.


    The first geothermal application of the Advanced Direct Contact Condenser (ADCC) technology developed by the National Renewable Energy Laboratory (NREL) is now operational and is being tested at The Geysers Power Plant Unit 11. This major research effort is being supported through the combined efforts of NREL, The Department of Energy (DOE), and Pacific Gas and Electric (PG&E). NREL and PG&E have entered into a Cooperative Research And Development Agreement (CRADA) for a project to improve the direct-contact condenser performance at The Geysers Power Plant. This project is the first geothermal adaptation of an advanced condenser design developed for the Ocean Thermal Energy Conversion (OTEC) systems. PG&E expects this technology to improve power plant performance and to help extend the life of the steam field by using steam more efficiently. In accordance with the CRADA, no money is transferred between the contracting parties. In this case the Department of Energy is funding NREL for their efforts in this project and PG&E is contributing funds in kind. Successful application of this technology at The Geysers will provide a basis for NREL to continue to develop this technology for other geothermal and fossil power plant systems.

  7. Kids, Adolescents, and Young Adults Cancer Study—A Methodologic Approach in Cancer Epidemiology Research

    Nancy J. Link


    Full Text Available Advances have been made in treatment and outcomes for pediatric cancer. However adolescents and young adults (AYAs with cancer have not experienced similar relative improvements. We undertook a study to develop the methodology necessary for epidemiologic cancer research in these age groups. Our goal was to create the Kids, Adolescents, and Young Adults Cancer (KAYAC project to create a resource to address research questions relevant to this population. We used a combination of clinic and population-based ascertainment to enroll 111 cases aged 0–39 for this methodology development study. The largest groups of cancer types enrolled include: breast cancer, leukemia, lymphoma, and melanoma. The overall participation rate is 69.8% and varies by age and tumor type. The study included patients, mothers, and fathers. The methods used to establish this resource are described, and the values of the resource in studies of childhood and young adult cancer are outlined.

  8. Drosophila models for cancer research.

    Vidal, Marcos; Cagan, Ross L


    Drosophila is a model system for cancer research. Investigation with fruit flies has facilitated a number of important recent discoveries in the field: the hippo signaling pathway, which coordinates cell proliferation and death to achieve normal tissue size; 'social' behaviors of cells, including cell competition and apoptosis-induced compensatory proliferation, that help ensure normal tissue size; and a growing understanding of how oncogenes and tumor suppressors cooperate to achieve tumor growth and metastasis in situ. In the future, Drosophila models can be extended beyond basic research in the search for human therapeutics.

  9. Research advance of the anti-cancer activity of chalcone compounds%查尔酮类化合物的抗癌活性研究进展

    王永波; 木合布力·阿布力孜


    Objective To screen the lead compounds of anti‐cancer with the characteristics of novel structure ,strong biological activ‐ity ,safe and effective from the traditional natural medicines .Methods Varieties of heterocyclic structure and its anticancer mecha‐nism of chalcone were analyzed and discussed .Results In the structure of chalcone ,the biological activity of chalcone compounds can be improved by the introduction of different groups ,changing the structure of relative configuration and so on .Conclusion Heterocyclic chalcones have strong anti‐cancer biological activity .According to its structure‐activitity relationship ,lead com‐pounds of anti‐cancer ,which have novel structure ,strong biological activity ,safe and effective ,could be selected from the tradi‐tional natural medicines .%目的:从传统天然药物中筛选出结构新颖、生物活性较强、安全有效的抗癌先导化合物。方法通过比较多种含杂环结构查尔酮类化合物及其抗癌机制来进行分析论证。结果在查尔酮结构中,引入不同的基团、改变结构相对构型等使所得化合物的抗癌活性有所提高。结论杂环查尔酮类化合物显示出较强的抗癌生物活性,根据其构型关系,从传统天然药物筛选出结构新颖、生物活性较强、安全有效的抗癌先导化合物。

  10. Top classic citations in pancreatic cancer research.

    Li, Qiang; Jiang, Yuan


    The number of times that articles are cited by is widely used to evaluate the impact of an article or an individual author has on its scientific community. This bibliometric analysis aimed to explore the top classic citations in pancreatic cancer (PC) research. A computerized literature search was conducted using the database, the Science Citation Index Expanded. The top 100 highly cited articles were included and further analyzed. The most cited article had 3,032 citations, with a mean of 626 citations per paper. These highly cited articles were published in 37 journals, led by Cancer Research (15 articles). Of the 100 articles, 40 were observational studies, 36 dealt with basic science, and 14 were randomized controlled trials. These articles came from 11 countries, with the USA contributing 79 articles. Fifty-one institutions produced these 100 citation classics, led by Johns Hopkins University (20 articles). Twenty-seven persons authored two or more of the top-cited articles, led by Kern SE (6) and Yeo CJ (5). This analysis of the top highly cited articles allows for the recognition of major advances in PC research and gives a historic perspective on the progress of this specialty of PC research.

  11. Advances in cancer epidemiology in Japan.

    Tanaka, Hideo


    Epidemiologists in Japan have been performing calculations to estimate nationwide cancer incidence rates as well as 5-year survival rates using population-based cancer registry data. There have been remarkable changes in cancer incidence and/or mortality in cancers of the lung, liver and stomach, which were thought to be attributed to the changing impact of exposure to cigarette smoking, chronic hepatitis C virus infection and Helicobacter pylori infection, respectively. In systematic reviews providing evidence in risk/protective factors for cancer sites using case-control and cohort studies of the Japanese population, there were associations between cancer sites (esophagus, stomach, colo-rectum, liver, pancreas, lung and breast) and various lifestyle factors. In the past 10 years, a hospital-based case-control study at Aichi Cancer Center provided valuable evidence of gene-environment interaction on the development of cancer [i.e., the effects of aldehyde dehydrogenase-2 (ALDH2) polymorphism and heavy alcohol drinking on esophageal cancer, ALDH2 polymorphism and smoking on lung cancer, methylenetetrahydrofolate reductase polymorphism and heavy alcohol drinking on pancreatic cancer]. The database with stored DNA was also used and identified seven loci containing significant but low-penetrance polymorphisms associated with the development of breast cancer. These findings together with established risk factors are likely to be useful to predict personalized breast cancer risk in East Asian women. In 2005, the Japan Multi-Institution Collaborative Cohort (J-MICC) study was launched to elucidate gene-environment interactions as well as to confirm preclinical diagnostic biomarkers of cancer. J-MICC, which has recruited 92,000 healthy individuals by the end of 2012, will follow the individuals until 2025.

  12. Management of locally advanced primary and recurrent rectal cancer

    J.H.W. de Wilt (Johannes); M. Vermaas (Maarten); F.T.J. Ferenschild (Floris); C. Verhoef (Kees)


    textabstractTreatment for patients with locally advanced and recurrent rectal cancer differs significantly from patients with rectal cancer restricted to the mesorectum. Adequate preoperative imaging of the pelvis is therefore important to identify those patients who are candidates for multimodality

  13. 宫颈癌治疗性疫苗临床研究进展%Clinical research advance in therapeutic vaccines against cervical cancer



    Persistent infection by high-risk human papillomavirus (HPV) has been found associated with most cervical cancers.With the further study on HPV and its pathogenic mechanism,several therapeutic vaccines against cervical cancer have been developed,and even in clinical trial phrase.In this paper,the progress in clinical trials and design strategies of therapeutic HPV vaccines are reviewed.%宫颈癌的发生与高危型人乳头瘤病毒( human papillomavirus,HPV)的持续感染有关.随着对HPV及其致病机制的深入研究,已经开发了多种用于宫颈癌生物免疫治疗的疫苗,有些已进入临床试验.此文对已进入临床试验阶段的宫颈癌疫苗的设计策略和临床试验进展做一综述.

  14. Advanced prostate cancer risk in relation to toenail selenium levels

    Geybels, M.S.; Verhage, B.A.J.; Schooten, F.J. van; Goldbohm, A.; Brandt, P.A. van den


    BACKGROUND: Selenium may prevent advanced prostate cancer (PCa), but most studies on this topic were conducted in populations with moderate to high selenium status. We investigated the association of toenail selenium, reflecting long-term selenium exposure, and advanced PCa risk in a population from

  15. Sipuleucel-T: immunotherapy for advanced prostate cancer

    Olson BM; McNeel DG


    Brian M Olson, Douglas G McNeelUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USAAbstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a ...

  16. FOREWORD: Conference on Advanced Metrology for Cancer Therapy 2011 Conference on Advanced Metrology for Cancer Therapy 2011

    Ankerhold, Ulrike


    Although physical treatments play a central role in cancer therapy, SI-traceable metrology has only been established for some of them. Several forms of treatment currently used (particularly intensity-modulated radiation therapy (IMRT), hadron therapy, high-intensity therapeutic ultrasound (HITU) and brachytherapy) suffer from the limited metrological support, which restricts the success of these techniques. Recognizing this deficit, the European Union identified metrology for health as one of the first four Targeted Programmes in the framework of the European Metrology Research Programme (EMRP) running from 2008 to 2011. This programme included two EMRP projects addressing metrology for cancer therapy: project T2.J06 dealing with brachytherapy project T2.J07 dealing with external beam cancer therapy using ionizing radiation and high-intensity therapeutic ultrasound. Primary measurement standards applicable to modern treatment conditions were developed under both projects, together with measurement techniques which are meant as a basis for future protocols for dosimetry, treatment planning and monitoring. In order to provide a platform for the presentation of current developments in clinical measurement techniques for cancer therapy, together with the achievements of both projects, an international Conference on Advanced Metrology for Cancer Therapy (CAMCT) was held from 29 November to 1 December 2011 at the Physikalisch-Technische Bundesanstalt (PTB) in Braunschweig, Germany. The main sessions of the conference: Primary and secondary standards of absorbed dose to water for IMRT and brachytherapy, 3D dose distributions and treatment planning for IMRT and brachytherapy, Hadron therapy (protons and carbon ions), High-intensity therapeutic ultrasound (HITU), were geared to the main foci of the projects. Metrologists and medical physicists from countries all over the world attended the conference and made it into a forum for the exchange of information and expertise

  17. The cancer translational research informatics platform

    Johnson Kimberly


    Full Text Available Abstract Background Despite the pressing need for the creation of applications that facilitate the aggregation of clinical and molecular data, most current applications are proprietary and lack the necessary compliance with standards that would allow for cross-institutional data exchange. In line with its mission of accelerating research discoveries and improving patient outcomes by linking networks of researchers, physicians, and patients focused on cancer research, caBIG (cancer Biomedical Informatics Grid™ has sponsored the creation of the caTRIP (Cancer Translational Research Informatics Platform tool, with the purpose of aggregating clinical and molecular data in a repository that is user-friendly, easily accessible, as well as compliant with regulatory requirements of privacy and security. Results caTRIP has been developed as an N-tier architecture, with three primary tiers: domain services, the distributed query engine, and the graphical user interface, primarily making use of the caGrid infrastructure to ensure compatibility with other tools currently developed by caBIG. The application interface was designed so that users can construct queries using either the Simple Interface via drop-down menus or the Advanced Interface for more sophisticated searching strategies to using drag-and-drop. Furthermore, the application addresses the security concerns of authentication, authorization, and delegation, as well as an automated honest broker service for deidentifying data. Conclusion Currently being deployed at Duke University and a few other centers, we expect that caTRIP will make a significant contribution to further the development of translational research through the facilitation of its data exchange and storage processes.

  18. Biologic therapies for advanced pancreatic cancer.

    He, Aiwu Ruth; Lindenberg, Andreas Peter; Marshall, John Lindsay


    Patients with metastatic pancreatic cancer have poor prognosis and short survival due to lack of effective therapy and aggressiveness of the disease. Pancreatic cancer has widespread chromosomal instability, including a high rate of translocations and deletions. Upregulated EGF signaling and mutation of K-RAS are found in most pancreatic cancers. Therefore, inhibitors that target EGF receptor, K-RAS, RAF, MEK, mTOR, VEGF and PDGF, for example, have been evaluated in patients with pancreatic cancer. Although significant activities of these inhibitors have not been observed in the majority of pancreatic cancer patients, an enormous amount of experience and knowledge has been obtained from recent clinical trials. With a better inhibitor or combination of inhibitors, and improvement in the selection of patients for available inhibitors, better therapy for pancreatic cancer is on the horizon.

  19. 非小细胞肺癌免疫治疗的研究进展%Advances on Immunotherapy Research in Non-small Cell Lung Cancer

    施博文; 乔文亮; 韩玉栋; 胡海洋; 陈珮; 林强


    肺癌(lung cancer)是全球发病率及死亡率最高的恶性肿瘤之一,非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的85%,其五年生存率只有15%,传统的抗肿瘤治疗方法(手术、放疗和化疗等)在抑制肿瘤进展中的作用有限,即使有手术机会,也有40%以上患者出现局部复发或远处转移.目前多学科治疗较大程度提高了晚期NSCLC的生存期,研究表明,免疫治疗(immunotherapy)可改善肺癌的预后,有望成为肺癌的重要辅助治疗方式.其中,治疗性肿瘤疫苗(vaccination)如MAGE-A3、L-BLP25、Belagenpumatucel-L等、免疫检查点抑制剂(immune checkpoint inhibition)如ipilimumab、nivolumab、pembrolizumab等得到广泛关注.一系列临床试验表明免疫治疗可以使非小细胞肺癌的死亡率得到缓解,本文就其原理、临床试验、不良反应及有待解决问题的临床研究作系统综述.

  20. 宫颈癌治疗性疫苗的临床研究现状%Advances in the clinical research of therapeutic vaccines for cervical cancer

    张立娜; 周志祥; 盛望; 曾毅


    Human papillomavirus (HPV) is a major etiological factor in cervical cancer, and it provides a promising target for the eradication of HPV-related malignancies. Although preventive HPV vaccines have been approved, the much-needed therapeutic vaccines targeted to HPV for cervical cancer require further development. Currently, a number of therapeutic vaccines have been developed and many have shown promise in both preclinical and clinical trials. This review discusses the therapeutic vaccines including live vector-based, peptide or protein-based, DNA-based and DC-based vaccines with emphasis on current progress of the clinical trials.%人乳头瘤状病毒(human papillomavirus,HPV)是宫颈癌的主要致病因子,也是研制宫颈癌防治性疫苗的理想靶点.虽然现在针对HPV感染的宫颈癌预防性疫苗已成功上市,但是对于急需的治疗型疫苗的研发还在进行中.目前有多种类型的治疗性疫苗已用于临床前期及临床试验,并显示出很好的治疗效果.本文从活载体疫苗、多肽/蛋白疫苗、DNA疫苗和DC疫苗几个方面综述了目前国内外宫颈癌治疗性疫苗的研究现状及进展,特别是进入临床阶段的疫苗,从而为治疗性疫苗的研究提供参考.

  1. [Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].

    Classe, J-M; Muller, M; Frenel, J-S; Berton Rigaud, D; Ferron, G; Jaffré, I; Gladieff, L


    The standard treatment for advanced ovarian cancer consist in complete surgical debulking and intravenous platin and taxane based chemotherapy. Despite research efforts, a lot of patients still die from peritoneal carcinomatosis. The aim of our work was to present the state of art about intraperitoneal chemotherapy. Intraperitoneal chemotherapy (IPC): three multi-institutional randomised trials showed that platin based IPC gave better results in term of overall and disease free survival when compared to standard intravenous treatment. Even so, IPC is not yet becoming a new international standard of treatment because a high rate of morbidity. Hyperthermic Intraperitoneal chemotherapy (HIPEC) represents an innovative alternative to IPC. HIPEC is based on a complete surgical debulking without any visible mass and an intraperitoneal chemotherapy with synergy of hyperthermia. Phase II trails have shown its feasibility. Randomised trials are needed to assess its efficiency in improving survival. Copyright 2010 Elsevier Masson SAS. All rights reserved.

  2. Chemotherapy resistance mechanisms in advanced skin cancer

    Bhuvanesh Sukhlal Kalal


    Full Text Available Melanoma is a most dangerous and deadly type of skin cancer, and considered intrinsically resistant to both radiotherapy and chemotherapy. It has become a major public health concern as the incidence of melanoma has been rising steadily over recent decades with a 5-year survival remaining less than 5%. Detection of the disease in early stage may be curable, but late stage metastatic disease that has spread to other organs has an extremely poor prognosis with a median survival of less than 10 months. Since metastatic melanoma is unresponsive to therapy that is currently available, research is now focused on different treatment strategies such as combinations of surgery, chemotherapy and radiotherapy. The molecular basis of resistance to chemotherapy seen in melanoma is multifactorial; defective drug transport system, altered apoptotic pathway, deregulation of apoptosis and/or changes in enzymatic systems that mediate cellular metabolic machinery. Understanding of alterations in molecular processes involved in drug resistance may help in developing new therapeutic approaches to treatment of malignant melanoma.

  3. New advances in gastrointestinal motility research

    Pullan, A; Farrugia, G


    Research into gastrointestinal motility has received renewed interest in part due to recent advances in the techniques for measuring the structure and function of gastrointestinal cells, tissue and organs. The integration of this wealth of data into biophysically based computation models can aid in interpretation of experimental and clinical measurements and the refinement of measurement techniques. The contents of this book span multiple scales - from cell, tissue, organ, to whole body and is divided into four broad sections covering: i) gastrointestinal cellular activity and tissue structure; (ii) techniques for measuring, analyzing and visualizing high-resolution extra-cellular recordings; (iii) methods for sensing gastroelectrical activity using non-invasive bio-electro-magnetic fields and for modulating the underlying gastric electrical activity, and finally; (iv) methods for assessing manometric and videographic motility patterns and the application of these data for predicting the flow and mixing behav...

  4. Advanced Materials for Exploration Task Research Results

    Cook, M. B. (Compiler); Murphy, K. L.; Schneider, T.


    The Advanced Materials for Exploration (AME) Activity in Marshall Space Flight Center s (MSFC s) Exploration Science and Technology Directorate coordinated activities from 2001 to 2006 to support in-space propulsion technologies for future missions. Working together, materials scientists and mission planners identified materials shortfalls that are limiting the performance of long-term missions. The goal of the AME project was to deliver improved materials in targeted areas to meet technology development milestones of NASA s exploration-dedicated activities. Materials research tasks were targeted in five areas: (1) Thermal management materials, (2) propulsion materials, (3) materials characterization, (4) vehicle health monitoring materials, and (5) structural materials. Selected tasks were scheduled for completion such that these new materials could be incorporated into customer development plans.

  5. REST advanced research topics and practical applications

    Wilde, Erik; Alarcon, Rosa


    This book serves as a starting point for people looking for a deeper principled understanding of REST, its applications, its limitations, and current research work in the area and as an architectural style. The authors focus on applying REST beyond Web applications (i.e., in enterprise environments), and in reusing established and well-understood design patterns. The book examines how RESTful systems can be designed and deployed, and what the results are in terms of benefits and challenges encountered in the process. This book is intended for information and service architects and designers who are interested in learning about REST, how it is applied, and how it is being advanced.

  6. Prostate cancer research in China

    Shan-Cheng Ren; Rui Chen; Ying-Hao Sun


    Prostate cancer (PCa) research in China has been on a rocketing trend in recent years.The first genome-wide association study (GWAS)in China identified two new PCa risk associated single nucleotide polymorphisms (SNPs).Next generation sequencing is beginning to be used,yielding novel findings:gene fusions,long non-coding RNAs and other variations.Mechanisms of PCa progression have been illustrated while various diagnosis biomarkers have been investigated extensively.Personalized therapy based on genetic factors,nano-medicine and traditional Chinese medicine has been the focus of experimental therapeutic research for PCa.This review intends to shed light upon the recent progress in PCa research in China and points out the possible breakthroughs in the future.

  7. Localization of thymidine phosphorylase in advanced gastric and colorectal cancer.

    Kobayashi, Michiya; Okamoto, Ken; Akimori, Toyokazu; Tochika, Naoshige; Yoshimoto, Tadashi; Okabayashi, Takehiro; Sugimoto, Takeki; Araki, Keijiro


    Thymidine phosphorylase (TP) is known to be more concentrated in human cancer tissues than in adjacent normal tissue based on findings using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry. However, the ultrastructural localization of TP in cancer tissues has not previously been demonstrated. We investigated the localization of TP in gastric cancer and colorectal cancer tissue by ELISA, immunohistochemistry, and immunoelectron microscopy. Between April 1997 and May 2000, we obtained surgically resected specimens from 42, 46, and 36 cases of advanced gastric, colon, and rectal cancer, respectively. ELISA demonstrated that the TP level was higher in cancer tissues than in adjacent normal tissue. Immunohistochemically, cancer cells were positive for the enzyme in some cases. However, in a number of cases immunopositive inflammatory cells were also present in cancerous tissues. At the electron microscope level, TP was diffusely distributed in the cytoplasm of cancer cells and in the mitochondria of the neutrophil in gastric cancer tissue. In rectal cancer tissues, cytoplasmic granules in macrophages in cancer tissues were immunoreactive for the TP. These findings suggest that TP is produced by macrophages and exists in neutrophils and cancer cells.

  8. An integrative literature review exploring the clinical management of delirium in patients with advanced cancer.

    Lawley, Hayley; Hewison, Alistair


    To present the findings of an integrative literature review of the evidence for the clinical management of delirium in patients with advanced cancer. Patients with advanced cancer frequently experience delirium which can be distressing for both patients and their families. Current guidelines recommend that underlying causes of the delirium be addressed and a course of antipsychotics considered. However, the research into the effectiveness of treatments for delirium in people with advanced cancer is limited. Integrative literature review. Systematic searches of the MEDLINE, CINAHL, ProQuest Nursing and Allied Health and PsychInfo databases were conducted in April 2016 to include papers published in 2000 and later. The returns were screened using inclusion and exclusion criteria, and the seven studies found to be suitable were subject to review. Findings of the seven papers were extracted, appraised critically and reviewed using a narrative approach. A number of interventions, including the use of atypical antipsychotics, opioid rotation, methylphenidate hydrochloride and coeliac plexus block, were reported; however, there was limited evidence of their effectiveness. One study reported the use of exercise therapy as a nonpharmacological intervention. A variety of interventions to treat delirium in patients with advanced cancer have been tested through nonblinded, nonrandomised trials which have not produced a clear evidence base for practice. The clinical management of delirium in patients with advanced cancer is poorly understood and remains a clinical issue which requires further research (particularity randomized control trials) in order to determine more effective treatments and management strategies. © 2017 John Wiley & Sons Ltd.

  9. Software Tools | Office of Cancer Clinical Proteomics Research

    The CPTAC program develops new approaches to elucidate aspects of the molecular complexity of cancer made from large-scale proteogenomic datasets, and advance them toward precision medicine.  Part of the CPTAC mission is to make data and tools available and accessible to the greater research community to accelerate the discovery process.

  10. Lung Cancer Clinical Trials: Advances in Immunotherapy

    New treatments for lung cancer and aspects of joining a clinical trial are discussed in this 30-minute Facebook Live event, hosted by NCI’s Dr. Shakun Malik, head of thoracic oncology therapeutics, and Janet Freeman-Daily, lung cancer patient activist and founding member of #LCSM.

  11. Neoadjuvant chemotherapy in locally advanced colon cancer

    Jakobsen, Anders; Andersen, Fahimeh; Fischer, Anders


    BACKGROUND: Neoadjuvant chemotherapy has proven valuable in several tumors, but it has not been elucidated in colon cancer. The present phase II trial addressed the issue in high-risk patients selected by computed tomography (CT) scan. MATERIAL AND METHODS: Patients with resectable colon cancer...

  12. Advances of Hypoxia and Lung Cancer

    Xuebing LI


    Full Text Available Lung cancer is one of the malignant tumors with fastest growing rates in incidence and mortality in our country, also with largest threat to human health and life. However, the exact mechanisms underlying lung cancer development remain unclear. The microenvironment of tumor hypoxia was discovered in 1955, but hypoxia in lung cancer tissues had not been successfully detected till 2006. Further studies show that hypoxia not only functions through the resistance to radiotherapy, but also regulates lung cancer development, invasion, metastasis, chemotherapy resistance and prognosis through an important oncogene HIF (hypoxia inducible factor, with its regulators PHD (prolyl hydroxylase domain and pVHL (product of von Hippel-Lindau gene. Therefore, hypoxia, HIF, PHD and pVHL should be considered as potential therapeutic targets for lung cancer pathogenesis and progression.

  13. Current advances in T-cell-based cancer immunotherapy.

    Wang, Mingjun; Yin, Bingnan; Wang, Helen Y; Wang, Rong-Fu


    Cancer is a leading cause of death worldwide; due to the lack of ideal cancer biomarkers for early detection or diagnosis, most patients present with late-stage disease at the time of diagnosis, thus limiting the potential for successful treatment. Traditional cancer treatments, including surgery, chemotherapy and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. Therefore, innovative and effective cancer treatments are urgently needed for cancer patients with late-stage and refractory disease. Cancer immunotherapy, particularly adoptive cell transfer, has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to standard therapies. In this review, we will highlight recent advances and discuss future directions in adoptive cell transfer based cancer immunotherapy.

  14. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02).

    Jost, Christian; Binek, Janek; Schuller, Jan C; Bauerfeind, Peter; Metzger, Urs; Werth, Baseli; Knuchel, Juerg; Frossard, Jean-Louis; Bertschinger, Philipp; Brauchli, Peter; Meyenberger, Christa; Ruhstaller, Thomas


    EUS response assessment in patients with locally advanced esophageal cancer undergoing neoadjuvant chemoradiation therapy (CRT) is limited by disintegration of the involved anatomic structures. Predictive and prognostic values of a prospectively defined maximum tumor thickness (MTT). Prospective open-label phase ll study (SAKK 75/02). Multicenter, nationwide. Of 66 patients with primary CRT, 56 underwent en bloc esophagectomy. EUS-measured MTT before and 2-5 weeks after CRT (yMTT). Cutoffs: (1) absolute thickness (yMTT) after CRT < or = 6 mm; (2) relative reduction compared with baseline (ratio yMTT/MTT) < or = 50%. Correlation between EUS measurements and histopathologic tumor regression grade (TRG) and overall survival (OS). Sixteen of 56 patients were not included for EUS evaluation (10 severe stenosis, 5 MTT not measured, 1 intolerance to second EUS). Characteristics (n = 40) were as follow: median age, 60 years; squamous cell carcinoma, 42%; and adenocarcinoma (AC), 58%. Initial stage was: 10 T2N1, 3 T3N0, 26 T3N1, 1 T3Nx; 14 of 23 AC Siewert type 1. Wilcoxon rank sum test showed significant correlation of TRG1 with yMTT < or = 6 mm (P = .008) and yMTT/MTT < or = 50% (P = .003). The effect of yMTT on TRG1 was significant (P = .0193; odds ratio, 0.687 [95% CI, 0.502-0.941]). The predefined cutoff of < or = 6 mm for yMTT was predictive for TRG1 (P = .0037; Fisher exact test). After a median follow-up of 28.6 months, there was a clear trend for benefit in OS with yMTT < or = 6 mm and yMTT/MTT < or = 50%. Small sample size. In a multicenter setting, MTT measured by EUS after CRT was highly predictive for response and showed a clear trend for predicting survival. Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

  15. Global strategies for the treatment of early-stage and advanced cervical cancer.

    Dueñas-González, Alfonso; Campbell, Sergio


    Recent peer-reviewed publications on the treatment of early, locally advanced and advanced cervical cancer patients are reviewed to gain insight into the main research done in the field. In early-stage patients where cure is offered to most patients, research focuses on more conservative or less morbid approaches to increase quality of life and reduce the treatment-related sexual dysfunction. No major advances have occurred for treating locally advanced disease since the introduction of concurrent chemoradiation, but efforts are directed to increase efficacy while reducing toxicity with the use of combination chemoradiation and modern radiation technologies. Molecular-targeted therapy and identification of targetable gene alterations as well as immunotherapy are actively pursued in patients with advanced disease. Although global statistics indicate a trend for decreased age-standardized incidence rates, social and economical factors impede the uptake of therapeutic advances achieved as many patients have no access even to basic resources for treating cancer. The adherence to quality indicators in delivery of optimized standard concurrent chemoradiation and adherence to guidelines in cervical cancer surgery must not be underestimated. Major efforts are needed in both the scientific and social aspects of cervical cancer treatment to reduce mortality.

  16. Hormone therapy for patients with advanced or recurrent endometrial cancer.

    Lee, Wen-Ling; Yen, Ming-Shyen; Chao, Kuan-Chong; Yuan, Chiou-Chung; Ng, Heung-Tat; Chao, Hsiang-Tai; Lee, Fa-Kung; Wang, Peng-Hui


    The "gold standard" treatment for endometrial cancer is completely staged surgery, followed by radiation or chemotherapy, based on the final pathological surgical stage and requirements. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is an attractive option, and many successful cases have been reported, although the majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed in recurrent disease; response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers are approximately 15-20% and nearly ≤ 10%, respectively. This review is focused on updated information and recent knowledge on the use of hormones in the management of women with advanced or recurrent endometrial cancers.

  17. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer

    Raquel Conde-Muíño


    Full Text Available There has been a high local recurrence rate in rectal cancer. Besides improvements in surgical techniques, both neoadjuvant short-course radiotherapy and long-course chemoradiation improve oncological results. Approximately 40–60% of rectal cancer patients treated with neoadjuvant chemoradiation achieve some degree of pathologic response. However, there is no effective method of predicting which patients will respond to neoadjuvant treatment. Recent studies have evaluated the potential of genetic biomarkers to predict outcome in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. The articles produced by the PubMed search were reviewed for those specifically addressing a genetic profile’s ability to predict response to neoadjuvant treatment in rectal cancer. Although tissue gene microarray profiling has led to promising data in cancer, to date, none of the identified signatures or molecular markers in locally advanced rectal cancer has been successfully validated as a diagnostic or prognostic tool applicable to routine clinical practice.

  18. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer.

    Conde-Muíño, Raquel; Cuadros, Marta; Zambudio, Natalia; Segura-Jiménez, Inmaculada; Cano, Carlos; Palma, Pablo


    There has been a high local recurrence rate in rectal cancer. Besides improvements in surgical techniques, both neoadjuvant short-course radiotherapy and long-course chemoradiation improve oncological results. Approximately 40-60% of rectal cancer patients treated with neoadjuvant chemoradiation achieve some degree of pathologic response. However, there is no effective method of predicting which patients will respond to neoadjuvant treatment. Recent studies have evaluated the potential of genetic biomarkers to predict outcome in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. The articles produced by the PubMed search were reviewed for those specifically addressing a genetic profile's ability to predict response to neoadjuvant treatment in rectal cancer. Although tissue gene microarray profiling has led to promising data in cancer, to date, none of the identified signatures or molecular markers in locally advanced rectal cancer has been successfully validated as a diagnostic or prognostic tool applicable to routine clinical practice.

  19. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer

    Hong Zheng; Jia-Yu Liu; Feng-Ju Song; Ke-Xin Chen


    Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70%of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30%because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.

  20. Basic Research and Progress against Pediatric Cancer

    An infographic about the importance of basic research for making progress against childhood cancers. Shows the milestones that led to development and approval of dinutuximab (Unituxin®) to treat neuroblastoma, a cancer seen mainly in children.

  1. NIH Research Leads to Cervical Cancer Vaccine

    ... Issues Sexually Transmitted Diseases NIH Research Leads to Cervical Cancer Vaccine Past Issues / Fall 2008 Table of Contents ... in women, the cause of the majority of cervical cancers. Photo courtesy of Judy Folkenberg, NLM Writer By ...

  2. Breast Cancer and the Environment Research Program

    The Breast Cancer and the Environment Research Program supports a multidisciplinary network of scientists, clinicians, and community partners to examine the effects of environmental exposures that may predispose a woman to breast cancer throughout her life.

  3. Skin Cancer: NIH Research to Results

    ... of this page please turn Javascript on. Feature: Skin Cancer NIH Research to Results Past Issues / Summer 2013 ... making a person immune to his or her skin cancer cells. Another method is to train a person's ...

  4. Advances of research on PET-CT hypoxia imaging in lung cancer%PET-CT乏氧显像及其在肺癌中的研究进展

    任树华; 华逢春; 赵军


    PET-CT, as a single imaging modality for whole body providing both anatomic and biological information, offer the possibility of in vivo mapping of regional tumor hypoxia with adequate anatomical resolution as well as monitoring therapy through follow-up mapping of hypoxia. Some new advances of research and clinical study on PET-CT hypoxia imaging in lung cancer were summarized briefly, including tracers, the detections of hypoxia, therapy planning, predictioas and outcome.%PET-CT乏氧显像可以在功能和形态上对活体肿瘤乏氧区进行高分辨率的勾画,从而可以对肿瘤的乏氧状况进行定量分析、及时监测.综述了PET-CT乏氧显像对肺癌的生物学评价、治疗方案选择、治疗效果监测及预后预测等方面的应用及存在的问题.

  5. 克里唑替尼治疗晚期非小细胞肺癌的临床研究进展%Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer

    朱海波; 徐小玉; 王玲


    At present,in the treatment of non-small cell lung cancer (NSCLC),targeted therapy has an important status.After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs),crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC.Phase Ⅰ and Ⅱ clinical trials prove that crizotinib is effective for treatment of activating EML4-ALK mutation in advanced NSCLC patients,little side-effect,and well tolerated.Recently,crizotinib can inhibit ROS1 receptor tyrosine kinase and show extraordinary significant antitumor activity in ROS1-rearranged NSCLC.Drug resistance also exists in crizotinib.The mechanism of drug resistance needs further research.In this study,a review is performed in the mechanism and pharmacokinetics of crizotinib,and the clinical progress of treatment in advanced NSCLC.%目前在非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗中,靶向药物治疗占有举足轻重的地位.继表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)之后,针对棘皮动物微管相关蛋白4-间变性淋巴瘤激酶(echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase,EML4-ALK)融合基因突变为靶点的克里唑替尼(crizotinib)成为了NSCLC靶向治疗领域的焦点.Ⅰ期、Ⅱ期临床试验均已证实:crizotinib治疗EML4-ALK阳性晚期NSCLC患者有效,并能改善患者症状,毒副作用小,患者耐受性较好.近期发现crizotinib对ROSI受体酪氨酸激酶也具有抑制作用.Crizotinib在ROS1基因重排NSCLC中显示出了非常明显的抗肿瘤活性.与其它TKIs一样,crizotinib也存在耐药现象,其耐药机制待进一步研究.现就crizotinib作用机制、药代动力学及治疗晚期NSCLC的临床研究进展做一综述.

  6. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: An explorative study


    textabstractBACKGROUND: Inflammation may underlie cancer-related fatigue; however, there are no studies that assess the relation between fatigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between cytokines and the separate dimensions of fatigue is unknown. Here, association of plasma levels of inflammatory markers with physical fatigue and mental fatigue was explored in advanced cancer patients and cancer survivors. METH...

  7. Conceptualizing prognostic awareness in advanced cancer: a systematic review.

    Applebaum, Allison J; Kolva, Elissa A; Kulikowski, Julia R; Jacobs, Jordana D; DeRosa, Antonio; Lichtenthal, Wendy G; Olden, Megan E; Rosenfeld, Barry; Breitbart, William


    This systematic review synthesizes the complex literature on prognostic awareness in cancer. A total of 37 studies examining cancer patients' understanding of their prognosis were included. Prognostic awareness definitions and assessment methods were inconsistent across studies. A surprisingly high percentage of patients (up to 75%) were unaware of their poor prognosis, and in several studies, even their cancer diagnosis (up to 96%), particularly in studies conducted outside of North America. This review highlights surprisingly low rates of prognostic awareness in patients with advanced cancer as well as discrepancies in prognostic awareness assessment, suggesting the need for empirically validated measures of prognostic awareness.

  8. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

    Vogelzang, Nicholas J; Benowitz, Steven I; Adams, Sylvia; Aghajanian, Carol; Chang, Susan Marina; Dreyer, Zoann Eckert; Janne, Pasi A; Ko, Andrew H; Masters, Greg A; Odenike, Olatoyosi; Patel, Jyoti D; Roth, Bruce J; Samlowski, Wolfram E; Seidman, Andrew D; Tap, William D; Temel, Jennifer S; Von Roenn, Jamie H; Kris, Mark G


    A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is expected to become the nation's leading cause of death in the years ahead as our population ages. I believe we can accelerate the pace of progress, provided that everyone involved in cancer care works together to achieve this goal. It is this viewpoint that has shaped the theme for my presidential term: Collaborating to Conquer Cancer. In practice, this means that physicians and researchers must learn from every patient's experience, ensure greater collaboration between members of a patient's medical team, and involve more patients in the search for cures through clinical trials. Cancer advocates, insurers, and government agencies also have important roles to play. Today, we have an incredible opportunity to improve the quality of cancer care by drawing lessons from the real-world experiences of patients. The American Society of Clinical Oncology (ASCO) is taking the lead in this area, in part through innovative use of health information technology. In addition to our existing quality initiatives, ASCO is working with partners to develop a comprehensive rapid-learning system for cancer care. When complete, this system will provide physicians with personalized, real

  9. Cancer cachexia, recent advances, and future directions.

    Penet, Marie-France; Bhujwalla, Zaver M


    Cancer cachexia is defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass with or without loss of fat mass. The syndrome cannot be fully reversed by conventional nutritional support, and despite an increased number of studies related to cancer cachexia, the underlying mechanisms are still poorly defined, and therapeutic options are limited. This review focuses on recent studies investigating mechanisms and pathways in cancer cachexia. The role of molecular and functional imaging in identifying cachexia at an earlier stage, in identifying potential metabolic targets and pathways, and in assessing treatment efficacy is also reviewed.

  10. Adapting Meaning-Centered Psychotherapy in Advanced Cancer for the Chinese Immigrant Population.

    Leng, Jennifer; Lui, Florence; Chen, Angela; Huang, Xiaoxiao; Breitbart, William; Gany, Francesca


    The Chinese immigrant community faces multiple barriers to quality cancer care and cancer survivorship. Meaning-centered psychotherapy (MCP) is an empirically-based treatment shown to significantly reduce psychological distress while increasing spiritual well-being and a sense of meaning and purpose in life in advanced cancer patients. However, it has not yet been adapted for racial and ethnic minority populations for whom the concept of "meaning" may likely differ from that of westernized White populations. In this study, we conducted a community needs assessment to inform the cultural adaptation of MCP for Chinese patients with advanced cancer, in accordance with Bernal et al. ecological validity model and the cultural adaptation process model of Domenech-Rodriquez and Weiling. We conducted interviews until saturation with 11 key Chinese-serving community leaders and health professionals with a range of areas of expertise (i.e. oncology, psychology, palliative care, cancer support services), to examine community needs, priorities, and preferences within the context of the MCP intervention. Sessions were audio recorded and transcribed. The research team analyzed the transcripts using Atlas.ti. Six frequently occurring themes were identified. Interviewees described the role of the family, traditional Chinese values, cancer stigma, and social norms (e.g. saving face) in adapting MCP. Researchers and clinicians should consider the role of the family in treatment, as well as specific social and cultural values and beliefs in adapting and delivering MCP for Chinese patients with advanced cancer.

  11. Sarcopenia and physical function in overweight patients with advanced cancer.

    Prado, Carla M M; Lieffers, Jessica R; Bowthorpe, Lindsay; Baracos, Vickie E; Mourtzakis, Marina; McCargar, Linda J


    Advanced cancer is associated with numerous metabolic abnormalities that may lead to significant body composition changes, particularly muscle loss or sarcopenia. Sarcopenia in cancer has been associated with poor clinical outcomes, including poor physical function. Accurate tools to assess body composition are expensive and not readily available in clinical settings. Unfortunately, little is known about the efficacy of affordable and portable techniques to assess functional status in patients with cancer. We investigated the prevalence of sarcopenia and its association with different portable and low-cost functional status measurement tools (i.e., handgrip strength testing, a two-minute walking test, and a self-report questionnaire) in overweight/obese patients (body mass index ≥ 25 kg/m²) with advanced cancer. Twenty-eight patients (68% men) aged 64.5 ± 9.5 years with advanced lung or colorectal cancer were included. Sarcopenia was assessed by measuring appendicular skeletal muscle (ASM) adjusted by height (ASM index), using dual energy X-ray absorptiometry. Approximately 36% of patients had sarcopenia. Average handgrip strength was greater in men without sarcopenia than in men with it (p=0.035). In men, ASM index was positively correlated with average (r=0.535, p=0.018) and peak handgrip strength (r=0.457, p=0.049). No differences were observed among female patients. Handgrip strength was associated with sarcopenia in male patients with advanced cancer, and therefore it may be used as a portable and simple nutritional screening tool.

  12. Myofacial trigger points in advanced cancer patients

    Hideaki Hasuo


    Full Text Available Myofascial pain syndrome is started to be recognized as one of important factors of pain in cancer patients. However, no reports on features of myofascial trigger points were found in terminally-ill cancer populations. This time, we encountered 5 patients with myofascial pain syndrome and terminal cancer in whom delirium developed due to increased doses of opioid without a diagnosis of myofascial pain syndrome on initial presentation. The delirium subsided with dose reductions of opioid and treatment of myofascial pain syndrome. The common reason for a delayed diagnosis among the patients included an incomplete palpation of the painful sites, which led to unsuccessful myofascial trigger points identification. The features of myofascial trigger points included single onset in the cancer pain management site with opioid and the contralateral abdominal side muscles of the non-common sites. Withdrawal reflexes associated with cancer pain in the supine position, which are increasingly seen in the terminal cancer patients, were considered to have contributed to this siuation.We consider that careful palpation of the painful site is important, in order to obtain greater knowledge and understanding of the features of myofascial trigger points.


    Femi Olaleye

    Running title: Epidural Anaesthesia in Advanced Carcinoma. INTRODUCTION ... underlying muscle. His respiratory rate was ... Digoxin and management of congestive heart failure Omole M.K.. 2. ... the ventricle and suggests an elevated.

  14. Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.

    Kamat, Ashish M; Agarwal, Piyush; Bivalacqua, Trinity; Chisolm, Stephanie; Daneshmand, Sia; Doroshow, James H; Efstathiou, Jason A; Galsky, Matthew; Iyer, Gopa; Kassouf, Wassim; Shah, Jay; Taylor, John; Williams, Stephen B; Quale, Diane Zipursky; Rosenberg, Jonathan E


    The 10th Annual Bladder Cancer Think Tank was hosted by the Bladder Cancer Advocacy Network and brought together a multidisciplinary group of clinicians, researchers, representatives and Industry to advance bladder cancer research efforts. Think Tank expert panels, group discussions, and networking opportunities helped generate ideas and strengthen collaborations between researchers and physicians across disciplines and between institutions. Interactive panel discussions addressed a variety of timely issues: 1) data sharing, privacy and social media; 2) improving patient navigation through therapy; 3) promising developments in immunotherapy; 4) and moving bladder cancer research from bench to bedside. Lastly, early career researchers presented their bladder cancer studies and had opportunities to network with leading experts.

  15. Advancing Women's Social Justice Agendas: A Feminist Action Research Framework

    Colleen Reid


    Feminist action research is a promising, though under-developed, research approach for advancing women's health and social justice agendas. In this article the foundations, principles, dimensions, promises, and challenges of engaging in feminist action research are explored.

  16. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.

    Davis, Mellar P; Khawam, Elias; Pozuelo, Leo; Lagman, Ruth


    Advanced cancer patients are polysymptomatic and often receive multiple medications for symptom relief. Common symptoms include anorexia, weight loss, delirium and depression. Olanzapine and mirtazapine may have several advantages over older agents despite increased acquisition costs. Both medications can treat several symptoms with a low risk for drug-drug interactions and with only once- or twice-daily dosing. Drug side effects are low, compared with more conventionally used agents. The pharmacokinetics and pharmacodynamics of both agents are unique and explain many of the benefits. More research and clinical experience will be necessary to define their role in the palliation of advanced cancer.

  17. Cancer research in India: national priorities, global results.

    Sullivan, Richard; Badwe, Rajendra A; Rath, Goura K; Pramesh, C S; Shanta, V; Digumarti, Raghunadharao; D'Cruz, Anil; Sharma, Suresh C; Viswanath, Lokesh; Shet, Arun; Vijayakumar, Manavalan; Lewison, Grant; Chandy, Mammen; Kulkarni, Priyadarshini; Bardia, M R; Kumar, Shaleen; Sarin, Rajiv; Sebastian, Paul; Dhillon, Preet K; Rajaraman, Preetha; Trimble, Edward L; Aggarwal, Ajay; Vijaykumar, D K; Purushotham, Arnie D


    Over the past 20 years, cancer research in India has grown in size and impact. Clinicians, scientists, and government and state policy makers in India have championed cancer research, from studies to achieve low-tech, large-scale health outcomes to some of the most advanced areas of fundamental cancer science. In this paper, we frame public policy discussions about cancer with use of an in-depth analysis of research publications from India. Cancer research in India is a complex environment that needs to balance public policy across many competing agendas. We identify major needs across these environments such as those for increased research capacity and training and protected time for clinical researchers; for more support from states and enhanced collaborative funding programmes from government; for development of national infrastructures across a range of domains (ie, clinical trials, tissue banking, registries, etc); and for a streamlined and rational regulatory environment. We also discuss improvements that should be made to translate research into improvements in cancer outcomes and public health. Copyright © 2014 Elsevier Ltd. All rights reserved.

  18. Photodynamic Cancer Therapy—Recent Advances

    Abrahamse, Heidi


    The basic principle of the photodynamic effect was discovered over a hundred years ago leading to the pioneering work on PDT in Europe. It was only during the 1980s, however, when "photoradiation therapy" was investigated as a possible treatment modality for cancer. Photodynamic therapy (PDT) is a photochemotherapeutic process which requires the use of a photosensitizer (PS) that, upon entry into a cancer cell is targeted by laser irradiation to initiate a series of events that contribute to cell death. PSs are light-sensitive dyes activated by a light source at a specific wavelength and can be classified as first or second generation PSs based on its origin and synthetic pathway. The principle of PS activation lies in a photochemical reaction resulting from excitation of the PS producing singlet oxygen which in turn reacts and damages cell organelles and biomolecules required for cell function and ultimately leading to cell destruction. Several first and second generation PSs have been studied in several different cancer types in the quest to optimize treatment. PSs including haematoporphyrin derivative (HpD), aminolevulinic acid (ALA), chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbiedes and purpurins all require selective uptake and retention by cancer cells prior to activation by a light source and subsequent cell death induction. Photodynamic diagnosis (PDD) is based on the fluorescence effect exhibited by PSs upon irradiation and is often used concurrently with PDT to detect and locate tumours. Both laser and light emitting diodes (LED) have been used for PDT depending on the location of the tumour. Internal cancers more often require the use of laser light delivery using fibre optics as delivery system while external PDT often make use of LEDs. Normal cells have a lower uptake of the PS in comparison to tumour cells, however the acute cytotoxic effect of the compound on the recovery rate of normal cells is not known. Subcellular

  19. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.

    Dorff, Tanya B; Quek, Marcus L; Daneshmand, Siamak; Pinski, Jacek


    While men with early stage prostate cancer typically enjoy long-term survival after definitive management, for those who present with locally advanced or metastatic disease, survival is compromised. Multimodality therapy can prolong survival in these patients, with state-of-the-art options including intensity-modulated radiation or brachytherapy in conjunction with androgen ablation, adjuvant androgen ablation and/or chemotherapy with radical retropubic prostatectomy. In addition, novel biological therapies are being explored to target the unique molecular changes in prostate cancer cells and their interactions with the microenvironment. With these advances the outlook will undoubtedly improve, even for patients presenting with advanced disease. Careful application of these emerging therapies to a select group of prostate cancer patients most likely to obtain benefit from them is the challenge for urologists, medical oncologists and radiation oncologists for the future.

  20. Advancing cervical cancer prevention in India: implementation science priorities.

    Krishnan, Suneeta; Madsen, Emily; Porterfield, Deborah; Varghese, Beena


    Cervical cancer is the leading cause of cancer mortality in India, accounting for 17% of all cancer deaths among women aged 30 to 69 years. At current incidence rates, the annual burden of new cases in India is projected to increase to 225,000 by 2025, but there are few large-scale, organized cervical cancer prevention programs in the country. We conducted a review of the cervical cancer prevention research literature and programmatic experiences in India to summarize the current state of knowledge and practices and recommend research priorities to address the gap in services. We found that research and programs in India have demonstrated the feasibility and acceptability of cervical cancer prevention efforts and that screening strategies requiring minimal additional human resources and laboratory infrastructure can reduce morbidity and mortality. However, additional evidence generated through implementation science research is needed to ensure that cervical cancer prevention efforts have the desired impact and are cost-effective. Specifically, implementation science research is needed to understand individual- and community-level barriers to screening and diagnostic and treatment services; to improve health care worker performance; to strengthen links among screening, diagnosis, and treatment; and to determine optimal program design, outcomes, and costs. With a quarter of the global burden of cervical cancer in India, there is no better time than now to translate research findings to practice. Implementation science can help ensure that investments in cervical cancer prevention and control result in the greatest impact.

  1. Sunitinib for advanced renal cell cancer

    Chris Coppin


    Full Text Available Chris CoppinBC Cancer Agency and University of British Columbia, Vancouver, CanadaAbstract: Renal cell cancer has been refractory to drug therapy in the large majority of patients. Targeted agents including sunitinib have been intensively evaluated in renal cell cancer over the past 5 years. Sunitinib is an oral small molecule inhibitor of several targets including multiple tyrosine kinase receptors of the angiogenesis pathway. This review surveys the rationale, development, validation, and clinical use of sunitinib that received conditional approval for use in North America and Europe in 2006. In patients with the clear-cell subtype of renal cell cancer and metastatic disease with good or moderate prognostic factors for survival, sunitinib 50 mg for 4 weeks of a 6-week cycle provides superior surrogate and patient-reported outcomes when compared with interferon-alfa, the previous commonly used first-line drug. Overall survival has not yet shown improvement over interferon and is problematic because of patient crossover from the control arm to sunitinib at disease progression. Toxicity is significant but manageable with experienced monitoring. Sunitinib therapy is an important step forward for this condition. High cost and limited efficacy support the ongoing search for further improved therapy.Keywords: renal cell cancer, targeted therapy, sunitinib

  2. Advances in Mycotoxin Research: Public Health Perspectives.

    Lee, Hyun Jung; Ryu, Dojin


    Aflatoxins, ochratoxins, fumonisins, deoxynivalenol, and zearalenone are of significant public health concern as they can cause serious adverse effects in different organs including the liver, kidney, and immune system in humans. These toxic secondary metabolites are produced by filamentous fungi mainly in the genus Aspergillus, Penicillium, and Fusarium. It is challenging to control the formation of mycotoxins due to the worldwide occurrence of these fungi in food and the environment. In addition to raw agricultural commodities, mycotoxins tend to remain in finished food products as they may not be destroyed by conventional processing techniques. Hence, much of our concern is directed to chronic health effects through long-term exposure to one or multiple mycotoxins from contaminated foods. Ideally risk assessment requires a comprehensive data, including toxicological and epidemiological studies as well as surveillance and exposure assessment. Setting of regulatory limits for mycotoxins is considered necessary to protect human health from mycotoxin exposure. Although advances in analytical techniques provide basic yet critical tool in regulation as well as all aspects of scientific research, it has been acknowledged that different forms of mycotoxins such as analogs and conjugated mycotoxins may constitute a significant source of dietary exposure. Further studies should be warranted to correlate mycotoxin exposure and human health possibly via identification and validation of suitable biomarkers.

  3. Eagleworks Laboratories: Advanced Propulsion Physics Research

    White, Harold; March, Paul; Williams, Nehemiah; ONeill, William


    NASA/JSC is implementing an advanced propulsion physics laboratory, informally known as "Eagleworks", to pursue propulsion technologies necessary to enable human exploration of the solar system over the next 50 years, and enabling interstellar spaceflight by the end of the century. This work directly supports the "Breakthrough Propulsion" objectives detailed in the NASA OCT TA02 In-space Propulsion Roadmap, and aligns with the #10 Top Technical Challenge identified in the report. Since the work being pursued by this laboratory is applied scientific research in the areas of the quantum vacuum, gravitation, nature of space-time, and other fundamental physical phenomenon, high fidelity testing facilities are needed. The lab will first implement a low-thrust torsion pendulum (physics and engineering models can be explored and understood in the lab to allow scaling to power levels pertinent for human spaceflight, 400kW SEP human missions to Mars may become a possibility, and at power levels of 2MW, 1-year transit to Neptune may also be possible. Additionally, the lab is implementing a warp field interferometer that will be able to measure spacetime disturbances down to 150nm. Recent work published by White [1] [2] [3] suggests that it may be possible to engineer spacetime creating conditions similar to what drives the expansion of the cosmos. Although the expected magnitude of the effect would be tiny, it may be a "Chicago pile" moment for this area of physics.

  4. [Research advances on interactions among bryophytes].

    Bu, Zhao-Jun; Chen, Xu; Jiang, Li-Hong; Li, Hong-Kai; Zhao, Hong-Yan


    This paper summarized the present research status and advances on the intra- and interspecific positive interaction, intra- and inter-specific competition, niche, and coexistence of bryophytes. Bryophytes are generally the dominant plants in harsh environments, and there is a trade-off between their water retention and light and nutrient resource availability. Because of the lesser importance of competition in harsh environments, the positive interaction among bryophytes is common, but the intra- and inter-specific competition among bryophytes and the competition between bryophytes and vascular plants are not rare. Competition hierarchy may exist among some bryophytes, but often changes with environments. In the process of bryophyte community formation, the random process, nature of colonization, and difference in regeneration strategy can result in the niche overlap and coexistence of bryophytes, and the niche differentiation resulted from competition is also one of the mechanisms for bryophytes coexistence. Bryophytes should not be simply classified as stress tolerated-ruderal life history strategists, and competition is still one of important factors for constructing some bryophyte communities and vegetations co-existed by bryophytes and vascular plants.

  5. Research progress on target therapy of advanced non-small cell lung cancer%晚期非小细胞肺癌靶向治疗的研究进展

    姜文丽; 黄才国


    生物标志物检测使得许多晚期非小细胞肺癌(NSCLC)患者获益。近年来,针对表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)突变呈阳性的NSCLC患者,以吉非替尼、厄洛替尼、阿法替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)和以克唑替尼为代表的ALK-TKI取得了卓越的疗效。但是,大多数第一代EGFR-TKI和ALK-TKI的疗效因为不可避免的继发性耐药而被减弱。目前,第三代EGFR-TKI正是基于第二代EGFR-TKI的耐药机制研发而成。除此之外,还有许多针对其他突变位点的晚期NSCLC维持治疗的靶向抑制剂。遗憾的是,针对突变比例最大的K-RAS突变,尚无疗效确切的靶向药物。因此,基于肿瘤驱动基因突变机制的探索和靶向药物的开发是目前NSCLC的研究热点。%Detection of biomarkers benefited many advanced non-small cell lung cancer (NSCLC ) patients .In recent years ,epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) represented by Gefitinib ,Erlotinib ,Afatinib and an-aplastic lymphoma kinase (ALK) TKIs represented by Crizotinib have remarkable efficacy .However ,the efficacy for most first-generation EGFR-TKI and ALK-TKI is weakened due to secondary resistance .Currently ,the third-generation EGFR-TKI which successfully against drug resistance is based on research and development of the second-generation .In addition ,there are many other targeted inhibitors of mutation sites for advanced NSCLC .Unfortunately ,the largest proportion of Kirsten rat sar-coma viral oncogene homolog (K-RAS) mutation is not targetable with small molecule inhibitors currently .Therefore ,based on mechanisms exploration of tumor driven gene mutation ,its target drug research and development will be greatly addressed in the future .

  6. Managing occupations in everyday life for people with advanced cancer living at home.

    Peoples, Hanne; Brandt, Åse; Wæhrens, Eva E; la Cour, Karen


    People with advanced cancer are able to live for extended periods of time. Advanced cancer can cause functional limitations influencing the ability to manage occupations. Although studies have shown that people with advanced cancer experience occupational difficulties, there is only limited research that specifically explores how these occupational difficulties are managed. To describe and explore how people with advanced cancer manage occupations when living at home. A sub-sample of 73 participants from a larger occupational therapy project took part in the study. The participants were consecutively recruited from a Danish university hospital. Qualitative interviews were performed at the homes of the participants. Content analysis was applied to the data. Managing occupations were manifested in two main categories; (1) Conditions influencing occupations in everyday life and (2) Self-developed strategies to manage occupations. The findings suggest that people with advanced cancer should be supported to a greater extent in finding ways to manage familiar as well as new and more personally meaningful occupations to enhance quality of life.

  7. Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management.

    Mulshine, James L; Avila, Rick; Yankelevitz, David; Baer, Thomas M; Estépar, Raul San Jose; Ambrose, Laurie Fenton; Aldigé, Carolyn R


    The Prevent Cancer Foundation Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management was held in New York, NY on May 16 and 17, 2014. The two goals of the Workshop were to define strategies to drive innovation in precompetitive quantitative research on the use of imaging to assess new therapies for management of early lung cancer and to discuss a process to implement a national program to provide high quality computed tomography imaging for lung cancer and other tobacco-induced disease. With the central importance of computed tomography imaging for both early detection and volumetric lung cancer assessment, strategic issues around the development of imaging and ensuring its quality are critical to ensure continued progress against this most lethal cancer.

  8. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer

    Jørgensen, Charlotte Levin Tykjær; Bjerre, Christina Annette; Ejlertsen, Bent Laursen


    classified as cancer cell TIMP-1 positive. No significant difference for TTP between TIMP-1 positive versus TIMP-1 negative patients was observed in multivariate analysis, and RR did not differ according to TIMP-1 status. However, patients with TIMP-1 positive tumors had a significant reduction in OS events...... and predictive marker in advanced breast cancer patients receiving docetaxel (D) or gemcitabine plus docetaxel (GD). METHODS: Patients with locally advanced or metastatic breast cancer who were assigned to D or GD by participation in a randomized phase III trial were included in the study. Assessment of TIMP-1...... status was performed retrospectively on primary tumor whole-tissue sections by immunohistochemistry and tumor samples were considered positive if epithelial breast cancer cells were stained by the anti-TIMP-1 monoclonal antibody VT7. Time to progression (TTP) was the primary endpoint. Overall survival...

  9. Treatment of advanced rectal cancer after renal transplantation

    Hai-Yi Liu; Xiao-Bo Liang; Yao-Ping Li; Yi Feng; Dong-Bo Liu; Wen-Da Wang


    Renal transplantation is a standard procedure for end-stage renal disease today. Due to immunosuppressive drugs and increasing survival time after renal trans-plantation, patients with transplanted kidneys carry an increased risk of developing malignant tumors. In this case report, 3 patients with advanced rectal can-cer after renal transplantation for renal failure were treated with anterior resection or abdominoperineal resection plus total mesorectal excision, followed by adjuvant chemotherapy. One patient eventually died of metastasized cancer 31 mo after therapy, although his organ grafts functioned well until his death. The other 2 patients were well during the 8 and 21 mo follow-up periods after rectal resection. We therefore strongly argue that patients with advanced rectal cancer should receive standard oncology treatment, including opera-tion and adjuvant treatment after renal transplantation. Colorectal cancer screening in such patients appears justified.

  10. New Perspectives in the Treatment of Advanced Gastric Cancer

    Mahlberg, Rolf; Lorenzen, Sylvie; Thuss-Patience, Peter


    available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed...... differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated, which led to the pivotal phase 3 trial First-Line Advanced Gastric Cancer Study (FLAGS). In FLAGS, 1,053 patients with advanced gastric cancer from 24 non-Asian countries were enrolled. S-1 plus cisplatin...... safety profile. This led to the approval of S-1 in combination with cisplatin in gastric cancer in Europe in 2011. This article reviews the mode of action of S-1, pivotal study results from an EU point of view, and future perspectives....

  11. Relatives' level of satisfaction with advanced cancer care in Greenland

    Augustussen, Mikaela; Hounsgaard, Lise; Pedersen, Michael Lynge


    from health professionals. They experienced a lack of security, worries about the future and a lack of support at home. The study showed a substantial level of dissatisfaction among relatives of patients with advanced cancer. We strongly recommend a focus on psychosocial care, more access......Palliative cancer care in Greenland is provided by health professionals at local level, the national Queen Ingrid's Hospital and at Rigshospitalet in Denmark. To improve and develop care for relatives of patients with advanced cancer, we conducted a mixed method study examining relatives' level...... (66%) and relatives were the most dissatisfied with the lack of inclusion in decision making related to treatment and care (71%) and the length of time required to diagnose cancer (70%). Responses to the open-ended questions revealed that relatives faced challenges in gaining access to information...

  12. Efficacy of c-Met inhibitor for advanced prostate cancer

    Christensen James G


    Full Text Available Abstract Background Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (AR signalling. This suggested that current androgen ablation therapy for prostate cancer activates c-Met expression and may contribute to development of more aggressive, castration resistant prostate cancer (CRPC. Therefore, we directly assessed the efficacy of c-Met inhibition during androgen ablation on the growth and progression of prostate cancer. Methods We tested two c-Met small molecule inhibitors, PHA-665752 and PF-2341066, for anti-proliferative activity by MTS assay and cell proliferation assay on human prostate cancer cell lines with different levels of androgen sensitivity. We also used renal subcapsular and castrated orthotopic xenograft mouse models to assess the effect of the inhibitors on prostate tumor formation and progression. Results We demonstrated a dose-dependent inhibitory effect of PHA-665752 and PF-2341066 on the proliferation of human prostate cancer cells and the phosphorylation of c-Met. The effect on cell proliferation was stronger in androgen insensitive cells. The c-Met inhibitor, PF-2341066, significantly reduced growth of prostate tumor cells in the renal subcapsular mouse model and the castrated orthotopic mouse model. The effect on cell proliferation was greater following castration. Conclusions The c-Met inhibitors demonstrated anti-proliferative efficacy when combined with androgen ablation therapy for advanced prostate cancer.

  13. Clinical experience with intraoperative radiotherapy for locally advanced colorectal cancer

    Shibamoto, Yuta; Takahashi, Masaharu; Abe, Mitsuyuki


    Intraoperative radiotherapy (IORT) was performed on 20 patients with colorectal cancer. IORT with a single dose of 20 to 40 Gy was delivered to the residual tumor, tumor bed, and/or lymphnode regions. Although most of the patients had advanced lesions, local control was achieved in 67 % of the patients when IORT was combined with tumor resection, and 4 patients survived more than 5 years. There were no serious complications, except for contracture or atrophy of the psoas muscle seen in 2 patients. IORT combined with external beam radiotherapy should be a useful adjuvant therapy to surgery for locally advanced colorectal cancer.

  14. Control study of arterial interventional chemotherapy before radical gastrectomy for gastric cancer and simple radical gastrectomy for gastric cancer in treatment of advanced gastric cancer

    Bin Liu


    Objective: To analyze the differences in effect of arterial interventional chemotherapy before radical gastrectomy for gastric cancer and simple radical gastrectomy for gastric cancer in treatment of advanced gastric cancer.Methods:A total of 86 cases of patients with advanced gastric cancer treated in our hospital were selected as research subjects and randomly divided into two groups, observation group received arterial interventional chemotherapy combined with radical gastrectomy for gastric cancer, control group received simple radical gastrectomy for gastric cancer, and then differences in prognosis-associated factors, MMP and Leptin contents as well as tumor marker and telomerase activity levels of two groups were compared.Results:Serum HER-2/neu ECD level of observation group was lower than that of control group, and serum DKK-1, TS and TP levels were higher than those of control group; at each point in time after treatment, serum CA72-4 and CA50 contents of observation group were lower than those of control group; intraoperative MMP-2, MMP-7, MMP-9 and Leptin levels in gastric cancer tissue of observation group were lower than those of control group; telomerase activity value in gastric cancer tissue of observation group after treatment was lower than that of control group, and both PGⅠ positive expression rate and PGⅠ/ PGⅡ ratio were higher than those of control group.Conclusion: Arterial interventional chemotherapy before radical gastrectomy for gastric cancer can lower tumor malignancy, promote the curative effect of radical gastrectomy for gastric cancer and improve long-term prognosis.

  15. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk

    Cheng, I.; Liu, X.; Plummer, S J; Krumroy, L M; Casey, G; Witte, J S


    Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of COX2 and long-term use of NSAIDs appears to modestly lower the risk of prostate cancer. We investigated whether common genetic variation in COX2 influences the risk of advanced prostate canc...

  16. Recent Advances in the Treatment of oral Cancer - An Overview

    M R Divya


    Full Text Available "Necessity is the mother of all inventions". This is also true in case of cancer therapy. Though malignant diseases are being treated by various therapeutic modalities, the greatest drawbacks are recurrence and distant metastases. Few of the treatment methods are also associated with serious side effects, disfigurement and disability. To overcome these setbacks, new treatment methods have been proposed, few of them seem to be very promising. This scientific paper is an overview of the recent advances in cancer therapy.

  17. Second-Line Therapy for Advanced Colorectal Cancer

    Guglielmi, Alessandra P.; Sobrero, Alberto F.


    The availability of irinotecan and oxaliplatin has dramatically altered both first- and second-line treatment of advanced colorectal cancer (CRC) compared with the era in which the sole treatment option in advanced disease was 5-fluorouracil (5-FU). Treatment options and strategies are becoming ever more enriched and complex with the recent availability of biologic agents such as bevacizumab and cetuximab. This article reviews randomized clinical trials assessing second-line treatment after f...

  18. Recent advances in mass spectrometry-based proteomics of gastric cancer

    Kang, Changwon; Lee, Yejin; Lee, J Eugene


    The last decade has witnessed remarkable technological advances in mass spectrometry-based proteomics. The development of proteomics techniques has enabled the reliable analysis of complex proteomes, leading to the identification and quantification of thousands of proteins in gastric cancer cells, tissues, and sera. This quantitative information has been used to profile the anomalies in gastric cancer and provide insights into the pathogenic mechanism of the disease. In this review, we mainly focus on the advances in mass spectrometry and quantitative proteomics that were achieved in the last five years and how these up-and-coming technologies are employed to track biochemical changes in gastric cancer cells. We conclude by presenting a perspective on quantitative proteomics and its future applications in the clinic and translational gastric cancer research. PMID:27729735

  19. Basic research on cancer related to radiation associated medical researches

    Lee, Jong In; Hwang, Dae Yong; Bang, Ho Yoon [and others


    Basic Research on Cancer related to Radiation Associated Medical Researches including 1. Establishment of animal model of colorectal cancer liver metastasis and measurement of angiogenesis, 2. Tissue expression of Tie-1 and Tie-2 in human colorectal cancer, 3. Enhancement of G2/Mphase Cell Fraction by Adenovirus-mediated p53 Gene Transfer in Ovarian Cancer Cell Lines, 4. Clinical Characteristics of the patients with Non-B Non-C Hepatocellular Carcinoma and Frequency of HBV, HCV and TTV Viremia in these Patients, 5. Significance of serum iron and ferritin in patients with stomach cancer, 6. Telomerase assay for early detection of lung cancer, 7. Study on the Usefulness of Aldehyde dehydrogenase-2 Genotyping for Risk Group of Alcohol-related Cancer Screening, 8. Gene therapy using hepatoma specific promoter, 9. Study on the Influence of DNA repair gene, XRCC1 Genotypes on the Risk of Head and Neck Cancer were performed.

  20. Insecure attachment predicts depression and death anxiety in advanced cancer patients.

    Scheffold, Katharina; Philipp, Rebecca; Koranyi, Susan; Engelmann, Dorit; Schulz-Kindermann, Frank; Härter, Martin; Mehnert, Anja


    The prevalence of depression as well as adjustment and anxiety disorders is high in advanced cancer patients, and research exploring intraindividual factors leading to high psychological distress is underrepresented. Cancer patients' feelings about security and trust in their healthcare providers have a significant influence on how they deal with their disease. The perception of social support is affected by patients' attachment styles and influences their reactions to feelings of dependency and loss of control. We therefore aimed to explore attachment and its association with psychological distress in patients with advanced cancer. We obtained data from the baseline measurements of a randomized controlled trial in advanced cancer patients. Patients were sampled from the university medical centers of Hamburg and Leipzig, Germany. The main outcome measures included the Patient Health Questionnaire, the Death and Dying Distress Scale, the Memorial Symptom Assessment Scale, and the Experience in Close Relationships Scale for assessing attachment insecurity. A total of 162 patients were included. We found that 64% of patients were insecurely attached (fearful-avoidant 31%, dismissing 17%, and preoccupied 16%). A dismissing attachment style was associated with more physical symptoms but did not predict psychological distress. A fearful-avoidant attachment style significantly predicted higher death anxiety and depression, whereas preoccupied attachment predicted higher death anxiety only. Overall, insecure attachment contributed to the prediction of depression (10%) and death anxiety (14%). The concept of attachment plays a relevant role in advanced cancer patients' mental health. Healthcare providers can benefit from knowledge of advanced cancer patients' attachment styles and how they relate to specific mental distress. Developing a better understanding of patients' reactions to feelings of dependency and distressing emotions can help us to develop individually

  1. Fighting liver cancer with combination immunotherapies | Center for Cancer Research

    A new clinical trial testing the effectiveness of immunotherapy treatment combinations against liver cancer is enrolling patients at the NIH Clinical Center in Bethesda, Maryland. Individually, immunotherapy drugs harness the power of the human immune system to better identify and kill cancer cells. Now, researchers at the NIH’s Center for Cancer Research have begun to find evidence that the drugs may work far more effectively when taken in combination with other therapies and with each other than when taken alone.

  2. The measurement of response shift in patients with advanced prostate cancer and their partners

    O'Boyle Ciaran


    Full Text Available Abstract Background There is increasing evidence to support the phenomenon of response shift (RS in quality of life (QoL studies, with many current QoL measures failing to allow for this. If significant response shift occurs amongst prostate cancer patients, it will be necessary to allow for this in the design of future clinical research and to reassess the conclusions of previous studies that have not allowed for this source of bias. This study therefore aimed to assess the presence of RS and psychosocial morbidity in patients with advanced prostate cancer and their partners. Methods 55 consecutive advanced prostate cancer patients and their partners completed the Prostate Cancer Patient & Partner questionnaire (PPP, shortly after diagnosis and again at 3 months and 6 months. At the follow-up visits, both patients and partners also completed a then-test in order to assess RS. Results Partners consistently showed greater psychological morbidity than patients in relation to the prostate cancer. This was most marked on the General Cancer Distress (GCD subscale (p Conclusion These results suggest the presence of RS in patients with advanced prostate cancer and their partners, with higher levels of psychosocial morbidity noted amongst partners. This is the first study to identify RS in partners and calls into question the interpretation of all studies assessing changes in QoL that fail to allow for this phenomenon.

  3. Microarray Applications in Cancer Research

    Kim, Il-Jin; Kang, Hio Chung


    DNA microarray technology permits simultaneous analysis of thousands of DNA sequences for genomic research and diagnostics applications. Microarray technology represents the most recent and exciting advance in the application of hybridization-based technology for biological sciences analysis. This review focuses on the classification (oligonucleotide vs. cDNA) and application (mutation-genotyping vs. gene expression) of microarrays. Oligonucleotide microarrays can be used both in mutation-genotyping and gene expression analysis, while cDNA microarrays can only be used in gene expression analysis. We review microarray mutation analysis, including examining the use of three oligonucleotide microarrays developed in our laboratory to determine mutations in RET, β-catenin and K-ras genes. We also discuss the use of the Affymetrix GeneChip in mutation analysis. We review microarray gene expression analysis, including the classifying of such studies into four categories: class comparison, class prediction, class discovery and identification of biomarkers. PMID:20368836

  4. Advanced research workshop: nuclear materials safety

    Jardine, L J; Moshkov, M M


    The Advanced Research Workshop (ARW) on Nuclear Materials Safety held June 8-10, 1998, in St. Petersburg, Russia, was attended by 27 Russian experts from 14 different Russian organizations, seven European experts from six different organizations, and 14 U.S. experts from seven different organizations. The ARW was conducted at the State Education Center (SEC), a former Minatom nuclear training center in St. Petersburg. Thirty-three technical presentations were made using simultaneous translations. These presentations are reprinted in this volume as a formal ARW Proceedings in the NATO Science Series. The representative technical papers contained here cover nuclear material safety topics on the storage and disposition of excess plutonium and high enriched uranium (HEU) fissile materials, including vitrification, mixed oxide (MOX) fuel fabrication, plutonium ceramics, reprocessing, geologic disposal, transportation, and Russian regulatory processes. This ARW completed discussions by experts of the nuclear materials safety topics that were not covered in the previous, companion ARW on Nuclear Materials Safety held in Amarillo, Texas, in March 1997. These two workshops, when viewed together as a set, have addressed most nuclear material aspects of the storage and disposition operations required for excess HEU and plutonium. As a result, specific experts in nuclear materials safety have been identified, know each other from their participation in t he two ARW interactions, and have developed a partial consensus and dialogue on the most urgent nuclear materials safety topics to be addressed in a formal bilateral program on t he subject. A strong basis now exists for maintaining and developing a continuing dialogue between Russian, European, and U.S. experts in nuclear materials safety that will improve the safety of future nuclear materials operations in all the countries involved because of t he positive synergistic effects of focusing these diverse backgrounds of

  5. Novel translational strategies in colorectal cancer research


    Defining translational research is still a complex task. In oncology, translational research implies using our basic knowledge learnt from in vitro and in vivo experiments to directly improve diagnostic tools and therapeutic approaches in cancer patients. Moreover, the better understanding of human cancer and its use to design more reliable tumor models and more accurate experimental systems also has to be considered a good example of translational research. The identification and characterization of new molecular markers and the discovery of novel targeted therapies are two main goals in colorectal cancer translational research. However, the straightforward translation of basic research findings, specifically into colorectal cancer treatment and vice versa is still underway. In the present paper, a summarized view of some of the new available approaches on colorectal cancer translational research is provided. Pros and cons are discussed for every approach exposed.

  6. 77 FR 19744 - Advanced BioPhotonics, Inc., Advanced Viral Research Corp., Brantley Capital Corp., Brilliant...


    ... COMMISSION Advanced BioPhotonics, Inc., Advanced Viral Research Corp., Brantley Capital Corp., Brilliant Technologies Corporation, 4C Controls, Inc., and 2-Track Global, Inc.; Order of Suspension of Trading March 29... information concerning the securities of Advanced BioPhotonics, Inc. because it has not filed any...

  7. Doxorubicin plus paclitaxel in advanced breast cancer

    Dombernowsky, P; Boesgaard, M; Andersen, E


    between administration of a short infusion of doxorubicin followed by a 3-hour infusion of paclitaxel was evaluated. Included were patients with metastatic breast cancer, who received doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2 at intervals of 30 minutes, 4 hours, and 24 hours every 3 weeks......The combination of bolus doxorubicin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) as a 3-hour infusion is highly active in patients with metastatic breast cancer, but it has considerable cardiotoxicity. In this ongoing study, the potential effect of increasing the interval....... As of February 1997, 34 patients have been enrolled, two patients are too early to evaluate, and 13 are continuing treatment. The preliminary response rate is 69% (95% confidence interval, 50% to 84%), ranging from 60% to 80% within the three schedules. The main toxicities consisted of grade 3/4 neutropenia...

  8. Recent advances and future challenges in cancer immunotherapy.

    Okuyama, Namiko; Tamada, Koji; Tamura, Hideto

    Remarkable advances have been made in cancer immunotherapy. Recent treatment strategies, especially chimeric antigen receptor-T (CAR-T) cell therapy and immune checkpoint inhibitors, reportedly achieve higher objective responses and better survival rates than previous immunotherapies for patients with treatment-resistant malignancies, creating a paradigm shift in cancer treatment. Several clinical trials of cancer immunotherapy for patients with various malignancies are ongoing. However, those with certain malignancies, such as low-immunogenic cancers, cannot be successfully treated with T-cell immunotherapy, and subsets of immunotherapy-treated patients relapse, meaning that more effective immunotherapeutic strategies are needed for such patients. Furthermore, the safety, convenience, and cost of cancer immunotherapy need to be improved in the near future. Herein, we discuss recent advances and future challenges in cancer immunotherapy, i.e., the identification of neoantigens for the development of individualized immunotherapies, the development of new CAR-T cell therapies, including so-called armored CAR-T cells that can induce greater clinical effects and thereby achieve longer survival, the development of off-the-shelf treatment regimens using non-self cells or cell lines, and effective cancer immunotherapy combinations.

  9. Technological advances in radiotherapy of rectal cancer

    Appelt, Ane L; Sebag-Montefiore, David


    PURPOSE OF REVIEW: This review summarizes the available evidence for the use of modern radiotherapy techniques for chemoradiotherapy for rectal cancer, with specific focus on intensity-modulated radiotherapy (IMRT) and volumetric arc therapy (VMAT) techniques. RECENT FINDINGS: The dosimetric....... Overall results are encouraging, as toxicity levels - although varying across reports - appear lower than for 3D conformal radiotherapy. Innovative treatment techniques and strategies which may be facilitated by the use of IMRT/VMAT include simultaneously integrated tumour boost, adaptive treatment...

  10. Recent advances in marine drug research

    Vinothkumar, S.; Parameswaran, P.S.

    of action against a panel of 39 cancer cell lines tested. The common cyclic depsipeptides or lipopeptides of sponge origin have lipids of mixed biogenesis (acetogenic or propionogenic), homo-proline or serine or multiple amino / amido groups. Several...

  11. Hypofractionated radiotherapy as local hemostatic agent in advanced cancer

    Malik Tariq Rasool


    Full Text Available Purpose : Tumor bleeding continues to remain a challenge in an oncological setting, and radiotherapy has been studied as a local hemostatic agent. We studied the role of local radiotherapy in controlling bleeding at our center. Materials and Methods : We reviewed 25 treated cases (cancer urinary bladder: 12, lung cancer: 5, cervical cancer: 4, uterine cancer: 1, rectal cancer: 2, schwanoma: 1 at our center from March 2008 to December 2010. All patients had either an advanced or recurrent disease. Radiotherapy schedule was either 20 Gray in 5 fractions or 15 Gray in 5 fractions and was delivered with Cobalt 60. Results and Conclusion : Of 25 patients, 22 (88% responded, and there was complete cessation of bleeding. Both 15 Gray and 20 Gray dose schedule had equal efficacy. Treatment was well tolerated without any intermission. Radiotherapy is a safe and effective option in controlling tumor bleeding.

  12. Advances in the understanding of cancer immunotherapy.

    Shore, Neal D


    The principal role of the immune system is to prevent and eradicate pathogens and infections. The key characteristics or features of an effective immune response include specificity, trafficking, antigen spread and durability (memory). The immune system is recognised to have a critical role in controlling cancer through a dynamic relationship with tumour cells. Normally, at the early stages of tumour development, the immune system is capable of eliminating tumour cells or keeping tumour growth abated; however, tumour cells may evolve multiple pathways over time to evade immune control. Immunotherapy may be viewed as a treatment designed to boost or restore the ability of the immune system to fight cancer, infections and other diseases. Immunotherapy manifests differently from traditional cancer treatments, eliciting delayed response kinetics and thus may be more effective in patients with lower tumour burden, in whom disease progression may be less rapid, thereby allowing ample time for the immunotherapy to evolve. Because immunotherapies may have a different mechanism of action from traditional cytotoxic or targeted biological agents, immunotherapy techniques have the potential to combine synergistically with traditional therapies.

  13. Genomic Datasets for Cancer Research

    A variety of datasets from genome-wide association studies of cancer and other genotype-phenotype studies, including sequencing and molecular diagnostic assays, are available to approved investigators through the Extramural National Cancer Institute Data Access Committee.

  14. Next generation distributed computing for cancer research.

    Agarwal, Pankaj; Owzar, Kouros


    Advances in next generation sequencing (NGS) and mass spectrometry (MS) technologies have provided many new opportunities and angles for extending the scope of translational cancer research while creating tremendous challenges in data management and analysis. The resulting informatics challenge is invariably not amenable to the use of traditional computing models. Recent advances in scalable computing and associated infrastructure, particularly distributed computing for Big Data, can provide solutions for addressing these challenges. In this review, the next generation of distributed computing technologies that can address these informatics problems is described from the perspective of three key components of a computational platform, namely computing, data storage and management, and networking. A broad overview of scalable computing is provided to set the context for a detailed description of Hadoop, a technology that is being rapidly adopted for large-scale distributed computing. A proof-of-concept Hadoop cluster, set up for performance benchmarking of NGS read alignment, is described as an example of how to work with Hadoop. Finally, Hadoop is compared with a number of other current technologies for distributed computing.

  15. Nebraska Prostate Cancer Research Program


    MacDonald, Richard G; Mehta, Parmender P; Mott, Justin L; Naslavsky, Naava; Palanimuthu Ponnusamy, Moorthy; Ramaley, Robert F; Sorgen, Paul L; regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell 19 (2011) 575–586. [29] B.J. Feldman , D... Feldman , The development of androgen-independent prostate cancer, Nat. Rev. Cancer 1 (2001) 34–45. [30] J.D. Debes, D.J. Tindall, Mechanisms of androgen

  16. Survey of cogeneration: Advanced cogeneration research study

    Slonski, M. L.


    The consumption of electricity, natural gas, or fuel oil was surveyed. The potential electricity that could be generated in the SCE service territory using cogeneration technology was estimated. It was found that an estimated 3700 MWe could potentially be generated in Southern California using cogenerated technology. It is suggested that current technology could provide 2600 MWe and advanced technology could provide 1100 MWe. Approximately 1600 MWt is considered not feasible to produce electricity with either current or advanced cogeneration technology.

  17. Value of intraoperative radiotherapy in locally advanced rectal cancer

    Ferenschild, Floris T. J.; Vermaas, Maarten; Nuyttens, Joost J. M. E.; Graveland, Wilfried J.; Marinelli, Andreas W. K. S.; van der Sijp, Joost R.; Wiggers, Theo; Verhoef, Cornelis; Eggermont, Alexander M. M.; de Wilt, Johannes H. W.


    PURPOSE: This study was designed to analyze the results of a multimodality treatment using preoperative radiotherapy, followed by surgery and intraoperative radiotherapy in patients with primary locally advanced rectal cancer. METHODS: Between 1987 and 2002, 123 patients with initial unresectable an

  18. Quality of pathology reports for advanced ovarian cancer

    Verleye, Leen; Ottevanger, Petronella B; Kristensen, Gunnar B


    To assess the quality of surgical pathology reports of advanced stage ovarian, fallopian tube and primary peritoneal cancer. This quality assurance project was performed within the EORTC-GCG 55971/NCIC-CTG OV13 study comparing primary debulking surgery followed by chemotherapy with neoadjuvant ch...

  19. Quality of pathology reports for advanced ovarian cancer

    Verleye, Leen; Ottevanger, Petronella B; Kristensen, Gunnar B


    To assess the quality of surgical pathology reports of advanced stage ovarian, fallopian tube and primary peritoneal cancer. This quality assurance project was performed within the EORTC-GCG 55971/NCIC-CTG OV13 study comparing primary debulking surgery followed by chemotherapy with neoadjuvant...

  20. Advanced Materials and Solids Analysis Research Core (AMSARC)

    The Advanced Materials and Solids Analysis Research Core (AMSARC), centered at the U.S. Environmental Protection Agency's (EPA) Andrew W. Breidenbach Environmental Research Center in Cincinnati, Ohio, is the foundation for the Agency's solids and surfaces analysis capabilities. ...

  1. Advanced Materials and Solids Analysis Research Core (AMSARC)

    The Advanced Materials and Solids Analysis Research Core (AMSARC), centered at the U.S. Environmental Protection Agency's (EPA) Andrew W. Breidenbach Environmental Research Center in Cincinnati, Ohio, is the foundation for the Agency's solids and surfaces analysis capabilities. ...

  2. Dietary patterns of patients with advanced lung or colorectal cancer.

    Prado, Carla M M; Lieffers, Jessica R; Bergsten, Gabriella; Mourtzakis, Marina; Baracos, Vickie E; Reiman, Tony; Sawyer, Michael B; McCargar, Linda J


    The purpose of this study was to identify dietary patterns among patients with advanced cancer. Differences between cancer groups are described, and food groups contributing higher proportions to overall caloric intake are identified. Patients with advanced cancer (n=51) were recruited from a regional cancer centre and completed a three-day dietary record. Food items were categorized according to macronutrient content. After adjustment for body weight, substantial variation in energy intake was observed (range: 13.7 to 55.4 kcal/kg/day). For 49% of patients, protein intake was below recommendations. Overall, patients consumed the largest proportion of their calories from meat (16%), other foods (11%), dessert (9%), fruit (9%), white bread (7%), and milk (7%). Only 5% of patients consumed meal replacement supplements. The results of this descriptive study provide important insights into the dietary habits of patients with advanced cancer. These insights could be translated into the development of effective recommendations for maintaining or improving health and quality of life.

  3. Nutrition and Cancer Prevention Research Practicum | Division of Cancer Prevention

    The Nutritional Science Research Group in the Division of Cancer Prevention at the National Cancer Institute, National Institutes of Health and the Department of Nutrition at the Clinical Center, National Institutes of Health are offering a one week educational opportunity in "Nutrition and Cancer Prevention Research" for individuals with a sustained commitment to nutrition and health promotion. This one-week intense learning session provides specialized instruction in the role of diet and bioactive food components as modifiers of cancer incidence and tumor behavior. |

  4. Proceedings of the first symposium on advanced photon research



    This report consists of 76 contributed papers of the First Symposium on Advanced Photon Research, which was held at Keihanna Plaza and JAERI Advanced Photon Research Center in Kyoto on November 8-9, 1999. The numbers of oral presentations including a special invited talk and poster presentations were 14 and 68, respectively. (J.P.N.)

  5. Concurrent chemoradiotherapy for advanced cervical cancer. A pilot study

    Kodama, Junichi; Hashimoto, Ichiro; Seki, Noriko; Hongo, Atsushi; Mizutani, Yasushi; Miyagi, Yasunari; Yoshinouchi, Mitsuo; Kudo, Takafumi [Okayama Univ. (Japan). School of Medicine


    Recently, attempts have made to use radiotherapy in combination with chemotherapy in various solid tumors including cervical cancer. Twenty-four patients with locally advanced cervical cancer were treated with concurrent Carboplatin (16-24 mg/m{sup 2}/day) or Nedaplatin (20 mg/m{sup 2}/week) and conventional radiotherapy. Of 13 evaluable patients, there were nine complete responders and four partial responders. There was no renal damage or grade 4 hematological toxicity. Gastrointestinal adverse reactions were mild. One patient had grade 3 dermatologic toxicity after delayed radiation therapy. This pilot study suggests that daily Carboplatin or weekly Nedaplatin administered with standard radiation therapy is safe, well-tolerated, and thus may be useful as a radiation sensitizer in the treatment of locally advanced cervical cancer. (author)

  6. Clinical evaluation of chemoradiotherapy for advanced cervical cancer

    Kaneyasu, Yuko; Okawa, Tomohiko [Tokyo Women`s Medical Coll. (Japan); Okawa-Kita, Midori


    Locally advanced cervical cancer has a poor prognosis, poor survival rate, and high local failure rate. A number of questions regarding the optimal agents and schedule of concurrent chemoradiation remain unanswered. To improve the cure rate for advanced or recurrent cervix cancer, we studied intra-arterial infusion chemotherapy (IAIC) with or without radiotherapy. We analyzed 52 cases of advanced or recurrent cervical cancer treated by IAIC with or without radiotherapy. IAIC regimen was separated into two groups: group I consisted of 5-FU+MMC{+-}ADM (30 cases) and group II of CDDP+MMC{+-}5-FU (22 cases). The tip of the catheter was placed in the bifurcation of abdominal aorta or the bilateral internal iliac arteries (7 cases). The overall response rate (CR+PR) was 71%, 87% in patients receiving radiotherapy, 50% in those without radiotherapy, and 100% in primary cases. The five-year survival rate was 20% in primary cases, 14% in recurrent cases, 3% in group I and 38% in group II by chemotherapy regimen. Severe (more than grade III) hematological acute side effects were found in 48% of all cases, but recovered by interruption of drugs. In 7 cases in which the tip of the catheter was placed in internal iliac arteries, there were severe skin ulcers in 2 cases and severe pain of leg or gluteal region which need narcotics in 2 cases. These data suggest that IAIC mainly with cisplatin with or without radiotherapy is one of the effective treatments for advanced or recurrent cervical cancer. But we should check blood flow distribution periodically, and control the concentration of drugs. To improve the survival rate for advanced or recurrent cervical cancer, we should discuss neoadjuvant chemotherapy followed by chemoradiotherapy and maintenance systemic chemotherapy. (author)

  7. Advanced medullary thyroid cancer: pathophysiology and management

    Ferreira CV


    Full Text Available Carla Vaz Ferreira, Débora Rodrigues Siqueira, Lucieli Ceolin, Ana Luiza MaiaThyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, BrazilAbstract: Medullary thyroid carcinoma (MTC is a rare malignant tumor originating from thyroid parafollicular C cells. This tumor accounts for 3%–4% of thyroid gland neoplasias. MTC may occur sporadically or be inherited. Hereditary MTC appears as part of the multiple endocrine neoplasia syndrome type 2A or 2B, or familial medullary thyroid cancer. Germ-line mutations of the RET proto-oncogene cause hereditary forms of cancer, whereas somatic mutations can be present in sporadic forms of the disease. The RET gene encodes a receptor tyrosine kinase involved in the activation of intracellular signaling pathways leading to proliferation, growth, differentiation, migration, and survival. Nowadays, early diagnosis of MTC followed by total thyroidectomy offers the only possibility of cure. Based on the knowledge of the pathogenic mechanisms of MTC, new drugs have been developed in an attempt to control metastatic disease. Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising agents for MTC treatment, and clinical trials have shown encouraging results. Hopefully, the cumulative knowledge about the targets of action of these drugs and about the tyrosine kinase inhibitor-associated side effects will help in choosing the best therapeutic approach to enhance their benefits.Keywords: medullary thyroid carcinoma, proto-oncogene RET, tyrosine kinase inhibitors

  8. MRI for advanced gastric cancer; Especially for scirrhous cancer of the stomach

    Homma, Hisato; Masuko, Eiichi; Saito, Tadanori; Ikeda, Shigeyuki (National Sapporo Hospital (Japan)); Mezawa, Synichi; Betsuyaku, Takashi; Niitsu, Yoshiro


    We conducted MRI examinations in 92 patients with advanced gastric cancer and evaluated the clinical potential of MRI for diagnosis of scirrhous cancer of the stomach. The feature of scirrhous cancer of stomach by MRI are: (1) thickened gastric wall, (2) shortening of T1 and T2 values; and (3) clear contrast between the gastric mucosae and cancer areas found in the T1 and T2 weighted images (preservation of the mucosae). MRI for scirrhous cancer of the stomach is thought a useful image diagnosis as an adjunct method to gastric X-ray and gastric endoscopy. (author).

  9. [Management of pregnant women with advanced cervical cancer].

    Vincens, C; Dupaigne, D; de Tayrac, R; Mares, P


    The purpose of this study is to update the management of pregnant women with advanced cervical cancer, thanks to a literature review indexed in Medline((R)) (from 1980 till 2006 using those keywords: advanced cervix cancer, neoadjuvant chemotherapy and pregnancy), ScienceDirect (from 1990 till 2006) and the French Encyclopédie Médico-Chirurgicale. It occurs that pregnancy is a privileged period to diagnose cervical cancer, particularly in early stages. We ought to beware of symptoms such as vaginal bleeding, which could be underestimated during pregnancy. Colposcopically selected biopsies are reference techniques to confirm the diagnostic. The assessment of extension includes an abdominal and pelvic MRI and echography and a radiography of the chest for locally advanced stages. The decision to interrupt pregnancy should be based on a collegial evaluation and depends on state and histology of disease, patient's desire for pregnancy, as well as gestational age and disease evolution. Cesarean is preferred to natural delivery even though survival rates are the same. The cesarean section prevents from short-term complications and recurrence on the episiotomy, but the hysterotomy type is controversial throughout literature. The prognosis of cervical cancer does not seem to be influenced by pregnancy. Management is the same, even though we have to adapt the treatment from the pregnancy state. No study could show the benefit and the safety of neoadjuvant chemotherapy during pregnancy, due to few cases, but it could be a solution with patients suffering from an advanced cancer and not willing to stop pregnancy. To conclude, the detection by cervical smears should be systematic during pregnancy. When cancer is diagnosed, cesarean section is the favourite way to deliver. Pregnancy does not modify disease's prognosis and the therapeutic choice depends on the stage of the disease.

  10. Research advances of K-ras mutation in the prognosis and targeted therapy of gastric cancer%K-ras 突变在胃癌预后及靶向治疗中的研究进展

    黄荧; 魏嘉; 刘宝瑞


    约30%的人类肿瘤均可发生 K-ras 突变,其中在胰腺癌、结直肠癌和肺癌中尤其常见。近年的研究表明,胃癌中也存在一定的 K-ras 突变,人们还对 K-ras 突变展开了一系列的功能研究。文章介绍了 K-ras 突变在胃癌中的研究现状,尤其是 K-ras 突变在胃癌中的发生情况、K-ras 突变与胃癌临床病理特点及预后的相关性、靶向 K-ras 突变的小分子抑制剂、K-ras 信号通路上相关靶点的靶向药物治疗,提出了未来有潜力的研究方向。%K-ras mutations have been described in 30% of human cancers with significantly different mutation frequencies.High K-ras mutation frequency is found in many cancers such as pancreas and lung cancers, whereas, gastric cancer has a relatively low K-ras mutation frequency.In recent years, numerous researches have focused on the K-ras mutation in gastric cancer.This review summarizes the K-ras mutation frequency in gastric cancer, the relationship of K-ras mutation with clinicopathologic features and prognosis of gastric cancer patients, targeted therapy for K-ras mutated gastric cancer, some small-molecular inhibitors of K-ras, and development of targeted therapy drugs for K-ras signaling pathway in gastric cancer.

  11. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.

    Cheng, I; Liu, X; Plummer, S J; Krumroy, L M; Casey, G; Witte, J S


    Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of COX2 and long-term use of NSAIDs appears to modestly lower the risk of prostate cancer. We investigated whether common genetic variation in COX2 influences the risk of advanced prostate cancer. Nine single-nucleotide polymorphisms (SNPs) in COX2 were genotyped among 1012 men in our case-control study of advanced prostate cancer. Gene-environment interactions between COX2 polymorphisms and NSAID use were also evaluated. Information on NSAID use was obtained by questionnaire. Three SNPs demonstrated nominally statistically significant associations with prostate cancer risk, with the most compelling polymorphism (rs2745557) associated with a lower risk of disease (odds ratio (OR) GC vs GG=0.64; 95% confidence interval (CI): 0.49-0.84; P=0.002). We estimated through permutation analysis that a similarly strong result would occur by chance 2.7% of the time. Nonsteroidal anti-inflammatory drug use was associated with a lower risk of disease in comparison to no use (OR=0.67; 95% CI: 0.52-0.87). No significant statistical interaction between NSAID use and rs2745557 was observed (P=0.12). Our findings suggest that variation in COX2 is associated with prostate cancer risk.

  12. Advances in the proteomic discovery of novel therapeutic targets in cancer

    Guo S


    Full Text Available Shanchun Guo,1 Jin Zou,2 Guangdi Wang3 1Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 2Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA, USA; 3Research Centers in Minority Institutions Cancer Research Program, Xavier University of Louisiana, New Orleans, LA, USA Abstract: Proteomic approaches are continuing to make headways in cancer research by helping to elucidate complex signaling networks that underlie tumorigenesis and disease progression. This review describes recent advances made in the proteomic discovery of drug targets for therapeutic development. A variety of technical and methodological advances are overviewed with a critical assessment of challenges and potentials. A number of potential drug targets, such as baculoviral inhibitor of apoptosis protein repeat-containing protein 6, macrophage inhibitory cytokine 1, phosphoglycerate mutase 1, prohibitin 1, fascin, and pyruvate kinase isozyme 2 were identified in the proteomic analysis of drug-resistant cancer cells, drug action, and differential disease state tissues. Future directions for proteomics-based target identification and validation to be more translation efficient are also discussed. Keywords: proteomics, cancer, therapeutic target, signaling network, tumorigenesis

  13. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

    Grob, Charles S; Danforth, Alicia L; Chopra, Gurpreet S; Hagerty, Marycie; McKay, Charles R; Halberstadt, Adam L; Greer, George R


    Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin. A clinical research unit within a large public sector academic medical center. Twelve adults with advanced-stage cancer and anxiety. In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment. Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance. This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field. Identifier: NCT00302744.

  14. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

    Loibl, S.; Schmidt, A.; Gentilini, O.; Kaufman, B.; Kuhl, C.; Denkert, C.; Minckwitz, G. von; Parokonnaya, A.; Stensheim, H.; Thomssen, C.; Calsteren, K. van; Poortmans, P.; Berveiller, P.; Markert, U.R.; Amant, F.


    Breast cancer during pregnancy (BCP), although rare, is becoming more common and treatment should be as similar as possible to that for nonpregnant young patients with breast cancer. A group of specialists convened to review current guidelines and provide guidance on how recent advances in breast ca

  15. Integrated Advanced Energy Systems Research at IIT

    Hamid Arastoopour


    This report consists of Two research projects; Sustainable Buildings and Hydrogen Storage. Sustainable Building Part includes: Wind and the self powered built environment by professor P. Land and his research group and experimental and computational works by professor D. Rempfer and his research group. Hydrogen Storage part includes: Hydrogen Storage Using Mg-Mixed Metal Hydrides by professor H. Arastoopour and his research team and Carbon Nanostructure as Hydrogen Storage Material by professor J. Prakash and his research team.

  16. Advances in target therapy in lung cancer

    Jean-Paul Sculier


    Full Text Available Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib, anaplastic lymphoma kinase rearrangements (e.g. crizotinib or angiogenesis (drugs under development, or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab or epidermal growth factor receptors (e.g. cetuximab. The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities.

  17. Advancements in medicine from aerospace research

    Wooten, F. T.


    A program designed to find second applications for space technology in the medical field is described. Illustrative examples and clinical test results are included for prosthetic urethral devices, ear oximeter for monitoring leukemia patients, devices for measuring low level CO effects on automobile drivers, radiation dosimeter probe for detecting radiation levels in cancerous areas, and electromyographic muscle trainer.

  18. Borrmann Type 4 Advanced Gastric Cancer: Focus on the Development of Scirrhous Gastric Cancer

    Jung, Kyoungwon; Park, Moo In; Kim, Sung Eun; Park, Seun Ja


    Early diagnosis of Borrmann type 4 advanced gastric cancer (AGC) is very important for improving the prognosis of AGC patients. Because there is no definite mass in most cases of Borrmann type 4 AGC, its accurate diagnosis via endoscopy requires an understanding of its pathogenesis and developmental process. Moreover, many people confuse linitis plastica (LP) type gastric cancer (GC), scirrhous GC, and Borrmann type 4 AGC. To distinguish each of these cancers, knowledge of their endoscopic an...

  19. Advanced imaging research and development at DARPA

    Dhar, Nibir K.; Dat, Ravi


    Advances in imaging technology have huge impact on our daily lives. Innovations in optics, focal plane arrays (FPA), microelectronics and computation have revolutionized camera design. As a result, new approaches to camera design and low cost manufacturing is now possible. These advances are clearly evident in visible wavelength band due to pixel scaling, improvements in silicon material and CMOS technology. CMOS cameras are available in cell phones and many other consumer products. Advances in infrared imaging technology have been slow due to market volume and many technological barriers in detector materials, optics and fundamental limits imposed by the scaling laws of optics. There is of course much room for improvements in both, visible and infrared imaging technology. This paper highlights various technology development projects at DARPA to advance the imaging technology for both, visible and infrared. Challenges and potentials solutions are highlighted in areas related to wide field-of-view camera design, small pitch pixel, broadband and multiband detectors and focal plane arrays.

  20. African Organization for Research and Training in Cancer: position and vision for cancer research on the African Continent

    Ogunbiyi, J. Olufemi; Stefan, D. Cristina; Timothy R. Rebbeck


    The African Organization for Research and training in Cancer (AORTIC) bases the following position statements on a critical appraisal of the state on cancer research and cancer care in Africa including information on the availability of data on cancer burden, screening and prevention for cancer in Africa, cancer care personnel, treatment modalities, and access to cancer care.

  1. Annual Advances in Cancer Prevention Lecture | Division of Cancer Prevention

    2016 Keynote Lecture Polyvalent Vaccines Targeting Oncogenic Driver Pathways A special keynote lecture became part of the NCI Summer Curriculum in Cancer Prevention in 2000. This lecture will be held on Thursday, July 21, 2016 at 1:30pm at Masur Auditorium, Building 10, NIH Main Campus, Bethesda, MD. This year’s keynote speaker is Dr. Mary L. (Nora) Disis, MD. |

  2. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies.

    Wang, Kui; Kievit, Forrest M; Zhang, Miqin


    Compared to conventional treatments, gene therapy offers a variety of advantages for cancer treatment including high potency and specificity, low off-target toxicity, and delivery of multiple genes that concurrently target cancer tumorigenesis, recurrence, and drug resistance. In the past decades, gene therapy has undergone remarkable progress, and is now poised to become a first line therapy for cancer. Among various gene delivery systems, nanoparticles have attracted much attention because of their desirable characteristics including low toxicity profiles, well-controlled and high gene delivery efficiency, and multi-functionalities. This review provides an overview on gene therapeutics and gene delivery technologies, and highlight recent advances, challenges and insights into the design and the utility of nanoparticles in gene therapy for cancer treatment.

  3. Advances on Driver Oncogenes of Squamous Cell Lung Cancer

    Wei HONG


    Full Text Available Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC of the lung is the most frequent histologic subtype in non-small cell lung cancer. Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. The squamous cell carcinoma of the lung has recently shown peculiar molecular characteristics which relate with both carcinogenesis and response to targeted drugs. So far, about 40% of lung squamous cell carcinoma has been found harbouring driver oncogenes, in which fibroblast growth factor receptor 1 (FGFR1 plays important roles. In this review, we will report the mainly advances on some latest driver mutations of squamous cell lung cancer.

  4. [Management of psychiatric inpatients with advanced cancer: a pilot study].

    Rhondali, Wadih; Ledoux, Mathilde; Sahraoui, Fatma; Marotta, Juliette; Sanchez, Vincent; Filbet, Marilène


    The prevalence of cancer is not well established and probably underestimated in long-stay psychiatric inpatients. Psychiatric patients do not have the same access for cancer screening and care. Therapeutic decision-making is a real ethical problem. In this context, access to medical care should be provided by the establishment of guidelines and/or recommendations for this specific population. The aim of our study was to assess how cancer was managed among long term psychiatric inpatients. For this pilot study, we used a mixed methodology: a quantitative part with a retrospective chart review of cancer patients in a psychiatric institution and a qualitative part based on semi-structured interviews with psychiatrists with discourse analysis. Delay in cancer diagnosis can be explained by communication and behavior disorders, inadequate screening, and additional tests often refused by patients. Compliance and ethical issues (i.e. obtaining informed consent) are many pitfalls to optimal cancer care that should be explored in further research.

  5. Clinical research of extensive regional field radiotherapy concurrent with chemotherapy for locally advanced esophageal cancer%局部晚期食管癌扩大野同期放化疗的临床研究

    周超; 杨海华; 胡炜; 柯文婷; 王碧云; 孔敏; 朱成楚


    (GTV) plus a 0.8 cm lateral margin,the tumor plus a nominal 3-5 cm cephalad and caudal margin.Extensive regional field radiotherapy was delivered in two steps:the CTV included the CTV of the involved field plus elective nodal region in the first step;in the second step,the CTV definition was same with the CTV of the involved field.Synchronous chemotherapy regimens included TP and NP.Results 90.1%patients completed planned radiotherapy,all patients in the concurrent chemotherapy groups completed at least one cycle of chemotherapy.The follow-up rate was 99%.Twenty-four and 42 patients completed followed-up more than 24 months in the radiotherapy alone and concurrent chemoradiotherapy group,respectively.The median survival time of the involved field radiotherapy group,involved field chemoradiotherapy group and extensive regional field chemoradiotherapy group was 13,21 and 19 months,respectively;the 2-year overall survival (OS) rate was 15%,48% and 46%,respectively for the three groups.The 2-year OS rate was improved significantly in the chemoradiotherapy group (x2 =6.83,P =0.033).Compared with radiotherapy alone group,the incidence of grade three or four bone marrow suppression was higher in the concurrent chemoradiotherapy group (53%: 0 %,x2 =32.94,P =0.000),the remaining adverse events (acute radiation pneumonitis,acute radiation esophagitis,esophageal fibrosis,late radiation lung injury) had no significant intergroup differences (x2 =5.56,6.70,2.39,0.42,P =0.235,0.349,0.881,0.981).Conclusions Compared with radiotherapy alone,concurrent chemoradiotherapy can improve the survival rate for locally advanced esophageal cancer.The side effects of the extensive regional field radiotherapy combined with chemotherapy is well tolerated.But the efficacy of the extensive regional field radiotherapy combined with chemotherapy needs further research.

  6. Women with inoperable or locally advanced breast cancer -- what characterizes them?

    El-Charnoubi, Waseem Asim Ghulam; Svendsen, Jesper Brink; Tange, Ulla Brix;


    Breast cancer is the most common cancer among Danish women. Locally advanced breast cancer occurs in a relatively large proportion of all new primary breast cancer diagnoses and for unexplained reasons 20-30% of women with breast cancer wait more than eight weeks from the initial breast cancer...

  7. Pancreatic Cancer: Updates on Translational Research and Future Applications

    Evangelos G Sarris


    Full Text Available Pancreatic cancer is one of the most lethal malignancies with a mortality rate almost equal to its incidence. It is ranked as the fourth leading cause of cancer-related deaths in the United States, and despite intensive basic and clinical research over the last few years, the survival benefit for the majority of patients with pancreatic cancer is still disappointing. Due to the absence of specific symptoms and the lack of early detection tests, pancreatic cancer is usually diagnosed at an advanced inoperrable stage and palliative chemotherapy with the purine analogue gemcitabine in combination with the targeted agent erlotinib, remains the mainstay method in the management of these patients. Therefore, there is an imperative need for new findings in the translational research field with prognostic, predictive and therapeutic value. In this paper we summarize five most interesting research abstracts as presented at the 2013 American Society of Clinical Oncology (ASCO Gastrointestinal Cancers Symposium. In particular, we focus on Abstract #141 which investigates the interaction between liver and pancreatic organ damage in patients with pancreatic cancer and the potential contribution of the patatin-like phospholipase domain containing 3 (PNPLA3 gene variation in pancreatic cancer development and on Abstract #149, in which, the prognostic and predictive role of SWI/SNF complex, a chromatin-remodeling complex, is examined. The key role of pharmacogenomics, in terms of predicting response and resistance to chemotherapy in pancreatic cancer patients, is analyzed in Abstract #142 and the contribution of circulating tumor cell detection in the early diagnosis of pancreatic cancer, allowing the avoidance of more invasive procedures like EUS-FNA, is discussed in Abstract #157. Lastly, in Abstract #164, the diagnostic utility of YKL-40 and IL-6 in pancreatic cancer patients is investigated.

  8. Targeting chemotherapy via arterial infusion for advanced gastric cancer

    Zhi-yu CAO


    Full Text Available Objective To evaluate the clinical effects of chemotherapy via arterial infusion in treatment of advanced gastric cancer.Methods Forty-seven patients with advanced gastric cancer were given chemotherapy via arterial infusion.Chemotherapy plan was as follows: 5-Fluorouracil(Fu 500mg/m2,cyclophosphamide(MMX 10mg/m2,Hydroxycamptothecin(HPT 20mg/m2,once per week,2 weeks as a course,a total of 2-3 courses.Results After chemotherapy via arterial infusion,complete remission(CR was achieved in 1 case,partial remission(PR in 28 cases,stabilization of disease(SD in 16 cases,progression of disease(PD was found in 2 cases,and rate with response(CR+PR was 61.7%.Four of 28 PR patients underwent tumorectomy,the pathology revealed the presence of cancer cells around the vascular vessels,manifesting karyopyknosis,karyorrhexis,coagulation and necrosis of cytoplasm,intercellular edema,hyperplasia of fibroblasts,inflammatory cell infiltration,thickening of endothelium,and thrombosis.One,two and three-year survival rates were 70.2%,14.9% and 2.1%,respectively.The average survival period was 17.2 months.Conclusion Targeting chemotherapy via arterial infusion,as a part of the combined treatment,is beneficial to the patients with unresectable advanced gastric cancer.

  9. Improving Goals of Care Discussion in Advanced Cancer Patients


    Primary Stage IV Hepatobiliary; Esophageal; Colorectal Cancer; Glioblastoma; Cancer of Stomach; Cancer of Pancreas; Melanoma; Head or Neck Cancer; Stage III; Stage IV; Lung Cancers; Pancreatic Cancers

  10. Advanced endoscopic imaging for gastric cancer assessment: new insights with new optics?

    Serrano, M; Kikuste, I; Dinis-Ribeiro, M


    The most immediate strategy for improving survival of gastric cancer patients is secondary prevention through diagnosis of early gastric cancer either through screening or follow-up of individuals at high risk. Endoscopy examination is therefore of paramount importance and two general steps are to be known in assessing gastric mucosa - detection and characterization. Over the past decade, the advent of advanced endoscopic imaging technology led to diverse descriptions of these modalities reporting them to be useful in this setting. In this review, we aim at summarizing the current evidence on the use of advance imaging in individuals at high-risk (i.e., advance stages of gastric atrophy/intestinal metaplasia) and in those harbouring neoplastic lesions, and address its potential usefulness providing the readers a framework to use in daily practice. Further research is also suggested.

  11. Activation of the hedgehog pathway in advanced prostate cancer

    McCormick Frank


    Full Text Available Abstract Background The hedgehog pathway plays a critical role in the development of prostate. However, the role of the hedgehog pathway in prostate cancer is not clear. Prostate cancer is the second most prevalent cause of cancer death in American men. Therefore, identification of novel therapeutic targets for prostate cancer has significant clinical implications. Results Here we report that activation of the hedgehog pathway occurs frequently in advanced human prostate cancer. We find that high levels of hedgehog target genes, PTCH1 and hedgehog-interacting protein (HIP, are detected in over 70% of prostate tumors with Gleason scores 8–10, but in only 22% of tumors with Gleason scores 3–6. Furthermore, four available metastatic tumors all have high expression of PTCH1 and HIP. To identify the mechanism of the hedgehog signaling activation, we examine expression of Su(Fu protein, a negative regulator of the hedgehog pathway. We find that Su(Fu protein is undetectable in 11 of 27 PTCH1 positive tumors, two of them contain somatic loss-of-function mutations of Su(Fu. Furthermore, expression of sonic hedgehog protein is detected in majority of PTCH1 positive tumors (24 out of 27. High levels of hedgehog target genes are also detected in four prostate cancer cell lines (TSU, DU145, LN-Cap and PC3. We demonstrate that inhibition of hedgehog signaling by smoothened antagonist, cyclopamine, suppresses hedgehog signaling, down-regulates cell invasiveness and induces apoptosis. In addition, cancer cells expressing Gli1 under the CMV promoter are resistant to cyclopamine-mediated apoptosis. All these data suggest a significant role of the hedgehog pathway for cellular functions of prostate cancer cells. Conclusion Our data indicate that activation of the hedgehog pathway, through loss of Su(Fu or overexpression of sonic hedgehog, may involve tumor progression and metastases of prostate cancer. Thus, targeted inhibition of hedgehog signaling may have

  12. Targeted treatment of advanced and metastatic breast cancer with lapatinib

    Brendan Corkery


    Full Text Available Brendan Corkery1,2, Norma O’Donovan2, John Crown1,21St. Vincent’s University Hospital, Dublin, Ireland; 2National Institute for Cellular Biotechnology, Dublin City University, Dublin, IrelandAbstract: Improved molecular understanding of breast cancer in recent years has led to the discovery of important drug targets such as HER-2 and EGFR. Lapatinib is a potent dual inhibitor of HER-2 and EGFR. Preclinical and phase I studies have shown activity with lapatinib in a number of cancers, including breast cancer, and the drug is well tolerated. The main known drug interactions are with paclitaxel and irinotecan. The most significant side-effects of lapatinib are diarrhea and adverse skin events. Rates of cardiotoxicity compare favorably with trastuzumab, a monoclonal antibody against HER-2. This paper focuses on lapatinib in advanced and metastatic breast cancer, which remains an important therapeutic challenge. Phase II and III studies show activity as monotherapy, and in combination with chemotherapy or hormonal agents. Results from these studies suggest that the main benefit from lapatinib is in the HER-2 positive breast cancer population. Combinations of lapatinib and trastuzumab are also being studied and show encouraging results, particularly in trastuzumab-refractory metastatic breast cancer. Lapatinib may have a specific role in treating HER-2 positive CNS metastases. The role of lapatinib as neoadjuvant therapy and in early breast cancer is also being evaluated.Keywords: HER-2, EGFR, erbB, lapatinib, Tykerb®, tyrosine kinase

  13. Psychological distress in parents of children with advanced cancer.

    Rosenberg, Abby R; Dussel, Veronica; Kang, Tammy; Geyer, J Russel; Gerhardt, Cynthia A; Feudtner, Chris; Wolfe, Joanne


    Parent psychological distress can impact the well-being of childhood cancer patients and other children in the home. Recognizing and alleviating factors of parent distress may improve overall family survivorship experiences following childhood cancer. To describe the prevalence and factors of psychological distress (PD) among parents of children with advanced cancer. Cohort study embedded within a randomized clinical trial (Pediatric Quality of Life and Evaluation of Symptoms Technology [PediQUEST] study). Multicenter study conducted at 3 children's hospitals (Boston Children's Hospital, Children's Hospital of Philadelphia, and Seattle Children's Hospital). Parents of children with advanced (progressive, recurrent, or refractory) cancer. Parental PD, as measured by the Kessler-6 Psychological Distress Scale. Eighty-six of 104 parents completed the Survey About Caring for Children With Cancer (83% participation); 81 parents had complete Kessler-6 Psychological Distress Scale data. More than 50% of parents reported high PD and 16% met criteria for serious PD (compared with US prevalence of 2%-3%). Parent perceptions of prognosis, goals of therapy, child symptoms/suffering, and financial hardship were associated with PD. In multivariate analyses, average parent Kessler-6 Psychological Distress Scale scores were higher among parents who believed their child was suffering highly and who reported great economic hardship. Conversely, PD was significantly lower among parents whose prognostic understanding was aligned with concrete goals of care. Parenting a child with advanced cancer is strongly associated with high to severe levels of PD. Interventions aimed at aligning prognostic understanding with concrete care goals and easing child suffering and financial hardship may mitigate parental PD.

  14. Requirement for a standardised definition of advanced gastric cancer.

    DE Sol, Angelo; Trastulli, Stefano; Grassi, Veronica; Corsi, Alessia; Barillaro, Ivan; Boccolini, Andrea; DI Patrizi, Micol Sole; DI Rocco, Giorgio; Santoro, Alberto; Cirocchi, Roberto; Boselli, Carlo; Redler, Adriano; Noya, Giuseppe; Kong, Seong-Ho


    Each year, ~988,000 new cases of stomach cancer are reported worldwide. Uniformity for the definition of advanced gastric cancer (AGC) is required to ensure the improved management of patients. Various classifications do actually exist for gastric cancer, but the classification determined by lesion depth is extremely important, as it has been shown to correlate with patient prognosis; for example, early gastric cancer (EGC) has a favourable prognosis when compared with AGC. In the literature, the definition of EGC is clear, however, there is heterogeneity in the definition of AGC. In the current study, all parameters of the TNM classification for AGC reported in each previous study were individually analysed. It was necessary to perform a comprehensive systematic literature search of all previous studies that have reported a definition of ACG to guarantee homogeneity in the assessment of surgical outcome. It must be understood that the term 'advanced gastric cancer' may implicate a number of stages of disease, and studies must highlight the exact clinical TNM stages used for evaluation of the study.

  15. Targeting hedgehog signaling in cancer: research and clinical developments

    Xie J


    Full Text Available Jingwu Xie, Christopher M Bartels, Scott W Barton, Dongsheng GuWells Center for Pediatric Research, Division of Hematology and Oncology, Department of Pediatrics, Indiana University Simon Cancer Center, Indiana University, Indianapolis, IN, USAAbstract: Since its first description in Drosophila by Drs Nusslein-Volhard and Wieschaus in 1980, hedgehog (Hh signaling has been implicated in regulation of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of Gorlin syndrome in 1996 by two independent teams. Later, it was shown that Hh signaling may be involved in many types of cancer, including skin, leukemia, lung, brain, and gastrointestinal cancers. In early 2012, the US Food and Drug Administration approved the clinical use of Hh inhibitor Erivedge/vismodegib for treatment of locally advanced and metastatic basal cell carcinomas. With further investigation, it is possible to see more clinical applications of Hh signaling inhibitors. In this review, we will summarize major advances in the last 3 years in our understanding of Hh signaling activation in human cancer, and recent developments in preclinical and clinical studies using Hh signaling inhibitors.Keywords: hedgehog, smoothened, PTCH1, cancer, signal transduction, clinical trials, animal model

  16. Afatinib treatment in advanced non-small cell lung cancer

    Hurwitz JL


    Full Text Available Jane L Hurwitz, Paula Scullin, Lynn CampbellDepartment of Medical Oncology, Northern Ireland Cancer Centre, Belfast, UKAbstract: Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC, prognosis for these patients remains poor. Small molecule epidermal growth factor receptor (EGFR tyrosine kinase inhibitors (TKIs have however provided a new therapeutic option in this disease setting and EGFR mutation testing is now routine practice for newly diagnosed NSCLC patients. A proportion of patients will not respond to first-generation EGFR-TKIs however, and those who do will ultimately develop resistance and disease relapse. Next-generation EGFR-TKIs which inhibit multiple members of the EGFR family are being developed in order to increase sensitivity and overcome resistance to existing agents. Afatinib (BIBW 2992 is an oral, irreversible inhibitor of EGFR and HER2 tyrosine kinases and is the most advanced of these agents in clinical development. Pre-clinical and early-phase clinical trials have demonstrated a favorable safety profile as a single agent and in combination with other anti-cancer agents, and provide evidence of clinical activity in advanced NSCLC. The LUX-Lung trials suggest that for selected patients, afatinib offers symptomatic improvement and prolonged progression-free survival, although this has not yet translated into improved overall survival. This article aims to review the use of EGFR-TKIs in the management of advanced NSCLC and the mechanisms underlying resistance to these agents. We will discuss the current pre-clinical and clinical data regarding afatinib, its potential to overcome resistance to first-generation TKIs, and its emerging role in advanced NSCLC treatment.Keywords: EGFR, tyrosine kinase inhibitor, mutation, LUX-lung

  17. Nutritional management of the patient with advanced cancer.

    Theologides, A


    Protein-calorie malnutrition, vitamin and other deficiencies, and weight loss frequently develop in cancer patients. Although there is no evidence that aggressive nutritional management prolongs survival, it may improve the quality of life. Efforts should be made to maintain adequate daily caloric intake with appropriate food selection and with control of complications interfering with nutrition. In selected patients, intravenous hyperalimentation can provide adequate nutrition during potentially effective chemotherapy or radiotherapy. Elemental diets also may be a source of complete or supplemental nutrition. Further experience with both approaches will help to clarify their role in the nutritional management of the patient with advanced cancer.

  18. Metabolomics approaches and applications in prostate cancer research.

    Zhang, Aihua; Yan, Guangli; Han, Ying; Wang, Xijun


    Prostate cancer is a leading cause of cancer deaths in men worldwide. Although prostate-specific antigen (PSA) has been extensively used as a serum biomarker to detect prostate cancer, this screening method has suffered from a lack of specificities and sensitivities. The successful prevention and treatment of prostate cancer relies on the early and accurate detection of the disease; therefore, more sensitive biomarkers are urgently needed. Prostate has long been known to exhibit unique metabolite profiles, fortunately, metabolomics, the study of all metabolites produced in the body, can be considered most closely related to a patient's phenotype. It may provide clinically useful biomarkers applied toward identifying metabolic alterations in prostate cancer and has introduced new insights into the pathology of prostate cancer. This advanced bioanalytic method may now open door for diagnostics. Metabolomics has a great and largely potential in the field of disease, and the analysis of the cancer metabolome to identify novel biomarkers and targets can now be undertaken in many research laboratories. In this review, we take a closer look at the metabolomics in the field of prostate cancer and highlight the interesting publications as references for the interested reader.

  19. Advance Care Planning Does Not Adversely Affect Hope or Anxiety Among Patients With Advanced Cancer.

    Green, Michael J; Schubart, Jane R; Whitehead, Megan M; Farace, Elana; Lehman, Erik; Levi, Benjamin H


    Many physicians avoid advance care planning (ACP) discussions because they worry such conversations will lead to psychological distress. To investigate whether engaging in ACP using online planning tools adversely affects hope, hopelessness, or anxiety among patients with advanced cancer. Patients with advanced cancer and an estimated survival of two years or less (Intervention group) and a Control group were recruited at a tertiary care academic medical center (2007-2012) to engage in ACP using an online decision aid ("Making Your Wishes Known"). Pre/post and between-group comparisons were made, including hope (Herth Hope Index), hopelessness (Beck Hopelessness Scale), and anxiety (State Trait Anxiety Inventory). Secondary outcomes included ACP knowledge, self-determination, and satisfaction. A total of 200 individuals completed the study. After engaging in ACP, there was no decline in hope or increase in hopelessness in either the Control or Intervention group. Anxiety was likewise unchanged in the Control group but decreased slightly in the Intervention group. Knowledge of ACP (% correct answers) increased in both the groups, but more so in the Intervention group (13% increase vs. 4%; Pplanning tools increases knowledge without diminishing hope, increasing hopelessness, or inducing anxiety in patients with advanced cancer. Physicians need not avoid ACP out of concern for adversely affecting patients' psychological well-being. Copyright © 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

  20. Research opportunities to advance solar energy utilization.

    Lewis, Nathan S


    Major developments, as well as remaining challenges and the associated research opportunities, are evaluated for three technologically distinct approaches to solar energy utilization: solar electricity, solar thermal, and solar fuels technologies. Much progress has been made, but research opportunities are still present for all approaches. Both evolutionary and revolutionary technology development, involving foundational research, applied research, learning by doing, demonstration projects, and deployment at scale will be needed to continue this technology-innovation ecosystem. Most of the approaches still offer the potential to provide much higher efficiencies, much lower costs, improved scalability, and new functionality, relative to the embodiments of solar energy-conversion systems that have been developed to date.

  1. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.

    Wilts, I T; Hutten, B A; Meijers, J C M; Spek, C A; Büller, H R; Kamphuisen, P W


    Procoagulant factors promote cancer progression and metastasis. Protein C is involved in hemostasis, inflammation and signal transduction, and has a protective effect on the endothelial barrier. In mice, administration of activated protein C reduced experimental metastasis. We assessed the association between protein C and mortality in patients with three types of cancer. The study population consisted of patients with advanced prostate, non-small cell lung or pancreatic cancer, who participated in the INPACT trial (NCT00312013). The trial evaluated the addition of nadroparin to chemotherapy in patients with advanced malignancy. Patients were divided into tertiles based on protein C at baseline. The association between protein C levels and mortality was evaluated with Cox proportional hazard models. We analysed 477 patients (protein C tertiles: C level was 107% (IQR 92-129). In the lowest tertile, 75 patients per 100 patient-years died, as compared to 60 and 54 in the middle and high tertile, respectively. Lower levels of protein C were associated with increased mortality (in tertiles: HR for trend 1.18, 95%CI 1.02-1.36, adjusted for age, sex and nadroparin use; as a continuous variable: HR 1.004, 95%CI 1.00-1.008, p=0.07). Protein C seems inversely associated with mortality in patients with advanced prostate, lung and pancreatic cancer. Further research should validate protein C as a biomarker for mortality, and explore the effects of protein C on progression of cancer. Copyright © 2017 Elsevier Ltd. All rights reserved.

  2. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

    Matter-Walstra, K; Ruhstaller, T; Klingbiel, D; Schwenkglenks, M; Dedes, K J


    Endocrine therapy continues to be the optimal systemic treatment for metastatic ER(+)HER2(-) breast cancer. The CDK4/6 inhibitor palbociclib combined with letrozole has recently been shown to significantly improve progression-free survival. Here we examined the cost-effectiveness of this regimen for the Swiss healthcare system. A Markov cohort simulation based on the PALOMA-1 trial (Finn et al. in Lancet Oncol 16:25-35, 2015) was used as the clinical course. Input parameters were based on summary trial data. Costs were assessed from the Swiss healthcare system perspective. Adding palbociclib to letrozole (PALLET) compared to letrozole monotherapy was estimated to cost an additional CHF342,440 and gain 1.14 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio (ICER) of CHF301,227/QALY gained. In univariate sensitivity analyses, no tested variation in key parameters resulted in an ICER below a willingness-to-pay threshold of CHF100,000/QALY. PALLET had a 0 % probability of being cost-effective in probabilistic sensitivity analyses. Lowering PALLET's price by 75 % resulted in an ICER of CHF73,995/QALY and a 73 % probability of being cost-effective. At current prices, PALLET would cost the Swiss healthcare system an additional CHF155 million/year. Palbociclib plus letrozole cannot be considered cost-effective for the first-line treatment of patients with metastatic breast cancer in the Swiss healthcare system.

  3. Advancing Administrative Supports for Research Development

    Briar-Lawson, Katharine; Korr, Wynne; White, Barbara; Vroom, Phyllis; Zabora, James; Middleton, Jane; Shank, Barbara; Schatz, Mona


    Research administrative supports must parallel and reinforce faculty initiatives in research grant procurement. This article features several types of developments that draw on presentations at the National Association of Deans and Directors of Schools of Social Work meetings. Key changes in social work programs are addressed, including the…

  4. Special Education Research Advances Knowledge in Education

    Vaughn, Sharon; Swanson, Elizabeth A.


    Research in special education has yielded beneficial outcomes for students with disabilities as well as typical achieving students. The authors provide examples of the valuable knowledge special education research has generated, including the elements of response to intervention (e.g., screening and progress monitoring), instructional practices…

  5. Japanese advances in fuzzy systems research

    Schwartz, Daniel G.


    During this past summer (1991), I spent two months on an appointment as visiting researcher at Kansai University, Osaka, Japan, and five weeks at the Laboratory for International Fuzzy Engineering Research (LIFE), in Yokohama. Part of the expenses for the time in Osaka, and all the expenses for the visit at LIFE, were covered by ONR. While there I met with most of the key researchers in both fuzzy systems and case-based reasoning. This involved trips to numerous universities and research laboratories at Matsushita/Panasonic, Omron, and Hitachi Corporations. In addition, I spent three days at the Fuzzy Logic Systems Institute (FLSI), Iizuka, and I attended the annual meeting of the Japan Society for Fuzzy Theory and Research (SOFT-91) in Nagoya. The following report elaborates what I learned as a result of those activities.

  6. An ecological framework for cancer communication: implications for research.

    Patrick, Kevin; Intille, Stephen S; Zabinski, Marion F


    The field of cancer communication has undergone a major revolution as a result of the Internet. As recently as the early 1990s, face-to-face, print, and the telephone were the dominant methods of communication between health professionals and individuals in support of the prevention and treatment of cancer. Computer-supported interactive media existed, but this usually required sophisticated computer and video platforms that limited availability. The introduction of point-and-click interfaces for the Internet dramatically improved the ability of non-expert computer users to obtain and publish information electronically on the Web. Demand for Web access has driven computer sales for the home setting and improved the availability, capability, and affordability of desktop computers. New advances in information and computing technologies will lead to similarly dramatic changes in the affordability and accessibility of computers. Computers will move from the desktop into the environment and onto the body. Computers are becoming smaller, faster, more sophisticated, more responsive, less expensive, and--essentially--ubiquitous. Computers are evolving into much more than desktop communication devices. New computers include sensing, monitoring, geospatial tracking, just-in-time knowledge presentation, and a host of other information processes. The challenge for cancer communication researchers is to acknowledge the expanded capability of the Web and to move beyond the approaches to health promotion, behavior change, and communication that emerged during an era when language- and image-based interpersonal and mass communication strategies predominated. Ecological theory has been advanced since the early 1900s to explain the highly complex relationships among individuals, society, organizations, the built and natural environments, and personal and population health and well-being. This paper provides background on ecological theory, advances an Ecological Model of Internet

  7. Research Areas: Causes of Cancer

    Understanding the exposures and risk factors that cause cancer, as well as the genetic abnormalities associated with the disease, has helped us to reduce certain exposures and to ameliorate their harmful effects.

  8. Impact of the Cancer Prevention and Control Research Network: Accelerating the Translation of Research Into Practice.

    Ribisl, Kurt M; Fernandez, Maria E; Friedman, Daniela B; Hannon, Peggy A; Leeman, Jennifer; Moore, Alexis; Olson, Lindsay; Ory, Marcia; Risendal, Betsy; Sheble, Laura; Taylor, Vicky M; Williams, Rebecca S; Weiner, Bryan J


    The Cancer Prevention and Control Research Network (CPCRN) is a thematic network dedicated to accelerating the adoption of evidence-based cancer prevention and control practices in communities by advancing dissemination and implementation science. Funded by the Centers for Disease Control and Prevention and National Cancer Institute, CPCRN has operated at two levels: Each participating network center conducts research projects with primarily local partners as well as multicenter collaborative research projects with state and national partners. Through multicenter collaboration, thematic networks leverage the expertise, resources, and partnerships of participating centers to conduct research projects collectively that might not be feasible individually. Although multicenter collaboration is often advocated, it is challenging to promote and assess. Using bibliometric network analysis and other graphical methods, this paper describes CPCRN's multicenter publication progression from 2004 to 2014. Searching PubMed, Scopus, and Web of Science in 2014 identified 249 peer-reviewed CPCRN publications involving two or more centers out of 6,534 total. The research and public health impact of these multicenter collaborative projects initiated by CPCRN during that 10-year period were then examined. CPCRN established numerous workgroups around topics such as: 2-1-1, training and technical assistance, colorectal cancer control, federally qualified health centers, cancer survivorship, and human papillomavirus. This paper discusses the challenges that arise in promoting multicenter collaboration and the strategies that CPCRN uses to address those challenges. The lessons learned should broadly interest those seeking to promote multisite collaboration to address public health problems, such as cancer prevention and control.

  9. DCB - Cancer Immunology, Hematology, and Etiology Research

    Part of NCI’s Division of Cancer Biology’s research portfolio, studies supported include the characterization of basic mechanisms relevant to anti-tumor immune responses and hematologic malignancies.


    A. D. Zikiryakhodzhaev


    Full Text Available Abstract:The article is devoted to studying the prospects of the use of selective intra-arterial chemotherapy in the treatment of locally advanced breast cancer IIIA, B, C stages. A review of literature on the methods of targent intra-arterial infusion of cytostatics and tumor embolization is performed, also it shows the results of treatment with different chemotherapeutic agents — epirubicin, doxorubicin, taxotere, cisplatin, 5‑fluorouracil, cyclophosphamide.

  11. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer

    Kwak, Yoo Kang; Lee, Jong Hoon; Lee, Myung Ah; Chun, Hoo Geun; Kim, Dong Goo; You, Young Kyoung; Hong, Tae Ho; Jang, Hong Seok [Seoul St. Mary' s Hospital, The Catholic University of Korea College of Medicine, Seoul (Korea, Republic of)


    Survival outcome of locally advanced pancreatic cancer has been poor and little is known about prognostic factors of the disease, especially in locally advanced cases treated with concurrent chemoradiation. This study was to analyze overall survival and prognostic factors of patients treated with concurrent chemoradiotherapy (CCRT) in locally advanced pancreatic cancer. Medical records of 34 patients diagnosed with unresectable pancreatic cancer and treated with definitive CCRT, from December 2003 to December 2012, were reviewed. Median prescribed radiation dose was 50.4 Gy (range, 41.4 to 55.8 Gy), once daily, five times per week, 1.8 to 3 Gy per fraction. With a mean follow-up of 10 months (range, 0 to 49 months), median overall survival was 9 months. The 1- and 2-year survival rates were 40% and 10%, respectively. Median and mean time to progression were 5 and 7 months, respectively. Prognostic parameters related to overall survival were post-CCRT CA19-9 (p = 0.02), the Eastern Cooperative Oncology Group (ECOG) status (p < 0.01), and radiation dose (p = 0.04) according to univariate analysis. In multivariate analysis, post-CCRT CA19-9 value below 180 U/mL and ECOG status 0 or 1 were statistically significant independent prognostic factors associated with improved overall survival (p < 0.01 and p = 0.02, respectively). Overall treatment results in locally advanced pancreatic cancer are relatively poor and few improvements have been accomplished in the past decades. Post-treatment CA19-9 below 180 U/mL and ECOG performance status 0 and 1 were significantly associated with an improved overall survival.

  12. Advanced imaging of colorectal cancer: From anatomy to molecular imaging

    García-Figueiras, Roberto; Baleato-González, Sandra; Padhani, Anwar R.; Marhuenda, Ana; Luna, Antonio; Alcalá, Lidia; Carballo-Castro, Ana; Álvarez-Castro, Ana


    Abstract Imaging techniques play a key role in the management of patients with colorectal cancer. The introduction of new advanced anatomical, functional, and molecular imaging techniques may improve the assessment of diagnosis, prognosis, planning therapy, and assessment of response to treatment of these patients. Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity. This paper will review recent...

  13. Prognostic Tools in Patients With Advanced Cancer: A Systematic Review.

    Simmons, Claribel P L; McMillan, Donald C; McWilliams, Kerry; Sande, Tonje A; Fearon, Kenneth C; Tuck, Sharon; Fallon, Marie T; Laird, Barry J


    In 2005, the European Association for Palliative Care made recommendations for prognostic markers in advanced cancer. Since then, prognostic tools have been developed, evolved, and validated. The aim of this systematic review was to examine the progress in the development and validation of prognostic tools. Medline, Embase Classic and Embase were searched. Eligible studies met the following criteria: patients with incurable cancer, >18 years, original studies, population n ≥100, and published after 2003. Descriptive and quantitative statistical analyses were performed. Forty-nine studies were eligible, assessing seven prognostic tools across different care settings, primary cancer types, and statistically assessed survival prediction. The Palliative Performance Scale was the most studied (n = 21,082), comprising six parameters (six subjective), was externally validated, and predicted survival. The Palliative Prognostic Score composed of six parameters (four subjective and two objective), the Palliative Prognostic Index composed of nine parameters (nine subjective), and the Glasgow Prognostic Score composed of two parameters (two objective) and were all externally validated in more than 2000 patients with advanced cancer and predicted survival. Various prognostic tools have been validated but vary in their complexity, subjectivity, and therefore clinical utility. The Glasgow Prognostic Score would seem the most favorable as it uses only two parameters (both objective) and has prognostic value complementary to the gold standard measure, which is performance status. Further studies comparing all proved prognostic markers in a single cohort of patients with advanced cancer are needed to determine the optimal prognostic tool. Copyright © 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

  14. CCR Interns | Center for Cancer Research

    The CCR "Cancer Research Interns" Program was inaugurated in 2004 to increase the diversity of trainee applicants to the CCR. We have placed 314 students from 2004 to 2016, in labs and branches across the Center for Cancer Research. The CCR Office of Training and Education provides the training dollars, some Service & Supply funds, and travel support for those students who meet the financial eligibility criteria (View/print the 2017 flier).

  15. Advancements in Research Synthesis Methods: From a Methodologically Inclusive Perspective

    Suri, Harsh; Clarke, David


    The dominant literature on research synthesis methods has positivist and neo-positivist origins. In recent years, the landscape of research synthesis methods has changed rapidly to become inclusive. This article highlights methodologically inclusive advancements in research synthesis methods. Attention is drawn to insights from interpretive,…

  16. Strategy to Promote Active Learning of an Advanced Research Method

    McDermott, Hilary J.; Dovey, Terence M.


    Research methods courses aim to equip students with the knowledge and skills required for research yet seldom include practical aspects of assessment. This reflective practitioner report describes and evaluates an innovative approach to teaching and assessing advanced qualitative research methods to final-year psychology undergraduate students. An…

  17. Advancing Women's Social Justice Agendas: A Feminist Action Research Framework

    Colleen Reid


    Full Text Available Feminist action research is a promising, though under-developed, research approach for advancing women's health and social justice agendas. In this article the foundations, principles, dimensions, promises, and challenges of engaging in feminist action research are explored.

  18. Strategy to Promote Active Learning of an Advanced Research Method

    McDermott, Hilary J.; Dovey, Terence M.


    Research methods courses aim to equip students with the knowledge and skills required for research yet seldom include practical aspects of assessment. This reflective practitioner report describes and evaluates an innovative approach to teaching and assessing advanced qualitative research methods to final-year psychology undergraduate students. An…

  19. Advances on research of metabolomics in malignant cancer diagnosis%代谢组学在恶性肿瘤诊断中的应用研究进展

    李雨萌; 陈莹


    Metabolomics for biological metabolite changes was widely accepted,the study of metabolomics is be⁃coming a powerful tool for disease diagnosis and disease mechanism in recent years.In this paper,we review the recent applications of metabonomics study in the diagnosis of malignant tumor.Literatures about the study of meta⁃bonomics in the diagnosis of malignant tumor were summarized according to the classification of tumors.In recent years,metabolomics is widely used in cancer diagnosis,mainly in gastric cancer,liver cancer,lung cancer,esoph⁃ageal cancer,breast cancer,ovarian cancer,prostate cancer,et al.Metabolomics play important role in the aspects of cancer pathogenesis,early diagnosis,differential diagnosis,staging and prognosis.With the development of anal⁃ysis techniques,metabolomics will become an important method in the research of malignant tumor.%近年来代谢组学研究成为疾病诊断、疾病机制研究等的有力手段,对于生物代谢物变化的研究思想已被广泛接受。本文总结了近年来代谢组学研究在恶性肿瘤诊断中的应用,将近几年国内外代谢组学在恶性肿瘤诊断方面相关文献按病种进行归纳整理、总结分析。目前代谢组学用于肿瘤诊断主要集中在胃癌、肝癌、肺癌、食管癌、乳腺癌、卵巢癌、前列腺癌等。代谢组学在恶性肿瘤的发病机制、早期诊断、鉴别诊断、分期及预后判断方面均显示出巨大的发展潜力。随着分析技术的不断发展和完善,代谢组学将成为恶性肿瘤研究的重要手段。

  20. China Advanced Research Reactor Project Progress in 2011


    2011, China Advanced Research Reactor (CARR) Project finished the B stage commissioning and resolved the relative technical problems. Meanwhile, the acceptance items and the cold neutron source were carrying out.

  1. Research and development of advanced materials using ion beam

    Namba, Susumu [Nagasaki Inst. of Applied Science, Nagasaki (Japan)


    A wide range of research and development activities of advanced material synthesis using ion beams will be discussed, including ion beam applications to the state-of-the-art electronics from giant to nano electronics. (author)

  2. The nature of communication work during cancer: advancing the theory of illness trajectories.

    Donovan-Kicken, Erin; Tollison, Andrew C; Goins, Elizabeth S


    More theory development about interpersonal communication during cancer is needed so that scholarship can be advanced and practical applications of findings can be best disseminated and applied. We proposed an evidence-based extension to the theory of illness trajectories based on findings from a qualitative study of cancer survivors' (n = 40) experiences with communication. Grounding our analysis in respondents' descriptions of the demands, obligations, and preparatory activities involved in discussing their cancer, we theorized the construct of communication work, which focuses on the labor and resources devoted to managing talk during cancer and living with illness. Findings are discussed in terms of how this conceptualization presents new opportunities for research and practice.

  3. [Current status and future prospect of internal medicine treatment for advanced esophageal cancer].

    Wang, F; Fan, Q X


    Esophageal cancer (EC) is one of common malignant tumors, and the incidence and mortality of EC in China rank the first place in the world. Because of the occult onset, the early atypical symptoms, and the lack of effective early diagnostic methods, most of patients are diagnosed at an advanced stage of the disease and lost the chance of surgery. Comprehensive treatment including palliative medical treatment, molecular targeted therapy, immunotherapy and so on is appropriate for these patients. How to choose the chemotherapy regimen and formulate reasonable treatment plan has become a hot spot in clinical research. Molecular targeted drugs have become a new developmental direction in cancer treatment because of their high specificity and antitumor activity, but the effects on esophageal cancer remain controversial. With the development of immune check point blockade treatment, breakthrough has been made in tumor immunotherapy, which has become an important means in cancer comprehensive treatment and shown a good prospect of treatment.

  4. Radiotherapy combined with surgery as treatment for advanced cervical cancer

    Perches, R.D.; Lobaton, A.T.; Garcia, M.C.


    Experience obtained in a group of 44 patients with advanced cervical cancer is reported. In this study, patients with residual cancer underwent laparotomy eight weeks after one or two different radiotherapy protocols. Sixty-eight percent of patients underwent radical surgery, 85% of patients pelvic exenterations, and 15% radical hysterectomies. In 27% of patients, no evidence of residual cancer was found in surgical specimens. Radical surgery was well tolerated, and one-third of patients were free of disease for one year or more. Control of disease was obtained in 50% of pelvic extenterations and in 60% of radical hysterectomies, regardless of prognosis, clinical stage or radiotherapy scheme. Although results show an improvement of up to 22% when comparing this to other more conventional treatments, it has been concluded that a wider experience in order to support the findings must be obtained.

  5. Radiotherapy combined with surgery as treatment for advanced cervical cancer

    Perches, R.D.; Lobaton, A.T.; Garcia, M.C.


    Experience obtained in a group of 44 patients with advanced cervical cancer is reported. In this study, patients with residual cancer underwent laparotomy eight weeks after one or two different radiotherapy protocols. Sixty-eight percent of patients underwent radical surgery, 85% of patients pelvic exenterations, and 15% radical hysterectomies. In 27% of patients, no evidence of residual cancer was found in surgical specimens. Radical surgery was well tolerated, and one-third of patients were free of disease for one year or more. Control of disease was obtained in 50% of pelvic extenterations and in 60% of radical hysterectomies, regardless of prognosis, clinical stage or radiotherapy scheme. Although results show an improvement of up to 22% when comparing this to other more conventional treatments, it has been concluded that we must obtain a wider experience in order to support the findingsmust be obtained.

  6. Radiotherapy combined with surgery as treatment for advanced cervical cancer.

    Perches, R D; Lobaton, A T; Garcia, M C


    Experience obtained in a group of 44 patients with advanced cervical cancer is reported here. In this study, patients with residual cancer underwent laparotomy eight weeks after one or two different radiotherapy protocols. Sixty-eight percent of patients underwent radical surgery, 85% of patients pelvic exenterations, and 15% radical hysterectomies. In 27% of patients, no evidence of residual cancer was found in surgical specimens. Radical surgery was well tolerated, and one-third of patients were free of disease for one year or more. Control of disease was obtained in 50% of pelvic exenterations and in 60% of radical hysterectomies, regardless of prognosis, clinical stage or radiotherapy scheme. Although results show an improvement of up to 22% when comparing this to other more conventional treatments, we have concluded that we must obtain a wider experience in order to support our findings.

  7. Evidence-based approaches to other symptoms in advanced cancer.

    Dy, Sydney Morss; Apostol, Colleen C


    Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer. We updated previous systematic reviews of how these symptoms can be alleviated with targeted literature searches. The approach to these symptoms requires comprehensive symptom assessment; treating underlying causes when benefits exceed risks; prioritizing treatment, as patients usually have many symptoms; and addressing psychosocial and spiritual distress. For dyspnea, evidence supports systemic opioids and nonpharmacological treatments such as a fan. The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction. For anorexia, enteral or parenteral nutrition is indicated with obstruction and expected prognosis of at least 6 weeks. Evidence supports several drugs for appetite affecting quality of life. For fatigue, evidence supports psychosocial interventions and methylphenidate. For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  8. Locally advanced colon cancer with cutaneous invasion: case report.

    Tenreiro, Nádia; Ferreira, Cátia; Silva, Silvia; Marques, Rita; Ribeiro, Artur; Sousa, Paulo Jorge; Luís, Fernando Próspero


    Locally advanced colon cancer with direct abdominal wall and skin invasion is an extremely rare finding with most data being derived from case reports, historical autopsy-based or single-center retrospective studies. We present a unique case of a colon cancer with direct cutaneous invasion and colocutaneous fistulization. Eighty-six year old Caucasian female with multiple comorbidities, referred to Surgical Consultation due to ulcerated skin lesion in the abdomen. She had a long-standing large umbilical hernia but with no previous episodes of incarceration or occlusive symptoms. She denied any digestive or constitutional symptoms. Physical examination showed a large non-reducible umbilical hernia, with an associated painless firm mass within the hernia sac and cutaneous ulcerated growth. Colonoscopy revealed transverse colon cancer (endoscopic biopsy of the tumor and skin punch biopsy confirmed adenocarcinoma of the colon). Computed tomography showed a tumoral mass within the umbilical hernia, with cutaneous infiltration and enlarged regional lymph nodes. Rapid local progression led to colocutaneous fistula with total fecal diversion. We performed an extended right hemicolectomy with en bloc excision of the hernia sac and infiltrating cutaneous mass. In the current era of widespread use of screening colonoscopies, initial diagnosis of locally advanced colon cancer is decreasing. However, this unique case presented an opportunity to recall the advantages of multivisceral resections.

  9. Individual Approach In Treatment Of Advanced Stomach Cancer

    D Juraev


    Full Text Available Background: To study efficiency of the combined treatment of advanced gastric cancer with inclusion Trastuzumab.Material: We present the intermediate analysis of the use of target therapy with Trastuzumab in patients with a HER2-positive gastric cancer. Up to 01.10.2009y 118 patients have been tested for HER-2 expression, and in 24 gastric cancer patients it is revealed HER2-positive status of tumor. It is lead chemotherapy to all patients by the PLF regimen and Herceptin in doze 6 mg/kg once in 3 weeks (6 cycles. In control group in 26 patients it is lead only chemotherapy by the PLF regimen once in 3 weeks without addition Trastuzumab (6 cycles.Results:  At the moment of the analysis of preliminary data, the median remission duration in compared groups has made 8.3 months, and 5.2 months, accordingly.Conclusion: At advanced gastric cancer with high level HER-2 expression Trastuzumab increases frequency of objective effect and the median remission duration.

  10. Postoperative chemoradiotherapy in high risk locally advanced gastric cancer

    Song, Sang Hyuk; Chie, Eui Kyu; Kim, Kyu Bo; Lee, Hyuk Joon; Yang, Han Kwang; Han, Sae Won; Oh, Do Youn; Im, Seok Ah; Bang, Yung Jue; Ha, Sung W. [Seoul National University College of Medicine, Seoul(Korea, Republic of)


    To evaluate treatment outcome of patients with high risk locally advanced gastric cancer after postoperative chemoradiotherapy. Between May 2003 and May 2012, thirteen patients who underwent postoperative chemoradiotherapy for gastric cancer with resection margin involvement or adjacent structure invasion were retrospectively analyzed. Concurrent chemotherapy was administered in 10 patients. Median dose of radiation was 50.4 Gy (range, 45 to 55.8 Gy). The median follow-up duration for surviving patients was 48 months (range, 5 to 108 months). The 5-year overall survival rate was 42% and the 5-year disease-free survival rate was 28%. Major pattern of failure was peritoneal seeding with 46%. Loco-regional recurrence was reported in only one patient. Grade 2 or higher gastrointestinal toxicity occurred in 54% of the patients. However, there was only one patient with higher than grade 3 toxicity. Despite reported suggested role of adjuvant radiotherapy with combination chemotherapy in gastric cancer, only very small portion of the patients underwent the treatment. Results from this study show that postoperative chemoradiotherapy provided excellent locoregional control with acceptable and manageable treatment related toxicity in patients with high risk locally advanced gastric cancer. Thus, postoperative chemoradiotherapy may improve treatment result in terms of locoregional control in these high risk patients. However, as these findings are based on small series, validation with larger cohort is suggested.

  11. Gemcitabine in elderly patients with advanced pancreatic cancer

    Olivia Hentic; Chantal Dreyer; Vinciane Rebours; Magaly Zappa; Philippe Lévy; Eric Raymond; Philippe Ruszniewski; Pascal Hammel


    AIM: To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS: All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC). RESULTS: Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer (metastatic: n = 20, locally advanced: n = 18) were studied. Among them, 30 (79%) were able to receive chemotherapy [median number: 9 infusions (1-45)]. Six patients (23%) had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients (11%) had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo). CONCLUSION: Tolerance and efficacy of gemcitabinebased chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.

  12. Conceptualizing and Advancing Research Networking Systems



    Science in general, and biomedical research in particular, is becoming more collaborative. As a result, collaboration with the right individuals, teams, and institutions is increasingly crucial for scientific progress. We propose Research Networking Systems (RNS) as a new type of system designed to help scientists identify and choose collaborators, and suggest a corresponding research agenda. The research agenda covers four areas: foundations, presentation, architecture, and evaluation. Foundations includes project-, institution- and discipline-specific motivational factors; the role of social networks; and impression formation based on information beyond expertise and interests. Presentation addresses representing expertise in a comprehensive and up-to-date manner; the role of controlled vocabularies and folksonomies; the tension between seekers’ need for comprehensive information and potential collaborators’ desire to control how they are seen by others; and the need to support serendipitous discovery of collaborative opportunities. Architecture considers aggregation and synthesis of information from multiple sources, social system interoperability, and integration with the user’s primary work context. Lastly, evaluation focuses on assessment of collaboration decisions, measurement of user-specific costs and benefits, and how the large-scale impact of RNS could be evaluated with longitudinal and naturalistic methods. We hope that this article stimulates the human-computer interaction, computer-supported cooperative work, and related communities to pursue a broad and comprehensive agenda for developing research networking systems. PMID:24376309

  13. Conceptualizing and Advancing Research Networking Systems.

    Schleyer, Titus; Butler, Brian S; Song, Mei; Spallek, Heiko


    Science in general, and biomedical research in particular, is becoming more collaborative. As a result, collaboration with the right individuals, teams, and institutions is increasingly crucial for scientific progress. We propose Research Networking Systems (RNS) as a new type of system designed to help scientists identify and choose collaborators, and suggest a corresponding research agenda. The research agenda covers four areas: foundations, presentation, architecture, and evaluation. Foundations includes project-, institution- and discipline-specific motivational factors; the role of social networks; and impression formation based on information beyond expertise and interests. Presentation addresses representing expertise in a comprehensive and up-to-date manner; the role of controlled vocabularies and folksonomies; the tension between seekers' need for comprehensive information and potential collaborators' desire to control how they are seen by others; and the need to support serendipitous discovery of collaborative opportunities. Architecture considers aggregation and synthesis of information from multiple sources, social system interoperability, and integration with the user's primary work context. Lastly, evaluation focuses on assessment of collaboration decisions, measurement of user-specific costs and benefits, and how the large-scale impact of RNS could be evaluated with longitudinal and naturalistic methods. We hope that this article stimulates the human-computer interaction, computer-supported cooperative work, and related communities to pursue a broad and comprehensive agenda for developing research networking systems.

  14. Cancer research and therapy: Where are we today?

    Sampada Sawant


    Full Text Available Till date scientists are struggling to understand the complete mechanism of carcinogenesis. In future, the real time detection of cancer may help scientists to identify some of the complicated biological mechanisms. Certain special features of cancer cells enable researchers to deliver the drug or to develop the right drug therapy. These cell properties include over expression or over activity in uptake of certain nutrients e.g. folic acid and increased permeability. Listed properties might vary depending upon the type of cancer and can be fully exploited by using nanoparticles either to detect the site of cancer or to direct the drug at the affected site. Product approach like drug conjugates, complexes serves as a good platform to solve issues like solubility, toxicity, poor penetration and stability related to cancer drugs. Beside this, several drug delivery platforms are under development by researchers in academia as well as in industry to deliver therapeutic molecules and new chemical entities to the targeted site in body. Amongst them, nanotechnology both at molecular and supramolecular level is a leading platform and can help to image, detect and treat cancer. Surface modification of nanoparticles by coating or anchoring their surface with special markers, materials, peptide, proteins, antibodies or antigens add extra feature and thereby can enhance the effectiveness. These treatments can be used individually or in combined form. In this review, advances on nanotechnological platform are discussed together with some assisting techniques like magnetic field, photo or light field, sonic rays are touched upon. New biological therapies that are advancing in this direction include the antisense therapy, cell therapy, gene therapy, radiation therapy and SiRNA interfaces which are discussed in brief in this article. This article gives short overview on use of complementary and alternative medicine for treatment of cancer such as traditional

  15. Research advance in wood composites in China


    Wood composites can generally be classified in three parts: laminated composites, mixed composites and penetrated composites. Every part has its own characteristic and can be further divided. This paper introduces the history and the state of development of wood composites in China. The research about glue-laminated timber is rare and the industry hardly comes to being. A great of achievements have been obtained in mixed composites and it is well industrialized. Many studies on scrimber have been done and the Chinese researchers are looking for a feasible way to develop the scrimber industry in China. Chinese researchers also spent so much energy in studying wood plastic composites (WPC), but it has not been industrialized due to the high cost.

  16. 人文关怀结合姑息护理在晚期癌症患者中的应用研究%The Applsed Research of Humanistic Care Combined with Palliative Care in Patients with Advanced Cancer



    Objective To explore and analyze humanistic care combined with palliative care in patients with advanced cancer. Methods 60 cases of patients with advanced cancer were selected from our hospital as the object of study, and divided into two groups randomly, observation group and control group, 30 in each group. Observation group was given humanistic care combined with palliative care, control group used palliative care treatment program. The clinical efficacy of two groups were observed and analyzed. Results Unamfortable reaction such as pain, anxiety, depression, loss of appetite in observation group were higher than control group, and nursing work satisfaction in this group was higher than control group (P<0.05), statistically significant. Conclusion In the course of treatment for patients with advanced cancer, humanistic care combined with palliative care treatment program is significantly better than any treatment programs without palliortive care.%目的:探究与分析人文关怀结合姑息护理在晚期癌症患者中的应用研究。方法选取我院收治的60例晚期癌症患者为研究对象,随机分为观察组和对照组,每组各30例。观察组采用人文关怀结合姑息护理的治疗方案;对照组采用常规护理方式。观察并分析两组患者经不同方案治疗后的临床疗效。结果观察组患者在癌症中的不适反应如疼痛、焦虑、抑郁、食欲不振等较对照组患者少,并且对本组护理工作的满意度较对照组高(P<0.05),具有统计学意义。结论在对晚期癌症患者的治疗过程中,人文关怀结合姑息护理治疗方案较不采用任何关怀的方案效果更加显著,不仅能够大大减轻癌症带来的痛苦,还能改善患者生活质量与心理状况,因此在临床上具有一定的积极意义。

  17. 姑息护理在86例晚期癌症患者中的应用研究%Research on Palliative Care in 86 Cases of Advanced Cancer Patients

    赖碧红; 周桂英; 瞿春霞; 朱燕华


    目的:研究姑息护理对晚期癌症患者生活质量的影响.方法:遴选86例晚期癌症患者进行姑息护理,内容包括基础护理、癌痛评估与控制、心理支持等.实施姑息护理前及实施1月后,用癌症患者生活质量自评量表对患者进行评分,并行统计学处理.结果:患者实施姑息护理后的生活质量显著提高,较姑息护理前差异有统计学意义 (P <0.05).患者住院期间死亡21例,死亡率24.42%,临终的时候患者安静平和,其家属可以接受失去亲人的事实.结论:进行姑息护理可以提高晚期癌症患者的生活质量,满足患者及亲属身心各方面需求,减轻患者疾病痛苦,使其平静接受死亡.%Objective: To study the palliative care for advanced cancer patients quality of life. Method : The selection of 86 cases of advanced cancer patients with palliative nursing care, including basic nursing, pain assessment and control, mental support. Implementation of palliative nursing care, a month later, evaluated the quality of life of patients in palliative nursing with self-rating scale. Result: Quality of life in patients improved significantly with palliative nursing care, the difference was statistically significant (P<0.05) in patients during hospitalization and 21 cases died, mortality was 24. 42% , dying patients are calm, families can reason to accept the fact that lost their loved ones. Conclusion: The implementation of a palliative care can improve the quality of life in patients with advanced cancer and their relatives, meet the physical and mental demands, relieve patients suffering, and to accept death calmly.

  18. Clinical research on treating the Qixu syndrome of advanced cancer with the Shenfu injection%参附注射液治疗晚期肺癌气虚证的临床研究

    杨万全; 王恳


    Objective: To observe clinical efifcacy of the Shenfu injection on advanced cancer of the Qixu syndrome. Methods: 60 cases were randomly divided into the treatment group and the control group, 30 cases in each group. The control group was treated by basic TCM, symptomatic treatment and nutritional support; the treatment group was given the Shenfu injection more. In treatment, symptoms of deifciency points, survival quality, cellular immune function and side effects in patients were observed, in order to evaluate the clinical effects with the Shenfu injection on advanced cancer of the Qixu syndrome. Results: In the treatment group, Qixu symptoms, the quality of life and the immune function which improved were better (P0.05). Conclusion: The Shenfu injection can have a good clinical effect on Qixu syndrome in patients with advanced lung cancer, which is safe and worthy of popularization.%目的:观察参附注射液治疗晚期肺癌气虚证的临床疗效。方法:将符合标准的病例共60例,采用随机数字法分为治疗组与对照组,每组各30例,对照组予中医基础抑瘤治疗、对症治疗及营养支持,治疗组在对照组的基础上予静滴参附注射液治疗,治疗周期结束时观察两组患者的气虚证症状总积分、生存质量评分、细胞免疫功能及毒副作用情况,评价参附注射液治疗晚期肺癌气虚证的临床疗效。结果:治疗组在改善患者的气虚证症状、提高生存质量、增强免疫功能方面均优于对照组(P0.05)。结论:参附注射液能对晚期肺癌患者的气虚证有较好的临床疗效,安全性好,值得推广使用。

  19. Clinical research on patients with advanced gastric cancer treated with mFOLFOX6%mFOLFOX6方案治疗28例进展期胃癌的临床研究

    李秀翠; 姜维美


    目的 观察改良FOLFOX6(mFOLFOX6)方案治疗进展期胃癌的临床疗效和毒副反应.方法 28例进展期胃癌采用奥沙利铂(L-OHP) 85 mg·m-2,d1(2 h);甲酰四氢叶酸(CF) 200 mg·m-2,d1(2 h);5-氟尿嘧啶(5-Fu) 400 mg·m-2,d1,5-Fu 2 400~3 000 mg·m-2,维持静脉滴注(CIV)46 h,每14 d为1周期,完成4周期后评价疗效.结果 全组28例,完全缓解2例(7.14%),部分缓解10例(35.71%),稳定11例(39.29%),进展5例(17.86%),近期有效率(CR+PR)为42.86%.最常见的毒副反应为血液学毒性、神经毒性及胃肠道毒性.结论 mFOLFOX6方案治疗进展期胃癌疗效可靠,毒副反应可以耐受.%Objective To study the efficacy and toxicity of the chemotherapy regimen mF0LF0X6 for 28 cases of patients with advanced gastric cancer. Methods L-OHP 85 mg · M-2 ,iv infusion for 2 hours,dl ,CF 200 mg · M-2 for 2 hours,dl ;5-Fu 400 mg · M-2 ,iv bolus,5-Fu 2 400 ~3 000 mg · M-2 ,civ infusion for 46 hours, repeated every 2 weeks. 28 patients with advanced gastric cancer were studied. Results There were 2 cases CR ( 7. 14% ) and 10 cases PR ( 35. 71% ), 11 cases SD ( 39. 29% ) and 5cases PD ( 17. 86% ). The overall response rate( CR + PR )was 42. 86% . The main toxicies were gastrointestinal adverse effects,bone marrow suppression and neuro-sensory toxicity. Conclusion mF0LF0X6 has better efficacy for advanced gastric cancer, and its toxicity is tolerable.

  20. Advanced energy projects; FY 1995 research summaries



    The AEP Division supports projects to explore novel energy-related concepts which are typically at an early stage of scientific development, and high-risk, exploratory concepts. Topical areas presently receiving support are: novel materials for energy technology, renewable and biodegradable materials, exploring uses of new scientific discoveries, alternate pathways to energy efficiency, alternative energy sources, and innovative approaches to waste treatment and reduction. There were 46 research projects during FY 1995; ten were initiated during that fiscal year. The summaries are separated into grant and laboratory programs, and small business innovation research programs.

  1. CRISPR-Cas9: from Genome Editing to Cancer Research.

    Chen, Si; Sun, Heng; Miao, Kai; Deng, Chu-Xia


    Cancer development is a multistep process triggered by innate and acquired mutations, which cause the functional abnormality and determine the initiation and progression of tumorigenesis. Gene editing is a widely used engineering tool for generating mutations that enhance tumorigenesis. The recent developed clustered regularly interspaced short palindromic repeats-CRISPR-associated 9 (CRISPR-Cas9) system renews the genome editing approach into a more convenient and efficient way. By rapidly introducing genetic modifications in cell lines, organs and animals, CRISPR-Cas9 system extends the gene editing into whole genome screening, both in loss-of-function and gain-of-function manners. Meanwhile, the system accelerates the establishment of animal cancer models, promoting in vivo studies for cancer research. Furthermore, CRISPR-Cas9 system is modified into diverse innovative tools for observing the dynamic bioprocesses in cancer studies, such as image tracing for targeted DNA, regulation of transcription activation or repression. Here, we view recent technical advances in the application of CRISPR-Cas9 system in cancer genetics, large-scale cancer driver gene hunting, animal cancer modeling and functional studies.

  2. Cancer systems biology: signal processing for cancer research

    Olli Yli-Harja; Antti Ylip(a)(a); Matti Nykter; Wei Zhang


    In this editorial we introduce the research paradigms of signal processing in the era of systems biology. Signal processing is a field of science traditionally focused on modeling electronic and communications systems, but recently it has turned to biological applications with astounding results. The essence of signal processing is to describe the natural world by mathematical models and then, based on these models, develop efficient computational tools for solving engineering problems. Here, we underline, with examples, the endless possibilities which arise when the battle-hardened tools of engineering are applied to solve the problems that have tormented cancer researchers. Based on this approach, a new field has emerged, called cancer systems biology. Despite its short history, cancer systems biology has already produced several success stories tackling previously impracticable problems. Perhaps most importantly, it has been accepted as an integral part of the major endeavors of cancer research, such as analyzing the genomic and epigenomic data produced by The Cancer Genome Atlas (TCGA) project. Finally, we show that signal processing and cancer research, two fields that are seemingly distant from each other, have merged into a field that is indeed more than the sum of its parts.

  3. Cancer systems biology: signal processing for cancer research.

    Yli-Harja, Olli; Ylipää, Antti; Nykter, Matti; Zhang, Wei


    In this editorial we introduce the research paradigms of signal processing in the era of systems biology. Signal processing is a field of science traditionally focused on modeling electronic and communications systems, but recently it has turned to biological applications with astounding results. The essence of signal processing is to describe the natural world by mathematical models and then, based on these models, develop efficient computational tools for solving engineering problems. Here, we underline, with examples, the endless possibilities which arise when the battle-hardened tools of engineering are applied to solve the problems that have tormented cancer researchers. Based on this approach, a new field has emerged, called cancer systems biology. Despite its short history, cancer systems biology has already produced several success stories tackling previously impracticable problems. Perhaps most importantly, it has been accepted as an integral part of the major endeavors of cancer research, such as analyzing the genomic and epigenomic data produced by The Cancer Genome Atlas (TCGA) project. Finally, we show that signal processing and cancer research, two fields that are seemingly distant from each other, have merged into a field that is indeed more than the sum of its parts.

  4. INEEL Advanced Radiotherapy Research Program Annual Report 2001

    Venhuizen, James R.


    This report summarizes the major activities and accomplishments of the Idaho National Engineering and Environmental Laboratory (INEEL) Advanced Radiotherapy Research Program for calendar year 2001. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, and neutron source design and demonstration are described. Contributions in the fields of physics and biophysics include development of advanced patient treatment planning software, feasibility studies of accelerator neutron source technology for Neutron Capture Therapy (NCT), and completion of major modifications to the research reactor at Washington State University to produce an epithermal-neutron beam for NCT research applications.

  5. INEEL Advanced Radiotherapy Research Program Annual Report 2001

    Venhuizen, James Robert


    This report summarizes the major activities and accomplishments of the Idaho National Engineering and Environmental Laboratory (INEEL) Advanced Radiotherapy Research Program for calendar year 2001. Applications of supportive research and development, as well as technology deployment in the fields of chemistry, radiation physics and dosimetry, and neutron source design and demonstration are described. Contributions in the fields of physics and biophysics include development of advanced patient treatment planning software, feasibility studies of accelerator neutron source technology for Neutron Capture Therapy (NCT), and completion of major modifications to the research reactor at Washington State University to produce an epithermal-neutron beam for NCT research applications.

  6. Advanced Energy Projects: FY 1993, Research summaries


    AEP has been supporting research on novel materials for energy technology, renewable and biodegradable materials, new uses for scientific discoveries, alternate pathways to energy efficiency, alternative energy sources, innovative approaches to waste treatment and reduction, etc. The summaries are grouped according to projects active in FY 1993, Phase I SBIR projects, and Phase II SBIR projects. Investigator and institutional indexes are included.

  7. Advances in Bayesian Modeling in Educational Research

    Levy, Roy


    In this article, I provide a conceptually oriented overview of Bayesian approaches to statistical inference and contrast them with frequentist approaches that currently dominate conventional practice in educational research. The features and advantages of Bayesian approaches are illustrated with examples spanning several statistical modeling…

  8. Advances in Design-Based Research

    Svihla, Vanessa


    Design-based research (DBR) is a core methodology of the Learning Sciences. Historically rooted as a movement away from the methods of experimental psychology, it is a means to develop "humble" theory that takes into account numerous contextual effects for understanding how and why a design supported learning. DBR involves iterative…

  9. Advancing translational research with the Semantic Web.

    Ruttenberg, Alan; Clark, Tim; Bug, William; Samwald, Matthias; Bodenreider, Olivier; Chen, Helen; Doherty, Donald; Forsberg, Kerstin; Gao, Yong; Kashyap, Vipul; Kinoshita, June; Luciano, Joanne; Marshall, M Scott; Ogbuji, Chimezie; Rees, Jonathan; Stephens, Susie; Wong, Gwendolyn T; Wu, Elizabeth; Zaccagnini, Davide; Hongsermeier, Tonya; Neumann, Eric; Herman, Ivan; Cheung, Kei-Hoi


    A fundamental goal of the U.S. National Institute of Health (NIH) "Roadmap" is to strengthen Translational Research, defined as the movement of discoveries in basic research to application at the clinical level. A significant barrier to translational research is the lack of uniformly structured data across related biomedical domains. The Semantic Web is an extension of the current Web that enables navigation and meaningful use of digital resources by automatic processes. It is based on common formats that support aggregation and integration of data drawn from diverse sources. A variety of technologies have been built on this foundation that, together, support identifying, representing, and reasoning across a wide range of biomedical data. The Semantic Web Health Care and Life Sciences Interest Group (HCLSIG), set up within the framework of the World Wide Web Consortium, was launched to explore the application of these technologies in a variety of areas. Subgroups focus on making biomedical data available in RDF, working with biomedical ontologies, prototyping clinical decision support systems, working on drug safety and efficacy communication, and supporting disease researchers navigating and annotating the large amount of potentially relevant literature. We present a scenario that shows the value of the information environment the Semantic Web can support for aiding neuroscience researchers. We then report on several projects by members of the HCLSIG, in the process illustrating the range of Semantic Web technologies that have applications in areas of biomedicine. Semantic Web technologies present both promise and challenges. Current tools and standards are already adequate to implement components of the bench-to-bedside vision. On the other hand, these technologies are young. Gaps in standards and implementations still exist and adoption is limited by typical problems with early technology, such as the need for a critical mass of practitioners and installed base

  10. Cancer Research Participation Beliefs and Behaviors of a Southern Black Population: A Quantitative Analysis of the Role of Structural Factors in Cancer Research Participation.

    Farr, Deeonna E; Brandt, Heather M; Comer, Kimberly D; Jackson, Dawnyéa D; Pandya, Kinjal; Friedman, Daniela B; Ureda, John R; Williams, Deloris G; Scott, Dolores B; Green, Wanda; Hébert, James R


    Increasing the participation of Blacks in cancer research is a vital component of a strategy to reduce racial inequities in cancer burden. Community-based participatory research (CBPR) is especially well-suited to advancing our knowledge of factors that influence research participation to ultimately address cancer-related health inequities. A paucity of literature focuses on the role of structural factors limiting participation in cancer research. As part of a larger CBPR project, we used survey data from a statewide cancer needs assessment of a Black faith community to examine the influence of structural factors on attitudes toward research and the contributions of both structural and attitudinal factors on whether individuals participate in research. Regression analyses and non-parametric statistics were conducted on data from 727 adult survey respondents. Structural factors, such as having health insurance coverage, experiencing discrimination during health care encounters, and locale, predicted belief in the benefits, but not the risks, of research participation. Positive attitudes toward research predicted intention to participate in cancer research. Significant differences in structural and attitudinal factors were found between cancer research participants and non-participants; however, directionality is confounded by the cross-sectional survey design and causality cannot be determined. This study points to complex interplay of structural and attitudinal factors on research participation as well as need for additional quantitative examinations of the various types of factors that influence research participation in Black communities.

  11. TCGA researchers identify 4 subtypes of stomach cancer

    Stomach cancers fall into four distinct molecular subtypes, researchers with The Cancer Genome Atlas (TCGA) Network have found. Scientists report that this discovery could change how researchers think about developing treatments for stomach cancer, also c

  12. Infectious Agents and Cancer Epidemiology Research Webinar Series

    Infectious Agents and Cancer Epidemiology Research Webinar Series highlights emerging and cutting-edge research related to infection-associated cancers, shares scientific knowledge about technologies and methods, and fosters cross-disciplinary discussions on infectious agents and cancer epidemiology.

  13. Accelerating cancer systems biology research through Semantic Web technology.

    Wang, Zhihui; Sagotsky, Jonathan; Taylor, Thomas; Shironoshita, Patrick; Deisboeck, Thomas S


    Cancer systems biology is an interdisciplinary, rapidly expanding research field in which collaborations are a critical means to advance the field. Yet the prevalent database technologies often isolate data rather than making it easily accessible. The Semantic Web has the potential to help facilitate web-based collaborative cancer research by presenting data in a manner that is self-descriptive, human and machine readable, and easily sharable. We have created a semantically linked online Digital Model Repository (DMR) for storing, managing, executing, annotating, and sharing computational cancer models. Within the DMR, distributed, multidisciplinary, and inter-organizational teams can collaborate on projects, without forfeiting intellectual property. This is achieved by the introduction of a new stakeholder to the collaboration workflow, the institutional licensing officer, part of the Technology Transfer Office. Furthermore, the DMR has achieved silver level compatibility with the National Cancer Institute's caBIG, so users can interact with the DMR not only through a web browser but also through a semantically annotated and secure web service. We also discuss the technology behind the DMR leveraging the Semantic Web, ontologies, and grid computing to provide secure inter-institutional collaboration on cancer modeling projects, online grid-based execution of shared models, and the collaboration workflow protecting researchers' intellectual property. Copyright © 2012 Wiley Periodicals, Inc.

  14. Research advances on transgenic plant vaccines.

    Han, Mei; Su, Tao; Zu, Yuan-Gang; An, Zhi-Gang


    In recent years, with the development of genetics molecular biology and plant biotechnology, the vaccination (e.g. genetic engineering subunit vaccine, living vector vaccine, nucleic acid vaccine) programs are taking on a prosperous evolvement. In particular, the technology of the use of transgenic plants to produce human or animal therapeutic vaccines receives increasing attention. Expressing vaccine candidates in vegetables and fruits open up a new avenue for producing oral/edible vaccines. Transgenic plant vaccine disquisitions exhibit a tempting latent exploiting foreground. There are a lot of advantages for transgenic plant vaccines, such as low cost, easiness of storage, and convenient immune-inoculation. Some productions converged in edible tissues, so they can be consumed directly without isolation and purification. Up to now, many transgenic plant vaccine productions have been investigated and developed. In this review, recent advances on plant-derived recombinant protein expression systems, infectious targets, and delivery systems are presented. Some issues of high concern such as biosafety and public health are also discussed. Special attention is given to the prospects and limitations on transgenic plant vaccines.

  15. Clinical cancer research: the past, present and the future.

    DeVita, Vincent T; Eggermont, Alexander M M; Hellman, Samuel; Kerr, David J


    In the past decade, we have witnessed unprecedented changes and some remarkable advances that have enabled true personalized medicine. Nevertheless, many challenges in clinical cancer research remain and need to be overcome if we are to witness similar progress in the next decade. Such hurdles include, but are not limited to, clinical development and testing of multiple agents in combination, design of clinical trials to best accommodate the ever increasing knowledge of heterogeneity of the disease, regulatory challenges relating to drug development and trial design, and funding for basic research. With this in mind, we asked four leading cancer researchers from around the world, and who have been associated with the journal since its launch in November 2004 what, in their opinion, we have learnt over the past 10 years and how we should progress in the next 10 years.

  16. Alliance Against Cancer, the network of Italian cancer centers bridging research and care.

    De Paoli, Paolo; Ciliberto, Gennaro; Ferrarini, Manlio; Pelicci, PierGiuseppe; Dellabona, Paolo; De Lorenzo, Francesco; Mantovani, Alberto; Musto, Pellegrino; Opocher, Giuseppe; Picci, Piero; Ricciardi, Walter; De Maria, Ruggero


    Alliance Against Cancer (ACC) was established in Rome in 2002 as a consortium of six Italian comprehensive cancer centers (Founders). The aims of ACC were to promote a network among Italian oncologic institutions in order to develop specific, advanced projects in clinical and translational research. During the following years, many additional full and associate members joined ACC, that presently includes the National Institute of Health, 17 research-oriented hospitals, scientific and patient organizations. Furthermore, in the last three years ACC underwent a reorganization process that redesigned the structure, governance and major activities. The present goal of ACC is to achieve high standards of care across Italy, to implement and harmonize principles of modern personalized and precision medicine, by developing cost effective processes and to provide tailored information to cancer patients. We herein summarize some of the major initiatives that ACC is currently developing to reach its goal, including tumor genetic screening programs, establishment of clinical trial programs for cancer patients treated in Italian cancer centers, facilitate their access to innovative drugs under development, improve quality through an European accreditation process (European Organization of Cancer Institutes), and develop international partnerships. In conclusion, ACC is a growing organization, trying to respond to the need of networking in Italy and may contribute significantly to improve the way we face cancer in Europe.

  17. Advancing gut microbiome research using cultivation

    Sommer, Morten OA


    Culture-independent approaches have driven the field of microbiome research and illuminated intricate relationships between the gut microbiota and human health. However, definitively associating phenotypes to specific strains or elucidating physiological interactions is challenging for metagenomic...... approaches. Recently a number of new approaches to gut microbiota cultivation have emerged through the integration of high-throughput phylogenetic mapping and new simplified cultivation methods. These methodologies are described along with their potential use within microbiome research. Deployment of novel...... cultivation approaches should enable improved studies of xenobiotic tolerance and modification phenotypes and allow a drastic expansion of the gut microbiota reference genome catalogues. Furthermore, the new cultivation methods should facilitate systematic studies of the causal relationship between...

  18. Advancing the Science of Qualitative Research to Promote Health Equity.

    Griffith, Derek M; Shelton, Rachel C; Kegler, Michelle


    Qualitative methods have long been a part of health education research, but how qualitative approaches advance health equity has not been well described. Qualitative research is an increasingly important methodologic tool to use in efforts to understand, inform, and advance health equity. Qualitative research provides critical insight into the subjective meaning and context of health that can be essential for understanding where and how to intervene to inform health equity research and practice. We describe the larger context for this special theme issue of Health Education & Behavior, provide brief overviews of the 15 articles that comprise the issue, and discuss the promise of qualitative research that seeks to contextualize and illuminate answers to research questions in efforts to promote health equity. We highlight the critical role that qualitative research can play in considering and incorporating a diverse array of contextual information that is difficult to capture in quantitative research.

  19. Advances in Researches of Functional Rice

    Mingjun; YU; Min; XIANG; Hechun; HUANG


    Functional rice has functions of adjusting human physiological functions of and preventing diseases. At present,there are researches both at home and abroad about the relationship between nutritional quality and physiological active substances of rice and human physiological activities. Through conventional breeding,gene mutation technology,and molecular-assisted selection( MAS) technology,it is feasible to select and breed new rice varieties and plants with certain health care functions.

  20. Advance and application of lake optics research


    The mainstreams of lake optics research in recent decades include optical properties of lakewater,observation, transmission and calculation of underwater radiation, determination of absorption coefficient S of yellow substance, influence of UV-B radiation of lake primary productivity by bio-optical model. Major lake optics applications, such as calculation of lake primary productivity and chl-a, analysis of factors restricting eutrophication, and protection against lake eutrophication are summarized.

  1. Microfluidic Devices in Advanced Caenorhabditis elegans Research

    Muniesh Muthaiyan Shanmugam


    Full Text Available The study of model organisms is very important in view of their potential for application to human therapeutic uses. One such model organism is the nematode worm, Caenorhabditis elegans. As a nematode, C. elegans have ~65% similarity with human disease genes and, therefore, studies on C. elegans can be translated to human, as well as, C. elegans can be used in the study of different types of parasitic worms that infect other living organisms. In the past decade, many efforts have been undertaken to establish interdisciplinary research collaborations between biologists, physicists and engineers in order to develop microfluidic devices to study the biology of C. elegans. Microfluidic devices with the power to manipulate and detect bio-samples, regents or biomolecules in micro-scale environments can well fulfill the requirement to handle worms under proper laboratory conditions, thereby significantly increasing research productivity and knowledge. The recent development of different kinds of microfluidic devices with ultra-high throughput platforms has enabled researchers to carry out worm population studies. Microfluidic devices primarily comprises of chambers, channels and valves, wherein worms can be cultured, immobilized, imaged, etc. Microfluidic devices have been adapted to study various worm behaviors, including that deepen our understanding of neuromuscular connectivity and functions. This review will provide a clear account of the vital involvement of microfluidic devices in worm biology.

  2. Clinical trials update: Medical management of advanced breast cancer.

    Major, Maureen A


    Selection of treatment for metastatic breast cancer depends on several factors: the status of estrogen receptors or progesterone receptors on breast cancer cells and the expression levels of human epidermal growth factor receptor-2. The presence of estrogen or progesterone receptors typically indicates slower-growing tumors that may be amenable to hormonal manipulation, which provides significant disease control while offering a better toxicity profile than conventional chemotherapy. The understanding of hormonal therapies in patients with postmenopausal metastatic breast cancer has advanced greatly in the past several decades. Aromatase inhibitors, although used initially as second-line therapy, recently have proved to be as effective as tamoxifen, if not superior to it, as first-line therapy for metastatic breast cancer. New data also suggest that letrozole provides significantly better objective responses than anastrozole as second-line therapy. Exemestane, a steroidal aromatase inhibitor, is an effective third-line therapy. Fulvestrant, an estrogen receptor antagonist with no known agonist effect, provides a new option for hormonal therapy. For patients with metastatic breast cancer and overexpression of human epidermal growth factor receptor-2 on tumor cells, the monoclonal antibody trastuzumab is the preferred option, either in combination with paclitaxel as first-line treatment, or as a single agent for second-line therapy. By extending the sequence of hormonal therapy, disease progression and the need for chemotherapy may be significantly delayed, potentially extending patient survival rates and improving quality of life.

  3. Advanced Prostate Cancer Presenting as Hemolytic Uremic Syndrome

    R. Ramos


    Full Text Available Introduction. Hemolytic uremic syndrome (HUS is characterized by endothelial dysfunction, consumption thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. HUS generally has a dismal prognosis, except when associated with gastroenteritis caused by verotoxin-producing bacteria. Cancer associated HUS is uncommon, and there are only scarce reports on prostate cancer presenting with HUS. Case Presentation. A 72-year-old man presented to the emergency department with oliguria, hematuria, and hematemesis. Clinical evaluation revealed acute renal failure, hemolysis, normal blood-clotting studies, and prostate-specific antigen value of 1000 ng/mL. The patient was started on hemodialysis, ultrafiltration with plasma exchange, and androgen blockade with bicalutamide and completely recovered from HUS. The authors review the 14 published cases on this association. Conclusion. The association of HUS and prostate cancer occurs more frequently in patients with high-grade, clinically advanced prostate cancer. When readily recognized and appropriately treated, HUS does not seem to worsen prognosis in prostate cancer patients.

  4. Advances in early diagnosis and therapy of pancreatic cancer

    Qiang Xu; Tai-Ping Zhang; Yu-Pei Zhao


    BACKGROUND: Pancreatic cancer remains a devastating disease with a 5-year survival rate of less than 5%. Recent advances in diagnostic methods and therapeutic approaches have increased the possibility of improving the existing poor prognosis. DATA  SOURCES: English-language articles reporting early diagnosis and therapy of pancreatic cancer were searched from the MEDLINE and PubMed databases, Chinese-language articleswerefromCHKD(ChinaHospitalKnowledgeDatabase). RESULT: The current literature about pancreatic cancer was reviewed from three aspects: statistics, screening and early detection, and therapy. CONCLUSIONS: Early detection and screening of pancreatic cancer currently should be limited to high risk patients. Surgical resection is the only curative approach available, with some recent improvement in outcomes. Gemcitabine has been a standard treatment during the last decade. Gemcitabine-based combination treatment, especially combined with newer molecular targeted agents, is promising. The rationale for radiotherapy is controversial, but with the recent development of modern radiation delivery techniques, radiotherapy should be intensified. Patients with borderline pancreatic cancer could benefit from neoadjuvant therapy but more evidence is needed and the best neoadjuvant regimen is still to be determined.

  5. Cancer research priorities and gaps in Iran: the influence of cancer burden on cancer research outputs between 1997 and 2014.

    Majidi, A; Salimzadeh, H; Beiki, O; Delavari, F; Majidi, S; Delavari, A; Malekzadeh, R


    As a developing country, Iran is experiencing the increasing burden of cancers, which are currently the third leading cause of mortality in Iran. This study aims to demonstrate that cancer research in Iran concentrates on the cancer research priorities based on the global burden of disease (GBD) reports. Descriptive evaluation of all cancers disability-adjusted life years (DALYs) was performed using GBD data. Also a comprehensive search was conducted using cancer-associated keywords to obtain all cancer-related publications from Iran, indexed in Web of Science. Multiple regression analysis and correlation coefficients (R(2)) were used to evaluate the possible associations between cancer research publications and GBD. During 1996-2014, the majority of cancer-related publications in Iran focused on breast cancer, leukaemia and stomach cancer, respectively. This study found hypothetical correlations between cancer publications in Iran in line with the burden of cancer as reported by GBD. Particularly, correlations between years lived with disability (YLD) and cancer-related publications were more obvious. This study introduces a new outline in setting cancer research priorities in the region. Copyright © 2016 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

  6. Advancing translational research with the Semantic Web

    Marshall M Scott


    Full Text Available Abstract Background A fundamental goal of the U.S. National Institute of Health (NIH "Roadmap" is to strengthen Translational Research, defined as the movement of discoveries in basic research to application at the clinical level. A significant barrier to translational research is the lack of uniformly structured data across related biomedical domains. The Semantic Web is an extension of the current Web that enables navigation and meaningful use of digital resources by automatic processes. It is based on common formats that support aggregation and integration of data drawn from diverse sources. A variety of technologies have been built on this foundation that, together, support identifying, representing, and reasoning across a wide range of biomedical data. The Semantic Web Health Care and Life Sciences Interest Group (HCLSIG, set up within the framework of the World Wide Web Consortium, was launched to explore the application of these technologies in a variety of areas. Subgroups focus on making biomedical data available in RDF, working with biomedical ontologies, prototyping clinical decision support systems, working on drug safety and efficacy communication, and supporting disease researchers navigating and annotating the large amount of potentially relevant literature. Results We present a scenario that shows the value of the information environment the Semantic Web can support for aiding neuroscience researchers. We then report on several projects by members of the HCLSIG, in the process illustrating the range of Semantic Web technologies that have applications in areas of biomedicine. Conclusion Semantic Web technologies present both promise and challenges. Current tools and standards are already adequate to implement components of the bench-to-bedside vision. On the other hand, these technologies are young. Gaps in standards and implementations still exist and adoption is limited by typical problems with early technology, such as the need

  7. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA)

    Iversen, P


    The study comprised 262 patients with previously untreated advanced carcinoma of the prostate. Patients were randomized either to undergo orchidectomy or to receive combined treatment with Zoladex, 3.6 mg every 4 weeks, plus flutamide, 250 mg t.i.d. At present the median follow-up is 39 months......' with Zoladex plus flutamide was not clinically superior to orchidectomy in the treatment of patients with advanced prostatic cancer....

  8. Rethinking cancer: current challenges and opportunities in cancer research.

    Cagan, Ross; Meyer, Pablo


    Cancer therapeutics currently have the lowest clinical trial success rate of all major diseases. Partly as a result of the paucity of successful anti-cancer drugs, cancer will soon be the leading cause of mortality in developed countries. As a disease embedded in the fundamentals of our biology, cancer presents difficult challenges that would benefit from uniting experts from a broad cross-section of related and unrelated fields. Combining extant approaches with novel ones could help in tackling this challenging health problem, enabling the development of therapeutics to stop disease progression and prolong patient lives. This goal provided the inspiration for a recent workshop titled 'Rethinking Cancer', which brought together a group of cancer scientists who work in the academic and pharmaceutical sectors of Europe, America and Asia. In this Editorial, we discuss the main themes emerging from the workshop, with the aim of providing a snapshot of key challenges faced by the cancer research community today. We also outline potential strategies for addressing some of these challenges, from understanding the basic evolution of cancer and improving its early detection to streamlining the thorny process of moving promising drug targets into clinical trials. © 2017. Published by The Company of Biologists Ltd.

  9. Perspectives of newly diagnosed advanced cancer patients receiving dignity therapy during cancer treatment.

    Dose, Ann Marie; Rhudy, Lori M


    Dignity therapy is a psychosocial intervention that has been used primarily at the end of life to improve quality of life and other patient outcomes, but many individuals are unable to complete it due to health decline and death. The purpose of this study was to identify what individuals with advanced pancreatic or lung cancer with limited life expectancy, undergoing active cancer treatment describe during the dignity therapy intervention as important to them when not immediately facing end of life. Twenty patients undergoing chemotherapy for advanced cancer participated in a dignity therapy intervention study. Initial interviews were analyzed using descriptive content analysis. Family provided the overall context and background for emerging themes of defining events, accomplishments, and God's plan, which led to lessons learned, and resulted in messages of hope. Interviews were often autobiographical in nature and contained much reminiscence, consistent with dignity therapy's intent. Few participants spoke about their cancer diagnoses during the interview. This study adds unique insight into the use of dignity therapy for those still receiving active cancer treatment, different from work by others in which it was offered only at end of life. As part of supportive care, clinicians need to validate the importance of family to those with advanced cancer and to provide opportunities for patients to share what they have learned throughout life and to impart messages of hope to those closest to them.

  10. Advanced ASON prototyping research activities in China

    Hu, WeiSheng; Jin, Yaohui; Guo, Wei; Su, Yikai; He, Hao; Sun, Weiqiang


    This paper provides an overview of prototyping research activities of automatically switched optical networks and transport networks (ASONs/ASTNs) in China. In recent years, China has recognized the importance and benefits of the emerging ASON/ASTN techniques. During the period of 2001 and 2002, the national 863 Program of China started the preliminary ASON research projects with the main objectives to build preliminary ASON testbeds, develop control plane protocols and test their performance in the testbeds. During the period of 2003 and 2004, the 863 program started ASTN prototyping equipment projects for more practical applications. Totally 12 ASTN equipments are being developed by three groups led by Chinese venders: ZTE with Beijing University of Posts and Telecommunications (BUPT), Wuhan Research Institute of Posts and Telecommunication (WRI) with Shanghai Jiao Tong University (SJTU), and Huawei Inc. Meanwhile, as the ASTN is maturing, some of the China"s carries are participating in the OIF"s World Interoperability Demonstration, carrying out ASTN test, or deploying ASTN backbone networks. Finally, several ASTN backbone networks being tested or deployed now will be operated by the carries in 2005. The 863 Program will carry out an ASTN field trail in Yangtse River Delta, and finally deploy the 3TNET. 3TNET stands for Tbps transmission, Tbps switching, and Tbps routing, as well as a network integrating the above techniques. A task force under the "863" program is responsible for ASTN equipment specifications and interoperation agreements, technical coordination among all the participants, schedule of the whole project during the project undergoing, and organization of internetworking of all the equipments in the laboratories and field trials.

  11. Advanced Research Workshop on Nonlinear Hyperbolic Problems

    Serre, Denis; Raviart, Pierre-Arnaud


    The field of nonlinear hyperbolic problems has been expanding very fast over the past few years, and has applications - actual and potential - in aerodynamics, multifluid flows, combustion, detonics amongst other. The difficulties that arise in application are of theoretical as well as numerical nature. In fact, the papers in this volume of proceedings deal to a greater extent with theoretical problems emerging in the resolution of nonlinear hyperbolic systems than with numerical methods. The volume provides an excellent up-to-date review of the current research trends in this area.

  12. Advances in Research of Garlic Virus Diseases


    Garlic virus infection is an important disease which affects garlic production,with the increasing years of planting,harm of virus is serious year by year,which seriously affect yield and quality of garlic.In order to know the garlic virus effectively,the paper reviewed the research situation of several important garlic virus in virus species,origin,distribution,host range,symptom,route of transmission,classification,genome and detection technique and the prevention technology of garlic viruses.At the same ...

  13. Advanced Waveform Research Methods for Geress Recordings


    24 2.6 Pre-Amplifier and A/D-Converter 24 2.7 Seismometer Generator Constant 25 2.8 Shaking Table Experiments 27 2.9 Electrical Excitation 29 2.10...January 1992- December 1992 Michael L. Jost 1.1 General The German Experimental Seismic System (GERESS) is a cooperative research program of Southern...hen Messung am GERESS Array im November 1992, BGR internal report GoldenK P., E. T. Herrin, and C. Hayward (1991). Development of an intelligent

  14. microRNA在结直肠癌中的研究及应用进展%Advances in The Research and Utilization of MicroRNA in Colorectal Cancer

    彭伟; 杨韵; 刘韵霄; 舒晔


    Objective To summarize the relationship between microRNA and the occurrence and progression of colorectal cancer,and to investigate the application value of microRNA in the diagnosis,treatment,and prognosis evaluation of colorectal cancer.Methods Domestic and international publications involving the relationship between microRNA and colorectal cancer were retrieved and reviewed.Results MicroRNA acted as an oncogene or tumor suppressor gene to participate in cell proliferation,differentiation,apoptosis,metabolism,tumor genesis,and tumor progression.The abnormal expression of microRNA was closely related to the occurrence and progression of colorectal cancer.As specific biomarker,microRNA could be applied in early diagnosis,chemotherapy strategy-making,and prognostic evaluation of colorectal cancer.Conclusion MicroRNA is definitely related to the occurrence and progression of colorectal cancer,and it has great prospect in the basic research and clinical applications of colorectal cancer.%目的 总结微小RNA (microRNA)与结直肠癌发生和发展的关系,及其在结直肠癌诊断、治疗和预后评价中的应用价值.方法 收集国内外关于microRNA与结直肠癌关系的文献并作综述.结果 microRNA通过其类癌基因或抑癌基因的作用直接或者间接参与细胞增殖、分化、凋亡、代谢、肿瘤发生和发展等生物学过程.其异常表达与结直肠癌的发生和发展均密切相关,可作为结直肠癌早期诊断、化疗方案制定及预后评价的生物学标志物.结论 microRNA与结直肠癌的发生和发展均相关,在结直肠癌的基础研究和临床应用中具有较大前景.

  15. A One Health overview, facilitating advances in comparative medicine and translational research


    Table of contents A1 One health advances and successes in comparative medicine and translational research Cheryl Stroud A2 Dendritic cell-targeted gorilla adenoviral vector for cancer vaccination for canine melanoma Igor Dmitriev, Elena Kashentseva, Jeffrey N. Bryan, David T. Curiel A3 Viroimmunotherapy for malignant melanoma in the companion dog model Jeffrey N. Bryan, David Curiel, Igor Dmitriev, Elena Kashentseva, Hans Rindt, Carol Reinero, Carolyn J. Henry A4 Of mice and men (and dogs!): ...

  16. Research Advances of Atherosclerosis in Translational Medicine

    YANG Zhuo-xin; DENG Rong; PI Min; YU Hai-bo


    Atherosclerotic cardiovascular diseases (ASCVD) are defined as a series of diseases caused by atherosclerosis (AS), including coronary heart disease (CHD), myocardial infarction (MI), stable or unstable angina pectoris, revascularization of coronary artery or other arteries, stroke, transient cerebral ischemic onset or atherosclerotic peripheral arterial disease. AS has common pathological basis with ASCVD as it is a general arterial regressive disease of human beings. With the industrialization progression, AS morbidity increases annually and it also leads to coronary atherosclerotic heart disease, cerebral stroke and peripheral artery stenosed occlusion or dilation, thus becoming the main cause for high disability and mortality. The main purpose of translational medicine is to break the intrinsic barrier between basic medicine with drug research and development as well as clinical and public healthcare, and establish a direct connection between them. It is also can rapidly transform basic research results to new clinical preventive and therapeutic methods. This study mainly reviewed AS from the aspect of translational medicine, aiming to provide a reliable basis for the prevention and treatment of AS.

  17. Advances in lactoferrin research concerning bovine mastitis.

    Shimazaki, Kei-Ichi; Kawai, Kazuhiro


    Lactoferrin is a multifunctional, iron-binding glycoprotein found in milk and other exocrine secretions. Lactoferrin in milk plays vital roles in the healthy development of newborn mammals, and is also an innate resistance factor involved in the prevention of mammary gland infection by microorganisms. Inflammation of the udder because of bacterial infection is referred to as mastitis. There have been many investigations into the relationships between lactoferrin and mastitis, which fall into several categories. The main categories are fluctuations in the lactoferrin concentration of milk, lactoferrin activity against mastitis pathogens, elucidation of the processes underlying the onset of mastitis, participation of lactoferrin in the immune system, and utilization of lactoferrin in mastitis treatment and prevention. This minireview describes lactoferrin research concerning bovine mastitis. In the 1970s, many researchers reported that the lactoferrin concentration fluctuates in milk from cows with mastitis. From the late 1980s, many studies clarified the infection-defense mechanism in the udder and the contribution of lactoferrin to the immune system. After the year 2000, the processes underlying the onset of mastitis were elucidated in vivo and in vitro, and lactoferrin was applied for the treatment and prevention of mastitis.

  18. Phenomenology in pediatric cancer nursing research.

    Fochtman, Dianne


    What does it mean to have cancer as a child or adolescent? To understand this, researchers must study the illness from the child's point of view and listen to these children's descriptions of their "lived world." Phenomenology is a qualitative research methodology that can be used to discover and interpret meaning. To use phenomenology congruently, the philosophical background must be understood as well as the adaptation of the philosophical basis to research in the caring sciences. Only when clinicians truly understand the meaning of this illness to the child can they design nursing interventions to ease suffering and increase quality of life in children and adolescents with cancer.

  19. Antiproton radiation found effective in cancer research


    "An international collaboration of scientists has completed the first ever antiproton beam experiments designed to reveal the biological effectiveness of antiproton radiation in terminating cells used for cancer research...PBar Labs assembled the collaboration at CERN (European Organization for Nuclear Research in Geneva) to perform the measurements" (1 page).

  20. Multidisciplinary treatment including chemoradiotherapy for advanced esophageal cancer

    Kobayashi, Kenji; Fukuda, Kazuhiro; Kikkawa, Nobuteru; Kobayashi, Tetsurou; Yagyu, Toshio; Hasuike, Yasunori; Mishima, Hideyuki; Shin, Eisei [Osaka National Hospital (Japan)


    Over 3 years, concurrent chemoradiotherapy was performed in 16 patients with advanced esophageal cancer (clinical Stage IV) and suspected noncurative resection. The subjects were {>=}A3 or N3, or were stage IV with distant metastasis on preoperative diagnosis. Two courses of 5FU and CDDP were given with concurrent radiotherapy. The predominant side effects were nausea, vomiting and anorexia. Mild or moderate leukopenia also occurred. The response was complete remission (CR) in two patients, partial remission (PR) in eight, minor response (MR) in two, no change (NC) in two and progressive disease (PD) in two. The overall response rate was 62.5%. Esophagectomy was performed in four patients (histological stage II in one, stage III in one, and stage IV in two). Two of 4 resected patients are alive (33.8 months), while the other died of unrelated causes. One of the 6 non-resected PR patients has survived for 18 months, but all other patients died of cancer within nine months of starting treatment. The survival rate of 16 patients undergoing chemoradiotherapy was 16.7% at one and two years. Thus, chemoradiotherapy may improve the prognosis of advanced esophageal cancer with suspected noncurative resection by increasing the response rate and the curative resection rate. (author)

  1. Breast Cancer Research Training Grant


    University 19 Dr. Arthur Sytkowski Selenium and prostate cancer. Beth Israel Hospital 26 Df David Cameron Structural and physiological aspects of retinal...Committee consists of: David Belier (Medicine), Leonard Glantz, (School of Public Health), Conan Kornetsky (Psychiatry), Wayne Lamorte (Surgery), Susan...8217, Bilgca. .ttsia Sigifianc BSTO REPimthy CINHen REERH ISN Onkog S ficant? Introduction: Teaching the Dog to Talk Conan Kornetsky, Ph.D. Professor of

  2. Photodynamic therapy for locally advanced pancreatic cancer: early clinical results

    Sandanayake, N. S.; Huggett, M. T.; Bown, S. G.; Pogue, B. W.; Hasan, T.; Pereira, S. P.


    Pancreatic adenocarcinoma ranks as the fourth most common cause of cancer death in the USA. Patients usually present late with advanced disease, limiting attempted curative surgery to 10% of cases. Overall prognosis is poor with one-year survival rates of less than 10% with palliative chemotherapy and/or radiotherapy. Given these dismal results, a minimally invasive treatment capable of local destruction of tumor tissue with low morbidity may have a place in the treatment of this disease. In this paper we review the preclinical photodynamic therapy (PDT) studies which have shown that it is possible to achieve a zone of necrosis in normal pancreas and implanted tumour tissue. Side effects of treatment and evidence of a potential survival advantage are discussed. We describe the only published clinical study of pancreatic interstitial PDT, which was carried out by our group (Bown et al Gut 2002), in 16 patients with unresectable locally advanced pancreatic adenocarcinoma. All patients had evidence of tumor necrosis on follow-up imaging, with a median survival from diagnosis of 12.5 months. Finally, we outline a phase I dose-escalation study of verteporfin single fibre PDT followed by standard gemcitabine chemotherapy which our group is currently undertaking in patients with locally advanced pancreatic cancer. Randomized controlled studies are also planned.

  3. Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group

    Iversen, P


    The value of combined androgen blockade in the treatment of patients with advanced prostate cancer is still controversial. In this review by the Scandinavian Prostatic Cancer Group, the literature addressing the concept and its clinical use is critically reviewed.......The value of combined androgen blockade in the treatment of patients with advanced prostate cancer is still controversial. In this review by the Scandinavian Prostatic Cancer Group, the literature addressing the concept and its clinical use is critically reviewed....

  4. Radiation related basic cancer research

    Lee, Seung Hoon; Yoo, Young Do; Hong, Seok Il [and others


    We studied the mechanism of radiation-induced apoptosis, the factors involved signaling, and the establishment of radiation-resistant cell lines in this study. During the TGF beta-stimulated epithelial mesenchymal transition(EMT), actin rearrangement occurred first and fibronectin matrix assembly followed. These two events were considered independent since cytochalasin-D did not inhibit TGF stimulated matrix assembly and fibronectin supplementation did not induce EMT. During EMT, alpha 5 beta 1 integrin and alpha v integrin have increased but MMP activation was not accompanied, which suggest that induction of extracellular matrix and activation of integrins may be main contributor for the EMT. Serum depriving induced apoptosis of HUVECs was prevented by vascular endothelial growth factor(VEGF) and PMA. The apoptosis prevention by VEGF and PMA were conformed by DNA fragmentation assay. The p53 expression level was down regulated by VEGF and PMA compared with serum deprived HUVECs. However, VEGF and PMA induces c-Myc expression level on these cells. We made the 5 radiation-resistant clones from breast, lung and cervical cancer cells. More than 70%, 100% and 50% increased resistance was detected in breast cancer cells, lung cancer cells, and cervical cells, respectively. We carried out differential display-PCR to clone the radiation-resistant genes. 9 out of 10 genes were analyzed their sequence.

  5. Cooperative research for human factors review of advanced control rooms

    Lee, Jung Woon; Park, Jae Chang; Lee, Yong Hee; Oh, In Seok; Lee, Hyun Chul


    This project has been performed as cooperative research between KAERI and USNRC. Human factors issues related to soft controls, which is one of key features of advanced HSI, are identified in this project. The issues are analyzed for the evaluation approaches in either experimental or analytical ways. Also, issues requiring additional researches for the evaluation of advanced HSI are identified in the areas of advanced information systems design, computer-based procedure systems, soft controls, human systems interface and plant modernization process, and maintainability of digital systems. The issues are analyzed to discriminate the urgency of researches on it to high, medium, and low levels in consideration of advanced HSI development status in Korea, and some of the issues that can be handled by experimental researches are identified. Additionally, an experimental study is performed to compare operator's performance on human error detection in advanced control rooms vs. in conventional control rooms. It is found that advanced control rooms have several design characteristics hindering operator's error detection performance compared to conventional control rooms.

  6. Advances in Biomarker Research in Parkinson's Disease.

    Mehta, Shyamal H; Adler, Charles H


    Parkinson's disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.

  7. idaho Accelerator Center Advanced Fuel Cycle Research

    Wells, Douglas; Dale, Dan


    The technical effort has been in two parts called; Materials Science and Instrumentation Development. The Materials Science technical program has been based on a series of research and development achievements in Positron-Annihilation Spectroscopy (PAS) for defect detection in structural materials. This work is of particular importance in nuclear power and its supporting systems as the work included detection of defects introduced by mechanical and thermal phenomena as well as those caused by irradiation damage. The second part of the program has focused on instrumentation development using active interrogation techniques supporting proliferation resistant recycling methodologies and nuclear material safeguards. This effort has also lead to basic physics studies of various phenomena relating to photo-fission. Highlights of accomplishments and facility improvement legacies in these areas over the program period include

  8. Sexual Objectification of Women: Advances to Theory and Research

    Szymanski, Dawn M.; Moffitt, Lauren B.; Carr, Erika R.


    Objectification theory provides an important framework for understanding, researching, and intervening to improve women's lives in a sociocultural context that sexually objectifies the female body and equates a woman's worth with her body's appearance and sexual functions. The purpose of this Major Contribution is to advance theory, research,…

  9. Advancing multilevel thinking and methods in HRM research

    Renkema, Maarten; Meijerink, Jeroen; Bondarouk, Tanya


    Purpose Despite the growing belief that multilevel research is necessary to advance HRM understanding, there remains a lack of multilevel thinking – the application of principles for multilevel theory building. The purpose of this paper is to propose a systematic approach for multilevel HRM research

  10. Fertility in Advanced Societies : A Review of Research

    Balbo, Nicoletta; Billari, Francesco C.; Mills, Melinda; Bilari, F.C.


    This paper provides a review of fertility research in advanced societies, societies in which birth control is the default option. The central aim is to provide a comprehensive review that summarizes how contemporary research has explained ongoing and expected fertility changes across time and space

  11. Overview of the Hemostasis Research Program: Advances and Future Directions


    advanced to treat such an injury in the field. The hypothesis was that a hemostatic material could be infused into a closed body cavity by a trocar ...Research Program of the US Army Medical Research and Material Command is to reduce the morbidity and mortality resulting from injuries on the

  12. Establishment of Research Infrastructure for National Advanced Radiation Technology

    Kuk, Il Hiun; Byun, Myung Woo; Jeong, Il Yun; and others


    Construction of fundamental analysis system for RT/RFT advancement and pilot scale laboratory/facility for industry support and Assembly/installation of 30 MeV cyclotron for RI production and research utilizing positron beam, and construction of /distribution system for industrial and medical purpose were carried out for fast settlement for research environment of ARTI (a Jeongeup branch of KAERI)

  13. Recent advances in aerosol research a bibliographical review

    Davies, C N


    Recent Advances in Aerosol Research: A Bibliographical Review presents a bibliographic review of advances in aerosol research covering the period from the beginning of 1957 to the end of 1962. Topics covered include chemical reactions, combustion, coagulation and diffusion, and adhesion of particles. References on filtration, evaporation and condensation, nucleation and growth, and laminar flow and impingement are also included. This volume is comprised of 19 chapters and begins by citing research on acoustic, ultrasonic, and shock wave effects, along with adhesion of particles, chemical react

  14. Proceedings of the 1st symposium on advanced science research



    The 1st symposium on advanced science research was held in Tokai-mura, Ibaraki-ken, on 23-24 March, 1995, under the auspices of JAERI. Two hundred and sixty scientists attended the symposium; over 40% of the attendants were from universities and laboratories outside JAERI. This proceedings consists of 6 oral presentations of the research activities in the Advanced Science Research Center, 70 poster presentations on the field of basic science from both the inside and outside of JAERI and 2 panel discussions on the actinide physics and biocrystallography. (author).

  15. About the Breast and Gynecologic Cancer Research Group | Division of Cancer Prevention

    The Breast and Gynecologic Cancer Research Group conducts and fosters the development of research on the prevention and early detection of breast cancer, cervix and human papillomavirus (HPV)-related cancers, endometrial cancers, ovarian cancers, and precursor conditions related to these cancers. |

  16. NATO Advanced Research Institute on the Efficiency of Manufacturing Systems

    Berg, C; French, D


    The Advanced Research Institute (A.R. 1.) on "the efficiency of Manufacturing Systems" was held under the auspices of the NATO Special Programm~ Panel on Systems Science as a part of the NATO Science Committee's continuous effort to promote the advancement of science through international co-operation. Advanced Research Institutes are organised for the purpose of bringing together experts in a particular field of interest to identify and make known the present state of knowledge in that area and, through informed debate, to make recommendations for directions for future research that would benefit the community at large. To this end two kinds of contribution were obtained by invitation. There were those papers which were about the current state of work in the area of manufacturing systems and its organisation; in addition three theme papers were presented to provide a stimulus to the discussion in terms of ways of thinking, both about the area and about the kind of research needed.

  17. Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer


    Breast Cancer; Chronic Myeloproliferative Disorders; Colorectal Cancer; Head and Neck Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Diseases; Prostate Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific

  18. The Clinical Impact of Recent Advances in LC-MS for Cancer Biomarker Discovery and Verification

    Wang, Hui; Shi, Tujin; Qian, Weijun; Liu, Tao; Kagan, Jacob; Srivastava, Sudhir; Smith, Richard D.; Rodland, Karin D.; Camp, David G.


    Mass spectrometry-based proteomics has become an indispensable tool in biomedical research with broad applications ranging from fundamental biology, systems biology, and biomarker discovery. Recent advances in LC-MS have made it become a major technology in clinical applications, especially in cancer biomarker discovery and verification. To overcome the challenges associated with the analysis of clinical samples, such as extremely wide dynamic range of protein concentrations in biofluids and the need to perform high throughput and accurate quantification, significant efforts have been devoted to improve the overall performance of LC-MS bases clinical proteomics. In this review, we summarize the recent advances in LC-MS in the aspect of cancer biomarker discovery and quantification, and discuss its potentials, limitations, and future perspectives.

  19. Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy

    Jian Cui; Hui Fang; Lin Zhang; Yun-Long Wu; Hai-Zeng Zhang


    Neoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete response (pCR) can be achieved in 12%e38% of patients. Patients with pCR have the most favorable long-term outcomes. Intensifying neoadjuvant therapy and extending the interval between termination of neoadjuvant treatment and surgery may in-crease the pCR rate. Growing evidence has raised the issue of whether local excision or observation rather than radical surgery is an alternative for patients who achieve a clinical complete response after neoadjuvant therapy. Herein, we highlight many of the advances and resultant controversies that are likely to dominate the research agenda for pCR of rectal cancer in the modern era.

  20. Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

    John F. Flynn


    Full Text Available This review will focus on recent advances in the application of antiepidermal growth factor receptor (anti-EGFR for the treatment of breast cancer. The choice of EGFR, a member of the ErbB tyrosine kinase receptor family, stems from evidence pinpointing its role in various anti-EGFR therapies. Therefore, an increase in our understanding of EGFR mechanism and signaling might reveal novel targets amenable to intervention in the clinic. This knowledge base might also improve existing medical treatment options and identify research gaps in the design of new therapeutic agents. While the approved use of drugs like the dual kinase inhibitor Lapatinib represents significant advances in the clinical management of breast cancer, confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety, pharmacokinetics, and clinical efficacy.

  1. Next-generation sequencing for endocrine cancers: Recent advances and challenges.

    Suresh, Padmanaban S; Venkatesh, Thejaswini; Tsutsumi, Rie; Shetty, Abhishek


    Contemporary molecular biology research tools have enriched numerous areas of biomedical research that address challenging diseases, including endocrine cancers (pituitary, thyroid, parathyroid, adrenal, testicular, ovarian, and neuroendocrine cancers). These tools have placed several intriguing clues before the scientific community. Endocrine cancers pose a major challenge in health care and research despite considerable attempts by researchers to understand their etiology. Microarray analyses have provided gene signatures from many cells, tissues, and organs that can differentiate healthy states from diseased ones, and even show patterns that correlate with stages of a disease. Microarray data can also elucidate the responses of endocrine tumors to therapeutic treatments. The rapid progress in next-generation sequencing methods has overcome many of the initial challenges of these technologies, and their advantages over microarray techniques have enabled them to emerge as valuable aids for clinical research applications (prognosis, identification of drug targets, etc.). A comprehensive review describing the recent advances in next-generation sequencing methods and their application in the evaluation of endocrine and endocrine-related cancers is lacking. The main purpose of this review is to illustrate the concepts that collectively constitute our current view of the possibilities offered by next-generation sequencing technological platforms, challenges to relevant applications, and perspectives on the future of clinical genetic testing of patients with endocrine tumors. We focus on recent discoveries in the use of next-generation sequencing methods for clinical diagnosis of endocrine tumors in patients and conclude with a discussion on persisting challenges and future objectives.

  2. Advances in Classification and Research Methods of Lung Epithelial Stem 
and Progenitor Cells

    Minhua DENG


    Full Text Available Isolation and characterization of lung epithelial stem and progenitor cells and understanding of their specific role in lung physiopathology are critical for preventing and controlling lung diseases including lung cancer. In this review, we summarized recent advances in classification and research methods of lung epithelial stem and progenitor cells. Lung epithelial stem and progenitor cells were region-specific, which primarily included basal cells and duct cells in proximal airway, Clara cells, variant Clara cells, bronchioalveolar stem cells and induced krt5+ cells in bronchioles, type II alveolar cells and type II alveolar progenitor cells in alveoli. The research methods of lung epithelial stem and progenitor cells were mainly focused on lung injury models, lineage-tracing experiments, three dimensional culture, transplantation, chronic labeled cells and single-cell transcriptome analysis. Lastly, the potential relationship between lung epithelial stem and progenitor cells and lung cancer as well as lung cancer stem cell-targeted drug development were briefly reviewed.

  3. Cancer Pain Control for Advanced Cancer Patients by Using Autonomic Nerve Pharmacopuncture

    Hwi-joong Kang


    Full Text Available Objectives: The purpose of this study is to report a case series of advanced cancer patients whose cancer pain was relieved by using autonomic nerve pharmacopuncture (ANP treatment. ANP is a subcutaneous injection therapy of mountain ginseng pharmacopuncture (MGP along the acupoints on the spine (Hua-Tuo-Jia-Ji-Xue; 0.5 cun lateral to the lower border of the spinous processes of vertebrae to enhance the immune system and to balance autonomic nerve function. Methods: Patients with three different types of cancer (gastric cancer, lung cancer, colon cancer with distant metastases with cancer pain were treated with ANP. 1 mL of MGP was injected into the bilateral Hua-Tuo-Jia-Ji-Xue on the T1-L5 sites (total 12 ─ 20 mL injection of each patient’s dorsum by using the principle of symptom differentiation. During ANP treatment, the visual analogue scale (VAS for pain was used to assess their levels of cancer pain; also, the dosage and the frequency of analgesic use were measured. Results: The cancer pain levels of all three patients improved with treatment using ANP. The VAS scores of the three patients decreased as the treatment progressed. The dosage and the frequency of analgesics also gradually decreased during the treatment period. Significantly, no related adverse events were found. Conclusion: ANP has shown benefit in controlling cancer pain for the three different types of cancer investigated in this study and in reducing the dosage and the frequency of analgesics. ANP is expected to be beneficial for reducing cancer pain and, thus, to be a promising new treatment for cancer pain.

  4. Updates in colorectal cancer stem cell research

    Chun-Jie Li


    Full Text Available Colorectal cancer (CRC is one of the world most common malignant tumors, also is the main disease, which cause tumor-associated death. Surgery and chemotherapy are the most used treatment of CRC. Recent research reported that, cancer stem cells (CSCs are considered as the origin of tumor genesis, development, metastasis and recurrence in theory. At present, it has been proved that, CSCs existed in many tumors including CRC. In this review, we summary the identification of CSCs according to the cell surface markers, and the development of drugs that target colorectal cancer stem cells.

  5. Postdoctoral Fellow | Center for Cancer Research

    A postdoctoral position is available in the lab of Dr. Steven A. Feldman, Surgery Branch of the National Cancer Institute for a highly-motivated individual to carry out translational research studies aimed at developing and improving novel adoptive T cell therapies for solid cancers. A major focus of the position will utilize gene editing strategies (ZFN and Crispr) to enhance T cell function and/or re-direct T cells by TCR insertion for development of novel personalized cancer therapies based on identifying and targeting immunogenic mutations expressed by a patient’s tumor. 

  6. Research advancements in palm oil nutrition*

    May, Choo Yuen; Nesaretnam, Kalanithi


    Palm oil is the major oil produced, with annual world production in excess of 50 million tonnes. About 85% of global palm oil produced is used in food applications. Over the past three decades, research on nutritional benefits of palm oil have demonstrated the nutritional adequacy of palm oil and its products, and have resulted in transitions in the understanding these attributes. Numerous studies have demonstrated that palm oil was similar to unsaturated oils with regards to effects on blood lipids. Palm oil provides a healthy alternative to trans-fatty acid containing hydrogenated fats that have been demonstrated to have serious deleterious effects on health. The similar effects of palm oil on blood lipids, comparable to other vegetable oils could very well be due to the structure of the major triglycerides in palm oil, which has an unsaturated fatty acid in the stereospecific numbers (sn)-2 position of the glycerol backbone. In addition, palm oil is well endowed with a bouquet of phytonutrients beneficial to health, such as tocotrienols, carotenoids, and phytosterols. This review will provide an overview of studies that have established palm oil as a balanced and nutritious oil. PMID:25821404

  7. Mutation Profiling of Clinically Advanced Cancers Using Next-Generation Sequencing for Targeted Therapy: A Lifespan Experience.

    Friedman, Kenneth; Resnick, Murray B; Safran, Howard


    The application of modern molecular tests such as next-generation sequencing (NGS) to human malignancies has led to better understanding of tumor biology and the design of targeted molecular therapies. In the research setting, important genomic alterations in tumors have been discovered with potential therapeutic implications but data regarding the impact of this technology in a real world oncology practice is limited. As a result, we decided to review the results of NGS in 144 advanced-stage cancer patients referred to the oncology practices of Lifespan-affiliated centers in Rhode Island. Most cancers revealed genomic alterations in genes commonly mutated in cancer. However, several unexpected genomic alterations were discovered in certain cancers with potential therapeutic intervention. Most cancers contained "actionable" genomic alterations despite being of advanced stage. Our experience demonstrates that application of NGS in the clinical setting contributes both to increasing the therapeutic armamentarium as well as our understanding of tumor biology.

  8. "Lassie," "Toto," and fellow pet dogs: poised to lead the way for advances in cancer prevention.

    Knapp, Deborah W; Dhawan, Deepika; Ostrander, Elaine


    Cancer causes substantial morbidity and takes the lives of over 8 million people worldwide each year. Advances in cancer prevention research are crucial, and animal models are key to this. There are many valuable experimentally induced cancer models, but these do not fully meet the needs for cancer prevention studies. Pet dogs with risks for naturally occurring cancer can fill important gaps in cancer prevention research. Using invasive urothelial carcinoma (iUC) as an example, the advantages of utilizing pet dogs include: (1) close similarities between dogs and humans in carcinogenesis, molecular and cellular features, invasive and metastatic behavior, and response to treatment, thus providing high relevance for comparative studies, (2) shared environment between dogs and humans to help identify not-yet-known environmental iUC risks, (3) strong breed-associated risk (5- to 21-fold increased risk compared with mixed breeds) that facilitates investigation of gene-environment interactions, screening, and early intervention, (4) large size of dogs (versus rodents) that allows collection of fluids and tissues via cystoscopy, and detailed imaging at multiple time points, and (5) acceptance for studies in which each participating dog can benefit while enjoying life in their family environment, and in which findings will help other dogs and humans. An ongoing 3-year study in Scottish Terriers (comparable to a 15- to 20-year study in humans) is aimed at defining genetic and environmental risk factors for iUC, effective methods for screening/early detection, and a successful secondary cancer prevention approach with very promising results to date. Pet dogs can indeed propel cancer prevention research.

  9. Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference

    Coleman, Robert E.; Guise, Theresa A.; Lipton, Allan; Roodman, G. David; Berenson, James R.; Body, Jean-Jacques; Boyce, Brendan F.; Calvi, Laura M.; Hadji, Peyman; McCloskey, Eugene V.; Saad, Fred; Smith, Matthew R.; Suva, Larry J.; Taichman, Russell S.; Vessella, Robert L.; Weilbaecher, Katherine N.


    Purpose Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies. Results A variety of specific recommendations were identified as important to advance research and clinical care over the next 5 years. Conclusions Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response to bone-directed treatments. PMID:18927277

  10. Current status of bevacizumab in advanced ovarian cancer

    Tomao F


    Full Text Available Federica Tomao,1,* Anselmo Papa,2,* Luigi Rossi,2 Davide Caruso,2 Pierluigi Benedetti Panici,1 Martina Venezia,2 Silverio Tomao21Department of Gynaecology and Obstetrics, "Sapienza" University of Rome, Policlinico "Umberto I," Rome, Italy; 2Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Oncology Unit, "ICOT," Latina, Italy*Authors contributed equally to this workAbstract: Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.Keywords: epithelial ovarian cancer, angiogenesis, bevacizumab, vascular endothelial growth factor, chemotherapy

  11. Hypothyroidism after Radiotherapy of Locally Advanced Head and Neck Cancer

    Lee, Jeong Eun; Eun; Kim, Jae Chul; Park, In Kyu [Kyungpook National Yonsei University School of Medicine, Daegu (Korea, Republic of); Yea, Ji Woon [Dongguk University Gyeongju Hospital, Gyeongju (Korea, Republic of)


    The aim of the present study was to retrospectively evaluate the incidence of hypothyroidism in locally advanced head and neck cancer patients who received radiotherapy (RT) either with or without neck dissection. From January 2000 to December 2005, 115 patients with locally advanced head and neck cancer and who received definitive RT or postoperative RT including standard anterior low-neck field were recruited to be part of this study. Nineteen patients had undergone ipsilateral neck dissection, whereas, 18 patients underwent bilateral neck dissection, and 78 patients were received RT alone. Patients' ages ranged from 28 to 85 years (median, 59 years) and there were a total of 73 male and 42 female patients. The primary tumor sites were the oral cavity, oropharynx, hypopharynx, larynx, and other sites in 18, 40, 28, 22 and 7 patients, respectively. Radiation dose to the thyroid gland ranged from 44 Gy to 66 Gy with a median dose of 50 Gy. Follow-up time ranged from 2 to 91 months, with a median of 29 months. The 1- and 3- year incidence of hypothyroidism was 28.7% (33 patients) and 33.0% (38 patients), respectively. The median time to detection of hypothyroidism was 8.5 months (range, 0 to 36 months). A univariate analysis revealed that neck node dissection was a risk factor for hypothyroidism (p=0.037). However, no factor was statistically significant from the results of a multivariate analysis. Patients treated for advanced head and neck cancer with radiotherapy with or without neck dissection will develop hypothyroidism. It is important to check the thyroid function periodically in these patients especially with the risk factor of neck node dissection.

  12. Expert Meeting Report: Advanced Envelope Research for Factory Built Housing

    Levy, E.; Mullens, M.; Tompos, E.; Kessler, B.; Rath, P.


    This report provides information about the expert meeting on advanced envelope research for factory built housing, hosted by the ARIES Collaborative on October 11, 2011, in Phoenix, Arizona. The goals of this meeting were to provide a comprehensive solution to the use of three previously selected advanced alternatives for factory-built wall construction, assess each option focusing on major issues relating to viability and commercial potential, and determine additional steps are required to reach this potential.

  13. Expert Meeting Report: Advanced Envelope Research for Factory Built Housing

    Levy, E.; Mullens, M.; Tompos, E.; Kessler, B.; Rath, P.


    This report provides information about the Building America expert meeting on advanced envelope research for factory built housing, hosted by the ARIES Collaborative on October 11, 2011, in Phoenix, Arizona. The goals of this meeting were to provide a comprehensive solution to the use of three previously selected advanced alternatives for factory-built wall construction, assess each option focusing on major issues relating to viability and commercial potential, and determine additional steps are required to reach this potential.

  14. Rethinking cancer: current challenges and opportunities in cancer research

    Ross Cagan


    Full Text Available Cancer therapeutics currently have the lowest clinical trial success rate of all major diseases. Partly as a result of the paucity of successful anti-cancer drugs, cancer will soon be the leading cause of mortality in developed countries. As a disease embedded in the fundamentals of our biology, cancer presents difficult challenges that would benefit from uniting experts from a broad cross-section of related and unrelated fields. Combining extant approaches with novel ones could help in tackling this challenging health problem, enabling the development of therapeutics to stop disease progression and prolong patient lives. This goal provided the inspiration for a recent workshop titled ‘Rethinking Cancer’, which brought together a group of cancer scientists who work in the academic and pharmaceutical sectors of Europe, America and Asia. In this Editorial, we discuss the main themes emerging from the workshop, with the aim of providing a snapshot of key challenges faced by the cancer research community today. We also outline potential strategies for addressing some of these challenges, from understanding the basic evolution of cancer and improving its early detection to streamlining the thorny process of moving promising drug targets into clinical trials.

  15. Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer

    Markauskas, Algirdas; Mogensen, Ole; dePont Christensen, René


    OBJECTIVE: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer....... MATERIALS AND METHODS: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. RESULTS: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT......-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively....

  16. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: An explorative study

    P.J. de Raaf (Pleun); S. Sleijfer (Stefan); C.H.J. Lamers (Cor); A. Jager (Agnes); J.W. Gratama (Jan-Willem); C.C.D. van der Rijt (Carin)


    textabstractBACKGROUND: Inflammation may underlie cancer-related fatigue; however, there are no studies that assess the relation between fatigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between cytokines and the separate dime

  17. Recent advances in radioiodine therapy for thyroid cancer

    Bae, Sang Kyun [Inje University College of Medicine, Busan (Korea, Republic of)


    Well-differentiated thyroid cancer is the most common endocrine malignancy with an increasing incidence. Most patients with well-differentiated thyroid caner have a favorable prognosis with high survival rate. While surgery and radioiodine therapy is sufficient treatment for the majority of patients with differentiated thyroid cancer, a minority of these patients experiences progressive, life-threatening growth and metastatic spread of the disease. Because there is no prospective controlled study to evaluate the differences of management of thyroid cancer, it is hard to choose the best treatment option. And there are still lots of controversies about the management of this disease, such as surgical extent, proper use of radioiodine for remnant ablation and therapy, use of rhTSH instead of withdrawal of thyroid hormone, long-term follow-up strategy, thyroglobulin as a tumor marker, etc. In this review, recent data related to these conflicting issues and recent advances in diagnosis, radioiodine therapy and long-term monitoring of well-differentiated thyroid cancer are summarized.

  18. [Satisfaction with immunotherapy in patients with advanced cancer].

    Moriyama, Yoshiaki; Fujisawa, Fumika; Kotani, Junko; Ohnishi, Masayuki; Watanabe, Toru


    Patient satisfaction with cancer immunotherapy, which is not covered by health insurance in Japan, was evaluated among 65 patients with advanced cancer who had received immunotherapy in our hospital for 2 years. Satisfaction measures were based on patients' expectations for medical care, cost, and staff services, and involved a questionnaire consisting of 25 items. Results of the questionnaire analysis showed that most patients, who expected much of antigen-specific vaccination such as dendritic cells (DC) pulsed tumor-associated antigens, were dissatisfied with the high cost of private immunotherapy(i. e., not covered by medical insurance), and were unable to perceive the effectiveness of the treatment because there was no quantitative analysis of killer T cells induced by immunotherapy. Therefore, it is critically important for us to confirm the safety and efficiency of cancer immunotherapy, before introducing medical insurance for cancer patients in Japan. In addition, the quantitative measurement of killer T cells induced by DC peptide vaccines should be considered, to meet patients' expectations.

  19. [Audit: medical record documentation among advanced cancer patients].

    Perceau, Elise; Chirac, Anne; Rhondali, Wadih; Ruer, Murielle; Chabloz, Claire; Filbet, Marilène


    Medical record documentation of cancer inpatients is a core component of continuity of care. The main goal of the study was an assessment of medical record documentation in a palliative care unit (PCU) using a targeted clinical audit based on deceased inpatients' charts. Stage 1 (2010): a clinical audit of medical record documentation assessed by a list of items (diagnosis, prognosis, treatment, power of attorney directive, advance directives). Stage 2 (2011): corrective measures. Stage 3 (2012): re-assessment with the same items' list after six month. Forty cases were investigated during stage 1 and 3. After the corrective measures, inpatient's medical record documentation was significantly improved, including for diagnosis (P = 0.01), diseases extension and treatment (P documentation for advanced directives (P = 0.145).

  20. Evidence of advanced stage colorectal cancer with longer diagnostic intervals

    Tørring, Marie Louise; Murchie, P; Hamilton, Willie


    population-based studies in Scotland, England, Canada, Denmark and Spain during 1997-2010 with a total of 11 720 newly diagnosed CRC patients, who had initially presented with symptoms to a primary care physician. Data were extracted from patient records, registries, audits and questionnaires, respectively...... of the primary care interval appears to have negative impact from day one.British Journal of Cancer advance online publication 8 August 2017; doi:10.1038/bjc.2017.236